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Abstract
In 1881, the German biologist August Weissman first proposed the theory that the ageing o f  tissues 
is related to the finite ability o f  somatic cells to replicate. Confirmation o f  this theory did not arrive 
until the 1960s with the work of Leonard Hayflick, who showed that somatic cells possess a finite 
ability to divide, before entering a state known as ‘replicative senescence’. This finite replicative 
lifespan was first proposed to be related to the ‘end replication problem’ shortly after the discovery 
o f  DNA and the DNA replication machinery by Watson and Crick in the 1970s. The end 
replication problem describes the inability of the DNA replication machinery to fully replicate the 
3 ’ end of linear chromosomes. As a result, shortening of the terminal end o f each chromosome 
occurs with every mitotic division. The structure that forms the end of linear chromosomes had 
been termed the ‘telomere’ by Muller in 1941, and proof that shortening o f the telomere with 
cumulative mitotic divisions is responsible for the finite ability o f  somatic cells to divide was 
finally provided by scientists at the Geron corporation in 1998.
The DNA structures that make up the telomere are highly conserved across a wide range of 
vertebrate and invertebrate species, and in all vertebrates a key feature is a variable number of 
repeats of the hexanucleotide sequence TTAGGG. In humans the TTAGGG repeat sequence 
comprises approximately 5-15 kb in length, as compared with 20 - 150kb in mice and 11 -  20 kb in 
dogs. Together with telomere-associated proteins, the telomeric DNA has been shown to form a 
number o f  three dimensional structures which are thought to be important for telomere function. 
Telomere shortening with accumulated mitotic divisions ultimately results in the onset of 
replicative senescence, activated through the p53 pathway in cells from a number of different 
lineages. This has been termed the M l,  or mortality 1, checkpoint. If the Ml checkpoint is 
bypassed, further cell divisions and telomere shortening occur, up to second checkpoint, known as 
the M2 checkpoint. Bypassing the M2 checkpoint in the absence o f  telomere-length maintenance 
mechanisms leads to end-to-end chromosome fusion through the non-homologous end joining 
(NHEJ) pathway, resulting in crisis and cell death. For this reason, telomere-shortening has been 
proposed as a major mechanism underlying the ageing o f somatic cells. Additional functions have 
been ascribed to telomeres, including putative roles in gene regulation and nuclear organisation.
A small number o f  cells can bypass the M2 checkpoint and achieve an immortal phenotype 
spontaneously. In the vast majority of these immortal cells, this occurs through the re-activation of 
telomerase, an RNA-dependent reverse transcriptase first characterised by Carol Greider. This 
enzyme, composed o f  a reverse transcriptase catalytic subunit (TERT), an RNA template (TR) and 
a number o f  associated proteins, is capable o f  adding nucleotides to the end o f telomeres, and thus 
circumvents telomere shortening. In vitro, enzyme function can be reconstituted with the TERT 
and TR components alone, and studies with fibroblasts have shown that expression of the TERT
subunit is the principal determinant o f telomerase activity. Telomerase activity in vivo is absent 
from the vast majority o f  somatic tissues in dogs and humans, but is present in some stem cell and 
germ cell populations. It is also present in the majority o f  cancers in humans in vivo and in cancer 
cell lines in vitro, suggesting that it is a potentially valuable target for novel anti-cancer strategies. 
Recent research has shown that dogs represent a potentially valuable model in which to investigate 
novel anti-cancer strategies, and are genetically more similar to humans than existing mouse 
models. In addition, telomerase activity in humans is more closely paralleled by telomerase 
activity in dogs than mice, adding to the value o f this model. For these reasons, this thesis aims to 
investigate the telomerase as a diagnostic and therapeutic tool in canine cancer.
Several large studies have shown that 85-90% of all human tumours possess telomerase activity. 
Brain tumours represent an important subset o f  these because of the debilitating symptoms 
associated with their effects and because survival rates for the most malignant subtype, 
glioblastoma multiforme, remain unchanged despite advances in anticancer treatment strategies 
over the past thirty years. Their canine counterparts show strikingly similar features both at the 
histological and genomic levels, and for this reason offer an attractive model for the development 
o f  novel therapies. Given the ubiquity o f telomerase activity in other tumour types, telomerase 
activity in human brain tumours has been extensively examined as a potential prognostic indicator. 
However, there appears to be a wide variation in the reported incidence o f telomerase activity in 
brain tumours which is likely to be the result o f  problems associated with the methods used to date. 
Studies have suggested that methods detecting telomerase activity in situ may resolve some of 
these problems. For this reason, we set out to investigate the immunohistochemical detection of 
telomerase activity using a number o f antibodies directed at TERT. One antibody, NCL-hTERT, 
was found to stain telomerase-positive D17 and CMT7 cells and telomerase-positive, formalin- 
fixed canine testis, at a concentration o f 1/200. This antibody was then used to examine the 
correlation between TERT staining and malignancy in a panel o f  93 canine brain tumours and to 
correlate telomerase activity with proliferation as assayed using the Ki-67 monoclonal antibody in 
a smaller subgroup. TERT staining was found to correlate significantly with malignancy in brain 
tumours overall as well as in the meningioma and oligodendroglioma subgroups. When TERT 
staining was correlated with proliferation, TERT staining was also found to correlate significantly 
with the MIB-1 labelling index in all tumours, and again in the meningioma and oligodendroglioma 
subgroups. These results suggest that the NCL-hTERT antibody represents a promising method 
with which to identify telomerase expression in formalin-fixed, paraffin-embedded material, and 
that the prevalence of telomerase activity in canine brain tumours is similar to their human 
counterparts.
Given the importance o f telomerase activation as a means for attaining an immortalised phenotype, 
considerable research has focused on its inhibition. Several approaches have been investigated: 
using strategies interfering with the function of either TR or TERT, strategies targeting telomerase-
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associated proteins, and strategies interfering with the interaction between telomerase and the 
telomere. A large number of naturally-occurring and synthesised molecules are now in existence 
that fall into one o f these categories. We set out to investigate two of these in canine telomerase- 
positive cell lines: the dominant negative mutant of human TERT, DN-hTERT, and the G- 
quadruplex inhibitor telomestatin, isolated from Streptomyces am datm . We tested the DN-hTERT 
dominant negative mutant by establishing cell lines stable transfected with this construct carried by 
the selection vector pCINeo, and found that over 50 population doublings, the DN-hTERT mutant 
failed to inhibit telomerase activity in telomerase-positive D17 and CMT7 cells. Over this period, 
growth rates and telomere lengths o f  transfected cells were similar to those o f negative control 
mock-transfected cells. Surprisingly, the same construct reactivated telomerase activity in 
telomerase-negative K9SF fibroblasts. Moreover, K9SF cells transfected with DN-hTERT 
appeared to undergo morphological changes consistent with a cancerous phenotype and exhibited 
accelerated growth as compared to negative controls. Investigation of telomestatin treatment of 
telomerase-positive cell lines yielded more encouraging results. Treatment of D17 and CMT7 cells 
with telomestatin at varying concentrations showed that a concentration o f  2 pM caused a decrease 
in telomerase activity by approximately 80% as compared with negative controls. Over a longer 
treatment period, telomestatin was also shown to cause slower growth and telomere shortening in 
these cell lines, together with an increase in the proportion o f cells undergoing apoptosis. 
Treatment of K9SF cells, however, did not cause any change in growth rate or apoptosis. These 
findings suggest that telomestatin treatment specifically abrogates telomerase activity in canine 
telomerase-positive cell lines and warrants further investigation of this promising telomerase 
inhibitor in canine cells.
Several anticancer therapies have been developed using either tissue-specific or cancer-specific 
gene promoters to drive the expression of transgenes. The only truly cancer-specific promoters 
currently known are the promoters o f  the TR and TERT genes involved in telomerase activity. 
Since telomerase activity is dependent principally on regulation o f the TERT gene, research as 
focused on the activity o f  this gene in normal and cancer tissues. Upregulation of the TERT gene 
depends primarily on transcriptional activity of its promoter, although post-transcriptional 
modification o f the TERT transcript and méthylation o f the TERT promoter may also play a role. 
The human TERT promoter is GC-rich, has no TATA box and contains multiple binding sites for 
transcription factors including Spl, c-Myc and p53. Using this promoter, several groups have 
developed a number o f  promoter-driven therapies to induce apoptosis or cell death by other means 
both in vitro and in vivo in nude mouse models, with considerable success. Some groups have also 
utilised the TR promoter in a similar fashion with good results.
In order to develop future TERT and TR promoter-driven therapies in dogs, we set out to sequence 
and characterise the canine TERT and TR promoters. We successfully sequenced approximately
5.4 Kb of the canine TERT promoter and created deletion constructs to identify the core promoter
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responsible for activity in telomerase-positive cells following luciferase assays. The core promoter 
was identified as a region 314 bp upstream of the ATG start codon, and conveyed approximately 
50% of the activity o f  a positive control vector in CMT7 and D17 cells. Importantly, inclusion of 
the initial part of the TERT gene with the core promoter reduced activity by approximately 75%, 
suggesting that important negative regulatory factors exist within the canine TERT gene. 
Transfection of other telomerase-positive cells with the core promoter construct showed promoter 
activity varied from between approximately 8% to 50% of the activity o f  the positive control. In 
addition, transfection o f  telomerase-negative fibroblasts with all deletion constructs showed that the 
activity of the TERT promoter was restricted to telomerase-positive cells. A number of potentially 
important putative transcription factor binding sites were identified within the core promoter, as 
well as within the TERT gene itself, although there were also significant differences between the 
canine promoter and its human counterpart. In addition to sequencing and characterising the TERT 
promoter, initial sequencing and analysis of the canine TR promoter was performed. In this 
experiment, genome walking was used to generate approximately 700 bp of the canine TR 
promoter sequence amplified from genomic DNA. The most remarkable finding in the TR 
promoter sequence was the presence o f multiple (TAAAA)„ repeats. Although the significance of 
these repeats is currently unknown, there is some evidence from the human literature to suggest 
that they are important for transcriptional regulation of some genes. Together, these experiments, 
by elucidating the canine TERT and TR promoters, provided an important tool that can be used in 
the design of future telomerase-specific promoter-driven therapies.
This thesis set out to investigate telomerase as tool for the diagnosis and treatment of canine 
cancer. The NCL-hTERT antibody investigation showed that the immunohistochemical 
recognition o f  TERT in paraffin-embedded tissue may provide a useful tool for the detection of 
telomerase in a wide range of canine cancers. It may also be useful as a means for examining 
telomerase activity in non-tumour tissues. However, further work still needs to be performed to 
characterise the true extent o f  telomerase activity in canine cancers, and to evaluate whether 
telomerase activity correlates with clinical outcome in dogs. The second part o f  this project was to 
investigate TERT as a target for therapy in canine cancers. We have shown that it is possible to 
inhibit telomerase activity in canine cancer cells, and that this leads to slowed growth, telomere 
shortening and cell death over a period of approximately 20 days in the cell lines examined. 
Finally, we have sequenced the canine TERT and TR promoters, and identified that core activity of 
the canine TERT promoter resides within a 314 bp region immediately upstream of the ATG start 
codon. Thus, we have identified two potential ways o f utilising telomerase as a target in canine 
cancer therapy -  firstly through direct inhibition o f the enzyme, and secondly by making it possible 
to design TERT promoter-directed gene expression for the targeted killing o f telomerase-positive 
cancer cells.
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C h a p t e r  I:
Ge n e r a l  In t r o d u c t io n  a n d  r e v ie w  o f  t h e
LITERATURE
1.1 Abstract
In 1881, the first theories concerning the ageing of somatic cells were proposed by a German 
biologist, August Weissman. However, definitive proof that somatic cells possess a finite 
proliferative lifespan was not published until the 1960s, by Leonard Hayflick and Paul Moorhead. 
In demonstrating that somatic cells are unable to replicate indefinitely, they introduced the concept 
o f  an internal mechanism, or replicometer, capable o f  counting the number o f cell divisions that a 
cell has undergone. This replicometer was then shown to be a structure comprising the terminal 
end o f  linear chromosomes, the telomere, in 1998. This structure is composed of a variable 
number o f  highly conserved repeat sequences, shown in vertebrates to be TTAGGG. The 
functions of the telomere are thought, at least in part, to be due to its ability to assume a number of 
tertiary structures, the most important o f  which is the T-loop. With every cell division, the 
terminal portion o f  the telomere is lost due to the inability o f the DNA replication machinery to 
fully replicate the end of linear chromosomes, a phenomenon known as the ‘end replication 
problem’. Ultimately, cumulative telomere shortening following successive rounds of mitotic 
division has been shown to trigger the onset of replicative senescence or crisis in somatic cells of a 
number o f different lineages, mediated by the p53 and pl6/Rb pathways. Thus, the discovery o f 
telomere shortening introduced a major new hypothesis explaining the ageing o f somatic tissues.
A number of organisms such as protozoa are able to replicate indefinitely, and a means by which 
cells o f  these organisms bypass the ageing process was uncovered in 1985 by Carol Greider and 
Elizabeth Blackburn through the discovery o f the enzyme telomerase. This enzyme, composed of 
a reverse transcriptase catalytic subunit (TERT), an RHA template (TR) and a number of 
associated proteins, is capable of adding nucleotides to the end o f  telomeres, and thus 
circumventing telomere shortening. In vitro, enzyme function can be reconstituted with the TERT 
and TR components alone, and studies with fibroblasts have shown that expression of the TERT 
subunit is the principal determinant o f  telomerase activity. Telomerase activity in vivo is absent 
from the vast majority o f  somatic tissues in dogs and humans, but is present in some stem cell and 
germ cell populations. It is also present in the majority o f  cancers in humans in vivo and in cancer 
cell lines in vitro, suggesting that it is a potentially valuable target for novel anti-cancer strategies. 
Recent research has shown that dogs represent a potentially valuable model in which to investigate 
novel anti-cancer strategies, and are genetically more similar to humans than existing mouse 
models. In addition, telomerase activity in humans is more closely paralleled by telomerase 
activity in dogs than mice, adding to the value of this model. For these reasons, this thesis aims to 
investigate the value o f telomerase as a diagnostic and therapeutic tool in canine cancer.
1.2 Historic Perspective
In 1881, German biologist August Weismann proposed that ‘death takes place because a worn-out 
tissue cannot forever renew itself, and because a capacity for increase by means of cell division is 
not everlasting, but finite’ (Shay & Wright 2000). However, this concept was challenged, and the 
opposite dogma -  namely that normal human cells are (at least in vitro) able to replicate 
indefinitely -  held sway up until the 1960s. Then, Leonard Hayflick and Paul Moorhead 
performed a series of experiments demonstrating the finite replicative capacity o f  normal human 
fibroblasts (Hayflick & Moorhead 1961; Hayflick 1965). In 1961, Hayflick and Moorhead showed 
that populations of cultured human fibroblasts doubled a finite number o f  times, after which cells 
stopped dividing and entered what Hayflick termed the ‘phase IIT phenomenon. He called the 
primary culture period phase I, the subsequent period o f expansive growth phase II, and the period 
when cell replication diminished and ultimately stopped, phase III (Hayflick & Moorhead 1961). 
The experiments which showed this were elegant in their simplicity. Normal human male 
fibroblasts at the fortieth population doubling were mixed in equal numbers with female 
fibroblasts at the tenth population doubling. Cells from each population were also maintained 
unmixed to serve as controls. At the point at which the male control population stopped dividing, 
Hayflick showed that the only remaining dividing fibroblasts in the mixed culture were female. 
This showed that the older cells retained a ‘memory’ o f their age, even when surrounded by young 
cells, and that other factors, such as culture conditions, could not be the reason for the cessation o f 
cell division. From these experiments arose the concept that normal cells have a finite capacity to 
replicate. Eventually, this work led Sir Macfarlane Burnett to coin the phrase ‘the Hayflick Limit’ 
for the first time in 1974 as a means o f describing a cell’s natural limit to replication (Burnett 
1974).
1.2.1 The Consequences o f  Senescence
Hayflick, as well as noting that normal somatic cells have a finite proliferative lifespan, also made 
the observation that the end o f that proliferative lifespan results in a quiescent, yet viable state 
which is now known as replicative senescence (Wynford-Thomas 1999). In this state, the celi- 
cycle is arrested in the GO phase o f division and a number of changes in gene expression occur that 
differentiate senescent cells from younger, actively growing cells (Shelton et al. 1999). These 
changes vary depending on the cell type studied, but include permanent growth arrest, repression 
of c-fos, repression of eye I in A and B and p galactosidase activity (summarised in (Kipling 2001)). 
Similar behaviour has been observed in a wide variety o f normal cell types, both mesenchymal and 
epithelial (Wynford-Thomas 1999). In the approach to replicative senescence, cells show a
gradual decline in the proportion of dividing cells within the population, and the timing o f  this 
decline varies between cell types and between sister clones (Thomas et al. 1997).
One o f  the most important implications of the finite lifespan o f  cells within tissues concerns the 
ageing process. It is perhaps useful when considering ageing in general to look at the interrelated 
processes that may be involved within any given tissue. Firstly, ageing may occur due to changes 
in the extracellular environment (such as the extracellular matrix, basement membranes etc). 
Secondly, ageing may occur due to changes within cells that are incapable o f  further division (eg 
mature neurons). Finally, ageing may occur due to changes within populations o f dividing cells 
(Kipling 2001). Replicative senescence is likely to contribute to the ageing of any tissue which 
contains a significant number o f dividing cells. For example, in those tissues for which cell 
division is an important part o f  day-to-day function such as the gastrointestinal tract, immune 
system and hair follicles, a reduction in the number of actively dividing cells is likely to have an 
impact on normal activity. Cell division is also important in other tissues for which proliferation is 
not an active feature, but which retain the ability to divide in response to damage or cell loss. This 
includes, for example, the ability o f  skin to undergo a localised burst o f  cell proliferation as part o f  
wound healing following trauma. In addition, cell division is required within tissues to 
compensate for physiological cell loss through wear and tear. In all o f  these situations, the process 
o f  cell division in older cell populations has the potential to produce senescent cells. 
Accumulation o f  senescent cells could then result in an altered tissue microenvironment, and 
produce an aged phenotype in affected tissues. For example, delayed wound healing is a hallmark 
o f  old age in people, consistent with this theory (Kipling 2001).
1.2.2 Telomeres: the ‘repHcometeT
In order to explain a limit to cellular proliferation, it is necessary to introduce another concept -  
that o f  a clock, or counting mechanism within each cell that could somehow track the number of 
divisions performed by the cell. This was first implied by two of Flayflick’s findings -  first, that 
normal cultured fetal cells undergo a finite number o f population doublings, and second, that 
cryogenically preserved cells can ‘remember’ how many times they have divided, even after being 
frozen. From this, the term ‘replicometer’ arose (Hayflick 1998), which in 1975 was shown to be 
located within the nucleus (Wright & Hayflick 1975).
Meanwhile, the discovery o f  DNA structure and replication in the early 1970s had revealed an 
inherent problem. Because o f  the nature o f  lagging strand synthesis, it was realised that cells are 
unable to fully copy the ends o f linear DNA. This is termed the ‘end replication problem’. During 
the S phase o f the cell cycle, DNA polymerase is unable to replicate the 3 ’ end of a linear DNA 
molecule. Lagging strand DNA synthesis proceeds as a series o f  discrete events with the
formation o f  Okazaki fragments, each o f  which requires an RNA primer. As there is no DNA  
beyond the 3 ’ end o f  the chromosome to which an RNA primer can anneal, DNA polymerase 
cannot fill in the gap between the final Okazaki fragment and the end o f  the chromosome. This is 
shown in Figure 1.1. Therefore, with every round o f  cell division, the terminal portions o f  the 
chromosome shorten slightly, with daughter chromatids inheriting slightly shorter chromosomes 
than their parent chromosomes.
Figure 1.1: DNA replication and the end replication problem
During DNA replication, the lagging strand is synthesised using Okazaki fragments. However, at 
the 3 ’ end o f  the lagging strand (circled) there is a gap that can not completely be reproduced 
because o f  the absence o f  a suitable primer.
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DNA helicase/ gyrase
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The first postulated mechanism that could act as a replicometer was proposed by Olovnikov in 
1973, not long after Watson and Crick had unravelled DNA replication (Olovnikov 1973). He 
proposed that the progressive erosion o f the ends of chromosomes with each cell division as a 
result o f  incomplete replication o f  one end of each DNA strand could act as a biological clock. 
Prior to this, the term telomere itself had first been used by Muller in 1938 in order to describe the 
terminal elements o f  linear chromosomes (Muller 1962). The theory that, in humans at least, the 
functions of the replicometer are provided by telomeres, was finally confirmed by scientists at the 
Geron institute in 1998, with the finding that mechanisms that extend telomeres in fibroblasts 
bypass replicative senescence (Bodnar et al. 1998). Since then, a large body o f research has 
advanced our knowledge o f  the structure and function o f telomeres. A review of the current 
understanding o f  telomere structure and function will be presented here as a background prior to 
discussing telomerase.
1.3 Telomeres: structure and function
1.3.1 Telomere Structure
Telomeres comprise the terminal portion o f linear chromosomes and consist of a complex o f  DNA 
together with a number o f telomere-associated proteins (TAP), the function o f many o f which are 
as yet unknown.
1.3.1.1 Telom eric D N A
The DNA structure at the ends o f chromosomes is remarkably conserved across all eukaryotes. 
The telomeric DNA sequences have been generally subdivided into 3 distinct areas: telomere 
associated sequences (TAS), double stranded telomeric repeats, and the terminal structure at the 
very end o f  the chromosomal DNA.
1.3.1.1.1 Telom ere A ssocia ted  Sequences
In all organisms in which sequencing of subtelomeric areas has been performed, the region of 
DNA proximal to the chromosome terminus contains a variety o f repeated elements known as 
Telomere Associated Sequences (TAS) (Biessmann & Mason 1992; Louis 1995). The actual 
amounts o f  TAS vary between chromosomes, even within the same species, and may make up a 
considerable portion o f  the total genome (Wellinger & Sen 1997). For example, allelic variation in 
the short arm of human chromosome 16 can lead to variation in TAS length of between 170 and 
450 kb (Wilkie et al. 1991 ). There are two different types of elements found in these subtelomeric 
areas. Relatively complex, middle-repetitive elements, varying from a few hundred to a few
thousand bp have been found in several species, including plants, fungi, invertebrates and 
vertebrates (including humans) (Bedbrook et al. 1980; Richards et al. 1992; Louis et al. 1994; 
Rubin 1978; Lopez et al. 1996; de Lange et al. 1990; Rouyer et al. 1990), although the location 
and copy number o f individual repeats are variable. Interspersed in between and within these 
complex repeats are shorter, tandemly repeated satellite-1 ike sequences. These repeats o f  20-1000 
bp seem to recombine and rearrange with high frequency, and may be the reason for the high 
degree o f  polymorphism in subtelomeric chromosomal regions (Louis 1995; Simmler et al. 1985; 
de Bruin et al. 1994), In addition to the complex repeats and short satellite-like repeats, in some 
yeasts, copies o f  genes have been found interspersed within some (but not all) o f  these 
subtelomeric regions (Louis 1995; Michels et al. 1992). However, in general, the subtelomeric 
areas contain very low numbers of genes and transcriptional activity (Wellinger & Sen 1997).
The reasons for the existence o f these large regions of (generally) non-encoding DNA are 
unknown. A number o f theories concerning their possible function have been proposed. Since, in 
yeast and Drosophila, genes located close to an actual chromosome end are subject to 
transcriptional repression (Levis et al. 1985; Gottschling et al. 1990; Nimmo et al. 1994), it has 
been argued that TAS provide a buffer zone between the actual terminal telomeric structure and 
more internal chromosomal domains (Louis 1995; Wright & Shay 1992). Secondly, they could 
also provide a region in which genes can undergo adaptive changes via amplification and 
recombination (de Bruin et al. 1994). Thirdly, since terminal telomeric repeats are identical for all 
telomeres in any given species, it could be that the highly variable arrays o f the different TAS 
specify telomere to telomere interactions. This would explain the finding that telomeres interact 
with each other non-randomly during mitosis and meiosis in several species (Gilson et al. 1993). 
Finally, TAS have been shown to provide alternative mechanisms for telomere maintenance via 
recombination or transposition in cases where the main telomere replication mechanism via 
telomerase is absent (Lundblad & Blackburn 1993).
1.3.1.1.2 D ouble-stranded Telom eric R epeats
Whilst the repeat sequence o f  the TAS of different species bear little resemblance to each other, 
the sequence found at the very end o f the chromosome is astonishingly well conserved (see Table 
1.1). The first terminal sequences to be identified were those o f  some ciliates such as 
Tetrahynterta (Blackburn & Gall 1978). For most species, the terminal repeats consist o f  short (6- 
8 bp) tandemly repeated sequences. In all vertebrates so far characterised, the telomere repeats are 
comprised o f  the 6 bp sequence TTAGGG. The actual number o f  repeats per telomere varies 
greatly between organisms. In some ciliates, such as Oxytricha and Eitplotes, there may be as few 
as 2-3 repeats, 20-30 bp in all (Klobutcher et al. 1981). In others, such as mice, there may be more 
than 10,000 copies, occupying more than 60-100 kb (Kipling & Cooke 1990; Starling et al. 1990).
As well as varying between organisms, the amount of telomeric repeats also varies between the 
chromosomes o f  the same cell, and may also change with growth and ageing (Sli jepcevic & Hande 
1999). The actual length of telomeric repeats are the result o f  a complicated interplay of 
competing activities which either lengthen or shorten the telomere (Biessmann & Mason 1992; 
Zakian 1995). For instance, whilst the telomeres in human cells contain from 500 to >2000 repeats 
(3 -  12 kb of telomeric repeat sequence), they gradually diminish in cycling cells of most somatic 
lineages (Moyzis et al. 1988; Harley et al. 1990). This variability in telomere length from a given 
species results in a very heterogenous collection of restriction fragments following digestion with 
endonucleases specific to the telomere sequence, and consequently a ‘smeary’ appearance of 
telomeric bands on southern blots.
Due to the base composition o f the telomeric repeat sequence, one strand of the telomere is usually 
rich in clusters o f  G residues. This strand, which in most species lacks any C residues, is known as 
the G strand, with its complementary partner known as the C strand. In those species which 
possess a G strand, the strand always forms the extreme 3 ’ end o f the chromosome (Wellinger & 
Sen 1997).
Whilst the majority o f  telomeric repeats occur at the end of chromosomes, it is important to note 
that telomeric repeats also occur at subtelomeric and non-telomeric chromosomal loci (Delany et 
al. 2000). The reason for these repeats existing at locations removed from the chromosome ends is 
unknown, but they may be remnants of recombination or transposition events involving telomeric 
repeats (Cherry & Blackburn 1985; Rossi et al. 1993). Alternatively, they may indicate telomere 
fusion points o f  aneestral chromosomes now joined together (IJdo et al. 1991).
Table 1.1: Telomeric repeat sequences o f  selected organisms
Organism Repeat Sequence
Protozoa 
Tetrahymena spp. 
Euplotes spp. 
Trypanosoma spp. 
Fungi 
Histoplasma .spp. 
Kliiyveromyces spp. 
Candida albicans 
Saccharomyces 
cerevisiae 
Invertebrates 
Ascaris spp.
Parascaris spp. 
Vertebrates 
Homo sapiens 
Mils nmsciilns 
M any other vertebrates
TTGGGG
TTTTGGGG
TTAGGG
TTAGGG
ACGGATTTGATTAGGTATGTGGTGT
ACGGATGTCTAACTTCTTGGTGT
(TG),.6TGG2-3
TTAGGG
TTGCA
TTAGGG
TTAGGG
TTAGGG
1.3.1.1.3 The term inal p a r t o f  the chrom osom e
Although several o f  the functions o f telomeres are likely to relate to the functions conferred by the 
structures at the very end, relatively little is known about these physical structures. End-labelling 
studies using linear rDNA molecules suggest that an overhang o f  the G strand over the C strand 
exists as a conserved feature o f  all eukaryotic chromosomes, although the length o f this overhang 
varies between species and organisms (Henderson & Blackburn 1989; Zahler & Prescott 1989; 
Wellinger et al. 1996). In humans, this overhang is several hundred nucleotides in length and 
plays an important role in the formation o f the T-loop (see 1.3.1.3; Three dimensional structures) 
which seems to provide many o f the protective roles conveyed by telomeres (Huffman et al. 2000; 
Wright et al. 1997). Whilst the 3 ’ overhang is important for telomere function, the mechanisms 
which allow for its existence are not fully known. Following lagging strand synthesis during DNA 
replication, removal o f  the last RNA primer is unlikely to leave an overhang o f the required length. 
It is generally believed, therefore, that maintenance o f 3’ protrusions in dividing cells requires an 
active exonucleolytic process at the C strand (de Lange 2002). Certainly, C-strand processing is 
required at the ends generated by leading strand DNA synthesis, since synthesis of the leading 
strand would be expected to produce a blunt end.
1.3.1.2 Telom ere-associated proteins
A large number o f  proteins have been identified which either bind to telomeric sequence directly 
or can be co-purified with telomeric sequence. Although the function o f some of these proteins 
has been partially elucidated, the function o f several has not. These are summarised in Table 1.2 
and will be discussed further in section 1.3.1.4: Assembling the telomere.
T able 1.2: Telomere-associated proteins identified in mam malian cells
N am e R ole at T elom ere
PO Tl Binds single-stranded T T A G G G  repeats
Necessary for telomere length maintenance and protection
T R F l Present in T loops
Binds double-stranded T T A G G G  repeats
Negative regulator o f  telomere length (dependent on telomerase)
TRF2 Present in T  loops
Binds double stranded T T A G G G  repeats
Negative regulator o f  te lomere length ( independent o f  telomerase) 
Loss o f  function causes end-to-end fusions
Loss o f  function leads to apoptosis and te lomere-induced senescence
T A N K ! Telomere-associated poly(ADP-ribose) polymerase 1 
Ribosylates T R F l
Positive regulator o f  telomere length
TA N K 2 Telomere-associated poly(ADP-ribose) polymerase 2 
Ribosylates T R F l
Positive regulator o f  te lomere length
TIN2 T R F l-b in d in g  protein 
Regulates telomere length
RAD50 DNA-repair  complex that binds TRF2
N B S l Possible role in T loop formation
M R E l 1 Negative role in telomere length regulation
Ku86 Negative regulator o f  te lomere length 
Role in telomere capping
D NA -PKcs Role in telomere capping
Putative role in post-replicative processing o f  telomeres
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1.3.1.3 Three dim ensional structures
Considerable attention has focused on the three dimensional arrangements assumed by the 
telomere, since it is thought that many o f  its functions are related to properties conveyed by these 
physical structures. The T-loop model has been shown to exist in vitro, whilst the G-quadruplex 
model has largely been proposed using theoretieal modelling techniques. However, as will be 
discussed in Chapter 4, the G-quadruplex model has important implications for the clinical 
treatment o f  cancer.
1.3.1.3.1 The T-loop m o d e l
When the telomere-binding protein TRF2 is inhibited, telomeric DNA remains largely intact, yet 
there is a rapid and eatastrophie loss of telomere function. Since TRF2 only binds duplex, and not 
single-stranded TTAGGG sequence, it would seem unlikely that loss o f  proteetion o f  the 3 ’ 
overhang by TRF2 is responsible for this. A neat solution to this puzzle was provided by Griffith 
and colleagues, who showed that TRF2 is capable of remodelling telomeric DNA into a structure 
known as the T loop (Griffith et al. 1999). When they provided the TRF2 protein with a model 
telomerie DNA substrate consisting o f a stretch o f  0.5 kb duplex TTAGGG repeats and a short 3 ’ 
overhang, they found that loops o f  approximately 0.5 kb in size and containing a large amount of 
TRF2 at their base were formed. When the DNA was then treated to generate interstrand 
crosslinks with psoralen and UV irradiation and the TRF2 subsequently removed, these loops were 
stable, showing that formation involved the invasion o f the duplex strand by the 3 ’ overhang 
(Griffith e/ a/. 1999).
T-loops are large duplex telomeric loops that are formed when the 3 ’ overhang enters the duplex 
part o f  the telomere repeat sequence (see Figure 1.2) (Griffith et al. 1999). The size of the loop 
can range from 0.3 kb in trypanosomes up to 30 kb in mice, and in some cases encompasses the 
whole telomere. Whilst the exact structure o f  the base o f the T loop is not known, the crucial 
feature appears to be invasion o f  the double-stranded telomeric DNA by the telomere terminus, 
which in turn displaces a short segment o f  single-stranded DNA, composed o f TTAGGG repeats, 
in a D-loop. This displaced segment is in the order of a few hundred nucleotides in many of the T 
loops (Griffith el al. 1999).
The T-loop would provide a neat architeetural solution to the problem of telomere protection. By 
sequestering the 3 ’ overhang, the telomere terminus is prevented from being mistaken for a site o f 
DNA damage (de Lange 2002). The T-loop structure resembles a DNA recombination
1 2
intennediate as it occurs during reinitiation o f  a stalled replication fork or during homologous 
recombination (de Lange & Petri ni 2000; Griffith et al. 1999).
In addition, the T-loop solution to telomere capping relies on the most conserved feature o f  
eukaryotic telomeres -  the presence o f  tandem telomeric repeats ending in a single stranded 
overhang (de Lange 2002).
Figure 1.2: T-loop Structure. T-loop function requires at least 3 factors: a) Minimal length 
o f TTAGGG repeats b) Integrity o f 3’ G strand overhang c) Telomere-binding proteins
a) Minimal length of TTACîGG repeats
c) Telomere 
binding proteins
b) Integrity of 3’ G strand overhang
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1.3.1.3.2 The G-quadruplex m o d e l
In 1987, Oka and Thomas reported an unusual cohesive structure formed by telomeric DNA 
purified from the protozoan Oxytricha (Oka & Thomas, Jr. 1987). Further investigation revealed 
that telomeric G-rich sequences were able to form higher-order structures such as G-G base pairs 
and four-stranded structures called G-quadruplexes, G-quartets or G4-DNA (Williamson et al.
1989). Although an extensive body o f literature has reported on the properties o f  some of these 
structures and proposed indirect evidence for their importance o f  telomere biology, they have not 
been reported to form under physiological salt and temperature conditions in vitro (Phan & 
Mergny 2002).
The potential formation o f  quadruplex complexes by telomeric G-strand sequences was first 
deduced from gel-mobility shift assays and chemical protection data (Sundquist & Klug 1989; 
Williamson et al. 1988). The quadruplex is formed by the chelation o f  a monovalent cation (either 
sodium or potassium) between two adjacent guanine quartets, each o f  which is formed by base- 
pairing between guanine residues. Two broad classes of structure, ‘paralleP and ‘anti-parallef- 
stranded quadruplexes were found to be formed, dependent on which cation is chelated. All of the 
proposed G-quadruplexes show three important properties: 1) structural polymorphism, 2) unusual 
interactions with specific monovalent and divalent cations, and 3) high thermodynamic stability 
with extraordinarily slow kinetics of formation and unravelling.
The possible existence o f G-quadruplexes has led to several theories explaining their functions in 
vivo. Firstly, the forming o f  G-G bonds within the quadruplex, rather than conventional Watson- 
Crick base-pairing, may represent a recognition of self. In this way, two or four identical single 
stranded DNA molecules can recognise one another and bind specifically via their G-rich termini 
(Sen & Gilbert 1988; Sundquist & Klug 1989). This self-recognition o f telomeres may occur at 
the onset o f  meiotic pairing o f  chromosomes. Secondly, the formation o f an alternative DNA 
structure, such as telomeric G-quadruplexes, at the late-S/G2 phase might serve as a signal for the 
completion of chromosome replication, and the cell cycle to progress normally without being 
recognised as a double stranded DNA break. Finally, G-quadruplexes, since they are an alternative 
form o f  DNA, are not a substrate for elongation by telomerase. This is due both to the inability o f  
the telomerase primers to aeeess the telomere in this form, and to limited extension o f primers by 
telomerase after binding. In this way, the formation o f G-quadruplexes might regulate telomere 
replication (Wellinger & Sen 1997).
Although telomeric DNA does not apparently exist as a G-quadruplex under physiological 
conditions, strong evidence for the importance of this structure in telomere biology has come from
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the activity o f a class of telomerase-inhibiting agents. These agents, which include drugs such as 
telomestatin and TMPyP4, bind and stabilise G-quadruplexes (Kim et al. 2003a; Seenisamy et al. 
2005) and efficiently inhibit telomerase activity (reviewed in greater detail in Chapter 4). 
Interestingly, these agents require 5-7 days for complete inhibition o f  telomerase activity in human 
cells, possibly reflecting the time required for conversion o f  all o f  the telomeric DNA into G- 
quadruplexes (Shammas et al. 2004). Following the application o f  these agents to telomerase- 
positive cells, telomere shortening and ultimately cell death occurs, after a lag phase of 10-14 days. 
This would confirm the important role that the G-quadruplex plays in regulating telomerase access 
to the telomere and thus regulating telomere extension.
1.3.1.4 Assem bling the telomere
The interaction o f the large number of proteins that bind telomeres is complex, and is likely to 
regulate both telomere length and function at several different levels. In yeast, telomere lengths 
appear to be regulated by a mechanism that involves counting the number o f proteins bound to 
telomere ends. It has been suggested that a similar mechanism exists for mammalian telomeres, 
possibly through counting o f  the telomere-binding proteins TRFl and TRF2, since overexpression 
o f  both proteins induces gradual shortening of telomeres, probably associated with accumulation 
o f  TRFl and TRF2 molecules at telomeres (Smogorzewska et al. 2000).
It would seem that formation o f the T-loop requires the action o f both TRFl and TRF2, linked by 
TIN2. TRFl binds to the duplex telomeric DNA and is capable o f  looping and pairing duplex 
DNA in vitro (Bianchi et al. 1997; Bianchi et al. 1999). Since TRF2 promotes T-loop formation in 
vitro and localises to the junction where the 3 ’ overhang enters the duplex tract, it seems likely that 
TRF2 aids invasion o f  the strand into the duplex, either through partially unwinding the duplex 
telomeric repeat array, or stabilising the displacement loop (Griffith et al. 1999) (Figure 1.2).
Taken together, these findings suggest that TRFl and TRF2 at least partly regulate telomere length 
through their ability to form T-loops. At the same time, these proteins are intimately involved in 
the physical capping o f telomeres and the processes which would cause end to end fusions and 
double strand break repair. When the T-loop is formed, the major telomere-elongating proeesses 
in mammalian cells are unable to access the telomere and elongate it. Alternatively, when TRFl 
and TRF2 are not bound in sufficient quantities the T-loop is not formed, and the telomere 
assumes an ‘open’ configuration. In this state, the exposure o f  the 3 ’ G-strand overhang leads to 
access by DNA-PK and the MREl 1 complex, as well as TANK I and TANK2. In turn this leads to 
NHBJ, homologous recombination and end-to-end fusions.
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1.3.1.5 Telomere lengths in humans and animals
In humans, telomeric DNA (excluding the subtelomeric regions) comprises on average between 5 
and 15 kb (Moyzis et al. 1988). In comparison, mice telomeres are between 20 and 150 kb in 
length and are highly polymorphic between inbred strains (Kipling & Cooke 1990; Starling et al
1990). This large difference between human and murine telomeres initially complicated research 
into telomere function, since first generation mTR ''' knockout mice, which were engineered in 
order to study the effects o f  telomere shortening, failed to show any i 11-effects associated with 
telomere dysfunction (Blasco et al. 1997). It was only after four generations o f  these mice had 
been bred that accumulated telomere shortening allowed the appearance o f an early-ageing 
phenotype, consistent with proposed theories of telomere function (see below).
In another small rodent, the Chinese hamster, telomere lengths are also considerably longer than in 
humans, at approximately 38 kb, although the telomere length varies between individual 
chromosomes (Slijepcevic & Hande 1999). In birds, considerable variation in telomere length has 
been reported, with telomere lengths ranging from 0.5 to 40 kb in length (Delany et al. 2000; Hall 
et al. 2004), In addition arrays of telomeric repeats several megabases in length are often found. 
In pigs, telomere lengths vary significantly between tissues, as does telomerase activity, but in 
general appear to be shorter than mouse telomeres, with most tissues carrying telomeres between 
10 and 30 kb in length (Fradiani et al. 2004). Another large mammal, the cow, seems to possess 
telomeres of similar size to those found in humans, ranging between approximately 12 and 20 kb 
in length (Miyashita et al. 2002). Along with the cow, perhaps the dog possesses telomeres most 
similar in length to human telomeres, ranging between 11 and 23 kb (Nasir et al. 2001; Yazawa et 
al. 2001).
1.3,2 Telomere Function
Specific functions attributed to telomeres include a role in cellular ageing, a gene regulatory role 
through suppression o f  genes in the subtelomeric regions, a role in nuclear organisation (as seen in 
their ability to attach to the nuclear matrix) and the prevention o f  chromosomes from illegitimate 
recombination and fusion. (Carroll et al. 1999). However, as shall be discussed below, it is likely 
that we do not yet know all o f  the functions for which telomeres are responsible. A brief review of 
the major functions o f  telomeres will be provided here.
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1.3.2.1 Telom eres, senescence and crisis
If human dermal fibroblasts are taken and cultured in the laboratory, the result is a cell strain 
which continues to divide typically to 50 population doublings (Hayfflick 1965; Hayflick & 
Moorhead 1961). At the end o f  this period, the cells enter a viable state known as senescence. 
The mechanisms involved in replicative senescence have been explained through a series o f  
checkpoints known as the M1/M2 (mortality 1, mortality 2) checkpoints. Continued cellular 
proliferation occurs up to a certain point, at which cell division ceases and cells become arrested in 
a GO or G 1-like stage. This is the onset of cellular senescence, also known as mortality stage 1 
(M l). At this point, the ‘replicometer’ informs the cell that a certain number o f cell divisions have 
elapsed, and thus triggers a senescent phenotype.
Those cells that are able to successfully avoid the functions of the p53/pl6/Rb tumour suppressor 
pathways proteins, either naturally or following transfection with the DNA tumour virus genes 
SV40T or HPVE6/7, can continue to proliferate until they reach another checkpoint of growth 
arrest known as mortality stage 2 (M2 -  also known as crisis) (Wynford-Thomas 1999). Crisis 
differs from senescence in that growth arrest is due to an increase in cell death rate rather than a 
decrease in cell proliferation. Other features o f M2 include chromosomal abnormalities, 
particularly end-to-end fusions, and widespread apoptosis. M2 is thought to be induced by 
critically shortened telomeres that have lost telomeric repeats to the extent that genomic instability 
and cell death ensue. Bypassing M2 can occur rarely as a spontaneous event (at a frequency of 
around 1 in 10  ^ cell divisions in human fibroblasts), but requires the stabilisation o f telomere 
length, the most common method being through the activity o f the enzyme telomerase (Sallinen et 
al. 1997; Carroll et al. 1999)
It is now known that, at least in fibroblasts, the function o f the replicometer is served by telomeres. 
However, other mechanisms may serve this function in other species or cell types (Wynford- 
Thomas 1999), and other potential candidates include changes in gene méthylation observed in 
senescing cultures and the accumulation o f random DNA damage (Holliday 1996; von Zglinicki et 
al. 1995). Three important observations all helped support the theory that telomeres are the 
replicometer in somatic cells, at least in humans. Firstly, human somatic cells were found to have 
shorter telomeres than sperm from the same individuals, suggesting that human telomeres shorten 
during development (de Lange et al. 1990; Hastie et al. 1990). Secondly, telomere lengths in 
fibroblasts and leukocytes from older individuals are shorter on average when compared with 
telomere lengths in somatic cells from younger people (Hastie et al. 1990; Harley et al. 1990). 
Thirdly, telomeres shorten during the passage o f  fibroblasts in culture (Hastie et al. 1990; Harley 
et al. 1990). All o f  these findings taken together suggest that telomere-shortening, ageing and
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senescence are inextricably linked, confirming the theory that telomeres function as the 
replicometer in human cells,
Induction o f senescence occurs through a number of pathways. One o f  the most important o f these 
involves p53 tumour suppressor gene function (Wynford-Thomas 1999). Whilst early studies 
using DNA tumour virus genes that allow fibroblasts to escape senescence suggested that loss of 
both the p53 and the pRb tumour suppressor genes was required to escape senescence, more recent 
studies have shown that loss o f  p53 is sufficient (Bond et a}. 1994; Rogan et al. 1995), showing 
that p53 forms part o f  an essential senescence-inducing pathway. The details o f  the mechanism by 
which p53 is activated, however, remain to be fully elucidated. Activation o f  p53 in turn leads to 
up-regulation o f  the cyclin-dependent kinase (CDK) inhibitor p21^'^''', which is involved with 
direct inhibition o f  the cell cycle machinery and senescence, illustrated by the close correlation 
between p21 expression and decreasing cell proliferation (Noda et al. 1994; Brown et al. 1997).
The onset o f  senescence in fibroblasts also correlates with up-regulation o f plb" '^ '^"'', another CDK 
inhibitor (Alcorta et al. 1996; Hara et al. 1996). This provides a p53-independent pathway to cell 
cycle inhibition. However, both p i 6 and p2l converge on pRb, suggesting that the common 
endpoint for both pathways is the up-regulation of pRb expression. In fibroblasts, these two 
pathways represent a backup plan in the event of uncontrolled growth. If p53 function is lost, for 
instance through the expression o f the HPV16E6 or mp53 genes, but p 16/Rb function retained, 
cells escape senescence but undergo growth arrest before reaching the M2 checkpoint (Bond et al.
1999). At this growth checkpoint, cell morphology is indistinguishable from M l. Thus, in 
fibroblasts the pi 6/Rb pathway provides an alternative means of inducing senescence if p53 
function is lost.
Other cell types studied seem to utilise the p53 and p i 6 pathways in the induction o f M l. 
However, in other cells, the order in which these pathways are induced varies. For example, when 
primary breast epithelial cells are cultured, a subpopulation arises which is able to undergo 30-40 
population doublings before the onset o f  Ml (Wynford-Thomas 1997). Initial studies showed that 
abrogation o f  p53 alone through the expression o f HPVE6 in these cells allows further 
proliferation up to M2 (Shay et al. 1993). Although these results apparently suggest that the p i 6 
pathway is non-functional in these cells, later work revealed that, in fact, the p i 6 pathway had 
been suppressed prior to the onset o f  M l, through méthylation o f  the pi 6 promoter (Foster el al. 
1998; Brenner et al. 1998). Therefore, these cells utilise both pathways, but rely mainly on 
activation o f  p53 as a barrier to proliferation, having abrogated p l6  early in life. However, the end 
result in both examples is the upregulation o f pRb and the onset o f  cellular senescence.
1.3.2.2 Telom eres distinguish chromosom e ends from D N A  strand 
breaks
The identification o f  telomeres began with the work o f Hermann J Muller in 1938 (Muller 1962). 
In irradiating Drosopholia with X-rays to produce mutations, Muller noticed that while ends o f 
fragments produced by radiation could be rejoined with other broken ends to produce 
chromosomal rearrangements, the natural ends o f  chromosomes did not fuse to other fragment 
ends (Muller 1962). Therefore, he proposed, a structure existed at the terminus of the 
chromosome which identified the chromosome end and effectively ‘sealed’ it from fusion with 
other chromosomes. This work was then augmented by Barbara McCIintock, working with maize 
(McClintock 1941). She engineered the formation o f  dicentric chromosomes by allowing 
rearranged chromosomes to recombine during meiosis. In doing so, she showed that the movement 
o f  the two centromeres to opposite spindle poles during cell division broke the dicentric 
chromosome at a variable location. The ends of these broken chromosomes, which were inherited 
by the daughter cells, could fuse with the ends o f their broken sister chromatids prior to mitosis, 
producing a breakage-fusion-bridge cycle that resulted in either gene amplification or deletion. 
McClintock proposed that telomeres protected normal chromosome ends from this process, further 
showing that telomeres are structures that are distinct from DNA breaks and which provide 
protection from processes that fuse broken chromosomes.
This theory has been supported by findings in knockout mice deficient in the RNA component o f  
telomerase. mTRV  mice, unlike their wild-type counterparts, lack telomerase activity in somatic 
tissues. As a result, telomeres shorten in tissues with progressive cell divisions. Although mice 
possess considerably larger telomeres than several other vertebrates studied, continued breeding of 
niTRY  mice eventually results in a phenotype with very short telomeres. In these late generation 
mice, there is a considerable increase in the number of signal-free ends (telomeres without 
detectable telomere repeats when analysed by FISH) and in end-to-end chromosome fusions 
(Blasco et al. 1997; Hemann et al. 2001). Chromosome ends that most frequently lack a FISH 
signal preferentially participate in end-to-end fusions, confirming that short or absent telomeres 
result in end-to-end fusions or non-homologous end joining (NHEJ).
1.3.2.3 Exceptions to the rule: problems with the current theories 
concerning telomere function
Whilst there is a considerable body o f circumstantial evidence that supports the functions o f 
telomeres as protecting chromosome ends and providing a mechanism for cell ageing, several 
observations do not easily fit this picture and suggest other functions as yet not fully established:
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1. Many eukaryotic cell types devote more o f  their resources to their chromosome ends than 
should be required simply to stop the loss o f  a few nucleotides at each replication. For 
examples, human chromosomes have up to 15 kb o f  telomeric DNA on each chromosome 
end -  considerably more than should be necessary to keep ahead o f sequence loss.
2 . The total amount o f  telomeric DNA is regulated in species-specific and cell type-specific 
ways, suggesting that the length o f telomeric DNA is important, possibly for different 
reasons in different cell types.
3 . Whilst telomeric repeats are very simple sequences, apparently minor changes in these 
sequences can have disastrous consequences. For example, the sequence which forms 
telomeres in Oxytrichia (G4T4/C4A4), when added to chromosome ends in Tetrahymena, 
caused chromosome division failure, despite the similarity o f  the sequence (G4T2/C4A2). If 
telomeric sequence was merely a DNA buffer, these two very similar sequences should be 
interchangeable.
4 . Linear viruses that live in eukaryotic cells and which also have to address the end 
replication problem, do so in a variety o f  ways, all of which seem to be simpler than the 
chromosomal solution. Despite this, RNA-dependent replication by telomerase is used by 
most, if not all, animals, plants and single-celled eukaryotes. It would appear that this 
solution offers organisms some advantage that viral solutions do not.
1.4 Telomerase: structure and function
The end replication problem, its consequences for telomere length and the concept that telomeric 
attrition limits cell proliferation all raise an important question; how do immortal organisms, 
germ line cells o f  higher organisms and cancer cells maintain the integrity o f  their telomeres and 
therefore avoid senescence? The solution for this problem arose through studies performed on the 
Tetrahymena organism by Carol Greider and Elizabeth Blackburn in 1985, who discovered an 
enzyme that could synthesise and elongate telomeres (Greider & Blackburn 1985). They called 
this enzyme telomerase. The structure and function o f this holoenzyme complex will be reviewed 
here as background for further discussion and for the studies which will follow.
L4.1 Telomerase structure
The progressive loss o f  TTAGGG repeats from telomeres can be prevented through the activity o f 
telomerase, a cellular reverse transcriptase. Telomerase comprises telomerase reverse 
transcriptase (TERT), the main catalytic subunit, and an mRNA template (known as TERC, TRT 
or TR) together with a number of associated binding proteins, and functions to add TTAGGG 
repeats onto pre-existing telomeres.
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1.4.1.1 Telom erase reverse transcriptase catalytic subunit (TERT)
Following the discovery o f  the telomerase enzyme in Tetrahymena by Carol Greider in 1985, 
several studies examined the components that go to make up the holoenzyme. Purification of 
telomerase from the ciliate EupJotes aediculatm  revealed two proteins o f  43 and 123 Kd in size, 
p i 23 was found to be a homologue o f the protein Est2, which in Saccharomyces cerevisiae is 
essential for telomere maintenance and telomerase activity (Lendvay et al. 1996; Counter et al. 
1997; Lingner et al. 1997). Est2 and p i 23 contain six o f  seven conserved reverse transcriptase 
(RT) motifs, and mutation o f  amino acids within the conserved RT motifs results in abrogation o f 
telomerase activity, suggesting that both p i 23 and Est2 are proteins that catalyse the RNA- 
dependent synthesis o f  telomeric sequence. In 1997, Flarrington et ai cloned and sequenced a 
human gene encoding a protein they termed TP2 (telomerase-associated protein 2) (Harrington et 
al. 1997). TP2 was found to share 30% amino acid identity with p i 23. BLAST searching 
revealed that TP2 was similar to several other reverse transcriptases, and homology with p i 23 was 
highest in the region that contained RT motifs similar to other RTs. TP2 was found to localise to 
the nucleus of telomerase-positive HeLa cells and was associated with telomerase activity (along 
with another telomerase-associated protein, TP 1 ). Importantly, mutation o f  aspartate residues in a 
region highly conserved across all RTs significantly reduced telomerase activity. Thus, TP2 
fulfilled all the criteria required o f  the reverse transcriptase catalytic subunit o f  telomerase.
The same protein was found by other groups at around the same time, who called their respective 
proteins TRTl and hEST2 (Meyerson e/c//. 1997; Nakamura e / <7/. 1997). Finally, the protein was 
renamed liTERT (human Telomerase Reverse Transcriptase) according to the HUGO 
Nomenclature Committee o f  the Genome Database (Counter et al. 1998a).
1.4.1.1.1 Organisation o f  the T E R T  g en e in hum ans an d  dogs
The hTERT gene has been characterised by several authors through a combination of cDNA 
library screening and genomic walking (Wick et al. 1999; Cong et al. 1999). hTERT is most likely 
encoded by a single copy gene and is composed o f  16 exons and 15 introns. Exons range from 62 
to 1354 bp in size, while introns vary in length from 104 to 8616 bp. The TGA translation stop 
codon is located within exon 16, together with a 3’-untranslated region. All exon/intron splice 
junctions contain GT/AG consensus sequences with the exception o f  intron 15 (Cong, et al. 1999). 
No putative polyadenylation signal has been identified either within exon 16 or in the following 3 ’ 
flanking region. The canine TERT gene appears to be organised in a similar way to the human 
TERT gene (Nasir et al. 2004).
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1.4.1.1.2 Structure o f  the T E R T  protein  in hum ans and dogs
The TERT protein contains seven RT motifs that are also found in other reverse transcriptases, 
designated 1, 2, A, B ’, C, D and E. In addition, TERT contains a telomerase-specific motif known 
as the T motif (Nakamura, et al. 1997). The T motif is located on exon 3, RT motifs 1 and 2 on 
exon 4, RT motif A on exon 9, RT motif B’ on exon 10 and RT motifs C and D on exon 11. RT 
motif A is the only motif to be encoded by two exons -  exons 5 and 6. These are shown in Figure
1.3 and in Figure 5.1, Chapter 5. The protein in vertebrates varies in size from 1191 to 1346 amino 
acids and has a predicted mass o f 127 -  155 kDa. In dogs, the TERT molecule is comprised of 
1123 amino acids and has a predicted molecular mass of 124 kDa (Nasir et al. 2004). Homology 
between the TERT molecules of different vertebrate species varies significantly, but is more 
tightly conserved within these motifs, with up to 75% of amino acids in some motifs conserved 
across a range o f species including dog, chicken, Xenopus, human, mouse, rat and hamster TERT 
(Nasir el al. 2004; Delany & Daniels 2004; Nakamura et al. 1997; Kuramoto et al. 2001; Santarlus 
et al. 1997). In addition, TERT contains several conserved regions both in the N-terminal and C- 
terminai regions o f  the protein that are conserved across several species. These have been termed 
regions v-1, v-II, v-IH and v-IV in the N-terminal region, and v-V, v-VI and v-VlI in the C-terminal 
region (Delany & Daniels 2004; Kuramoto, Ohsumi, Kishimoto, & Ishikawa 2001). Between the 
v-1 and v-11 regions o f  the TERT protein there exists a flexible linker region which varies 
considerably between species in length and amino acid content. O f the species so far examined, 
the chicken TERT possess the longest flexible linker, with 298 amino acids, compared with 199, 
154, 158 and 161 fov Xenopm , human, mouse, rat and hamster respectively (Delany & Daniels
2004).
The N-terminal region of TERT is essential for telomerase activity (Bachand et al. 2001). Within 
this area are three functional regions that have been termed motif GQ, motif CP and motif QFP 
(see Figure 1.3) (Xia et al. 2000). These regions overlap with the v-I -  v-IV domains (motif GQ 
corresponding to v-1 and motif QFP corresponding to v-lV) which in yeast have been shown to be 
essential for viability, with v-III necessary for RNA binding (Friedman & Cech 1999; Xia et al.
2000). Similarly, abolition o f  amino acids 1-350 of the hTERT molecule abolishes telomerase 
activity, and a 287-residue fragment o f  the N-terminal region has been shown to bind hTR, 
suggesting that this region is also important in vertebrates for binding RNA and allowing 
telomerase activity (Bachand & Autexier 2001). In addition to the motifs mentioned above, a 
region called the DAT domain (Dissociates Activities o f  Telomerase) within the N-terminal region 
has been shown to be necessary for in vivo telomere elongation. In humans this domain has been 
mapped to residues 69-134 aa o f  hTERT (Armbruster et al. 2001). Other functions ascribed to the 
N-terminal region o f  TERT include telomerase RNP assembly, catalysis and interaction with p23 
(Bachand et al. 2001 ; Bachand & Autexier 2001 ; Friedman & Cech 1999).
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Figure 1.3: Diagram o f conserved motifs in the human and canine TERT proteins. Reproduced from 
(Nasir, Gault, Campbell, Veeram alai, Gilbert, McFarlane, Munro, & Argyle 2004)
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The reverse transcriptase and T motifs are important for catalytic function of the TERT subunit. 
Motif E is known as the ‘primer grip’ in reverse transcriptases, and mutations to this region affect 
RNA priming (Jacobo-Molina et al, 1993; Powell et al. 1997). It is likely, therefore that the TERT 
uses this region to bind the telomere as a DNA template and then catalytically copies the template 
sequence of the tightly bound RNA subunit in a repetitive manner (Nakamura et al. 1997).
The carboxy terminal region of TERT is less well characterised than the N-terminal region. Two 
important functions ascribed to this region include enzyme processivity and multimerisation with 
other TERT molecules (Beattie et al. 2001). The hTERT molecule C-terminus contains a CRM 1 
and a 14-3-3 binding site, both o f which appear to regulate nuclear export (Seimiya el al. 2000). 
Banik and colleagues also identified four regions in human TERT downstream of the E motif 
which are essential for in vivo function, termed E-l, E-11, E-lIl and E-IV (Banik et al. 2002). E-l 
forms a continuous stretch o f sequence with motif E, and E-Il is reported to bind 14-3-3 protein 
(Seimiya et al. 2000). In addition, deletion of a three amino acid residue DAT domain in the C- 
terminus abolishes in vivo function of telomerase but retains in vitro activity (Banik et al. 2002). 
Several studies show that in several species, the functional telomerase holoenzyme includes a 
dimer formed by two TERT molecules, and results are consistent with a model whereby 
dimérisation occurs through N- to C- terminal interactions. It appears that the C-terminal 
extension and a section o f  the RT domain are essential for multimer formation to occur, but the 
region of the N-terminus involved in these interactions remains to be elucidated (Beattie et al. 
2001). Other functions conveyed by the C-terminus include competence for telomere recruitment, 
nucleolar localisation, primer binding and processive elongation (Banik et al. 2002; Counter et al.
1998b; Peng et al. 2001 ).
The tertiary structure o f  the TERT molecule is similar to that o f  other reverse transcriptases, and 
has been compared to being similar to a human right hand, with a ‘thumb’, ‘palm’ (composed o f 
motifs A, B ’, C D and E) and ‘fingers’ (composed o f motifs 1 and 2 - Figure 1.4) (Nakamura et al. 
1997).
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Figure 1.4: Conserved tertiary structure o f reverse transcriptase enzymes showing ‘thum b’, palm ’ 
and ‘finger’ regions. Reproduced with permission from (Nakamura, Morin, Chapman, W einrich,
Andrews, Lingner, Harley, & Cech 1997).
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Overall these results produce a picture o f  an enzyme which evolved from reverse transcriptases in 
an ancestor o f  present day eukaryotes. The reverse transcriptase domains have been conserved, 
together with a telomerase-specific T motif, across phylogenetically diverse species. The N- and 
C- terminal regions, however, have been less well conserved. Despite this, and unlike other 
reverse transcriptases, TERT relies on the N- and C-terminal regions for catalytic activity in 
addition to the conserved RT motifs. The N- and C- terminal regions are also required for a 
number o f other important functions, including binding o f the telomerase RNA component, 
binding telomerase-associated proteins, forming multimers and localising the enzyme within the 
nucleus.
1.4.1.2 Telom erase RNA (TR)
The RNA subunit o f  telomerase was the first component o f the telomerase enzyme to be cloned, by 
Carol Greider and Elizabeth Blackburn in 1989 (Greider & Blackburn 1989). Its size and 
sequence varies dramatically amongst mammals, ranging from 382 to 559 nucleotides in length 
(Chen ei al. 2000). Yeast and ciiiate RNA size and sequence also vary in length, from 148 to 209 
nucleotides in length in the case o f  ciliates, and up to approximately 1300 nucleotides in length in 
yeast (Singer & Gottschling 1994; Chen & Greider 2003). Whilst the RNA sequence shows some 
variation, the secondary structure of the RNA component seems to be conserved across species. 
Indeed, this conservation extends to the point where the telomerase RNA of several ciliates is 
functionally interchangeable in vivo (Bhattacharyya & Blackburn 1997). Phylogenetic 
comparison and mutational analysis o f vertebrate telomerase RNAs suggests that the secondary 
structure has also been highly conserved across vertebrate species (Chen et al. 2000).
Sequence analysis o f  the telomerase RNA gene from birds, mammals, reptiles and amphibians has 
revealed a highly conserved core structure with ten conserved helical regions formed by nucleotide 
pairing that are present in all the vertebrate RNAs so far examined (Chen et al. 2000). These ten 
helices constitute four distinct structural domains: the ‘pseudoknot’ fragment, located at the 5’ end 
of the molecule, the CR4-CR5 fragment, the BoxH/ACA domain and the CR7 domain (see Figure 
1.5) (Chen et al. 2000). The exact location o f these domains within the molecule varies slightly 
between species. For example, in humans the pseudoknot fragment extends from nucleotides 44 - 
184, whilst in the mouse the fragment starts at nucleotide I and extends through to nucleotide 145.
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Figure 1.5: Minimum consensus Vertebrate Telomerase RNA. Reproduced with permission from 
(Chen, Blasco, & Greider 2000). Regions denoted by P represent helical regions formed by base 
pairing. Regions denoted by J represent junctions between helices. Numbers 5 and 3 in black circles 
represent the 5 ’ and 3 ’ ends o f the molecule respectively. Note that not all species possess the PI 
paired region. These include mouse, rat and hamster.
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The pseudoknot region contains the RNA template located at its 5 ’ end (extending from nucleotide 
44 in humans and nucleotide 1 in mice) that binds the telomere and serves as a primer for further 
elongation (Figure 1.5). This potential template region varies across vertebrate species from 8-11 
nucleotides in length. Eight o f  these nucleotides are absolutely conserved across all o f  the 
vertebrate species so far examined, including sharks, amphibians and mammals (Figure 1.6) (Chen 
et ai. 2000). Within this region, the first six nucleotides (5 ’-CUAACC-3’) serve as the actual 
template for DNA polymerisation, while the last two nucleotides (5 ’-CU-3’) are required for 
primer alignment during translocation o f  the telomerase complex. The four bases extending in the 
3 ’ direction from this region are conserved to varying degrees across species. Importantly, when 
these nucleotides are complementary to telomere sequence, they cumulatively enhance the 
processivity of the telomerase holoenzyme (the number o f nucleotides synthesised before the 
enzyme dissociates)(Greider 1991; Hammond & Cech 1997). The observation that humans have a 
significantly more processive enzyme when compared with the mouse is therefore explained by the 
fact that human telomerase possesses a TR molecule with 11 nucleotides complementary to the 
telomere as opposed to the mouse TR molecule with only 8 complementary nucleotides (Prowse et 
ol. 1993; Greider 1991). In addition, reconstituting mouse telomerase by adding the human 
pseudoknot fragment to the mouse TERT protein results in an enzyme with significantly greater 
processivity than the original murine telomerase holoenzyme (Chen & Greider 2003).
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Figure 1.6: Sequence conservation in the template region of the pseudoknot domain of vertebrate 
telomerase RNA. The sequence alignment and adjacent region o f 35 vertebrate telomerase RNAs is 
shown. Nucleotides conserved in all species are shown in black. Nucleotides that are moderately 
conserved are shown in grey. Reproduced with permission from (Chen & Greider 2003)
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Within the pseudoknot fragment, several secondary and tertiary structures that have also been 
conserved across species. PI, P2 and P3 are the three first three paired (P) helices, with P2 and P3 
forming the stem and loop o f  the pseudoknot respectively (Figure 1.5). Mutations of nucleotides 
in the single-stranded regions flanking the P2a-1 helix or near the P3 loop in human TR produce an 
enzyme that is significantly less functional than wild-type telomerase, suggesting that these areas 
are important for a functional holoenzyme (Chen & Greider 2003). The P3 loop of the RNA 
molecule allows for individual RNA molecules to form a dimer under physiological conditions 
through a reaction that requires interstrand complementarity at this location (Figure 1.5) (Ly et aJ. 
2003). Ly and colleagues suggested that this dimérisation is required for enzymatic function o f  the 
telomerase molecule without interfering with binding of TR to TERT, since mutations in this area 
result in a monomeric molecule that is still able to coimmunoprecipitate with Flag-epitope-tagged 
TERT but which is catalytically inactive (Ly et al. 2003). However, recently Theliner and 
colleagues have suggested that mutations within the P3 helix cause telomerase defects by altering 
or disrupting the ability o f  TR to form a pseudoknot, regardless o f whether the pseudoknot is 
formed by one (monomer) or two (dimer) molecules (Theimer et al. 2005).
The CR4-CR5 fragment contains a high affinity site for contact with TERT that is essential for 
catalytic function (Bachand et al. 2001). The pseudoknot and CR4-CR5 fragments can bind 
independently to TERT and the presence o f both is required to reconstitute telomerase activity in 
vitro and in vivo (Chen et al. 2002).
14.1.3 Telom erase-associated proteins
Whilst the structure o f  TR and TERT have been remarkably conserved across a range of 
phylogenetically diverse species, the proteins associated with them have not. As yet there exists 
no conserved set o f  proteins universally associated with telomerase in all organisms (Nugent & 
Lundblad 1998). The telomerase holoenzyme complex varies between different organisms and 
under different developmental stages, ranging from 230 to greater than 5000kDa in size (Wenz el 
al. 2001; Harrington 2003).
In mammals, the protein TEPl has been cloned as a telomerase RNA-binding protein associated 
with telomerase activity in cell extracts (Nakayama et al. 1997). This was found to be a 
mammalian homo log o f  p80, a protein o f 80 kDa first discovered in Tetrahymena following its co- 
purification with telomerase activity (Collins et al. 1995). TEPl interacts with TERT through the 
RT domain, but it is not known whether this interaction is direct or indirect (Beattie et al. 2000). 
TEPl also binds an RNA component, vRNA, which is present within the cytoplasmic vault 
complex (Kickhoefer et al. 1999). Loss o f TEPl in telomerase-positive cells leads to greatly
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reduced vRNA levels, together with a loss o f  TEPl and vRNA from vault caps, but does not affect 
either telomerase activity or telomere length (Kickhoefer et al. 2001). Thus, TEPl,  whilst binding 
other RNA species, does not appear to be essential for telomerase function.
The mammalian protein La has also been found to associate with telomerase activity (Ford et al.
2001). La is a protein important for RNA Polymerase II transcript maturation (Aigner et al. 2000), 
and a homolog, p43, has also been identified that co-purifies with telomerase activity in the ciiiate 
Eitplotes aedicidatus (Lingner & Cech 1996). Although telomerase RNA is a product o f RNA 
Polymerase 11, the overexpression of La leads to gradual telomere shortening in human cells. 
Other proteins associated with telomerase RNA include proteins that bind the H-ACA motif 
(including dyskerin, G A R l, NF1P2 and Nop 10 -  see 1.4.1.4: Assembling the telomerase 
holoenzyme), the hnRNP proteins 1, CI/C2 and D (Ford et al. 2002), mammalian Staufen (Stau) 
and L22 (Le et al. 2000). Recently, the product o f  the survival motor neuron gene (SMN), a 
protein implicated in RNP biogenesis, has also been identified as a human telomerase associated 
protein (Bachand et al. 2002).
Proteins known to interact either directly or indirectly with TERT include 14-3-3, p23, p90, 
phosphatase 2A, Akt, cTbl, p53, PARP and PinXl (Kharbanda et al. 2000; Cao et al. 2002; Kang 
et al. 1999; Li et al. 1997). The 14-3-3 proteins are involved in signalling pathways and as 
molecular chaperones, and consistent with this a mutant version o f  14-3-3 which is still able to 
bind TERT results in a holoenzyme restricted to the cell cytoplasm and which is unable to 
translocate to the nucleus (Seimiya et al. 2000). The p23 and p90 proteins are foldasomes that 
stably associate with hTERT and which may promote maintenance o f an active conformation of 
the telomerase RNP (Holt et al. 1999). Phosphatase 2A, Akt, cAbI, p53 and PARP have all been 
implicated in the post-translational modification and regulation of TERT and telomerase activity 
(Li et al. 1999; Zhou & Lu 2001). Finally PinXl is a nucleolar protein which inhibits telomerase 
activity by competitively binding TERT at a domain which overlaps with the RNA-binding domain 
(Zhou & Lu 2001). As a result, PinXl may act as a tumour suppressor by sequestering TERT in a 
non-active state within the nucleolus (Blackburn 2005). The roles o f  all these proteins as so far 
described are summarised in Table 1.3.
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T able 1.3: Proteins associated with telomerase activity in mam malian species
Protein R ole in telom erase function O ther roles?
T E P l Association with but not Vault RNA (vRNA) stability
required for telomerase activity
Stall Binds TR Nucleocytoplasmic transport
La Associated with telomerase Involved with T R  transcription?
activity
L22 Binds TR Ribosom e component
D yskerin /G A R 1/N H P2/ N op 10 Bind TR Telom erase RNP processing
p23/p90 Bind N -terminus o f  T ER T Foldasomes/chaperones
hnRNPs (A 1 ,C 1 /C 2 ,  D) Associated with te lomerase RNP assembly/RNA splicing
activity; affect telomere length
SMN Associated with telomerase R N P synthesis
activity
Phosphatase 2A, Akt, c A b l , Post-translational modification Regulation o f  T ER T  and
P53, PARP telomerase activity
PinXl Inhibition o f  telomerase activity Competitive binding to RNA-
binding m otif  o f  T ER T
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1.4.1.4 A ssem bling the telomerase holoenzym e
The mammalian telomerase holoenzyme is a multimeric complex o f  1000 kDa or more, whose 
composition is not fully known (Nakamura et aL 1997). However, after weakly interacting 
proteins are removed from the complex by salt-stripping, the smallest telomerase complex that 
retains enzymatic activity in humans has a mass of approximately 600 kDa. This is consistent with 
a molecule containing two copies each o f  TR and TERT (Wenz et al. 2001). This multimerisation 
has been confirmed in vivo in yeast and humans (Prescott & Blackburn 1997; Ly et al. 2003; Wenz 
et ai. 2001) and involves the pseudoknot domain of the TR molecule and the N-terminal region of 
TERT (Moriarty et al. 2002; Ly et al. 2003). Formation of a dimer appears to be important for 
telomerase activity to occur, but it is possible that the three-dimensional structure of the resultant 
enzyme is responsible for function, rather than the number o f molecules involved (Theimer et al.
2005).
The RNA component o f  all vertebrates and o f yeasts is produced by RNA polymerase 11 (Chen et 
al. 2000). The accumulation o f most cellular non-coding RNA requires active processing of a 
primary transcript, including events such as precursor cleavage, base and sugar modifications and 
directed assembly o f proteins that protect the RNA from nuclease digestion (Collins & Mitchell
2002). In the first part o f  this process, RNA polymerase 11 transcription o f  telomerase RNA 
beyond the mature RNA 3 ’ end creates a precursor that must be then cleaved to generate a final 
product. Whilst creation o f the mature product is critical in the formation o f  functional telomerase 
RNA in all species, it is accomplished by different organisms in different ways. For example, in 
budding yeast, the RNA precursor is polyadenylated before being processed in association with 
Sm proteins (Chapon et al. 1997; Seto et al. 1999). Whilst these details are not known in humans, 
no evidence for a polyadenylated precursor RNA molecule has been found, suggesting that 
transcription termination without adénylation may occur (Collins & Mitchell 2002).
Once the mature version o f telomerase RNA has been synthesised, it accumulates within the 
nucleus of telomerase-positive cells together with TERT. In humans localisation has been shown 
to occur within intranuclear structures known as Cajal bodies (Zhu el al. 2004), with a small 
fraction (approximately 7%) found in nucleoli. In humans and in mice TERT also accumulates in 
the nucleus, in a punctate or speckled pattern (Martin-Rivera et al. 1998; Harrington et al. 1997). 
\n Xenopus oocytes, telomerase has also been shown to accumulate in Cajal bodies, and within the 
nucleolus (Lukowiak et al. 2001; Narayanan et al. 1999). Localisation requires the H/ACA RNA 
motif composed o f  primary and secondary structure elements in an overall hairpin-Hinge-hairpin- 
ACA configuration located towards the 3 ’ end of the RNA molecule (Figure 1.5) (Mitchell &
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Collins 2000). Alterations to the stem and loop structures within the H/ACA domain either 
prevent telomerase RNA from accumulating, or prevent correct folding o f  the molecule, resulting 
in a molecule that is able to accumulate but which does not convey telomerase activity (Mitchell 
& Collins 2000), The H/ACA motif associates with four proteins, in humans known as dyskerin 
(homologue o f  CbfSp in yeast), NHP2, NOP 10 and GARl (Collins & Mitchell 2002). Alteration 
to at least one o f  these proteins, dyskerin, also results in dysfunctional telomerase, due to a 
decrease in the rate o f  accumulation and processing of telomerase RNA, through interaction at the 
H/ACA motif. This demonstrates that several associated proteins are required for synthesis o f  TR 
within a stable ribonucleoprotein (RNP) complex. The telomerase enzyme accumulates within the 
nucleus, and is at least partially distributed to the nucleolus, consistent with the finding that most 
other H/ACA motif RNA species also localise to the nucleolus (Mitchell & Collins 2000).
The synthesis and characterisation o f  TERT is less well known. Once TERT has been synthesised, 
it appears that it associates with TR that has been assembled into a stable RNP, and that binding 
occurs via the pseudoknot and CR4/CR5 domains o f  TR (see Figure 1.5). Although the exact 
binding sites have not been defined, one hypothesis that fits the accumulated data is that binding 
occurs at several core domain elements (including the pseudoknot and CR4/5 domains) but that 
each individual interaction is weak. This would then allow for temporary association and 
disassociation o f  the two molecules required for the translocation involved in telomere synthesis 
(Theimer et al. 2005).
In cells that possess telomerase activity but which have not been transformed, the TERT subunit 
has been shown to localise to the nucleolus (Wong ef al. 2002). Telomerase is then released to the 
nucleoplasm at the expected time of telomere elongation. By contrast, in tumour cells and cells 
transformed by SV40, telomerase seems to be mainly excluded from the nucleolus and remains 
largely confined to the remainder o f  the nucleoplasm. However, DNA damage due to ionising 
radiation is sufficient to induce reassociation o f telomerase with the nucleolus (Wong ei al. 2002).
Î.4.2 Telomerase function
Telomerase activity is not present in sufficient quantities to prevent telomere shortening in most 
normal adult somatic cells. However, telomerase aetivity is present in adult germ cells and a sub­
population o f  adult stem cells. In addition, telomerase activity is present in a high proportion o f all 
human cancers. A more detailed review of telomerase activity in relation to cancer will be 
provided in Chapter 3. However, a broad review of the other functions of telomerase will be 
provided here.
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1.4.2.1 Telom erase activity
1.4.2.1.1 Telom erase activity  is reconstitu ted  b y  TR and T E R T
Although several telomerase-associated proteins have been identified in various organisms, it has 
been shown in humans that in faet the minimal components required to restore telomerase activity 
are TR and TERT. Weinrieh et al showed that the in vitro transcription and translation of hTERT, 
when either mixed or co-synthesised with liTR, conveyed the enzymatic properties o f  native 
telomerase (Weinrieh et aJ. 1997). Enzymatic activity could be restored irrespective of whether 
the hTERT was synthesised in conjunction with or separate to hTR. In addition, mutations to the 
hTERT sequence abrogated this activity, confirming that hTERT is the reverse catalytic subunit o f  
the holoenzyme. This important work was the first step in later research examining the importance 
o f TERT as the major determinant o f telomerase activity.
1.4.2.1.2 The reverse transcriptase catalytic subunit is the rate-lim iting factor in telomerase 
activity'
Although TR and TERT are minimally required to generate telomerase activity in vitro, several 
findings suggest that in fact the presence of TERT is the prime determinant of telomerase activity 
in vivo. Work by Counter et al showed that ectopic expression o f hTERT in telomerase-negative 
human fibroblasts is sufficient to restore telomerase activity to levels comparable with immortal 
telomerase-positive cells (Counter et al. 1998a). Two other findings support this idea. Firstly, TR 
has been shown to be widely expressed in telomerase-negative somatic tissues (Feng et al. 1995). 
Secondly, hTERT mRNA can be found in telomerase-positive tissues, eancer cell lines and 
tumours, but not in cells or tissues known to lack enzymatic activity (Kilian et al. 1997; Meyerson 
et al. 1997; Nakamura et al. 1997). Together these findings suggest that hTERT is the primary 
determinant o f  telomerase activity in telomerase-positive cells.
1.4.2.1.3 Telom erase activity during developm ent
In humans, telomerase activity is detectable at the blastocyst stage but is lost from almost all 
embryonic tissues by 20 weeks o f  gestation. As well as being present at high levels in the 
blastocyst, telomerase is seen in essentially all human tissues tested during the first trimester. As 
gestation proceeds, telomerase activity continues in a subset o f  fetal somatic tissues (liver, kidney, 
intestine, lung, skin, muscle and adrenal glands) but is no longer detectable in brain or bone 
extracts after 16 weeks o f  gestation, despite ongoing cell division in those tissues (Wright et al. 
1996).
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The mechanism or mechanisms by which telomerase is switched off  during development is 
unknown. However, regulation would appear, at least in some tissues, to involve alternative 
splicing o f hTERT mRNA (Forsyth er al. 2002). Using hTR levels as a surrogate marker for 
telomerase activity during development, some researchers suggested telomerase activity was 
present in tissues up to and beyond week 21 o f  gestation (Yashima et al. 1998). However, a 
second study revealed that while fetal heart, liver and kidney tissues displayed the presence o f  hTR 
at all gestational ages tested (from 8-21 weeks), telomerase activity disappeared from heart after 13 
weeks, and from kidney after 17 weeks. In heart tissue, hTERT mRNA was no longer detectable 
after 13 weeks o f gestation, but from the 17* week, the transcript was present in kidney as an 
inactive alternative splice variant (Ulaner et al. 1998).
IA.2.1.4 Telom erase activity' in stem  ceils
In multicellular organisms, the requirement for telomerase to maintain telomere length depends on 
species, cell type and stage of development. This may in part be due to the considerably longer 
telomeres found in multicellular as compared to unicellular organisms, where telomeres are 
measured in kiiobases rather than hundreds o f bases respectively. In the majority o f animals, this 
large reserve could be expected to cope with the shortening associated with the limited number of 
cell divisions required by somatic cells. It would be reasonable to assume, then, that within a 
multi-cellular organism, those cells with a capacity for self-renewal might parallel the situation 
found in single-celled organisms which are by their very nature also self-renewing. In particular, 
this situation might apply to stem cells, which are required to undergo a much greater number of 
divisions over the lifetime o f  the individual. In fact, this is partly true. In humans and mice, at 
least, many stem cells with the ability to generate cells o f  several lineages do possess telomerase 
activity. However, telomerase activity is absent from some cell types, including mesenchymal and 
stromal cells derived from human bone marrow (which differentiate to form skeletal tissues) and 
from haemopoietic stem cells derived from umbilical cord blood (Greenwood & Lansdorp 2003; 
Banfi et al. 2002; Gronthos et al. 2003; Parsch et al. 2004; Zimmermann et al. 2003; Samper et al. 
2002; Allsopp et al. 2003). As expected, telomeres in many o f  these cells progressively shorten 
with time, although this has not been proven in all. Stem cells and progenitor cells in humans that 
do possess telomerase activity include neuronal stem cells, haematopoietic stem cells and 
embryonic stem cells (Harrington 2004).
In addition to these cells, low levels o f  telomerase activity have been deteeted in other stem and 
stem-like cell populations in adult humans. This lower level of activity is apparently sufficient to 
slow, but not prevent, telomere shortening, since the progeny o f  these cells exhibit telomere 
shortening as a function o f  ageing. Examples o f these cells include basal kératinocytes in skin, 
crypt cells in the intestines, basal cells o f  the trachea and bronchi, kidney collecting ducts and
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urotheliuni, glandular prostate tissue, germinal centres and parafollicular areas o f  lymphoid tissue, 
and squamous epithelial basal cells and hair follicle bulbs (Forsyth et al. 2002). It is possible that 
some stem cell types do not need to maintain telomere length simply because limited telomere 
attrition can be tolerated in those stem cells only undergoing a small number of population 
doublings during the lifetime o f the organism. The progeny o f  these cells, however, may represent 
rapidly dividing progenitor cells, and thus it may be that a more important factor is the activation 
of telomerase activity in these stem cell successors (Harrington 2004). Examples o f  this have been 
demonstrated in blood and skin (Hiyama a/. 1995; Weng g/ <3/. 1996; Bickenbach et al. 1998).
1.4.2.2 Telomere elongation by telomerase
The principal effects of telomerase relate to the ability o f  the enzyme to add nucleotide repeats to 
the end o f telomeres. Telomere elongation can be divided into three steps: binding, elongation 
and translocation. These are shown pictorially in Figure 1.7. In the first step, the telomerase 
holoenzyme binds to the telomere through alignment o f the telomerase RNA template region with 
TTAGGG repeats. During the second step, the TERT subunit functions to extend the telomere by 
adding nucleotides to the end o f the telomere using the TR template as a guide. In the third step, 
the holoenzyme dissociates from the telomere, translocates to the end o f the telomeric sequence, 
and re-binds the telomere via the RNA template, ready for another round o f  elongation.
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Figure 1.7: Schematic representation o f the steps involved in telomerase elongation o f telomeres
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Before the telomerase is able to extend shortened telomeres, the holoenzyme must find and extend 
a chromosome 3 ’ end. The extent to which telomerase interacts with the telomere by direct 
binding to single-stranded DMA rather than through protein-protein interactions is unclear. For 
most o f  the cell cycle, telomeres are packaged into the chromatin structure responsible for end 
protection (Collins & Mitchell 2002). The T-loop formed by the folding back o f the 3 ’ overhang 
back into the duplex repeat region of the same chromosome seems likely to restrict elongation of 
the telomere in this state. During the S phase of the cell cycle there would appear to be an interval 
when T-loops are disassembled by the DNA replication machinery, allowing access to telomeric 
DNA by telomerase (Ray ei al. 2002). In addition, POT I may mediate binding of telomerase to 
the telomere during the S phase by stabilising telomeres in the ‘open’ configuration (Baumann et 
a/. 2002). However, the relative scarcity o f  telomerase would suggest that active recruitment is 
also required (Collins & Mitchell 2002). Proteins that could possibly be involved in this role in 
mammals include the hnRNP proteins Al and C (Collins & Mitchell 2002). Recombinant hnRNP 
Al can simultaneously bind TR and a telomeric DNA substrate, and overexpression o f  hnRNP Al 
in a hnRNP A 1-deficient mouse strain results in telomere elongation (Fiset & Chabot 2001). 
Similarly, recombinant hTR can also interact with hnRNP C, and antibodies against hnRNP C 
immunopurify endogenous telomerase but not telomerase assembled from C-terminally epitope- 
tagged TERT in vitro (Ford et a!. 2000).
Following recruitment o f  telomerase to the telomere, one mode o f  substrate recognition involves 
hybridization of the telomerase RNA to the substrate, telomeric DNA (Lingner & Cech 1996). 
This does not seem to require absolute complementarity at the 3 ’ end o f  the RNA template, 
depending on the organism involved. Substrate recognition also involves an ‘anchor site’, found 
within the TERT subunit. G-rich DNA at the 5 ’ end o f the oligonucleotide is recognised distal to 
the catalytic centre, at this anchor point (Hammond et al. 1997).
Following substrate recognition, telomerase RNA then directs the next nucleotide to be added to 
the telomeric DNA substrate, depending on its alignment with the telomere. In adding nucleotides, 
the affinity o f  TERT to different nucleotides varies, with highest affinity for dGTP, although other 
dNTPs, I'GTP and ddNTP can all be incorporated by most telomerases (Collins & Greider 1995). 
Interestingly, as well as being required for telomere synthesis, dGTP appears to affect TERT 
activity, since the concentration o f dGTP influences the ability o f  telomerase to processively 
elongate DNA substrates (Bryan et al. 2000). In addition, elongation may involve a dGTP binding 
site separate from the dNTP binding site utilised during polymerisation (Hammond & Cech 1997). 
During the elongation step, telomerase RNA does not form base pairs with all nucleotides in the 
template, and RNA-DNA bonds break at the distal end o f the template at the same time as new 
bonds are formed at the proximal end (Hammond & Cech 1998).
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1.4.2.3 Telom erase is involved in bypassing senescence
Given the ability o f  telomerase to extend telomeres, it would be reasonable to expect that 
expressing telomerase in normal cells extends lifespan past the point at which replicative 
senescence or crisis would be expected to occur. Several researchers have confirmed this 
hypothesis. Condon et al showed that expression o f  hTERT in human myométrial cells led to a 
cell line capable o f  division continuously in culture, yet which retained almost all the phenotypic 
characteristics o f  normal smooth muscle cells in vitro (Condon et al. 2002). Jiang et al showed 
similar findings in fibroblasts, and Bodnar et al confirmed this in retinal pigment epithelial (RPE) 
cells (Jiang et al. 1999; Bodnar et al. 1998). Importantly, telomerase increases the proliferative 
capacity o f  cells, but is not in itself an oncogene, as the immortalisation process is not associated 
with the development o f  a malignant phenotype (such as the ability to grow in low-serum 
conditions or in soft agar) (Jiang et al. 1999; Morales et al. 1999).
These initial findings suggested that the presence o f  telomerase activity alone is all that is required 
for the immortalisation o f  cells. However, when some groups attempted to immortalise other cell 
lines, they found that telomerase on its own was not sufficient. Human foreskin kératinocytes 
(HFKs), human mammary epithelial cells (HMECs) and human adenoidal epithelial cells (HAKs) 
all required the additional abrogation of the Retinoblastoma (Rb) pathway, either through 
expression o f human papilloma virus E7 protein, or inhibition of p i ( K i y o n o  et al. 1998; 
Farwell et al. 2000). The HFK and HAK cell lines examined in more detail by Far we II et al all 
possessed hypermethylated Rb, either following méthylation o f  the pi promoter, large scale 
deletion o f chromosome 9p (the location o f the plô*^ *^ "^ ” gene), or with complete down-regulation 
o f pi (Farwell et al. 2000). Thus, the processes involved in immortalisation would appear to 
vary between cell types, although telomerase activity seems to be an essential requirement for 
those cell lines with telomerase-dependent telomere-elongating mechanisms.
It is not always the case that such findings in vitro are paralleled in vivo. However, confirmation 
that reconstitution o f  telomerase activity in telomerase-deflcient mice results in preferential 
elongation o f  short telomeres, preventing senescence and end-to-end fusions was provided by 
Hemann and colleagues in 2001 (Hemann et al. 2001). This finding added further weight to the 
theoi*y that telomerase is involved in immortalisation and that this holds true in several mammalian 
species. Interestingly, restitution of telomerase activity in mTERT-/- mice (lacking telomerase 
activity) does not necessarily restore telomere length to the original, wild-type state but maintains 
telomeres at a level which is sufficient to escape senescence but shorter than that o f  normal cells 
(Blasco 2002). This occurs in several cancer cell lines as well which possess high levels o f  
telomerase activity but generally short telomeres (Hastie et al. 1990; de Lange et al. 1990).
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The elongation o f  short telomeres by telomerase is required to allow immortal growth o f  eeiis with 
short telomeres. Telomerase is often activated at early stages o f  tumour progression in human 
cancers, probably reflecting the proliferative or differentiation status of the tumour. This 
activation may be the result of transcriptional or post-transcriptional activation by various 
oncogenic alterations. However, the implications for tumour development of early telomerase 
activation are not known (Blasco 2002).
1.4.2.4 Telom erase activity allows cells to escape from crisis
Cells which have undergone transformation such that they are able bypass replicative senescence 
are not, in themselves, immortal. Halvorsen e( al showed that human pancreatic cell lines 
transformed with SV40 large T antigen proliferate beyond Ml but then show slowed growth, 
altered cell morphology, chromosomal instability and high rates o f  cell death associated with 
crisis. However, adding hTERT to these cells allows them to continue proliferating indefinitely 
(Halvorsen et aJ. 1999). Counter et al reported very similar findings in human embryonic kidney 
(HEK) cells, with telomere length maintained at approximately 9Kb, and Davies et al with human 
ovarian surface epithelial cells (Counter et al. 2003; Davies et al. 2003). Thus, whilst expression 
o f  oncogenes in many cell lines allows the first mortality checkpoint to be overcome, 
immortalisation o f  these cells and bypassing crisis requires telomerase activity.
Whilst the findings o f  Counter et al suggested that telomere length maintenance was vital for the 
avoidance o f  erisis, the findings of Zhu et al appeared, initially at least, to contradict this. They 
showed that following immortalisation with SV40 and hTERT, human fibroblasts contained 
telomeres that continued to shorten for a further 50 population doublings before stabilising at 
approximately 5-6 Kb in length (Zhu et ai. 1999). These cells bypassed the crisis undergone by 
control cells which showed large numbers o f  dicentric and abnormal chromosomes associated with 
M2. Initially these findings were suggested to be due to a physical role played by telomerase in 
capping the ends o f short telomeres, such that telomerase activity, in addition to immortalising 
cells, allowed the resetting o f the minimal critical telomere length compatible with continued cell 
division (Zhu et al. 1999). Previously, Counter et al had shown that modification of hTERT to 
include an influenza virus haemagglutinin (HA) epitope tag at the carboxyl terminus produces a 
mutant form of TERT that conveys soluble telomerase activity but does not prevent telomere 
shortening (Counter ef al. 1998b). Cells containing this construct, despite being telomerase 
positive, continue to undergo telomere shortening and enter crisis when telomere length reaches 
approximately 4 Kb suggesting that physical interaction between hTERT and telomeres via the 
carboxy-terminal end o f  the reverse transcriptase subunit is important for telomere elongation to
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occur. This would be consistent with the proposed role for telomerase in capping the end o f  short 
telomeres suggested by Zhu el al. 1999.
However, Ouellette et al proposed an alternative theory for this finding. They found that when 
pre-senescent BJ foreskin fibroblasts that had been immortalised with hTERT were then 
transfected with a plasmid expressing an inactive hTERT mutant, a further 20 population 
doublings elapsed with associated shortening o f telomeres before the onset o f  senescence 
(Ouellette et al. 2000). Since this mutant varied in sequence from wild type hTERT by only a 
single amino acid, it is unlikely that the proposed role for capping short telomeres would be lost -  
only that telomere length maintenance would have ceased in these cells. If the capping o f short 
telomeres by hTERT was important for division to continue at these critically short lengths, it was 
suggested, then replacement o f  catalytically active hTERT at telomere ends with the catalytically- 
inactive mutant should have resulted in complete cessation o f  cell division. Thus, these 
researchers reasoned that rather than telomerase playing a physical role in capping critically-short 
telomeres, factors that recruit telomerase to the shortest telomeres must be involved. It must be 
remembered, though, that the work o f Ouellette et al was performed in cells that were bypassing 
the Ml checkpoint rather than the M2 checkpoint, and that it is possible different roles for 
telomerase may be played at different checkpoints.
1.4.2.5 Telom erase and cell proliferation
The ability o f  cells to bypass senescence and crisis, and thereby become immortal, is an important 
step in the development o f  a cancerous phenotype. However, whilst substantial evidence has 
accumulated from tissue culture systems to suggest that telomerase is able to immortalise cells, 
evidence from mice suggests that telomerase may play other roles in the development of tumours. 
mTRY  knockout mice lack the telomerase RNA component and are consequently unable to 
synthesise telomerase. Gonzalez-suarez and colleagues engineered m TRY  mice that constitutively 
expressed the catalytic subunit o f  telomerase specifically in basal kératinocytes in the skin. These 
mice were found to be viable and showed histologically normal epithelium. However, when the 
carcinogenic phenol esters DMBA and TPA were applied to their skin, these mice displayed 
significantly more papillomas compared with wild type mice. In addition, these mice showed 
greater mortality as a result o f  the development o f other tumours not seen in wild type littermates 
(Gonzalez-Suarez el al. 2001). In addition, the skin surrounding these papillomas displayed a 
marked hyperplasia not seen in wild-type littermates, suggesting an increased proliferative 
response to treatment with mitogens. Whilst the increased skin proliferation in response to 
mitogenic stimulation resulted in tumours, a more positive finding was that wound healing 
following the creation o f  circular lesions was significantly faster in these mice than in wild-type
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littermates. All o f  these findings suggest that telomerase, when expressed constitutively in vivo, 
conveys a proliferative advantage to cells.
1.4.2.6 Telom erase and oncogenesis
The ability o f  telomerase to rescue shortened telomeres raises an intriguing paradox. It could be 
that the genetic instability induced by telomere shortening is an important part of tumorigenesis, 
allowing the genetic mutations to arise that bypass mechanisms that would normally prevent a cell 
becoming malignant. Thus, telomerase, it eould be argued, prevents the genetic instability 
required for cells to develop a cancerous phenotype. However, the presence of telomerase, in 
allowing cells to bypass the normal checkpoints o f  replicative senescence and crisis, provides for 
unlimited potential to divide, a hallmark o f  all malignant tumours. Depending on which angle one 
takes, telomerase could be seen to be both a tumour suppressor and a tumour promoter.
Support for the theory that telomere shortening contributes to genetic instability comes from the 
mTRY  telomerase knockout mouse. In these mice there is a 4-6-fold increase in spontaneous 
tumours in late generations with short telomeres, and the age of tumour onset is younger than in 
wild-type mice (Rudolph et al. 1999). Tumours arise particularly from highly proliferative tissues, 
and therefore those tissues that have the shortest telomeres. Importantly, m TRY  tumours have a 3- 
18-fold increase in chromosome fusions and a twofold increase in aneuploidy compared to 
tumours o f  m TR Y ' mice (Rudolph et al. 1999). Thus, the absence o f  telomerase activity allows 
telomere shortening and consequently an increase in genetic instability which promotes tumour 
formation, consistent with the telomerase as tumour suppressor theory.
Support for the theory that telomere shortening inhibits tumour formation is harder to come by. In 
primary human cell culture systems, the model o f  replicative senescence induced by telomere 
shortening following continued cell division is well established (Harley et al. 1990). That 
bypassing senescence leads to crisis and death of the majority o f  cells in culture has also been well 
established, suggesting that telomere shortening in culture systems provides a barrier to tumour 
growth. Consistent with this is the finding that telomeres are shorter in human tumour cells 
compared to surrounding normal tissue (de Lange et al. 1990). However, it has not yet been 
definitively demonstrated that telomere shortening limits the formation of tumours in vivo. 
Perhaps the best evidence that telomere shortening does inhibit tumour formation comes from 
human cancer cell lines in which telomerase activity is abrogated. Transfection of telomerase- 
positive cancer cells with a dominant negative mutant o f  TERT results in loss of telomerase 
activity, telomeric shortening and loss o f  capacity for growth following a lag period (Hahn et al. 
1999a; Zhang et al. 1999). Similarly, dominant negative TERT inhibition o f  telomerase activity in 
these cells eliminates their ability to form tumours in nude mice.
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In addition, evidence from mouse models have suggested a significant role for telomerase in 
tumour formation. In the m T R f  telomerase knockout mouse model, early generation mice with 
long telomeres show a 33% lower incidence o f papillomas when compared with wild-type mice 
(Gonzalez-Suarez et al. 2000). In the p-actin-mTERT transgenic mouse model, TERT expression 
is driven by the P-actin constitutive promoter (Artandi et al. 2002). Overexpression of TERT is 
found in most tissues in these mice, which show an increased incidence o f  mammary tumours as 
they age, compared with wild-type mice, despite the fact that they have very long telomeres. 
Taken together, these findings from both humans and mice suggest that telomere shortening does 
in fact inhibit the formation o f  tumours, and that telomerase is a tumour promoter.
Reconciling these dual functions o f  telomerase could potentially be explained by the timing o f 
telomerase activation. The in vitro findings o f senescence, crisis and immortalisation in primary 
cells suggest a model in which the activation o f telomerase expression occurs as a discrete event 
that permits passage through crisis and cellular immortalisation (Kolquist et al. 1998). This, 
together with the fact that many human cancers express telomerase whilst having short telomeres, 
has been taken as evidence that the activation o f telomerase typically occurs late in tumour 
progression, after many rounds o f  cellular proliferation have resulted in significant telomere 
shortening (Kolquist et al. 1998). In contrast, chromosomal and genetic instability are thought to 
arise early in tumorigenesis (Shih et al. 2001). Thus, telomerase activity arising after the initiation 
of genetic instability prevents further instability by stabilising chromosome ends at the same time 
as it provides for unlimited tumour growth (DePinho 2000; Rudolph et al. 2001). However, some 
researchers have found that this may be an oversimplification o f  telomerase activation in vivo. 
Kolquist and colleagues reported that TERT expression (and consequently telomerase activity) 
was present in lesions that were early precursors to breast carcinogenesis, and that TERT 
expression increased during the progression from pre-neoplastic to malignant lesions (Kolquist el 
al. 1998). Their findings suggest that in vivo, telomerase activation may not occur as a simple 
step, and that cells might be continuously selected for incrementally higher levels o f  telomerase 
activity as they proliferate and acquire the genetic changes associated with invasive cancer.
14.2.7 Telom erase maintains telomere structure in normal cells
The observation that telomere attrition in normal fibroblasts occurs with progressive cell divisions 
led to the proposal that telomere shortening in normal cells occurs due to the strong repression of 
telomerase in those cells (Harley ef al. 1990). However, some researchers have found that hTERT 
expression is detectable in some somatic cells (Broccoli et al. 1995; Masutomi et al. 2003). 
Moreover, telomere length does not always correlate with the onset o f  replicative senescence
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(Karlseder et al. 2002), Together, these findings suggest that the relationship between telomere 
length, telomerase expression and proliferative lifespan are more complex than previously thought.
Further evidence suggesting that telomerase and telomeres interact in normal cells came from 
Masutomi et al, who found that in fact TERT is transiently expressed in normal human fibroblasts 
during the S phase o f  the cell cycle (Masutomi et al. 2003). This regulated expression produces 
functional TERT activity. Disruption o f this expression slows proliferation, with delayed entry 
into the S phase and exit from the G 2/M phases. Disruption o f telomerase expression also results 
in a reduction in the proliferative lifespan of these cells and accelerated entry into senescence, 
although overall shortening o f telomeres is not accelerated in normal fibroblasts with hTERT 
inhibition. However, the 3 ’ overhang in these cells is significantly shorter than those of controls 
(Masutomi et al. 2003).
Taken together, these findings suggest that telomerase expression is involved with transit of 
normal human cells through the cell cycle, and that inhibition o f  TERT function affects lifespan by 
accelerating entry into senescence. This may be because disruption o f  telomerase function in the S 
phase prevents telomerase from maintaining the integrity o f  the normal telomeric cap.
1.4.2.8 Other functions of telomerase
There is growing evidence to suggest that in addition to the functions mentioned above, telomerase 
may play other roles in cells.
In the brain, it would appear that the telomerase plays a role in cell survival in the face of 
apoptosis. Suppression o f TERT in developing hippocampal neurons from mice results in an 
increase in apoptosis, whilst overexpression o f TERT conveys a protective effect to the same cells 
when exposed to a number o f  situations known to induce apoptosis, including withdrawal o f 
trophic factors, DMA damage and exposure to ^-amyloid (Fu et al. 2000; Lu et al. 2001 ; Zhu et al.
2000). This ability o f  TERT to influence cell death and apoptosis could have an important role to 
play in the developing brain. Natural neuron death occurs in most regions o f  the nervous system at 
late embryonic or early postnatal stage together with synaptogenesis. At the same time, TERT 
expression is decreasing in the developing mammalian brain. Since competition for a limited 
supply o f  trophic factors is thought to be an important determinant o f  which cells live and which 
die during this period o f  organogenesis, telomerase may play an important role during brain 
formation (Mattson et al. 2001).
As well as playing a possible role in brain development, telomerase may also play a role in 
response to injury in mature neurons. Following occlusion o f the middle cerebral artery (MCAO)
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in mice, levels o f  TERT RNA rise significantly in the cerebral cortex, suggesting an upreguiation 
of TERT expression. In addition, transgenic mice overexpressing TERT show significantly 
reduced areas o f cortical infarction and neuronal death following MCAO when compared to wild- 
type controls (Kang et al. 2004). Interestingly, TERT seems to protect neurons from death 
induced by exictotoxic neurotransmitters (egNM DA), but has no significant effect on apoptosis or 
death due to reactive oxygen species.
Telomerase also appears to promote cell survival in other organs. The a-MHC-mTERT transgenic 
mouse was engineered to target TERT expression to the heart using the a  myosin heavy chain 
(MHC) promoter to investigate whether upreguiation o f TERT could prevent ventricular myocytes 
from exiting the cell cycle and so prevent heart failure with age (Oh et al. 2001). Unexpeetedly, 
TERT expression in myocytes from these mice seems to confer protection from apoptosis. Similar 
findings have been reported in human mammary epithelial cells exposed to TGF-a (Stampfer et al. 
2 0 0 1 ).
All o f  these findings suggest that telomerase promotes cell survival in a range of situations. It has 
been proposed that the presence o f telomerase activity in mammalian cells could occur as a signal 
to cells that ‘it is safe to divide', incurring the activity of survival and growth signals that are 
independent o f  telomere length but dependent on telomerase activity (Blasco 2002). The 
mechanisms behind this are currently unknown. It could be that physical interaction between 
telomerase and the telomere provides a signal for cell survival. Alternatively, telomerase activity 
may be required for a complete telomeric cap which could signal cell proliferation and survival 
independent o f  telomere length. Alternatively, active telomerase could have a role in suppressing 
or processing DNA damage in the genome, thereby favouring cell survival and proliferation 
(Blasco 2002).
1,4.3 Telomerase activity: species variation
Whilst the primary biological function of telomerase in all organisms so far examined is to add 
nucleotides to the ends o f  telomeres, the importance o f telomere maintenance varies between 
species. Single celled organisms with a capacity for self-renewal, such as ciliates and yeast 
maintain, and in some instances lengthen, their telomeres. For example, in the yeast 
Saccharomyces cerevisisae the average telomere length in cells is maintained at 350 +/- 50 bp. 
This length is maintained by the balance between the opposing activities of telomerase and 
telomere-shortening processes, such as the mechanisms of lagging-strand synthesis and possible 
exonuclease activity (Weliinger et al. 1996). Eliminating telomerase activity from these cells 
either through disrupting the telomerase RNA or reverse transcriptase subunits allows the 
telomere-shortening processes to dominate, and consequently leads to progressive telomere erosion
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with an eventual increase in chromosome instability and infertility until the population becomes 
‘senesecent’ (Lendvay et al. 1994; McEachern & Blackburn 1995; Miller & Collins 2000). Thus, 
in these organisms for which self renewal is an integral part o f  day-to-day function, and for which 
ageing does not play an important survival-limiting role, telomerase activity is maintained 
continually.
In vertebrates, continual telomerase activity can also be found in multiple tissues in some species. 
In particular, the laboratory mouse, M m  m m ciilm , was found early on to possess telomerase 
activity in multiple tissues including skin, lung, liver, colon and uterus((Prowse & Greider 1995) 
and reviewed in (Kipling 1997)). In fact, this discovery, together with the finding that mouse 
telomeres are considerably larger than those found in humans, initially proved difficult to reconcile 
with the growing circumstantial evidence supporting the theory o f  telomere-driven ageing which 
could be overcome through telomerase activity. However, the mouse has proved not to be the only 
vertebrate to possess telomerase activity in tissues composed o f  terminally differentiated somatic 
cells. Telomerase activity has also been found to be present in spleen, lymph node, lung and 
kidney o f  the pig (Fradiani et al. 2004).
By way o f contrast, surveys o f telomerase activity in humans have shown that telomerase activity 
is absent from the vast majority of somatic tissue. Exceptions include those tissues containing 
stem cells, or cells with high proliferative potential, including bone marrow, skin, hair follicles, 
gastrointestinal tract and endometrium (reviewed in (Collins & Mitchell 2002)). Dogs seem to 
regulate telomerase activity in a similar way to humans, with telomerase activity being absent from 
all tissues examined with the exception o f testis, gastrointestinal tract and mammary gland (Nasir 
et al. 2001; Yazawa et al. 2001). Birds would appear to regulate telomerase activity in a manner 
more similar to humans and dogs than mice. During organogenesis in chickens, all tissues display 
strong telomerase activity (Taylor & Delany 2000), after which organ-specific variability emerges. 
Most tissues retain telomerase activity at hatching, with the exception of pancreas and brain, but 
by adulthood, telomerase activity is only present in testes, kidney and spleen (Venkatesan & Price 
1998). Thus, although telomerase activity is present in most tissues for slightly longer than is seen 
in humans, ultimately it is undetectable in the majority of somatic tissues in the adult bird.
1.5 Alternative Lengthening of Telomeres (ALT)
Although the majority o f  immortalised mammalian cell lines maintain their telomere length 
through the activity o f the telomerase holoenzyme, a substantial minority do not. These cell lines 
maintain telomere length through the activity o f  a different mechanism, known as the alternative 
lengthening o f telomeres (ALT) pathway. To date, approximately 10% o f  cell lines have been 
reported to possess the ALT mechanism (Henson et al. 2002). In addition, a number o f tumours
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have also been reported to possess the ALT pathway within cells, including osteosarcomas, soft 
tissue sarcomas, glioblastoma multiforme, renal cell carcinoma, adrenocortical carcinoma, breast 
carcinoma, non-small cell carcinoma o f  the lung and ovarian carcinoma (Redde! 2003). In the 
glioblastomas examined, the proportion o f tumours possessing the ALT pathway is higher than the 
incidence seen in other malignant cell types, with 25% of these tumours using the ALT mechanism 
to maintain telomere length (Hakin-Smith et a!. 2003).
The mechanisms underlying the ALT pathway remain to be fully characterised. Four mechanisms 
have been proposed, all o f  which are consistent with a model in which telomeres use other 
telomeres or extrachromosomal telomeric DNA as copy template, following invasion by the 3 ’ 
overhang o f the telomere being elongated. In some cases, activation o f the ALT pathway can also 
use TTAGGG repeats in the subtelomeric region of critically-shortened telomeres to prime further 
repeats, leading to replacement o f  the most distal variant subtelomeric repeats with TTAGGG 
sequences (Varley et al. 2002). These mechanisms are reviewed more fully in the article by 
Henson et al. (Henson et al. 2002). In addition, some forms o f  ALT exist in which polymerase- 
mediated extension is unnecessary, with telomere-lengthening being dependent on recombinational 
chromosome exchange mechanisms (Londono-Vallejo et al. 2004; Bailey et al. 2004). Consistent 
with all these mechanisms, examination o f telomere lengths in cells utilising the ALT pathway 
reveals a wide variation in telomere length between cells. Telomere lengths in human cells 
gradually shorten to approximately 5-8 kb m vitro before the onset o f  replicative senescence, and 
tumour cell lines possess telomeres with a mean telomere length less than 10 kb. In contrast, 
telomeres in cells that have activated the ALT pathway have a very wide length distribution with a 
mean o f  approximately 20 kb and a range of between 3 kb and 50 kb (Bryan & Reddel 1997). 
Examination o f  individual chromosomes within a single cell using FISH reveals that some cells 
have undetectable telomeres whilst others have extremely strong telomeric signals (Perrem et al. 
2001). The dynamics o f telomere length in ALT-positive cells also supports a recombinational 
mechanism for telomere-lengthening. Prior to the activation o f  ALT, the telomeres of some cells 
shorten to less than 200 bp, before a rapid and heterogeneous increase in length occurs (sometimes 
>20 kb) (Henson et al. 2002). In other cells, such increases can also occur without prior 
shortening.
The implications of the ALT pathway potentially impose limitations on strategies targeting 
telomerase as part o f  cancer therapy. In some tumours, both ALT and telomerase have been shown 
to be activated in different cells (Reddel & Bryan 2003). Treatment o f  such tumours with either 
telomerase inhibitors or telomerase-targeting strategies is likely to select for the population of cells 
that maintain telomere length through other mechanisms, leading to a ‘resistant’ phenotype. This 
important possibility will need to be addressed before such strategies are tested in clinical settings. 
However, some findings suggest that in fact selection of ALT-positive cells may not necessarily be
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a negative outcome. For example, glioblastomas positive for ALT have a significantly better 
outcome than those tumours which are positive for telomerase activity (Hakin-Smith et al. 2003). 
Evidence that telomerase contributes more to a malignant phenotype than simply the extension o f 
lifespan suggests that removing the population o f cells within a tumour that is positive for 
telomerase may slow cell division and tumour growth (Stewart et al. 2002). Additionally, one 
class o f  telomerase-inhibitors, the G-quadruplex ligands, has also been shown to cause apoptosis 
and cell death in ALT-positive cell lines (Kim et al. 2003a). For this reason, the existence o f ALT 
mechanisms in a minority o f  tumours should not prevent the investigation o f telomerase-targeting 
techniques as novel cancer treatment strategies.
1.6 Telomeres, Telomerase and Cancer
The functions o f telomerase raise an important question -  is telomerase potentially a useful target 
in the treatment o f  cancer? Several strands o f  evidence point towards telomerase activity being a 
central part of the acquisition of a malignant phenotype by cancer cells. Firstly, the ability o f 
telomerase to circumvent pathways triggering both senescence and crisis suggests that acquiring 
telomerase activity would allow tumour cells to proliferate without limit, and thus acquire 
immortality. In addition, telomere shortening can be viewed as a means for generating the genetic 
mutations that underpin the evolution of cancer, with the activation o f telomerase a final step in 
rescuing cells from end-to-end chromosome fusion and crisis. Secondly, the strong links between 
telomerase activity and the cell cycle (see 1.4.2.5: Telomerase and cell proliferation) suggest that 
telomerase is also intimately involved in mechanisms o f  proliferation. Together these two findings 
point to the importance o f  telomerase in cancer cells. Following on from this, a large body of 
evidence has now accumulated reviewing the extent to which telomerase can be detected in 
cancers in humans, and confirms that the majority of cancers and cancer-derived cell lines now in 
use possess telomerase activity. In fact, Shay and Bachetti, in reviewing a large number o f 
tumours o f  different origin have reported that in excess o f  80% o f  all human cancers are positive 
for telomerase activity (Shay & Bacchetti 1997). This will be discussed in greater detail in 
Chapter 3. Although less is known about telomerase activity in dogs, the reports published to date 
have suggested that a similar percentage o f tumours in this species are also positive for telomerase 
(Argyle & Nasir 2003). Despite the significant effort applied to finding new molecular targets 
over the past three decades, few other candidates appear to be as ubiquitous in cancer as does 
telomerase. Thus, telomerase would seem to represent a potentially valuable target in developing 
new anti-cancer strategies.
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1.7 Dogs as a model for cancer research in humans
Over the past two decades or so, major advances in molecular biology and genetics have increased 
our understanding o f the biology o f  cancer in all species enormously. However, these advances, 
perhaps unsurprisingly, have outstripped our ability to apply this new knowledge to clinical 
applications. A number o f factors have contributed to the lag phase between the acquisition and 
application o f this knowledge, but undoubtedly one of the most important must be the lack o f 
suitable in vivo cancer models in which these advances can be tested. Whilst a number o f mouse 
models have been used in the preclinical testing o f new treatment strategies designed for humans, 
few o f  these are characterised by spontaneous cancer development in immune competent and 
syngeneic hosts. Dogs provide several advantages in this respect: Firstly, dogs share many
environmental risk factors with their human owners, suggesting that they might provide useful 
sentinels of disease (Kelsey ef al. 1998). Secondly, the strong genetic similarities between dogs 
and man have meant that dogs with spontaneous cancers can be used in the identification o f 
cancer-associated genes (Khanna ef al. 2004; Lingaas et al. 2003). This has recently been 
facilitated by the completion o f  the canine genome project and the publication of several studies 
which have provided a high quality map of the canine genome at a resolution o f 1 Mb and also 
mapped canine genes to the human genome (Kirkness et al. 2003; Guy on et al. 2003; Breen et al.
2001). Furthermore, the canine genome has now been shown to share more similarities with the 
human genome than either do with the mouse genome (Cooper et al. 2003). Thirdly, canine 
cancers share aspects of tumour biology, prevalence and behaviour with human cancer, and in 
many cases have identical histological appearances and response rates to conventional 
chemotherapies (Withrow & MacEwan 2001). Recent studies also suggest that these similarities 
extend to the level o f  the genome (Thomson et al. 2005). Fourthly, in most cases the prevalence of 
many canine cancers, including brain tumours, is sufficient to allow preclinical trials and 
biological studies to be performed, although numbers are generally smaller than is the case with 
human tumours. Their size also allows relatively easy (and affordable) translation of dose 
regimens from humans. Furthermore, due to the lack o f well-defined ‘gold standards’ o f  therapy, 
early and ethical testing o f  novel therapies allow clinical trials to be performed, which generally 
are completed more rapidly than in humans. Hansen and Khanna have provided a comprehensive 
comparison o f  important aspects o f  tumours in humans and dogs, to which the reader is referred 
for further information (Hansen & Khanna 2004).
Given the importance o f  telomerase as a target for anticancer strategies, and the potential 
usefulness o f  dogs as a clinical model for human cancer, the principal aim of this thesis was to 
examine a number o f  ways in which telomerase could be used as a diagnostic and therapeutic tool 
in dogs.
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C h a p t e r  II
M a t e r i a l s  a n d  M e t h o d s
2.1 Materials
Materials in regular use, such as equipment, general reagents and solutions are detailed in this 
section.
2.1.1 Cell culture materials
2.1.1.1 Plasticware
Tissue culture flasks, 6-well plates. Falcon conical centrifuge tubes (15 and 50ml) and pipettes (5, 
10, 25, 50ml) were supplied by Greiner (Gloucestershire, UK).
2.1.1.2 Solutions, m edia and supplements
All solutions and media for cell culture were supplied by Invitrogen, UK, unless otherwise stated.
2.1.1.3 Media
All media were supplied as sterile solutions and stored at 4° C.
Dulbecco’s Modified Eagle’s Medium (DMEM) with Glutamax-1 with sodium pyruvate, glucose 
and pyridoxine was supplied by Invitrogen, UK.
Dulbecco’s Modified Eagle’s Medium (EMEM) with glucose and sodium bicarbonate, without
L-Glutainine was supplied by Sigma-Aldrich, UK
Minimal Essential Media (MEM-a) was supplied by Invitrogen, UK.
RPMI 1640 was supplied by Invitrogen, UK
2.1.1.4 Supplements
Foetal Calf Serum (FCS): virus and mycoplasma screened. PCS was heat inactivated at 56° C for 
30 minutes, then stored in 50ml aliquots at -20° C.
L-gliitamine: supplied as 200mM (lOOx) stock solution and stored at -20° C in 5 ml aliquots. 
Penicillin/streptomycin (P/S): supplied as a lOOx stock solution o f 10,000 units penicillin and 
10,000 units streptomycin per ml and stored in 5 ml aliquots at -20° C.
Fungizone: supplied as a lOOx stock solution and stored in 5 ml aliquots at -20° C.
Trypsin-EDTA: supplied as a lOOx stock solution and stored in 5 ml aliquots at -20° C.
Sodium pyruvate: supplied as a lOOmM stock solution and stored at 4° C.
Non Essential Amino Acids (NEAA): supplied as a lOOx stock solution and stored at 4° C. 
Epithelial Growth Factor: supplied as 200 mM stock solution and stored at -20° C in 5 ml 
aliquots
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CML 10, D17, MDCK, A72 and GHK cell lines were cultured in DMEM (Invitrogen, UK) 
supplemented with 10% fetal calf serum.
CMT3, CMT7 and CMT8 cell lines were cultured in RPMI (Invitrogen, UK) supplemented with 
10% fetal calf serum and 2mM L-glutamine.
Canine primary skin fibroblasts were cultured in MEM-a (Invitrogen, UK) supplemented with 10% 
fetal calf serum 2mM L-glutamine and epithelial growth factor.
U-87 MG cells were cultured in EMEM supplemented with 10% fetal calf serum, 2mM Glutamine, 
1% Non Essential Amino Acids (NEAA) and ImM Sodium Pyruvate.
2.1.1.5 Freeze M edium
Medium for cryopreservation o f cells was prepared by mixing 9m 1 growth medium (appropriate to 
the cell line being stored) with 9m 1 fetal calf serum and 2m 1 DMSO (45% medium/45% fetal calf 
serum/10% DMSO).
2.1.1.6 Cell Hnes
MDCK, CMLIO, D-17 and A~72 cells were all supplied by the American Type Culture Collection 
(ATCC), Manassas, VA.
GHK cells (canine kidney)
CMT3, CMT7 and CMT8 cells were donated by G. Ruttemann, Department o f  Clinical Sciences 
o f Companion Animals, Faculty of Veterinary Medicine, University o f  Utrecht, PC Box 80.154, 
3508 TD Utrecht, The Netherlands.
K9SF cells (canine primary skin fibroblast) cultures were generated and maintained by Mrs 
Elizabeth Gault from post mortem skin biopsy samples taken with informed owner consent at 
Glasgow University Veterinary School..
U87-MG cells (human glioblastoma) were supplied by the European Collection of Cell Cultures 
(ECACC), Porton Down, Wiltshire, UK.
2.1.2 General chemicals
Chemicals used were o f  analytic, ul trapu re or molecular grade quality and were supplied by a range 
of biotech companies.
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2.1.3 Complete Idts
QIAquick® PCR Purification Kit (QIAGEN, UK)
QIAquick® Gel Extraction Kit (QIAGEN, UK)
QIAprep® PCR Spin Miniprep Kit (QIAGEN, UK)
EndoFree® Plasmid Maxi Kit (QIAGEN, UK)
GeneRacer™ Kit (Invitrogen, UK)
Universal GenomeWalker Kit (Clontech, UK)
TOPO TA Cloning® (Invitrogen)
Dual-Luciferase® Reporter Assay System (Promega, UK)
ECL-PLUS Western Botting Detection Reagents (Amersham Pharmacia Biotech, UK)
DNA Sequencing Kit Big Dye™ Terminator Version 3.0 Cycle Sequencing Ready Reaction (ABI 
Applied Biosystems, UK)
TeloTAGGG Telomerase PCR ELISA (Roche Applied Science, UK)
2.1.4 Bacterial strains
2.1.4.1 E. coli One Shot® TOPIO
Chemically Competent E.coli Cells (>1 x lO'  ^cfu/pg) (Invitrogen, UK). Genotype: F- mcrA A(mrr- 
hsdRMS-mcrBC)(j)80 lacZAM l5 AlacX74 recAl araD139 A(ara-leu)7697 galU galK rpsL (Str'^) 
end AI nupG.
2.1.5 DNA
Plasmid, molecular weight markers and oligonucleotide DN As were stored at -20°C.
2.1.5.1 Plasmid vectors 
2 .1 J J J  pCR®2J-TOPO®
pC R® 2.1-T0P0®  (3900 bp), supplied by Invitrogen, UK, contains lacZ+, Beta-lactamase (ampr) 
and Kanamycin resistance (Kanr) genes. This plasmid is designed for directly cloning PCR 
products with 3' deoxyadenosine residues (A overhangs), generated by the non-template dependent 
activity o f Taq polymerase. The vector is supplied as linearised DNA with single 3' 
deoxythymidine (T) residues and topoisomerase attached, allowing for efficient ligation o f the
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target sequence to the vector. T7 promoter and M l 3 forward and reverse primer binding sites are 
also present to allow sequencing o f  cloned products.
2.1.5.1.2 p C IN eo
The pCI-Neo mammalian expression vector (5472 bp) was supplied by Promega and contains the 
neomycin phosphotransferase selectable marker under the regulation o f  the SV40 enhancer and 
early promoter region. In addition, pCI-Neo carries the human cytomegalovirus (CMV) immediate- 
early enhancer/promoter region to promote constitutive expression o f cloned DNA inserts in 
mammalian cells, and a multiple cloning region containing restriction enzyme sites. Expression of 
the neomycin phosphotransferase gene derived from Tn5 confers resistance to the antibiotic G-418, 
an aminoglycoside antibiotic produced by streptomycetes that induces cytotoxicity by blocking 
translation. Neomycin phosphotransferase inactivates G-418 through phosphorylation, thereby 
blocking its toxic effects. The pCl-Neo vector allows for stable expression of desired genes by 
selecting transfected cells with the antibiotic G-418.
2.1.5.1.3 pBAB E puro
The pBABEpuro vector was kindly supplied by RA Weinberg of the Whitehead Institute. 
pBABEpuro is a plasmid 5169bp in length that contains both ampicillin and puromycin resistance 
genes, together with a multiple cloning site.
2.1.5.1.4 pG L 3-basic Vector
pGL3-basic Vector (4818 bp), supplied by Promega, UK, lacks eukaryotic promoter and enhancer 
sequences, allowing cloning o f  putative regulatory sequences into the multiple cloning site (MCS). 
The coding region for firefly (Photinus pyralis) liiciferase gene (Iuc+) is followed by a SV40 
poly(A) signal. This vector also contains Beta-lactamase gene (ampr) and RV3, RV4 and GL2 
primer binding sites.
2.1.5.1.5 pG L 3-con tto l Vector
pGL3-control Vector (5249 bp), supplied by Promega, UK, contains a SV40 promoter, enhancer, 
late and up-stream poly(A) sequences resulting in strong expression of firefly (Photinus pyralis) 
luciferase gene (luc+) in many types o f mammalian cells. Beta-lactamase gene (ampr) and RV3, 
RV4 and GL2 primer binding sites are also present.
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2.1.5.1.6 pR L -C M V  VectoRO
pRL-CMV Vector^'^ (4079 bp), supplied by Promega, UK, eontains the CMV immediate-early 
enhancer/promoter region providing strong constitutive expression o f  Ren il la {Renilla reniformis) 
[sea pansy] luciferase in a variety o f cell types, The Beta-lactamase gene {amp^) and SV40 late 
polyadenylation signal are also present.
2.1.5.2 Molecular Size Standards
All markers were supplied by Invitrogen, UK and include 1 kb DNA Ladder (size range: 75- 
12,216 bp), 1 Kb Plus DNA Ladder™ (size range: 100- 12,000 bp), and 100 bp DNA Ladder (size 
range: 100-2072 bp).
2.1.5.3 O ligonucleotide primers
Oligonucleotides for use in polymerase chain reactions (PCR) and cycle sequencing were 
synthesised by MWG Biotech and Sigma-Genosys. Primers were either reverse phase, desalted or 
Poly Acrylamide Gel electrophoresis (PAGE) purified and supplied as lyophilised DNA. Primers 
were reconstituted in dH 2Ü and stored at -20°C in 500 pi aliquots at lOpM.
2.1,6 Enzym es
All enzymes were stored at -20°C, being removed immediately before use.
2.1.6.1 Restriction enzym es
All restriction enzymes and their associated buffers were supplied by Promega, with the exception 
o f  Hinfl and Rsal, which were supplied by Roche Applied Science. These are detailed in Table 
2 . 1 .
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Table 2.1: Restriction Enzymes
Enzyme Cutting Site 
[5’ - 3 ’]
Buffer % Activity Temperature
CC)
EcoR 1 [G I AATTC]
Xho l [GGTAC 1 C]
Sma i [CGC | GGG]
Xba 1 [T I CTAGA]
Sac 1 
Sal 1
Hinfl 
Rsal 
StLl 1
Dra 1
[GAGCT i C] 
[G I TCGAC]
[G I ANTC] 
[GT I AC] 
[AGG I CCT]
Buffer H
Buffer D
Multi-Core™
Buffer D
Multi-Core™
Buffer J
Multi-Core™
Buffer D
Multi-Core™
Multi-Core™
Buffer D
Multi-Core'^'^
React®2
React®3
Buffer B
[TTT I AAA] Buffer B
PvLilI [CAG I CTG] Buffer B
EcoR V [GAT I ATC] Multi-Core^
100%
50-75%
100%
100%
10-25%
100%
100%
100% 
100% 
100% 
100% 
< 10% 
100% 
100% 
100%
100%
100%
100%
37
37
37
37
37
25
25
37
37
37
37
37
37
37
37
37
37
37
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2.1.6.2 T 4 D N A L ig a se
T4 DNA ligase was provided by Promega with ligation buffer (used at a final concentration o f  30 
mM Tris-HCl (pH 7.8), 10 mM M gCf, 10 mM DTT and 1 mM ATP) to catalyse the joining o f  two 
strands o f  DNA between the 5'-phosphate and the 3'- hydroxyl groups o f  adjacent nucleotides in 
either a cohesive-ended or blunt-ended configuration.
2.1.6.3 Taq D N A  polymerase
Taq DNA polymerase was provided by Invitrogen and has 5' to 3' exonuclease activity and non­
template dependant activity with the addition o f  3' deoxyadenosine (A) residues to PCR products 
for TA cloning.
2.1.6.4 Platinum® Taq D N A  Polymerase H igh Fidelity
Platinum® Taq DNA polymerase high fidelity, provided by Invitrogen, is an enzyme mixture 
composed o f  recombinant Taq DNA polymerase, Pyrococcus species GB-D polymerase, and 
Platinum® Taq antibody. Pyrococcus species GB-D polymerase possesses a proofreading ability 
by virtue o f its V  to 5’ exonuclease activity. Mixture o f the proofreading enzyme with Taq DNA 
polymerase increases fidelity approximately six times over that o f  Taq DNA polymerase alone and 
allows amplification o f simple and complex DNA templates over a large range o f target sizes. The 
enzyme mixture is provided with an optimised buffer that improves enzyme fidelity and 
amplification of difficult templates. An m i\-Taq  DNA polymerase antibody complexes with and 
inhibits polymerase activity. Activity is restored after the dénaturation step in PCR cycling at 
94°C, thereby providing an automatic “hot start” for Taq DNA polymerase in PCR, which provides 
increased sensitivity, specificity and yield while allowing assembly o f reactions at room 
temperature.
2.1.6.5 ThermalAce D N A  Polymerase
TherrmalAce'^*'^ DNA Polymerase, supplied by Invitrogen, is a thermostable enzyme from a 
proprietary archebacterium that is specifically designed for high-yield PCR amplification of GC- 
rich templates (>65% GC content). The enzyme retains full activity after incubation at 95°C for 4 
hours and has approximately five times greater processivity than Taq DNA polymerase.
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2.1.6.6 Taq PCRx D N A  Polymerase
Zb^PCRx DNA Polymerase is provided by Invitrogen and contains standard Taq DNA Polymerase 
together with an optimised buffer system consisting o f  Amplification buffer, 50mM MgSO^ and 
PCRx Enhancer solution. Enhancer solution (the co-solvent) is a novel PCR co-solvent that 
facilitates efficient amplification of GC-rich sequences and problematic templates. Titration o f the 
Enhancer solution to various concentrations ranging from Ox through to 4x in the final mixture 
allows rapid optimisation o f  appropriate conditions for amplification.
2.1.6.7 KOD HotStartTaq
KOD Hot Start DNA Polymerase, provided by Novagen, is a premixed complex of KOD HiFi 
DNA Polymerase, derived from Thermococcus kodakaraensis and two monoclonal antibodies that 
inhibit the DNA polymerase and 3’ to 5’ exonuclease activities during assembly of the PCR 
reaction at ambient temperatures. KOD HiFi DNA Polymerase acts with high fidelity, fast 
extension and high processivity, enabling amplification o f targets up to 20 Kbp and efficient 
amplification o f GC-rich targets. The antibodies allow a hot start to be performed by reducing non­
specific amplification due to mispriming events during set up and initial temperature increase.
2.1.6.8 HotStaftTaq®
HotStarTaq DNA Polymerase, provided by Qiagen, is a modified form of a recombinant 94-kDa 
DNA polymerase originally isolated from Thermus aquaticus, cloned in E.coli. The Polymerase is 
provided in an inactive state with no polymerase activity at ambient temperatures in order to 
prevent the formation o f  misprimed products and primer-dimers at ambient temperatures. 
Activation o f the polymerase occurs following a 15 minute 95°C incubation step. In addition, 
HotStarTaq DNA Polymerase is provided with Q-solution, a PCR additive that facilitates 
amplification o f difficult templates containing GC-rich sequences or a high degree o f secondary 
structure by modifying the melting behaviour o f  DNA.
2.1.6.9 Failsafe^^ PCR System
The Failsafe™ PCR premix selection kit is provided by Cambio and contains a blend of 
thermostable DNA polymerases together with twelve reaction premixes. The Failsafe PCR enzyme 
mix provides proofreading fidelity approximately three times greater than taq DNA polymerase 
alone. The twelve premixes contain a buffered salt solution together with dNTPs and various 
amounts o f  MgC^ and Failsafe PCR Enhancer which contains betaine and is designed to rapidly 
optimise amplification o f  long (up to 20 Kbp) and difficult templates. The presence o f beatine 
improves the yield and specificity o f  amplification o f many target sequences, especially those
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containing a high GC content or secondary structure. Betaine may also enhance PCR by protecting 
DNA polymerases from thermal degradation.
2.1.6.10 Advantage Genomic Polymerase Mix
Advantage® Genomic Polymerase was provided by Clontech and provides amplification of 
genomic DNA templates using a combination of the primary Tth DNA polymerase (thermostable 
DNA polymerase from Thermus thermophilus), a minor amount o f  a second DNA polymerase to 
provide 3' to 5' proof reading activity (Venta) and T thStaif  ^  Antibody to provide automatic Miot- 
start’ PCR. This antibody reduces non-specific amplification products and primer-dimer artifacts 
created prior to the onset of thermal cycling. The antibody inhibits enzymatic activity during PCR 
reaction set-up at ambient temperatures. Polymerase activity is restored at the onset o f  thermo­
cycling because the antibody is denatured at high temperatures. The loss o f  inhibition is complete 
and irreversible, so the polymerase regains full activity for PCR.
2.1.6.11 Ready-To-Go™ PCR beads (Amersham, Pharmacia)
Ready-To-Go™PCR beads (Amersham, Pharmacia) are designed as pre-mixed, pre-dispensed 
reactions for performing PCR amplifications. When brought to a final volume of 25 p.1, each 
reaction contains Taq DNA Polymerase (1.5 units), 10 mM Tris-HCL, (pH 9.0 ), 50 mM KOI, 1.5 
mM M gCf, 200pM o f each dNTP and Bovine Serum Albumin (BSA).
2.1.6.12 Murine M oloney Virus Reverse Transcriptase Enzym e
Murine Moloney Leukaemia Virus Reverse Transcriptase (MMLV-RT) enzyme, provided by 
Invitrogen, uses single stranded RNA in the presence of a primer to synthesise a complementary 
DNA strand. The enzyme is isolated from E.CoIi expressing a portion of the p o l gene o f the M- 
MLV on a plasmid.
2.1.6.13 Avian M yeloblastosis Virus Reverse Transcriptase (AML-RT)
Avian Myeloblastosis Virus Reverse Transcriptase functions in a similar manner to MMLV-RT.
2.1.6.14 Superscript III Reverse Transcriptase
Superscript III™-RT, provided by invitrogen, is a version o f MMLV-RT that has been engineered 
to reduce RNase H activity and provide increased thermal stability.
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2.1.6.15 RNaseOUT™  Recombinant Ribonuclease Inhibitor
RNaseOUT™ Recombinant Ribonuclease Inhibitor, provided by Invitrogen, is an acidic protein 
with a very high binding affinity for ribonucleases such as RNase A, B, C and is a non-competitive 
inhibitor.
2 .1.6.16 Alkaline Phosphatase
Calf Intestinal alkaline phosphatase provided by Promega catalyses the hydrolysis of 5'- phosphate 
groups from DNA.
2.1.6.17D N ase I: DNA-free™
DNase 1, provided by Ambion, is a deoxyribonuclease I enzyme that cleaves double-stranded or 
single stranded DNA. Cleavage preferentially occurs adjacent to pyrimidine (C or T) residues, and 
the enzyme is therefore an endonuclease. Major products are 5'-phosphorylated di, tri and 
tetranucleotides. In the presence o f  magnesium ions, DNase I hydrolyzes each strand of duplex 
DNA independently, generating random cleavages. In the presence o f manganese ions, the enzyme 
cleaves both strands of DNA at approximately the same site, producing blunt ends or fragments 
with 1-2 base overhangs. DNase 1 does not cleave RNA.
2.1.7 Eqmpmen t
2.1.7.1 Major Equipm ent
Beiichtop centrifuge: CPR Centrifuge (Beckman)
Micro centrifuges: Centrifuge 5402, 5415R and Minispin (eppendorf) 
Water baths: Sub 36, and W6 (Grant)
Spectrophotometer: G e n e Q u a n t R N A / D N A  calculator 
Automatic Sequencing Apparatus: ABI 3 100 
Pipettes: Finnipipette Techpette (0.5-10, 5-40, 40-200, 200-1000 pi) 
Ultraviolet trans-illuminator: T2201 (Sigma Chemical Company) 
Gel documentation system: Uvi tec (Thistle Scientific) 
Liiminometer: Dynex MLX
Horizontal orbital shaker: 4628-ICE Labiine Instruments inc (IL) 
Incubator: B5042 (Heraeus)
Gel systems: Hoefer HE 33 Mini Horizontal Submarine Unit 
Power packs: PAB 35-0.2 (Kikusui electronics corp)
Balance: Précisa 100A-300M (Précisa Balances Ltd, Bucks, UK)
Stirrer: Magnetic Stirrer Hotplate (Stuart Scientific, UK)
PCR Machines: GeneAmp PCR System 2400, 2700 and DNA Thermal Cycler 480 (Perkin Elmer) 
Flow Cytometer; Epics XL Flow Sorter (Beckman-Coulter Inc., Miami, FL)
2.1.7.2 Consumables
Syringe top filters (0.2pm pore size) were supplied by Nalgene™, (NY, USA) for sterilisation of 
ampicillin and tissue culture reagents.
Ependorf tubes: screw top 1.5ml and 0.5ml and 1.5ml flip top tubes were supplied by Thermo 
Life Sciences.
Pipette tips were supplied by Greiner.
Filter tip pipette tips (10, 100, 200, lOOOpl) were supplied by Finnitip (Thermo Lab Systems)
Petri dishes were supplied by Sterilin (Staffs, UK)
Bijoux were supplied by Greiner
Universals were supplied by Greiner
Scalpel blades were supplied by Swan-Morton (Sheffield)
Parafilm was supplied by Sigma
2.1.8 Buffers, solutions and growth media
2.1.8.1 Water
Sterile water for procedures involving recombinant DNA, PCR etc was supplied by Baxter. 
Vivendi Water systems (USE ELGA) was used to supply water for preparation o f general solutions 
and media.
2.1.8.2 Antibiotics
Ampicillin: Reconstituted with dHiO to lOmg/ml, filter sterilised and stored in 1 ml aliquots at 
-20°C until use.
G-418: Supplied by promega in 50 mg/ml solution and stored at -20°C.
2.1.8.3 Buffers and solutions
Ammonium persulphate: 10% (w/v) stock solution in dH20
50 X TAE Buffer Solution: Tris base 484.5g, NaOAc 272.15 g, NaCl 116.8 g, Na2EDTA 74.45 g. 
pH adjusted to 8.15 with glacial acetic acid and made up to 2 L volume.
TBE Buffer Solution: 0.09M Tris Borate, and 0.002M EDTA
Lysis Buffer: 25mM Tris HCL pH 8.0 with glacial acetic acid and made up to 2 L volume
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Lysis Buffer for Western Blotting: 0.5% NP40, 150mM NaCl, 50mM TrisHCL adjusted to pH 
8 .0 , protease inhibitor tablet (1 per 10 ml o f  lysis buffer)
IM  Tris HCL: 121 g Tris base, 800ml dHiO. Adjusted to the desired pH with concentrated HCL 
and made up to 1L.
TE Buffer: lOmM Tris-HCL (pH 8.0), ImM EDTA
1 X PBS: 140mM NaCl, 2.7mM KCL, lOmM NasHPO^, 1.8 mM KH2PO4 (pH 7.3)
0.2M (2x) Phosphate Buffered Saline (PBS): 0.2M Na2HP0 4 , 0.2M NaH2P04, 1.8% w/v NaCl, 
pH 7.4
lOx DNA Gel Loading Buffer: 20% w/v Ficoll 400, O.IM Na2EDTA, pH 8, 1.0% w/v sodium 
dodecyl sulphate, 0.25% bromophenol blue, 0.25% xylene cyanol. Stored at room temperature and 
used at a 1 :10  dilution.
Ethidium bromide: made to a working dilution o f lOmg/ml with dEfO in a fume cupboard. Stored 
away from light.
X-Gal solution: (5-bromo-4-chloro-3-indole-b-galactoside) prepared as 50 mg/ml stock in 
dimethylformamide; stored at -20°C in the dark.
Transfast™ Transfection Reagent: (Promega) Supplied as dried lipid film that forms multi- 
lamellar vesicles upon hydration with nuclease-free water (400p.l) and stored a t-20oC .
DEPC water: 0.5ml of Diethylpyrocarbonate in 500ml water, overnight at room temperature in the 
fume cupboard and autoclaved.
Lysis mix: 0.32M sucrose, lOmM Tris, 5mM MgCl, 1% Triton X 
Nuclei lysis mix: lOmM Tris, 0.4 NaCl, 2mM EDTA 
TRIS-EDTA: (10/1 pH 7.4)
TRIS-EDTA: (10/0.1 pH7.5)
NU-PAGE Transfer Buffer: supplied by Invitrogen and diluted 1:20 
NU-PAGE Running Buffer: supplied by Invitrogen and diluted 1:20
lOx Ponceau’s Red Stain: 2 g Ponceau S, 30 g Trichloroacetic acid (TCA), 30 g Sulphopalicylic 
acid. Made up to 100 ml by addition o f  dH2 0
TBS-Tween: 150 mM NaCl (8.77 g), 50 mM Tris (6.06 g) and 0.05% Tween (0.5 ml). Made up to 
1L by addition of dH2 0
Blocking Buffer: 1 g non-fat skimmed milk powder in 20 ml TBS-Tween 
Antibody diluent: 0.2 g non-fat skimmed milk powder in 20 ml TBS-Tween.
2.1.8.4 Bacteriological Media
Media was sterilised by autoclaving at 12TC for 15 minutes, unless stated otherwise
LB Medium: 20g tryptone, 20g NaCl, lOg Yeast Extract to 2L with dH 20 , pH adjusted to 7.0 with 
NaOH.
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soc Medium: 2% tryptone, 0.5% yeast extract, lOmM NaCl, 2.5 mM KCI, lOmM MgCb, lOmM 
MgSO^, 20mM glucose.
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2.2 Methods
Common methods used throughout the thesis are described in this chapter, whilst techniques 
specific to one area are described in later chapters. Many o f  the methods described are based on 
standard techniques, which are detailed in Current Protocols in Molecular Biology Volumes 1 & 2 
(Ausubel et al. 1994).
2.2.1 Growth and manipulation o f  mammalian cells
2.2.1.1 Basic techniques
Techniques used in the culture and manipulation o f  mammalian cells were performed under aseptic 
procedures. Where possible all procedures were performed in a laminar flow hood.
2.2.1.1.1 Cell cryopreserva tion an d  storage
For long term storage o f  cell line stocks, cells were stored in liquid nitrogen. Prior to storage, cells 
were grown to mid-log phase and trypsinised with trypsin-EDTA at a concentration o f 0.25% (w/v) 
and transferred to a sterile 15 ml centrifuge tube. The cells were centrifuged at 1200g for 5 
minutes, the supernatant discarded and cells re-suspended in freezing medium (appropriate culture 
medium supplemented with fetal calf serum at 45% and DMSO at 10%) to a concentration o f  2-4 x 
10*" cells/ml. The ceil suspension was transferred in 1 ml aliquots to labelled cryovials 
(NALGENE™) and brought to -70°C at a controlled rate (-l°C/min) using a NALGENE™ Cryo 
1°C Freezing Container (NALGENE, USA) transferred to a -70°C freezer overnight. Finally, vials 
were transferred to a liquid nitrogen freezer for long term storage. Cell stocks were revived by 
rapid thawing in a 37°C water bath and subsequently used following standard techniques as 
described below.
2.2.1.1.2 Cell Counting
Cells were counted using a haemocytometer. Following trypsinisation or revival from frozen
stocks, cells were transferred to a 15 ml centrifuge tube and centrifuged at 1200g for 5 minutes.
Supernatant was discarded and cells were resuspended in 5 ml o f complete medium. A 25 p.1
sample was withdrawn and added to 25 pi trypan blue (Sigma) resulting in a two-fold dilution. A
sample o f this mixture was then introduced to the haemocytometer chamber and counted using an
inverted microscope at 40x magnification. Cells lying on the top and right hand perimeter o f  each
large (1 ml) square were included whilst those on the bottom and left hand perimeter were
excluded. Cell concentrations (cells/ml) were calculated by multiplying the mean number of cells
per large square by 10"' and 2 to correct for the dilution factor. Where an estimation o f live cell
numbers was required the cell suspension was allowed to incubate for five minutes at room
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temperature prior to counting. Non-viable cells stained blue and were counted as above and 
expressed as a percentage o f the total cell count.
2.2.1.1.3 Preparation o f  cell pelle ts
Cells obtained from tissue culture were used in a number o f  applications including genomic DNA 
extraction, TRAP assays, RNA extraction and protein extraction. Following trypsinisation and 
counting as described above, cells were transferred in either 2 x 10  ^(for use in TRAP assays) or 2 x 
10  ^(for all other applications) aliquots in 1.5 ml eppendorf tubes. Cells were centrifuged at 4°C at 
3000 rpm for 5 minutes and growth medium discarded. Cells were then washed in 500 pi 
phosphate buffered saline (PBS) and centrifuged again at 4°C at 3000 rpm for 5 minutes and saline 
decanted. A final wash in 500 pi PBS was repeated before final centrifugation and decanting of 
saline. Cells were then rapidly frozen in liquid nitrogen before being stored a t-80°C  prior to use.
2.2.1.2 Cell lines
All cell lines were grown as an adherent monolayer in culture, in either 25 or 75 cm^ tissue culture 
flasks stored in an incubator at 37°C with 5% CO] unless stated otherwise.
A72 Cells
The A l l  cell line is an immortal canine cell line derived from an 8 year old female dog, with cells 
possessing a fibroblast morphology. Cells were maintained in DMEM with gluatamax-1 
supplemented with 10% FCS, 100 lU/ml penicillin, 100 lU/ml streptomycin and 1,25 pg/ml 
fungizone. Cultures were trypsinised and reseeded at an approximate ratio o f  1:5 every 3-4 days.
CMLIO Cells
CMLIO cells were obtained following biopsy o f  melanoma in a 10 year old female dogs. Cells 
possessed an epithelial morphology and were maintained in DMEM with glutamax-1 supplemented 
with 10% FCS, 100 lU/ml penicillin, 100 lU/ml streptomycin and 1.25 pg/ml fungizone. Cultures 
were tiypsinised and reseeded, typically 1:5 every 3-4 days when sub-confluent.
CMT3 Cells
The CMT3 cell line is an immortal cell line derived from a canine mammary tumour. CMT3 cells 
were grown in RPMI medium supplemented with 10% FCS, 100 lU/ml penicillin, 100 lU/ml 
streptomycin and 1.25 pg/ml fungizone. Cells were trypsinised as standard every 3-4 days and 
reseeded at an approximate ratio of ! :5.
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CMT7 Cells
The CMT7 cell line is an immortal canine mammary tumour cell line. Culture conditions were as 
for CMT3 cells.
CMT8 Cells
The CMT8 cell line is an immortal canine mammary tumour cell line. Culture conditions were as 
for CMT3 cells.
D17 Cells
The D17 cell line was derived from an osteosarcoma obtained from an 11 year old female poodle. 
Cells were maintained in DMEM with glutamax-1 supplemented with 10% FCS, 100 lU/ml 
penicillin, 100 lU/ml streptomycin and 1.25 pg/ml fungizone in 75 cm^ tissue culture flasks. Cells 
were typically trypsinised and reseeded at a ratio of 1 ;5 every 3-4 days.
GHK Cells
The GHK immortal canine cell line was derived from renal epithelial cells taken from a greyhound 
o f  unknown age and gender at GUVS. Cells were maintained in DMEM with glutamax-1 
supplemented with 10% FCS, 100 lU/ml penicillin, 100 lU/ml streptomycin and 1.25 pg/ml 
fungizone.
K9SF Cells
The K9SF canine skin fibroblast cell line was obtained following skin biopsy taken from an 8 year 
old female newfoundland at GUVS. Cells were maintained in MEM-alpha medium supplemented 
with 10% FCS, 100 lU/ml penicillin, 100 lU/ml streptomycin, 1.25 ug/ml fungizone and 2 mM L- 
glutamine. Cells were passaged routinely after 5-7 days. Confirmation o f  the species o f  origin was 
performed using RT-PCR and sequence analysis for the canine cyclophilin gene. Cultures were 
trypsinised and reseeded at an approximate ratio o f  1:5 when confluent.
MDCK Cells
The MDCK cell line was derived from a kidney o f an apparently normal female cocker spaniel in 
September 1958 by S.H. Mad in and N.B. Darby. Cells were cultured in DMEM with glutamax-1 
supplemented with 10% FCS, 100 lU/ml penicillin, 100 lU/ml streptomycin and 1.25 pg/ml 
fungizone. Cultures were split, typically 1:9 every 3-4 days when sub-confluent and were 
trypsinised and seeded into new flasks.
U87-MG Cells
The U-87 immortal human cancer cell line is derived from a malignant glioma from a female 
patient by explant technique. It is reported to produce a malignant tumour consistent with 
glioblastoma in nude mice. Cells grow in an adherent monolayer with epithelial morphology and
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were cultured in EMEM supplemented with 10% FCS, 2 mM L-glutamine, 1% Non Essential 
Amino Acids (NEAA), ImM Sodium Pyruvate (NaP), 100 lU/ml penicillin, 100 lU/ml 
streptomycin and 1.25 ug/ml fungizone. Cells were trypsinised and reseeded at an approximate 
ratio o f 1:5 every 5-7 days.
2.2.2 Preparation o f  canine genom ic DNA from peripheral blood 
mononuclear cells
Since genomic DNA is identical in every cell from a given individual, any canine cell could be 
used for isolating canine gDNA for use as a template in PCR reactions. For ease o f  obtaining 
samples, peripheral blood mononuclear cells (PBMCs) were selected. Canine whole blood samples 
(5 ml) were mixed with lysis mix (45 ml) and incubated on ice for 10 mins. The mixture was then 
centrifuged at 2800g for 10 mins at 4° C and the pellet re-suspended in nuclei lysis mix (3 ml). 
After the addition of 10% SDS (200pl) and 75pi of proteinase K (lOmg/ml) the mixture was 
incubated at 55° C for 2 hours or at 37 C overnight. Two extractions with 3ml phenol/chloroform 
(50:50) were then performed, each centrifuged for 10 mins at 2800g at room temperature. The 
upper aqueous phase was then transferred to a fresh tube and the DNA precipitated by adding 3 
volumes o f  100% ethanol. The DNA was then re-suspended in 250pl o f  TE Buffer and the quantity 
and quality o f  gDNA was assessed using UV spectrophotometry and agarose gel electrophoresis.
2.2.3 Recombinant DNA techniques
2.2.3.1 Growth and storage of plasm id-containing E. coli
Plasmids were maintained in the One Shot® TOP 10 strain of E.coli. Storage of transformed bacteria 
containing the desired plasmid was carried out following preparation of glycerol stocks. The 
desired bacterial culture was streaked onto a 1.5% agar plate (1.5% agar in LB medium). In cases 
where the plasmid contained a selectable ampicillin-resistance gene, medium was supplemented 
with 50-100pg/mI ampicillin. The plate was incubated overnight at 37°C and the next day single 
colonies were picked using a pipette tip into approximately 5 ml LB medium (supplemented with 
50-100jLig/ml ampicillin) in a sterile universal tube. The resultant cultures were incubated at 37°C 
overnight in a horizontal orbital incubator at 225 rpm. In order to confirm that the culture was 
derived from bacteria containing the desired plasmid, DNA extraction and restriction digestion 
were performed (cross ref).
For long term storage, glycerol stocks (15%) were prepared by the addition o f  90pl o f glycerol 
(diluted 50% in distilled water and sterilised) to 21 Opl o f  culture, and the resultant stock stored at
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-20° C. For subsequent work requiring these stocks, a sterile pipette tip was used to scratch the 
surface o f  the stock, following which it was streaked onto an agar plate as described above.
2.2.3.2 Extraction and purification of plasmid D N A
Plasmid DNA was isolated using a modification o f  the alkali lysis technique (Birnboim & Doly 
1979).
2.2.3.2.1 Large Scale P lasm id  Preparations
For techniques such as sequencing or transient transfections, large quantities of high quality 
endotoxin-free plasmid DNA were obtained using the EndoFree® Plasmid Maxi Kit (QIAGEN, 
UK). A starter culture (5 ml) of the desired transformant was grown as described above and used to 
seed a larger culture by diluting 1/500 to 1/1000 into 250 ml o f  LB medium containing 50- 
lOOpg/ml ampicillin. This was then grown overnight at 37° C with horizontal shaking at 225 rpm. 
The culture was then aliqnoted into 50 ml Falcon tubes and spun at 3000 rpm for 30 minutes at 4°C 
for harvesting o f bacterial cells. The supernatant was then discarded and the remainder o f  the 
protocol performed according to the manufacturer’s instructions. DNA was stored at -20°C.
2.2.3.2.2 Small Scale P lasm id  Preparations
For other purposes such as restriction endonuclease digestion or sequencing, smaller quantities o f 
high quality plasmid DNA were purified from 5 ml o f an overnight culture o f  transformed bacteria 
using the QIAprep® PCR Spin Miniprep Kit (QIAGEN, UK). In order to harvest the bacteria, the 
culture was spun at 3000 rpm for 10 minutes and the supernatant removed. DNA was then purified 
from the pelleted cells according to the manufacturer’s instructions. Lysis o f  the cells was 
performed in this procedure in order to release the plasmid DNA, which was separated from 
bacterial cell debris by centrifugation and then attached to a filter and washed with a buffer before 
being eluted in sterile water (50pl). DNA was stored at -20°C.
2.2.3.3 Determ ination o f (ribo)nucleic acid concentration
2.2.3.3.1 D eterm ination b y  spectrophotom etry
DNA and RNA samples were diluted 1:50 by addition o f 2 jal o f  sample to 98 pi of dH20. The 
optical density was measured at 260 nm and 280 nm, in comparison to a reference o f dH20. An 
optical density (OD) reading o f  1.0 at 260 nm corresponds to an approximate concentration o f  50 
pg/ml for double stranded DNA, 40 pg/ml for RNA, or 33 pg/ml for single stranded
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oligonucleotides. The ratio o f  the OD readings at 260 nm and 280 nm (OD260/OD280) was used to 
estimate sample purity, with pure preparations o f DNA and RNA producing an OD260/OD280 o f  1.8 
and 2.0, respectively. A lower value suggests possible protein or phenol contamination o f  the 
sample.
2.2.3.3.2 E stim ation  o f  double stranded D N A  concentration via g e l  electrophoresis
In some instances, insufficient concentration of (ribo)nucleic acid or verification o f the purity of 
DNA fragments o f  a particular size did not allow quantification via spectrophotometry. In these 
cases, the concentration of double stranded DNA was determined by running the sample on a 1% 
agarose gel along with a marker o f known quantity and size. The intensity o f  the sample 
fluorescence was compared to that o f  a mass marker (Low DNA Mass™ Ladder) following staining 
with ethidium bromide and visualisation by UV transillumination.
2.2.3.4 Restriction endonuclease digestion
Typically, 1-2 pg o f DNA were digested in a 20 pi reaction mix containing the appropriate buffer 
and 5 to 10 units o f  desired restriction enzyme. The reactions were incubated at the recommended 
temperature (typically 37° C) for a minimum of one hour. Where the isolation o f restriction 
fragments was required, larger quantities o f  DNA, generally 5-10 pg, were digested, with the 
reaction volume and components being increased proportionally.
Recombinant plasmids contain a variety of restriction enzyme sites. One or more appropriate 
restriction enzymes can be incubated with DNA constructs at 37° C in the correct buffer, as 
determined by the manufacturer’s recommendations, to cut at specific positions and produce 
fragments o f  different sizes. The sizes o f  these fragments could be pre-determined and then viewed 
by gel electrophoresis.
2.2.3.5 Electrophoresis o f D N A
DNA fragments o f  0.1-10 kb were separated and identified by agarose gel electrophoresis using a
Hoefer HE 33 Mini Submarine Electrophoresis Unit (Amersham Pharmacia Biotech, San
Francisco, CA). Typically, 0.5 -  0.1 g of agarose was added to 50 ml o f 0.5x TAE buffer, melted in
the microwave (medium for 1.5 minutes), and mixed to produce a 1 to 2% gel. Once the gel mix
had cooled to 55°C, 1.5pi o f  ethidium bromide (lOOmg/ml) was added and the gel poured into a gel
support (100 X 65 m m ) in its ca st in g  tray and an appropriate g e l co m b  (tw e lv e  or tw en ty  w e ll)
inserted. The gel was allowed to solidify before transferring to an electrophoresis tank; the gel was
immersed 0.5x TAE buffer and the comb carefully removed. DNA samples were prepared by the
addition o f  an appropriate volume of I Ox gel loading buffer. Molecular size standard DNA was
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prepared similarly and the samples loaded into the wells using a micropipette. Gels were run at 100 
volts for 20 to 30 minutes depending on the agarose percentage, then removed from the gel 
apparatus and visualised on a UV transilluminator (UVi tec, Thistle Scientific) and photographed 
using a Mitsubishi P91 photographic unit.
2.2.3.6 Purification of restriction enzyme fragments
Where purification of DNA fragments was required for construction of recombinant plasmids, 
DNA was purified from agarose gels using the QIAquick® Gel Extraction Kit (QIAGEN). 
Following electrophoresis, DNA fragments of interest were excised from agarose gels using a clean 
scalpel and the remainder o f  the procedure was performed according to the manufacturer’s 
instructions.
2.2.3.7 Ligation of restriction digested D N A  fragments
Fragments o f  DNA generated by restriction digestion were ligated into approximately 50-100 ng o f 
vector using T4 DNA ligase (Promega) according to the manufacturer’s instructions. Using a 
known (eg 100 ng) quantity of vector, the quantity o f  insert DNA was calculated using the 
following equation, with ligation performed at either a 1:1 or 1:3 vector:insert ratio:
X ng vector x Y kb .  ^ ^ - . ,  --------------------- X insert : vector molar ratio = ng o f  insert required
Z kb vector insert
Vector and insert were mixed with ligation buffer (Ix) and DNA ligase (1 unit), in a total volume 
o f  10 pi. Ligation reactions were allowed to proceed at 16°C overnight.
2.2.3.8 Ligation using TA cloning methods
Ligations o f DNA fragments generated by Taq Polymerase during PCR were carried out according 
to the manufacturer’s instructions with the pCR2.1®TOPO TA Cloning Kit (Invitrogen). Briefly, 
freshly purified PCR products (15 ng) were directly cloned into the pCR®2.1-TOPO plasmid vector 
(0.5pl), incubated for 5 minutes at room temperature. Topoisomerase 1 is covalently bound to the 
ends of the linearised vector to facilitate the cloning procedure.
All ligations were stored at -20°C if not used immediately. A negative control ligation, omitting the 
DNA insert, was generally set up in parallel to the above, in order to check for ‘background’ when 
performing subsequent transformations.
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2.2.3.9 Transformation of bacteria with plasmid D N A
In addition to the transformation with recombinant plasmid, the bacteria were also transformed 
with a control plasmid (as a positive control) and a ligation reaction from which the insert DNA 
had been omitted (as a negative control).
2.2.3.lOTransformation of TOPIO cells
Cells were thawed on wet ice, gently mixed and 25-50 pi of cells was transferred to chilled 
microcentrifuge tubes for each transformation as required. Ligation reaction (0.5-5pl) or control 
plasmid (pUC18) was added to cells (1-20 ng DNA), moving the pipette through the cells while 
dispensing in order to facilitate mixing. Cells were left on ice for 30 minutes, then heat shocked in 
a 42° C water bath for 30 seconds. After heat shocking, the cells were placed on ice for 2 minutes, 
200 pi o f  SOC medium was added and the tubes were incubated at 37° C for 1 hour with shaking at 
225 rpm. Variable volumes of cells were plated onto LB plates containing ampicillin (100 mg/ml) 
and X-Gal stock (35 pi) solution was spread on the plate one hour prior to use if blue-white colour 
selection was used and all plates incubated overnight at 37°C.
2.2.3.11 Screening of transformants for desired recombinant plasmids
Most plasmids used in this project conferred ampicillin resistance upon the host bacteria, allowing 
selection and maintenance o f transformed bacteria with ampicillin supplemented media.
2.2.3.11.1 a - com plém entation
The pCR2.1®T0P0 plasmids contain genes encoding the lacZa  fragment o f  the p-galactosidase 
and the lac promoter and are therefore capable o f  a-complementation with the cp fragment encoded 
by the E.coli host strains DH5a, J M 109 and TOPIC One Shot™ giving active j3-galactosidase. The 
incorporation o f X-gal into LB agar plates allows the selection o f transformants based on blue- 
white screening. Disruption o f the lacZa  expression occurs with the cloning o f fragments into the 
MCS of the vector, hence recombinants with plasmid containing insert DNA appear white whilst 
non-recombinants, expressing a functional (3-galactosidase, appear blue.
2.2.3.11.2 Restriction analysis o f  small-scale p lasm id  preparations
Plasmid DNA, isolated as described in 2.2.3.2: Extraction and purification o f  plasmid DNA, was 
subjected to restriction digestion with the appropriate enzyme(s) (Table 2.1), and the resulting 
products o f  digestion were run on an agarose gel. Bacteria with plasmids containing inserts o f  the
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desired size were stored as glycerol stocks as detailed in section 2.2.3.1: Growth and storage o f 
plasmid-containing E. coli.
2.2.3.11.3 PCR amplification o f  broth or small-scale p la sm id  preparations
A  sample o f bacterial culture (50 pi) was removed and heated at 95°C for 6 minutes and 
centrifuged at 12,000 rpm for 6 minutes. Aliquots o f  the supernatants (lOpl) were then used as 
template in PCR reactions.
2.2.4 RNA techniques
Clean, full-length RNA is essential as the starting material for molecular techniques, hence when 
isolating the RNA it was necessary to ensure that all the preparation material is free from 
ribonuclease (RNAse) activity. This is a very stable, active and ubiquitous enzyme that degrades 
RNA requiring no cofactors for function. Inhibition of this enzyme was instigated by wiping all 
equipment with RNase ERASE (ICN Biomedicals, Inc, Ohio) followed by a thorough rinse with 
DEPC treated water. All plastic-ware was treated by soaking overnight in DEPC treated water 
followed by autoclaving and drying. All solutions were prepared using DEPC treated water. Gloves 
were worn and changed frequently.
2.2.4.1 Extraction and Purification of RNA
2.2.4.1.1 R N A  extraction using RNAwiz^^^
Various methods have been used for the isolation of undegraded RNA (Chirgwin et al. 1979). 
Several procedures have now been elucidated which isolate RNA isolation in a single-step 
procedure (Chomczynski & Sacchi 1987). The R N A zof^  B methods promote formation of 
complexes o f RNA with guanidinium and water molecules and abolishes hydrophilic interactions 
o f  DNA and proteins. In effect, the DNA and proteins are efficiently removed from the aqueous 
phase with the RNA remaining in this phase during the sample extraction.
In this project, RNA was extracted from a variety o f sources: from tissues snap-frozen in liquid 
nitrogen and stored at -80° C, from cells grown as a monolayer in tissue culture flasks, and from 
cell pellets stored at-80°C . In order to extract RNA from frozen tissue, tissue was ground in liquid 
nitrogen using a mortar and pestle to create a powder to which was added RNAwiz™ at a ratio of 
1ml per 100 pg o f  tissue. RNA extracted directly from cells grown as a monolayer was performed 
using RNAwiz^"^ at a ratio o f  1 ml per lOcm^ of tissue culture flask area. RNA was also extracted 
by cell pellets containing 2 x 1 0 ^  cells stored at -80°C (see 2.2.1.1.3: Preparation o f  cell pellets) 
using RNAwiz™ at a ratio o f  0,2 ml per cell pellet.
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Following the addition o f  RNAwiz'^'^ solution, cells/tissue were homogenised by pipetting up and 
down vigorously several times. The homogenate was then incubated at room temperature for 5 
minutes to allow dissociation o f nucleoproteins from nucleic acids. Then, chloroform (without 
isoamyl alcohol or other additives) was added at a ratio of 0.2x the starting volume of RNAwiz^'^ 
used and the mixture agitated by shaking vigorously for approximately 20 seconds. Samples were 
then centrifuged at 13,000 rpm at 4° C for 15 minutes in order to separate the homogenate into 3 
phases: an upper aqueous phase (containing RNA), a semi-solid interphase (containing most o f  the 
DNA), and a lower organic phase. The upper phase was carefully removed by pipetting and 
transferred to a clean, DEPC-treated 1.5 ml eppendorf. RNAse-free (DEPC-treated) water was 
added at a ratio o f  0.5x the starting volume of RNAwiz'''"' mixed thoroughly. Isopropanol was then 
added (using the same volume as the starting volume of RNAwiz™), the sample was mixed, and 
then incubated at room temperature for 10 minutes. The sample was then centrifuged at 13,000 
rpm at 4°C for 15 minutes in order to pellet the RNA. The supernatant was decanted carefully and 
the RNA pellet washed in ice-cold 75% ethanol before centrifugation at 13,000 rpm at 4° C for 5 
minutes. Following this final centrifugation step, ethanol was decanted and the RNA pellet dried 
for no longer than 10 minutes (overdrying makes resuspension difficult) before being resuspended 
in 30 pi o f  DEPC-treated water. Samples were stored a t-80°C  prior to use.
2,2.4,1.2 D N a se  Treatm ent o f  RN A
Contaminating DNA was removed from RNA samples using DNA-free™ (Ambion) methods. 
Briefly, O.I volume of lOx DNase 1 buffer (final concentration: 10 mM Tris-HCl pH7.5, 2.5 mM 
MgCb, 0.1 mM CaCb) and 2 units of DNase 1 were added directly to the RNA samples, mixed and 
incubated at 37°C for approximately 60 minutes. The enzyme reaction was stopped by the addition 
o f DNase Inactivation Reagent (5pl) for two minutes at room temperature Because o f the nature of 
the DNase Inactivation Reagent, tubes were periodically agitated to ensure resuspension in the 
RNA sample. Samples were then centrifuged at 10,000g for one and a half minutes to pellet the 
Inactivation Reagent and the supernatant containing the pure RNA was then transferred to a clean 
ependorf tube.
2.2.4.Î.3 A ssessm en t o f  R N A  quality using agarose g e l  electrophoresis
RNA samples were assessed by agarose gel electrophoresis on a 1% agarose TAE gel by 
comparing the bands to a 100 bp molecular weight standard (INVITROGEN, UK). The quality of 
the RNA samples were assessed by examining the integrity o f  the 18S and 28S ribosomal RNA 
bands. The 188 ribosomal unit runs at approximately 4.5 Kb and the 288 at approximately 1.2 Kb.
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The 18S subunit should appear at twice the intensity of the 28S subunit. mRNA appears as a smear 
from 0.5 through to 12 Kb.
2.2.5 First Strand cDNA synthesis
The synthesis o f  complementary DNA (cDNA) requires the Reverse Transcriptase enzyme, 
initially identified as the enzyme responsible for forming DNA-RNA hybrids in retrovirus 
replication. Reverse transcriptase utilises an RNA template to synthesise a complementary DNA 
strand from a primer base-paired to the RNA that contains a free hydroxyl group at the 3 ’ end. 
Primers that can be used are either random primers, designed to prime at multiple sites throughout 
the RNA, gene specific primers (GSPs) designed to prime at the gene of interest, or oligo-dT 
primers which pair with the poly-A sequence at the 3' end of most eukaryotic mRNA molecules. 
All instigate the synthesis of cDNA strands in the presence o f the four dNTPs. The RNA-DNA 
hybrid is subsequently hydrolysed by raising the pH (unlike RNA, DNA is resistant to alkaline 
hydrolysis) or by using a ribonuclease, The 3'- end o f the newly-synthesised DNA strand then 
forms a hairpin loop which enables priming o f the synthesis o f  the opposite DNA strand. SI 
nuclease, which recognises unpaired nucleotides, then removes the hairpin loop.
Superscript III™ reverse transcriptase was used for first strand cDNA synthesis. Superscript III™ 
is a version o f  MMLV-RT that has been engineered to reduce RNase H activity and provide 
increased thermal stability. Briefly, total RNA samples (up to 5 pg total RNA) were added to lul 
of primer (either oligo(dT), GSP or random primers) and 1 pi of lOmM dNTPs, and DEPC water 
was added to lOpl total volume. This mixture was then denatured to remove any RNA secondary 
structure by heating for 5 minutes at 65° C and before quenching on ice. First strand synthesis 
reactions were performed using the heat-treated RNA in a reaction mix containing reverse 
transcription buffer ( 1 Ox), reverse transcriptase (200 units), DTT (0.1 M), RNase inhibitor 
(RNaseOUT™ 40 units) and MgC12 (25 mM). The reaction was incubated at 50° C for 50 minutes 
if oligo(dT) primer was used, or 25° C for 10 minutes followed by 50° C for 50 minutes if other 
primers were used, and was incubated at 85-95° C for 5 minutes to terminate the reaction before 
being placed on ice. Finally, RnaseH (1 pi) was added and the mixture incubated at 37° C for 20 
minutes to remove the RNA template from the DNA-RNA hybrid. A Perkin-Elmer (PE) thermal 
cycler 480 was used for the reaction. cDNA was stored at 4° C before immediate use or -20° C for 
long term storage.
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2.2,6 Amplification o fDNA by the polym erase chain reaction
The polymerase chain reaction (PCR) is a powerful technique for amplification o f specific DNA 
sequences from a complex mixture o f DNA. The procedure was developed by Mullis and co­
workers in the mid I980’s (Mullis el al. 1986; Mullis & Faloona 1987) enabling large amounts o f  a 
single copy gene to be generated from genomic (Saiki et al. 1988) or viral DNA (Kwok et al.
1987). The initial method used the Klenow fragment of DNA polymerase I, which had to be 
replenished during each cycle as it is readily denatured by the amplification conditions used. The 
substitution o f  the thermostable Taq polymerase, isolated from Thenims aquaticm , circumvented 
this problem and allowed the automation of thermal cycling (Saiki et al. 1988).
PCR enables the amplification o f  any unknown DNA sequence by the simultaneous extension of 
primer pairs, flanking the unknown sequence, each complimentary to opposite strands of DNA. 
The uses o f  PCR are many although it has been superseded by more conventional molecular 
biological methods in many areas, including sequencing (Innis et al. 1988), cloning (Scharf 1990) 
and detection and analysis o f  RNA. An extensive overview of PCR and its applications is available 
(Innis & Gelfand 1990) but an overview of the procedure is given below, with more detail in the 
appropriate chapters.
2.2.6.1 Primer design
Primer design was aided by some basic guidelines (Innis & Gelfand 1990). An optimal primer pair 
should hybridise efficiently to the sequence o f interest with negligible hybridisation to other 
sequences present in the sample. The distance between primers is rather flexible, ranging up to 10 
kbp, however the PCR reaction is considerably less efficient with distances > 3kbp (Jeffreys et al.
1988). Smaller distances between primers lessen the ability to obtain much sequence information 
and to reamplify with nested internal oligonucleotides, if required. For any given pair, the 
annealing temperatures (Tm) and GC % were balanced.
For many applications, primers are designed to be exactly complementary to the template. For 
others, however, such as engineering for mutagenesis or new restriction endonuclease sites or for 
efforts to clone or detect gene homologues where sequence information is lacking, base-pair 
mismatches will be intentionally or unavoidably created. It is best to have mismatches, such as in a 
restriction endonuclease linker, at the 5' end o f  the primer; the closer to the 3' end o f the primer, the 
more likely a mismatch will prevent extension.
The annealing portion o f  primers should generally be 18-30 nucleotides in length; it is unlikely that
longer primers will help to increase specificity significantly. Additional sequences such as
restriction enzyme sites, epitope tags or other desired motifs can be added to the 5' end o f  the
primer, and may effect specificity o f  primer binding at low temperatures on complex templates so
76
these primers are successfully used when amplifying from a single template vector. Primers should 
be designed with a GC content similar to that o f  the template, avoiding unusual sequence 
distributions such as stretches of polypurines or polypyrimidines if possible. The formation o f a 
secondary structure such as hairpin loops greatly effects efficiency o f annealing.
Primer-dimers are a common artifact most frequently observed when small amounts of template are 
taken through many amplification cycles. They form when the 3' end of one primer anneals to the 
3' end o f the other primer and polymerase then extends each primer to the end of the other. 
Therefore, these can be avoided by using primers without complementai’y sequences, especially in 
the 3' end (this can be minimised by optimising the MgCb concentration).
2.2.6.2 Preparation o f PCR reactions
As PCR is such a sensitive procedure it is essential to take stringent precautions to avoid PCR 
contamination from tube to tube or carry over o f  PCR products (Saiki, et al. 1988). All PCR 
reactions were set up in a designated separate room, at the side o f  the main laboratory where PCR 
products were handled. A set o f  micropipettes was kept for the sole purpose of setting up PCR 
reactions. Filter tip pipette tips were used to decrease the risk of reaction components passing from 
one tube to the next. A bulk reaction mix was used in order to minimise the number of pipetting 
steps. Reaction components (including primers) were al {quoted prior to use and stored at -20°C.
2.2.6.3 Reaction conditions
The use o f high quality reagents is essential for the success of PCR; to facilitate this a number o f 
PCR amplification kits, each containing the necessary reagents, were used following the 
manufacturers’ instructions. Typically reaction mixes were set up in either 50 \i\ or 25 pi volumes 
using thin walled ependorf tubes (0.5 ml or 0.2 ml respectively). Variable concentrations o f primers 
(pM), dATPs, dCTP, dTTP and dGTP (mM), M gC f (mmol/L), DNA polymerase (Units), Ix PCR 
Buffer containing Tris-HCI (mM), KCI (mM) and gelatin was mixed with an appropriate volume of 
DNA or cDNA template (ng). Thermal cycling was carried out using DNA thermal cyclers (Perkin 
Elmer). Two PCR machines were generally used, a Perkin Elmer (PE) 480 which required 
overlaying the reaction mix with mineral oil in 0.5 ml ependorf tubes, and a Perkin Elmer (PE) 
2400 size for the 0.2 ml ependorf tubes requiring no mineral oil. Cycles varied between reactions 
but most commonly consisted o f an initial dénaturation o f 94° C for five minutes, followed by 25- 
45 cycles of the following; dénaturation at 94° C for one minute; annealing at 55-72° C for one 
minute; extension at 72° C for one minute; with a final extension step at 72° C for 4 - 3 0  minutes. 
Reaction products were visualised by agarose gel electrophoresis, generally using 5-10 pi of 
reaction product per well.
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2.2.6.4 Purification and assessm ent of PCR products
Single PCR products were purified following the QIAquick®PCR purification kit protocol, 
(QIAGEN). Briefly, the DNA adhered to the filter within the column, separating it from all other 
components of the PCR reaction which were washed away with various buffer solutions. The PCR 
products were finally eluted in 30-50pl o f sterile water, 4pl o f which were assessed by gel 
electrophoresis on a 1% agarose TAE gel by comparing the bands created to a 100 bp molecular 
weight standard (INVITROGEN, UK)
2.2.7 DNA sequence analysis
2.2.7.1 Automated sequencing
Sanger dideoxy DNA sequencing is the most commonly used method for DNA sequencing, 
particularly in large-scale genomic sequencing (Sanger et a i  1977). A variation o f automated DNA 
sequencing using dye-labelled terminators, in which the dyes are attached to the terminating 
dideoxynucieoside triphosphates (Prober et al. 1987) has been used in this project. Primers used 
for automated sequencing are shown in Table 2.2.
Table 2.2: Primers commonly used for DNA sequencing
Prim er name Primer sequence (5' to 3') T m  (°C) & GC 
(%) content
M13 Reverse (M13F) CAGG7\AACAGCTATGAC 68.0 °C : 55 .6%
MI3Forward (-20) (M I3R) GTAAAACGACGGCCAG 70.9 °C: 58.6%
GL2 C TT T A T G T T T T T G G C G T C T T C C A 57.1 °C : 39.1 %
RV3 CTAGCAAAATAGGCTGTCCC 57.3 °C; 50.0%
RV4 GACGATAGTCATGCCCCGCGCCCACCGGAA 87.0 °C : 66.7 %
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2.2.7.2 Sample préparation
During sample preparation, DNA fragments in a sample are chemically labelled with fluorescent 
dyes. The dyes facilitate the detection and identification o f  the DNA. Typically each DNA 
molecule is labelled with one dye molecule, but up to five dyes can be used to label the DNA 
sample. More specifically, PCR reactions were performed using plasmid DNA samples (200- 
500ng) in a total volume o f  20pl containing 0.5pM of primers, 40mM Tris-HCI, Immol/L MgCb 
and 4pl of Big Dye™ Terminator Cycle Sequencing Ready Reaction (ABI Prism). Samples were 
prepared in the PE 2400 thermal cycler incorporating 25 cycles o f  amplification, each cycle 
consisting o f  a dénaturation step 96° C for 10 seconds followed by an annealing temperature of 50° 
C for 5 seconds, and an elongation step o f 60° C for four minutes. DNA was then purified by 
precipitation methods using 3M sodium acetate (Sigma) and ethanol (95%), room temperature for 
15 minutes. Pelleted DNA (14,000 rpm for 20 minutes) was washed in ethanol (70%) and re­
pelleted (14,000 rpm for 5 minutes) before all ethanol was removed and dried at 90° C for I minute. 
Template Suppression Reagent (25pil) was then added and the mixture heated to 95° C for 5 
minutes and chilled before transfer to genetic analyser sample tubes.
2.2.7.3 Sample sequencing
Samples were finally loaded and run on the ABI PRISM® 3100 Genetic Analyzer (PE Applied 
Biosystems, UK) under standard sequencing conditions for generation o f automated sequence data. 
The ABI PRISM® 3100 Genetic Analyzer is a multi-colour fluorescence-based DNA analysis 
system using the proven technology o f capillary electrophoresis with 16 capillaries operating in 
parallel. The 3100 Genetic Analyzer is fully automated from sample loading to data analysis.
2.2.7.4 Sequence evaluation
The length o f read is 750 bases at the 98.5% base calling accuracy with less than 2% ambiguity. 
The output is in the form o f  a chromas file. A series o f different computational software programs 
were utilised for sequence analysis including the ‘Blasf search engine contained within the NCBI 
database, VectorNTI (Invitrogen), ClustalW ('http://www.ch.embnet.org/software/ClustalW.html), 
Transfac and Motif Search.
2.2.8 Transient transfection o f mammalian cells
Cationic liposome mediated transfection involves the incubation o f  cationic lipid-containing 
liposomes and DNA to associate and compact the nucleic acid (Kabanov & Kabanov l995;Labat- 
Moleur et ah 1996), presumably from electrostatic interactions between the negatively charged
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nucleic acid and the positively charged head group of the synthetic lipid. The liposome/nucleic acid 
complex is dispersed over the culture, entering cells by the processes of endocytosis, or fusion with 
the plasma membrane via the lipid moieties o f  the liposome (Gao & Huang 1995). The Trans™Fast 
Transfection Reagent (Promega) is comprised o f  the synthetic cationic lipid, (+)-N,N [bis (2- 
hydroxyethyl)-N-methyl-N-[2,3-di(tetradecanoyloxy)propyl] ammonium iodide and the neutral 
lipid, DOPE, designed for high efficiency transfer o f DNA into mammalian cells and was used in 
all cell types for this project.
Cells were seeded onto plates at various concentrations one day before the transfection experiment 
and incubated overnight at 37° C, 5% CO?. For optimal assay conditions the cells should be 
approximately 80% confluent on the day o f transfection. The Trans Fast™ Reagent was thawed, 
warmed to room temperature and mixed thoroughly by vortexing while the serum-free media was 
pre-warmed to 37° C. DNA to be transfected was re-suspended in TE buffer to a final concentration 
o f  0.1-0.5 jLig/p.1 and the DNA purity checked by determining the ratio o f  absorbency at 260nm 
(A260) and 280nm (A280) using a spectrophotometer. Transient transfections were carried out using 
a 1:1 ratio of Trans™Fast reagent with DNA according to the manufacturer’s instructions. More 
specifically, total DNA (50-l00ng) was added to pre-warmed serum free media (40pl) and 
thoroughly mixed before addition o f Trans Fast™ Reagent (0.3j.il) calculated per well using a 96- 
well plate. The DNA/transfection reagent samples were incubated for 10-15 minutes at room 
temperature to allow complex formation before the growth medium on the 96-well plates was 
aspirated and replaced with the transfection samples. The cells were incubated with the complexes 
for I hour at 37° C, 5% CO2 before pre-warmed complete medium was added for cell recovery 
overnight at 37° C. Initially an optimisation procedure was performed, testing various amounts of 
DNA (0.25, 0.5, 0.75, 1.0 j.ig per well) at charge ratios (TransFast''''^ Reagent to DNA) of 1:1 and 
2:1. For this initial optimisation, serum-free conditions with adherent cells in 24 well plates, using 
an exposure time o f  one hour was performed.
2.2.8.1 Genetic reporter systems
Genetic reporter systems are widely used to study eukaryotic gene expression and cellular 
physiology. Applications include the study o f  receptor activity, transcription factors and 
intracellular signalling in this study.
A dual reporter Assay system has been used in this project to improve experimental accuracy, by
correcting for transfection efficiency. The term ‘dual reporter’ refers to the simultaneous
expression and measurement of two individual reporter enzymes within a single system. In the
Dual-Luciferase® Reporter (DLR™) Assay System, the experimental firefly {Photinus pyralis)
luciferase reporter (de Wet et al. 1985) is correlated with the effect o f  specific experimental
conditions, while activity o f  the co-transfected control Renilla {Renilla remformis) luciferase
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reporter (Lorenz et al. 1991) provides an internal control, which serves as a baseline response. 
Normalising the activity o f  the experimental reporter to the activity of the internal control 
minimises experimental variability caused by differences in cell viability or transfection efficiency. 
Other sources of variability, such as differences in pipetting volumes, cell lysis efficiency and assay 
efficiency can be effectively eliminated. Thus dual reporter assays often allow more reliable 
interpretation o f the experimental data by reducing extraneous influences.
Both firefly and Renilla  luciferase are immediately active upon mRNA translation, and as neither is 
naturally present in mammalian cells, their assays are not interfered with by endogenous enzymatic 
activities. As a dual-reporter system these enzymes also offer the advantage of having completely 
separate evolutionary histories and thus independent biochemistries, allowing their luminescent 
reactions to be distinguished.
DLR™ assays were performed in triplicate 72 hours post transfection according to the 
manufacturer’s protocol. More specifically, media was removed from the adherent cell mono-layer, 
washed once with PBS and lysed with Passive Lysis Buffer (PLB) (Ix) for 15 minutes at room 
temperature. Using a Dynex, MLX luminometer, the activities o f  firefly and Renilla luciferase 
activities were measured sequentially from single samples (per well). The firefly luciferase reporter 
was measured first by adding Luciferase Assay Reagent II (LAR II) (50pl) to generate a ‘glow- 
type’ luminescent signal. After quantifying the firefly luminescence over 12 seconds, the Stop & 
Glo® Reagent ( 5 0 j l l I )  was then added to the same well to quench the first reaction ( 3  seconds) and 
then quantify the second ‘glow-type’ signal of Renilla luciferase activity which decayed slowly 
over the course of the 12 seconds measurement. Firefly and Renilla luciferases, because of their 
distinct evolutionary origins, have dissimilar enzyme structures and substrate requirements, 
enabling the discrimination between their respective bio-luminescent reactions. Firefly and Renilla 
luciferase values were obtained for each well and analysed using an Excel Spread- Sheet.
2.2.9 Protein Analysis
2.2.9.1 Estim ating Protein Concentration
2.2.9J . l  B icinchonic A ssay
The bicinchonic acid (BCA) assay was used to quantify the amount o f  protein in samples. The 
principle o f  the assay is a colour change that occurs when bicinchonic acid forms a complex with 
reduced copper (Cu'^) to produce a purple colour that is detectable at 562 nm. The reduction of 
Cu^^ (present in copper sulphate solution) to C u‘ ' occurs through the action o f the Biuret complex 
in alkaline solutions o f protein as the result o f  the interaction of copper and BCA with cysteine,
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cystine, tryptophan and tyrosine amino acid residues. The product of this reaction is stable and 
increases in a proportional fashion over a broad range of increasing protein concentration.
To perform the B C A  assay, a solution of CUSO4.5 H2O (4% w/v. Sigma, UK) was made up in 
Bicinchonic Acid ( B C A ,  Sigma, UK) using I part CL1S O 4 to 50 parts B C A .  For each sample to be 
tested, 10 pi o f  a 1/10 dilution o f  the sample was added to a single well of a 96-well plate. In 
addition, 10 pi of dH20 was added to each o f 3 extra wells to serve as blanks, and 10 pi o f  each o f 
6 known albumin standards (80 pg/ml, 100 pg/ml, 200 pg/ml, 400 pg/ml, 1000 pg/ml, 2000 pg/ml) 
was added to a further 6 wells. To each o f the test, blank and standard wells, 200 pi o f  the 
C U S O 4 / B C A  developing solution was added. The samples were then incubated at 37° C for 30 -  60 
minutes to allow colour change to occur. At the end of the incubation period the plate was then 
scanned using a microtitre plate reader with a wavelength o f 562 nm. The readings for the 6 
albumin standards were used to create a standard curve against which the readings of the samples 
were measured to calculate the protein concentration.
2.2.10 M easurement ofTelom erase A ctivity
2.2.10.1 Telomerase repeat amplification protocol
Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELISA'"’"^^  assay 
(Roche Molecular Biochemicals, UK), following the manufacturers recommended protocol.
2.2.10.1.1 Sample Prépara tion
Samples used for telomerase assay analysis included cell pellets from cultured cells (DI7, CMT7, 
K9SF and U87 cell lines) and protein extracts derived from tissue samples. Cells were harvested 
and counted as described in chapter 2. Aliquots o f  2 x 10  ^ cells were harvested for each assay. 
Cells were pelleted at 3000g for 5 minutes at 4°C, the supernatant withdrawn, and following a brief 
resuspension in 100 pi o f  PBS the cells were again pelleted and the supernatant carefully removed. 
Cell pellets were then resuspended in 200 pi o f  ice-cold lysis reagent (Roche Molecular 
Biochemicals, UK) and incubated on ice for 30 minutes. The lysate was then centrifuged at 
I6,000g for 20 minutes at 4° C and the 175 pi supernatant was carefully removed with a 
micropipette, taking care not to disturb the pellet of cellular debris. Cell extracts were then either 
used immediately or snap frozen in liquid nitrogen and stored at -80° C.
Samples o f  normal tissue (brain) were placed in tumour pots and snap frozen immediately after 
harvesting, before being stored at -80° C. This was to preserve the integrity o f  telomerase RNA 
and the catalytic subunit in order to reduce the likelihood o f  false negative results. Thin slices o f
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frozen samples were then removed (approximately 5-10 slices being sufficient) using a sterile 
scalpel blade on a disposable Petri dish. Samples were then immediately transferred to Rnase-free 
1.5 ml eppendorf homogenisation tubes and 200 pi o f  ice-cold lysis reagent (Roche Molecular 
Biochemicals, UK) was added. Samples were then thoroughly homogenised using a sterile pestle 
and stored on ice for 30 minutes to achieve thorough lysis. Following lysis, samples were 
centrifuged at I6,000g for 20 minutes at 4°C and the protein-rich supernatant carefully removed 
with a micropipette as for cell pellets. Protein concentrations were then measured using the 
Bradford assay (Sigma UK) as described in Chapter 2. Tissue extracts were either used 
immediately for the TRAP assay or snap frozen in liquid nitrogen and stored at -80° C for later use.
2.2.10.1.2 Prim er E longation and Am plification
All steps in preparation for the TRAP PCR procedure were carried out on ice, including thawing o f 
samples prior to analysis. Master mixes were made up for all samples and controls consisting o f  25 
pi o f  a 2x reaction mixture (Roche Molecular Biochemicals) and 5 pi o f  the 216 bp internal 
standard. A 30 pi volume of the mix was placed into a PCR tube for each sample and to this was 
added I pi o f  the cell extract, or a volume equivalent to 5 pg o f total protein. A I pi volume o f  a 
positive control was used, and I pi o f  lysis buffer alone was used as a negative control. Additional 
negative controls were provided by adding I pi o f  each sample that had been previously heated to 
85°C for 10 minutes in order to inactivate telomerase activity. All reactions were then made up to a 
total volume o f  50 pi using Rnase free water (Roche Molecular Biochemicals, UK) and transferred 
to a DNA thermal cycler (Perkin Elmer) for the combined primer elongation/amplification reaction.
2.2.10.1.3 Prim er E longation/A m plification  Reaction Protocol
Cycles used for primer amplification consisted o f initial primer elongation at 25°C for 20 minutes 
followed by a telomerase inactivation cycle of 94°C for 5 minutes. This was then followed by 30 
cycles of amplification (94°C for 30 seconds), annealing (50°C for 30 seconds) and extension (72°C 
for 30 seconds) followed by a final extension step of 72°C for 10 minutes. Finally, samples were 
held at 4°C until ready for analysis.
2.2.10.1.4 H ybridisation an d  ELISA
Hybridisation steps were carried out in 0.5ml eppendorf tubes placed in colour-coded racks to 
differentiate between test, internal standard and negative (including heat inactivated) controls. A 
2.5 pi volume o f  amplification product each sample of the previous step was added to 10 pi o f  a 
dénaturation reagent (Roche Molecular Biochemicals, UK) in the corresponding eppendorf tube. 
These mixtures were then incubated at room temperature for 10 minutes before addition o f 100 pi 
o f  either a test hybridisation buffer (to test and control samples) or an internal standard buffer (to
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internal control samples). These buffers contained DIG-labelled detection probes specific for 
telomeric repeats and the internal standard respectively. Thorough mixing o f the contents o f  all 
tubes was performed by briefly vortexing before 100 pi o f  the contents of each sample was 
removed and placed in a corresponding well of a streptav id in-coated microtitre plate (Roche 
Molecular Biochemicals, UK) according to a predetermined pipetting scheme. A plate contained 
12 modules of 8 wells each, and modules could be removed to facilitate separate analysis such that 
more than one assay could be performed per kit.
Microtitre plate wells were then clearly labelled, covered with an adhesive strip to prevent 
dehydration, and incubated at 37° C on a heated plate shaker (Dynatech, UK) rotating at 300 rpm 
for 2 hours. This allowed immobilisation of the telomerase and internal standard products with 
their corresponding detection probes to the streptavidin-coated walls of the plate wells, via the 
biotin label o f  the kit primer. Following hybridisation the solutions were completely removed from 
the wells, after which the wells were washed three times for a minimum o f  30 seconds per wash 
with 250 pi o f  wash buffer (Roche Molecular Biochemicals, UK) to ensure buffer was completely 
removed from the wells between steps.
The anti-DIG working solution was a polyclonal antibody (Roche Molecular Biochemicals, UK) 
raised in sheep and conjugated to horseradish peroxidase (HRP), that was diluted to a concentration 
o f 10 mU/ml in a conjugate dilution buffer (Roche Molecular Biochemicals, UK). A 100 pi 
volume of this anti-DIG-HRP working solution was then added to each o f the wells which were 
then again covered with adhesive film and incubated for 30 minutes at room temperature on a plate 
shaker rotating at 300 rpm. The working solution was then removed completely from the wells and 
five 30-second wash steps performed as described previously. Following this, 100 pi o f  a substrate 
solution, equilibrated to room temperature and containing the HRP-sensitive compound 3,3% 5,5’- 
tetramethylbenzidine (TMB) was added to each well and the plate covered and incubated for colour 
development at room temperature for 10 minutes, whilst rotating at 300 rpm. Without removing 
the substrate solution from the well, 100 pi o f  a stop reagent (<5% sulphuric acid, Roche Molecular 
Biochemicals, UK) was then added. The stop solution was designed to stop the reaction and 
simultaneously cause a colour change of the reacted HRP substrate from blue to yellow, increasing 
the sensitivity of the reaction. The absorbance o f the samples was then immediately measured at 
450 nm with a reference wavelength of 690 nm using a microtitre plate reader (Dynex 
Technologies, UK). Samples were regarded as telomerase positive if the absorbance was higher 
than 0.2 arbitraiy units (A450nnrA690nm)- The absorbance reading obtained with the positive control 
supplied with the kit was always higher than 2.0 U.
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2.2,10.1.5 QuütitiGcation o f  Telomerase Activity
The level of telomerase activity in samples was determined from the absorbance obtained using 1 
pi o f  the positive control template. Low and high activity control templates provided were 
identical to a telomerase elongation product of 8 telomeric repeats and were at a concentration of 
0,001 amol/mi (low activity) and 0.1 amol/ml (high activity). The amplification o f both 
telomerase-specific products and internal standards was semi-competitive since the same primers 
were used to amplify both products. In most cases, low activity control template was used. The 
relative telomerase activity (RTA) was determined by normalising the absorbance o f the sample to 
that o f  the internal standard and expressing this as a proportion o f the positive control. The formula 
used was as follows:
RTA = AAs/Àsn x 100
( A tS8-AtS8.o) /A jsS.IS
where:
As -  absorbance o f the sample
Aso = absorbance o f the sample (heat-inactivated) negative control
Aso = mean o f  all heat inactivated samples
AAs = corrected absorbance o f each sample (calculated by subtracting Asofrom As)
Ats8 = absorbance o f  the control template
Ays8.0 "  absorbance o f lysis buffer
A tss.is “  absorbance o f the control template’s internal standard
Tests were performed on each sample in duplicate and results only considered valid if less than 
10% variation was found between sample results. The values (Atss-Ats8,o)/Ats8,is obtained using I 
j L i l  o f the control template were considered acceptable if within the range o f  2.0-4.0 and 0.2-0.5 for 
high and low activity templates respectively, following 10 minutes o f  substrate reaction. Test 
samples with absorbance readings greater than twice the background reading and with AAs/Aso > 
2.0 (sample reading greater than twice mean background absorbance) were considered to be 
telomerase positive. In addition, results were only considered positive if less than 10% variability 
was found between tests performed in duplicate.
8 5
Ch a p t e r  III
IMMUNOHISTOCHEMICAL DETECTION OF
T e l o m e r a s e  A c t iv it y  i n  Ca n i n e  B r a in  T u m o u r s
3.1 Abstract
The ability o f  telomerase to maintain telomere length represents an important means by which 
cancer cells can escape the onset of senescence and crisis given their enhanced proliferative 
capacity. Surveys have shown that 85-90% of all human tumours possess telomerase activity. 
Brain tumours represent an important subgroup because o f  the debilitating symptoms associated 
with their effects and because survival rates for the most malignant remain unchanged despite 
advances in anticancer treatment strategies over the past thirty years. Their canine counterparts 
show strikingly similar features both at the histological and genomic levels, and for this reason 
offer an attractive model for the development o f  novel therapies. Given the ubiquity of telomerase 
activity in other tumour types, telomerase activity in human brain tumours has been extensively 
examined as a potential prognostic indicator. However, there appears to be a wide variation in the 
reported incidence o f  telomerase activity in brain tumours which is likely to be due to problems 
associated with the methods used to date. In this chapter we aimed to investigate the 
immunohistochemical detection o f  telomerase activity using a number o f  antibodies directed at 
TERT. One antibody, NCL-hTERT, was found to stain telomerase-positive D17 and CMT7 cells 
and telomerase-positive, formalin-fixed canine testis, at a concentration of 1/200. This antibody 
was then used to examine the correlation between TERT staining and malignancy in a panel o f  93 
canine brain tumours and to correlate telomerase activity with proliferation as assayed using the Ki- 
67 monoclonal antibody in a smaller subgroup. TERT staining was found to correlate significantly 
with malignancy in brain tumours overall as well as in the meningioma and oligodendroglioma 
subgroups. When TERT staining was correlated with proliferation, TERT staining was also found 
to correlate significantly with the MIB-I labelling index in all tumours, and again in the 
meningioma and oligodendroglioma subgroups. These results suggest that the NCL-hTERT 
antibody represents a promising method with which to identify telomerase expression in formalin- 
fixed, paraffin-embedded material, and that the prevalence o f telomerase activity in canine brain 
tumours is similar to their human counterparts.
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3.2 Introduction
The aim o f  this chapter was to examine telomerase activity in a group of tumours that is seen 
commonly in the dog -  intracranial tumours. This survey was performed for two reasons: firstly, 
to evaluate telomerase expression as a diagnostic and prognostic tool in canine brain tumours, and 
secondly as a prelude for the development of telomerase-targeted therapies. An important 
prerequisite for the development of such therapies in any group of tumours is an accurate 
knowledge o f  the incidence o f  telomerase activity -  such therapies would be o f little cinical benefit 
if the incidence o f telomerase activity is low. This introduction will review the current knowledge 
o f  telomerase activity in brain tumours in humans and will briefly review the biology o f their 
canine counterparts. In addition, it will be o f  some value to examine the methods currently in use 
to detect telomerase activity, as a background to determining its value as a prognostic and 
diagnostic tool.
3,2.1 Brain Tumours in Humans
Brain tumours comprise about 1% o f  all cancers in humans, but they contribute to 2.5% of overall 
cancer mortality, and are the third leading cause o f death due to cancer in patients between 15 and 
34 years of age (Santarius et al. 1997). Whilst outcomes for many patients with brain tumours 
have significantly improved with the development o f  improved surgical, radiation therapy, and 
chemotherapeutic techniques, the most malignant subtype, glioblastoma multiforme, remains an 
intractable problem. Median life expectancy for patients with this diagnosis has remained 
unchanged at 12 months for the past 30 years, despite the advent o f  sophisticated therapies such as 
radiosurgery (Markert 2003). In addition to short survival times, the clinical symptoms o f  brain 
tumours, as with other diseases affecting the brain, are often particularly severe and debilitating. 
For these reasons, considerable attention has been focused on improving the diagnosis and 
treatment o f  these tumours.
3.2.1.1 Tumour Biology
Several findings suggest that tumorigenesis in humans is a multistep process, and that these steps 
reflect genetic alterations that transform normal cells into malignant cells. Many cancers occur 
with an incidence related to the age of the individual affected, implicating four to seven stochastic 
events (Hanahan & Weinberg 2000). A large body o f  work now indicates that the genomes of 
tumour cells have invariably undergone modification at multiple sites through changes as small as 
point mutations to changes in chromosome complement (Kinzler & Vogel stein 1996). The
establishment o f  a cancerous cell line in vitro has also been demonstrated to require a multistep 
process -  rodent cells require at least two introduced genetic changes before they acquire 
tumorigenic competence, whilst human cells are even more difficult to transform (Hahn et al. 
1999b). Together these findings suggest that tumour development proceeds in a fashion not unlike 
Darwinian evolution, in which a succession o f genetic changes, each conferring a growth or 
survival advantage, leads to the progressive conversion o f normal cells into cancer cells (Hanahan 
& Weinberg 2000).
Whilst a highly complex body of knowledge has developed from the study o f cancer biology, it is 
likely that the vast range of cancer cell genotypes and phenotypes so far elucidated are all 
connected by a small number o f  important functions. It has been suggested that in fact there are 
only 6 critical physiological functions that dictate cancerous growth (Hanahan & Weinberg 2000). 
These are:
1) Self-sufficiency in growth signals
2) Insensitivity to anti-growth signals
3) Evasion o f  apoptotic pathways
4) Limitless replicative potential
5) Sustained angiogenesis
6) Tissue invasion and metastasis
The gain o f  each o f these functions represents the successful breaking down of an anticancer 
mechanism that is ‘hardwired’ into the genome of normal cells. Restoring telomerase activity 
provides a means for acquiring two of these functions: the ability to evade apoptosis and to divide 
indefinitely. The acquisition o f  all 6 leads to the development o f  a cancer that is able to grow 
indefinitely and metastasise to parts of the body distant from the cell o f  origin. However, the order 
in which these functions are acquired may vary with each tumour, and it is possible that not all 
tumours acquire all 6 functions before causing the death o f the host. As an example, brain tumours 
arising in the brainstem may lead to fatal herniation without becoming very large. Therefore, death 
o f the host may occur before cell numbers expand enough to allow for selection o f metastatic 
ability. In fact, this may be one explanation for the finding that metastasis of primary brain 
tumours to extracraniai locations occurs extremely rarely. For the same reason, the ability to 
replicate indefinitely may not be crucial for all brain tumours. Interestingly, if one extends this 
theory by removing the bulk o f the tumour and allowing continued growth without the death of the 
host, this may allow the continued ‘evolution’ o f  a cancerous phenotype. If this is the case, one 
would expect that mechanisms that allow limitless replication may appear in some tumours after 
initial debulking. Indeed, with some tumours in humans, including pituitary adenomas and 
meningiomas, that theoi-y appears to hold true (Harada et al. 2000a).
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These findings suggest that when benign tumours are treated, the evolution of a more malignant 
phenotype which includes the ability to replicate indefinitely, becomes an important consideration. 
For this reason, telomerase has been investigated both as a means o f diagnosing malignant 
transformation, and as a target for therapy.
3.2.1.2 Conventional therapies for human brain tumours
The mainstay o f  treatment for many tumours remains surgical excision in those parts o f the brain 
for which this is feasible. However, some, ‘eloquent’ parts of the brain are not amenable to this 
approach. The advent o f  sophisticated imaging techniques, including functional and intraoperative 
Magnetic Resonance Imaging (MRI), have allowed refinement of surgical techniques and the 
ability to resect more tumour tissue whilst sparing important functional areas of the brain. 
However, even with these techniques complete surgical excision is not always possible (Henson et 
al. 2005).
Radiotherapy, either as adjunctive therapy following surgery, or as the primary treatment for 
surgically inaccessible tumours, has become another important treatment modality. Since the first 
demonstration that radiotherapy improved survival in patients with brain tumours in 1976, 
improvements have led to escalation and refinement o f  dose administration and developments such 
as stereotactic radiosurgei’y (Fiveash & Spencer 2003). Although for some tumours these 
refinements have increased survival times, this is not the case for patients diagnosed with 
glioblastoma, for whom the outlook has remained grim.
The use of chemotherapeutic agents has met with success in some tumour types. 
Oligodendrogliomas have long been known to be sensitive to chemotherapeutic protocols, the most 
common of which include the use of procarbazine, carinustine (CCNU) and vincristine (PCV) (van 
den Bent 2004). Cytogenetic studies have revealed that this chemosensitivity is associated with 
loss of heterozygosity (LOH) on chromosome arms Ip and I9q, and that tumours with mixed 
oligodendroglial and astrocytic components that possess this genetic makeup are similarly 
chemosensitive (Bigner et al. 1999; Cairncross et al. 1998; Engelhard et al. 2002). However, other 
tumours, such as meningiomas and glioblastomas, have proved remarkably resistant to 
chemotherapeutic approaches (Lusis & Gutmann 2004; Parney & Chang 2003). For these reasons, 
considerable attention has been directed towards the development o f  new therapeutic strategies.
3.2.1.3 Prognosis
Whilst the figures for median survival times for most brain tumours are well known, providing a 
prognosis for individual patients can be challenging. For patients with a diagnosis o f  glioblastoma 
multiforme, median survival is a mere 12 months. However, 5% of these patients will survive 5
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years or longer, and a small group will survive up to 20 years following initial diagnosis (Senger et 
al. 2003). Similarly, whilst the majority o f  patients diagnosed with meningioma are cured 
following gross total resection, up to 19% of patients will suffer a recurrence and have a poorer 
outlook (Maes et al. 2005). Various histopathological features have been associated with 
aggressive behaviour and recurrence, but there appears to be little agreement on which features are 
most important to prognosis with the exception o f the proportion of cells undergoing proliferation 
(Carroll et al. 1999; Rushing el al. 1998). Predicting which patients will respond to therapy and 
which will go on to suffer relapse, therefore, is o f  considerable interest. A summary o f  survival 
times for the most commonly encountered brain tumours in humans is given in Table 3.1. For a 
full review, the reader is referred to two excellent sources: (Kleihues & Cavenee 2000) and
(Lantos et al. 2002)
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T able 3.1: W H O  classification  and survival for the m ost com m on hum an brain tum our types
Tumour type WHO
Classification
5 year survival (Kleihues 
& Cavenee 2000)
Astrocytom as
Pilocytic astrocytoma 1 100%'
Diffuse astrocytoma 2 b
Anaplastic astrocytoma 3 c
G lioblastom a multiforme 4 <1%‘‘
O ligodendrogliom as
Oligodendrogliom a 2 3 8 - 4 7 %
Anaplastic  oligodendrogliom a 3 23-41%
O ligoastrocytom a 2 58%
Anaplastic  oligoastrocytom a 3 36%
Choroid  plexus tumous
Choroid  plexus papilloma 1 100%
Choroid  plexus carcinoma 3 40%
M eningiom as
Benign meningiom as 1 >100%'
Atypical mening iom a 2
Anaplastic m eningiom a 3
a A s a g ro u p  these  tum ours , m ost com m o n ly  seen  in paed ia tric  p a tien ts, are  slow  g ro w in g  and m ay at any po in t stab ilise  
o r even  reg ress  and  are  u n co m m o n ly  fatal.
b O verall m ean su rv iv a l is app ro x im ate ly  6-8 years. H ow ever, su rv ival is m ain ly  determ ined  by the length  o f  tim e befo re  
p ro g ressio n  to m ore  m alig n an t phen o ty p e  (e ither anap las tic  a s tro cy to m a or g lio b lasto m a), u sua lly  app rox im ate ly  4-5 
years.
c K ey d e te rm in an t o f  su rv ival tim e is the tim e in terval b efo re  p ro g ressio n  to g lio b lasto m a, w hich  varies considerab ly . 
M ean overall su rv ival is 3 years, w ith  m ean o f  2 y ears to d ev e lo p m en t o f  g liob lastom a. S urvival tim e is longer for those 
tum ours w ith  an o lig o d en d ro g lia l com p o n en t (>7 years).
d M ean su rv ival lim e for g lio b lasto m a is less than  1 year. S urv ival a t 3 y ea rs  is 1.8%.
e T h e  m ajor d e te rm in an t o f  surv ival tim e for p a tien ts w ith  m en in g io m as is tim e to recu rrence , w hich  in turn is largely 
related  to the  ex ten t o f  su rg ica l excision  ach ieved . B enign m en in g io m as hav e  a  recu rren ce  rate o f  betw een  7%  and 2 0 %  
For atypical varian ts  (in c lu d in g  c lea r  cell and cho rd o id  v arian ts) th is figu re  r ises to 29  -  40% , and  for anap las tic  varian ts 
(in c lu d in g  p ap illa ry  and rhabdo id  v arian ts) th is  rises to 50 - 78% .
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Conventional predictors o f prognosis for patients diagnosed with a brain tumour include age at the 
onset o f disease, clinical status, tumour location and radiological appearance. In addition, the 
histopathological appearance o f many tumours and features such as micro vascular proliferation, 
mitotic figures and necrosis are all important in producing a grading scheme related to prognosis. 
The development o f techniques to analyse the genetic makeup o f tumours has also refined some of 
these predictors, and has even made some redundant (Buckner 2003; Cairncross el al. 1998). 
However, whilst the genetic profile o f many tumours is now known, remarkably few mutations are 
common to the majority o f tumours within a given type, perhaps with the exception o f LOH of 
chromosomes I and 19 in oligodendrogliomas (Cairncross e/ri/. 1998). For instance, glioblastomas 
are thought to arise either as primary, or de novo, tumours (usually in older patients) or as 
secondary tumours as a progression from more benign astrocytic tumours (Lantos et al. 2002). 
Mutations or alterations o f the EGFR, TP53, MDM2, CDKN2A, RBI, PTEN and DMBTI 
(‘deleted in malignant brain tumours-1’) genes have all been reported in glioblastomas, with some 
o f these found predominantly in primary tumours and others in secondary tumours (Lantos et al.
2002). The finding that these tumours arise by one o f a number o f pathways makes the prediction 
o f prognosis for individual patients difficult.
One o f the most consistent predictors o f biological behaviour for many tumours has been the 
degree o f proliferation within neoplastic cells, as assessed using a variety o f immunohistochemical 
stains. The proportion o f cells within a tumour undergoing proliferation has been shown to 
correlate well with histological features o f malignancy, such as necrosis, neovascularisation and 
mitotic figures (W ikstrand et al. 1998). In addition, separate studies have shown that proliferation 
is associated with shorter survival times, independent o f other characteristics o f malignancy. A 
large body o f research has now shown this for most tumour subtypes, including meningiomas, 
astrocytomas and oligodendrogliomas (Ho et al. 1998; Kros et al. 1996; Pollack et al. 2002; 
Sal linen et al. 2000; Sharma et al. 2004; Takahashi et al. 2004). Several histological techniques 
have been employed to assess cell proliferation, including the Ki-67 and Proliferating Cell Nuclear 
Antigen (PCNA) immunohistochemical stains and Bromodeoxyuridine (BrdU) labelling (Madewell 
2001).
3.2.1.3.1 B rdU
BrdU is a thymidine analogue that is incorporated with DNA synthesis during the S-phase o f the 
cell cycles. Once taken up by cells, it can be detected using either radio-labelling or 
immunohistochemical means. However, BrdU use is limited by several factors. Firstly, BrdU can 
only be absorbed by living cells, either grown in culture or shortly after sample collection. As a 
corollary to this fact, cells within biopsies immersed in BrdU for labelling purposes will only be 
labelled to a depth o f 4 mm from the surface due to its inability to penetrate the entire sample
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(Zacchetti et al. 2003). This therefore precludes its use in archival material. Secondly, BrdU is 
only taken up by those cells involved in the S-phase o f the cell cycle, such that proliferating cells in 
the G I and G2 phases o f the cell cycle will not be detected (Zacchetti et al. 2003). Thirdly, the use 
o f BrdU is complicated by its significant mutagenic potential and hazardous nature (Zacchetti et a l  
2003).
3.2.1.3.2 Proliferating Cell N uclear Antigen (PCNA)
PCNA is a subunit o f  DNA polymerase-delta, with a mass o f 36Kd (Madewell 2001). PCNA is 
essential both for replication o f DNA and for DNA repair. Maximal expression occurs in the G I 
and S phases and decreases in the G2 and M phases o f the cell cycle. Whilst PCNA can be used on 
archival material, other factors complicate interpretation. As PCNA is involved in DNA repair (as 
well as replication) and has a relatively long half-life o f between 8 and 20 hours (leading to its 
detection in early GO), overestimation o f the number o f proliferating cells is possible (Bravo & 
Macdonald-Bravo 1987; Scott et al. 1991; Toschi & Bravo 1988). Finally, titration o f the 
concentration o f antibody used must be undertaken with care, as the number o f positive-staining 
cells increases with antibody concentration and with staining time (Madewell 2001).
3.2.1.3.3 K i-67 /M IB -l
The Ki-67 antigen, detected by the monoclonal antibody M IB-I, is a large protein o f 345 Kd 
(Bruno & Darzynkiewicz 1992). Whilst it is present in all stages o f the cell cycle, it reaches 
maximal expression during mitosis, and is rarely detectable in GO due to its short half-life of 
approximately I hour (Bruno & Darzynkiewicz 1992; Du et al. 1991; Gerdes e ta l. 1984). For this 
reason, it is less likely to overestimate cellular proliferation than PCNA. Additionally, Ki-67 may 
be used with archival material, unlike BrdU, which makes it an attractive method for the 
assessment o f proliferation.
In humans, Ki-67 has been used in a wide range o f tumours, including intracranial neoplasms. In 
meningiomas, astrocytic tumours, oligodendrogliomas, gangliogliomas and ependymomas, a high 
MIB-I LI has been found to correlate well in tumours with aggressiveness, tumour recurrence and 
short survival times (Engelhard et al. 2002; Ho et al. 1998; Ho et al. 2002; Hsu et al. 1998; 
Konstantinidou et al. 2001; Nagai et al. 1995; Pollack et al. 1998; Sallinen et al. 2000; Takahashi 
et al. 2004). This large body o f evidence suggests that proliferation, as assessed by Ki-67 staining, 
is an important predictor o f tumour behaviour.
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3.2.1.4 Telom erase activity in human brain tumours
Because o f the strong link between telomerase activity and oncogenesis, a number o f researchers 
have examined the ability o f telomerase expression to provide a prognostic indicator of outcome in 
human brain tumours. One o f the most comprehensive surveys o f  telomerase activity in human 
tumours overall was published in 1997 by Shay and Bacchetti (Shay & Bacchetti 1997). This 
review encompassed almost all tumour types, the vast majority o f  which were sampled using the 
Telomerase Repeat Amplification Protocol (TRAP) assay. Another excellent review of telomerase 
activity in brain tumours specifically was provided by Falchetti et al, to which the reader is also 
directed (Falchetti et al. 2002). Overall, the clinical picture suggests that approximately 85-90% o f 
all human cancer specimens express telomerase activity. However, the grade and stage at which it 
is expressed for each given tumour type is variable, with telomerase expression especially 
characteristic o f high grade neoplasms (Kleinschmidt-DeMasters et al. 1998a) Although the 
overall proportion o f tumours positive for telomerase expression was very high in the review by 
Shay and Bacchetti, within the brain tumours sampled, telomerase activity varied between 10% and 
100% o f the tumours sampled. Given this wide variation, a more detailed survey is provided here, 
along with possible explanations for some o f this variation.
3.2.1.4.1 Glial tumours
Several studies have examined the activity o f telomerase in glial tumours, with varying results. 
Information on telomerase expression in glial tumours, including astrocytomas, 
oligodendrogliomas, ependymomas, oligo-astrocytomas, and high grade gliomas, has been limited 
and somewhat conflicting, with several studies showing that a significant percentage o f 
glioblastomas and anaplastic astrocytomas are negative for telomerase expression (Carroll et al. 
1999). This is an unexpected finding given the high degree o f malignancy that characterises these 
tumours (Kleinschmidt-DeM asters et al. 1998a).
One o f the earliest studies, reported by Langford et al (Langford et al. 1995), analysed telomerase 
activity in 90 gliomas. In this study, glioblastomas displayed telomerase activity in 38 of 51 cases 
(75%) overall, with 78% o f primary tumours and 68% o f recurrent tumours positive. Anaplastic 
astrocytomas, on the other hand, displayed very limited telomerase activity, with only 2 o f 20 
(10%) positive. Oligodendrogliomas in this study were uniformly found to display telomerase 
activity, with 19 o f 19 tumours positive for the TRAP assay. Overall, the telomerase activity in this 
study correlated well with histological assessment o f malignancy.
Nakatani et al reported slightly different results in their study o f 41 brain tumours (Nakatani et al. 
1997). In this study, 12 o f 20 (60%) o f glioblastomas were found to be positive for telomerase 
activity (57% o f primary GBMs and 67% of recurrent GBMs). None o f  3 anaplastic and 4 low
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grade astrocytomas displayed telomerase activity, however, while 2 o f 2 oligodendrogliomas were 
found to be positive for telomerase expression. In contrast to the study reported by Langford et al, 
however, there was no significant correlation between pathological diagnosis and telomerase 
activity, or between MIB-I staining and telomerase activity. The relatively small number o f 
samples o f each tumour type, however, make interpretation o f these results difficult.
Carroll et al examined telomerase activity in several glioblastomas as part o f  an investigation into 
the presence o f dicentric chromosomes in brain tumours (Carroll et al. 1999). In the glioblastomas 
examined, telomerase activity was present in only 7 o f 25 (28%), a figure substantially lower than 
earlier studies. None o f the 4 low grade glial tumours demonstrated telomerase activity. The 
apparent disparity between the levels o f telomerase activity detected in tumours o f this study and 
previous studies may be explained by the different versions o f the TRAP assay used in different 
studies. Earlier studies described telomerase activity in gliomas and meningiomas using the 
upstream primer TS and a downstream primer CX. These primers have been reported to result in 
primer-dimer formation and false positive generation, as reflected by Southern blots o f TRAP assay 
products. However, as with several other reports, a relatively small number o f tumours was 
examined, making comparison between tumour types difficult.
Santarius et al found that a small percentage o f low grade astrocytomas, 71% o f anaplastic 
astrocytomas and 89% o f glioblastomas were positive for telomerase activity (Santarius et al. 
1997). In contrast, Morii et al found no significant correlation between tumour malignancy (as 
assessed by WHO grade) and telomerase activity (Morii et al. 1997). In this study, 20 tumours 
were examined, including 1 pilocytic astrocytoma, 7 oligo-astrocytomas, 1 anaplastic astrocytoma 
and 11 glioblastomas, with 63% o f grade I and II tumours and 67% o f grade III and IV tumours 
displaying telomerase activity respectively. As with the study reported by Nakatani et al however, 
the small number o f tumours examined hinders accurate assessment o f telomerase activity with 
respect to proliferation.
A larger study that provided evidence for telomerase involvement in tumour progression was 
reported by Hiraga et al (Hiraga et al. 1998). This study examined telomerase activity and 
telomere length in 170 brain tumour tissues, and found telomerase expression in 20% (3 o f IS) o f 
grade II astrocytomas, 40% (6 o f 15) anaplastic astrocytomas, and 72.3% (34 o f 47) o f 
glioblastomas. Overall, telomerase activity was present in 61.7% (66 o f 107) of the neuroepithelial 
tumours examined. However, in grade II and anaplastic astrocytomas, telomerase activity was 
significantly correlated with early histological progression and reduced survival. Furthermore, a 
number o f recurrent tumours which had been previously telomerase-negative were found to display 
telomerase activity following recurrence and progression to a higher grade. Telomerase activity 
was also detected in all primitive neuroectodermal tumours, anaplastic oligoastrocytomas, 
neuroblastomas and oligodendrogliomas. Telomere length was found to be significantly shorter in
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tumours with telomerase activity present, including 10 glioblastomas which had progressed from 
lower grade tumours with normal telomere lengths, and which had acquired telomerase activity. 
Interestingly, this study also found that telomerase activity appeared to be a pre-requisite for the 
establishment o f cell lines from tumour tissue, as cell lines were cultured from 5 o f 29 (17.2%) 
telomerase-positive neuroepithelial tumours but not from telomerase-negative tumours.
Within the glioblastoma subgroup, Harada and colleagues provided evidence that the route to 
telomerase activation might vary between primary, or de novo tumours, and secondary tumours 
arising as a progression from more benign variants (Harada et al. 2000b). Primary tumours, which 
arise in older patients and are associated with EGFR and MDM2 gene mutations, and with LOH in 
chromosome 10, carry a worse prognosis than secondary tumours, which generally arise in patients 
under the age o f 45 and which are associated with inactivation o f p53. Harada and colleagues 
found that only 36% o f primary tumours possessed telomerase activity, as assessed by TRAP assay, 
as compared with 90% o f secondary tumours. In addition, liTERT expression was higher in 
secondary tumours with telomerase activity than in primary tumours with telomerase activity. 
Overall, 62% o f all the glioblastomas examined had telomerase activity.
Kleinschmidt-DeMasters et al (Kleinschmidt-DeMasters et al. 1998a) examined gross total 
resection samples to determine whether sampling o f multiple regions throughout tumours could 
also explain the conflicting findings o f  previous studies. In addition, telomerase expression was 
examined to determine whether there was any connection with the histological features o f each 
type o f tumour, along with proliferation (as characterised by MIBI staining) and p53 staining. In 
this study, 3 o f 10 oligodendrogliomas were found to express telomerase activity. Interestingly, o f 
the 10 tumours, 9 were found to possess uniform activity with all regions sampled either uniformly 
positive or negative for telomerase expression. In contrast, high grade astrocytomas showed more 
variable telomerase activity. O f the 11 glioblastomas examined, all tumours showed at least one 
region positive for telomerase expression. However, only 3 tumours showed homogenously 
positive activity, the remainder exhibiting negative telomerase activity in some of the samples 
taken from each tumour. Negative telomerase activity was not explained by the presence of 
necrosis (as assessed from mirrored histological samples). O f the anaplastic astrocytomas 
examined, 2 o f 3 showed heterogenous positive telomerase activity. Interestingly, although not 
statistically significant given the small number o f these tumours examined, there was a tendency 
for regions positive for telomerase expression to display histological anaplasia. Interestingly, the 
study by Cabuy and de Ridder supported the finding that telomerase activity varies across different 
regions o f glioblastomas (Cabuy & de Ridder 2001). Overall, this study found strong statistical 
association between the presence o f telomerase activity and MIBI staining, but not with any other 
histological feature or with p53 staining. The variation in telomerase activity within tumours may 
well provide an explanation for previous, conflicting results.
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Another method that evaluates telomerase activity within selective regions o f tumours rather than 
within the entire tumour, was described by Weil et al (Weil et al. 1999). In this study, the authors 
used microdissection to evaluate telomerase activity via the TRAP assay in specific areas o f 
tumours, free o f other components such as vascular proliferation, necrosis and inflammation. 
Using this method, 8 o f 8 glial tumours (comprising I low grade oligodendroglioma, 1 anaplastic 
oligodendroglioma, 3 anaplastic astrocytomas and 3 glioblastomas) were positive for telomerase 
activity, in addition to an aggressive B cell lymphoma. In contrast, normal brain tissue and a 
meningioma were negative for telomerase activity. These findings, along with those of 
Kleinschmidt-DeMasters et al (Kleinschmidt-DeMasters et al. 1998a) suggest that a high 
proportion, if not all, malignant glial tumours express telomerase activity, but that detection may 
require analysis o f  selective areas within tumour tissue.
Chong et al focused specifically on non-astrocytic glial tumours in their study o f 45 cases (Chong 
et al. 2000). Telomerase activity along with liTERT mRNA expression was examined in 27 
oligodendrogliomas (11 oligodendrogliomas, 10 anaplastic oligodendrogliomas, 4 oligo- 
astrocytomas and 2 anaplastic oligo-astrocytomas) and 18 ependymal tumours (14 ependymomas, I 
anaplastic ependymoma, I myxopapillary ependymoma and I subependymoma). Telomerase 
activity appeared to correlate with malignancy, with 3 of II (27%) grade II and 7 of 12 (58%) 
grade III oligodendrogliomas positive for telomerase activity as assessed by the TRAP assay. O f 
the oligoastrocytomas, I o f 4 (25%) grade II and I o f 2 (50%) anaplastic tumours were telomerase- 
positive. Interestingly, no statistical difference was found between telomere lengths o f telomerase 
positive and negative tumours, or between telomere length and degree o f malignancy, although 
other authors have reported short telomeres in telomerase positive gliomas (Hiraga et al. 1998; 
Morii et al. 1997). This study also examined mRNA expression o f liTERT and found that the 
expression o f liTERT mRNA was significantly greater in telomerase positive (100%) vs 
telomerase-negative (50%) oligodendrogliomas. These results suggest that the expression of 
liTERT mRNA is an important factor for telomerase activation. However, the significance o f the 
presence o f iiTERT mRNA in telomerase-negative tumours is unclear, as it is possible the PCR 
product detected in this study may have been derived from alternative, non-functional spliced 
transcripts o f liTERT.
While the majority o f reports describe detection o f telomerase activity by the TRAP method, some 
researchers have utilised in situ  hybridisation (ISH) to assess telomerase activity. Sallinen et al 
(Sallinen et al. 1997) examined telomerase activity in 46 astrocytic tumours, consisting o f 2 grade 
I, 16 grade II, 4 grade III and 24 grade IV tumours (glioblastomas), using ISH directed against 
hTR. This study found that liTR expression was significantly higher in malignant (grade III and 
IV) than benign (grade I and II) tumours. In addition, hTR expression was significantly correlated 
with proliferation in the tumours studied, although the significance o f this is unclear given the lack 
o f correlation between hTR and telomerase activity reported by other authors, and since hTR is
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commonly expressed in both cancerous and non-cancerous tissue (Gunther et a l  2000) (Chong et 
al. 2000).
3.2.1.4.2 M eningiom as
Meningiomas constitute the most common benign neoplasm affecting the central nervous system in 
both humans and dogs. In humans they are divided into three histopathological grades: benign, 
atypical and anaplastic (Kleihues & Cavenee 1999), which possess features consistent with an 
increased growth rate (mitotic figures and increased likelihood o f recurrence following surgery). In 
concordance with their generally benign nature, telomerase activity in these tumours has been 
generally reported to be low or absent in the benign variant. In the study o f 41 tumours reported by 
Nakatani et al (Nakatani et al. 1997), 9 were meningiomas, all o f  which were found to be negative 
for telomerase activity. Similarly, Carroll et al (Carroll et a l  1999) found that none o f 25 
meningiomas expressed telomerase activity, including 4 atypical variants. Another study found 
that 7/26 (27 %) o f benign meningiomas assessed with TRAP and RT-PCR possessed telomerase 
activity, as compared with 6/6 (100 %) o f atypical and anaplastic variants (Boldrini et al. 2003).
The study reported by Carroll et al also examined the presence o f dicentric chromosomes and their 
relationship with telomerase activity. Dicentric chromosomes have been considered to represent 
telomere end associations associated with very short telomeres in cells approaching senescence, 
and have been described in up to 50% o f meningiomas (Carroll et a l 1999). Consequently, 
dicentric chromosomes should be absent in cells which possess telomerase activity (Park et al. 
1996). This study reported that o f the telomerase negative meningiomas examined, 11 o f 23 were 
found to have dicentric chromosomes present. The authors o f this study remarked that earlier 
studies had utilised TRAP assays with primers that could form primer-dimer associations, resulting 
in false positive results (Kim & Wu 1997; Krupp et a l  1997), and that their study utilised a TRAP 
assay designed to prevent these associations. Consequently, this could explain the lower number o f 
TRAP positive tumours detected.
Simon et al (Simon et al. 2000), in their study o f 53 meningiomas, found that telomerase activity 
correlated strongly with malignancy and progression of meningiomas. In this study, 7 o f 34 (21%) 
benign, 9 o f 12 (75%) atypical, and 7 o f  7 (100%) anaplastic meningiomas displayed telomerase 
activity as reported by TRAP assay. The involvement o f telomerase activity in tumour progression 
was also supported by the finding that one possible radiation-induced tumour was found to be 
TRAP-positive, while tumour multiplicity was not associated with telomerase activity. Radiation 
induced tumours are known to follow a more aggressive course. Additionally, all recurrent 
tumours and tumours that recurred during the follow up period were found to be telomerase 
positive. In this study, expression o f liTERT mRNA as assessed by Reverse Transcriptase PCR 
(RT-PCR) was also found to correlate with malignancy. However, o f  30 tumours positive for
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liTERT mRNA expression, only 23 were TRAP positive. The level o f telomerase activity in this 
study was not found to correlate with malignancy, with some malignant tumours displaying low 
levels o f TRAP activity.
3.2.1.4.3 P itu ita iy  tum ours
Tumours arising from the pituitary gland in humans are frequently benign, with the most common 
variant being the pituitary adenoma. Pituitary adenomas themselves are amongst the most benign 
of CNS neoplasms, and rarely metastasise. However, in rare instances, these tumours may 
transform. Harada et al reported on a pituitary adenoma in which both activation o f telomerase 
activity and decreasing telomere length measured over successive resections were associated with 
malignant transformation and metastasis (Harada et a l  2000a).
3.2.1.4.4 N euroblastom as
A number o f studies have focused on neuroblastomas, the most common solid tumour in children 
younger than 5 years o f age (Falchetti et al. 2002). As a tumour group, they are markedly 
heterogenous in terms o f their biologic, morphologic and clinical characteristics (Poremba et al. 
2000a). Additionally, approximately 80% o f a particular subset o f metastatic neuroblastomas 
(defined by localised primary tumour and distant metastasis including liver, skin and/or bone 
marrow) often regress spontaneously independently o f anticancer therapies (Falchetti et. al. 2002). 
Several characteristics have been identified that are associated with clinical outcome, including 
age, stage, histology, MYCN copy number, deletions within the short arm o f chromosome I, DNA 
content and TPK-A (high-affinity receptor protein for nerve growth factor) expression (Streutker et 
al. 2001). However, none o f these factors alone has been sufficient to accurately predict tumour 
behaviour. Telomerase, however, has been shown to be a prognostic indicator by several groups 
(Isobe et al. 2004; Krains et al. 2003; Poremba et al. 2000a; Poremba et al. 2000b; Streutker et al. 
2001), Hiyama and colleagues found that 94% of neuroblastomas overall express telomerase 
activity (Hiyama et al. 2003). Importantly, 75% o f tumours with high telomerase activity in this 
study had a poor prognosis, as compared with 97% o f tumours with low telomerase activity, which 
had a good prognosis. Indeed, 100% o f tumours without detectable telomerase activity regressed. 
Telomerase activity also correlates strongly with expression o f the full length hTERT transcript in 
these tumours (Krams et al. 2001; Krams et al. 2003). Other studies have corroborated these 
findings and have suggested that, apart from tumour stage, telomerase is the only independent 
predictor o f survival (either disease-free or overall), and that telomerase activity increases with 
tumour progression (Poremba et al. 2000a; Streutker et al. 2001). Collectively, these studies 
strongly recommend that telomerase activity should be assessed in all patients with newly 
diagnosed neuroblastoma as an important prognostic indicator. Moreover, they provide two 
possible pathways for the development o f neuroblastomas. Firstly, it may be that since
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neuroblastomas arise in infancy or early childhood, telomerase activity is present due to the 
inappropriate retention o f activity in underlying stem cells which form the precursor for the 
tumour. In this group, such tumours have lower levels o f telomerase activity, similar to that found 
in normal adrenal glands. Alternatively, it may be that telomerase activity is switched off during 
normal development, but then reactivated as a consequence o f a transforming event (eg expression 
o f other oncogenes). Neuroblastomas in this second group then show much higher levels o f 
telomerase activity.
3.2.1.4.5 M e tastases
Metastatic tumours commonly affect the brain as it receives 15% o f cardiac output (Johnson 1990). 
In the human field, the incidence o f silent brain métastasés suggests that most epidemiological 
studies underestimate their occurrence, reported to comprise between 30% and 50% of all CNS 
neoplasms. Up to 20% o f people with malignant tumours have brain métastasés at death, but many 
o f these patients die o f systemic disease before these métastasés become symptomatic. Telomerase 
activity has been investigated rarely in metastatic CNS tumours, but has been detected with high 
frequency. Kleinschmidt-DeMasters et aJ found that 32 o f 35 (91%) brain métastasés were positive 
for telomerase activity using the TRAP assay (Kleinschmidt-DeMasters et a/. 1998b). This study 
examined tumours that commonly metastasise to the brain, including melanoma, adenocarcinoma 
(with primary sites including breast, lung, prostate, gastrointestinal and colon), squamous cell 
carcinoma, hepatocellular carcinoma, mixed embryonal-yolk sac germ cell neoplasm, osteogenic 
sarcoma and secondary immunobiastic lymphoma. However, quantification o f telomerase products 
showed high variability (fourfold logarithmic variation) and no correlation o f telomerase levels 
with tumour subtype, or with survival times, even within one tumour type. It was noted that one 
tumour in this study showed a rise in telomerase activity with progression, such that the highest 
telomerase levels were found in the sample closest to patient demise, but the small number o f 
tumours studied made interpretation o f this finding difficult.
3.2.1.4.6 Telom erase activation and crisis
The occurrence o f dicentric chromosomes has been proposed to be due to telomere associations and 
is considered to represent abnormal telomere functioning. Post crisis, telomere association 
formation stabilises or decreases, and cells acquire telomerase activity. In the study reported by 
Carroll et al, approximately 50% o f meningiomas were found to show random dicentric 
chromosomes (Carroll et a i  1999). However, malignant glioblastomas did not demonstrate 
telomere associations despite telomerase activity being present in a considerable percentage o f the 
tumours examined. If the M I/M 2 hypothesis is applicable to tumours o f the nervous system, 
meningiomas with no telomerase activity and a high percentage o f dicentric chromosomes would 
be consistent with a pre-crisis state. In addition, those tumours that are followed over multiple
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resections during progression frequently evolve telomerase activity (Harada et a i 2000a; Hiraga et 
a i  1998; Simon et a i  2000). These findings would suggest that immortalisation is not necessarily 
a prerequisite for tumour formation in the central nervous system, but that it occurs only in some 
tumours. Most commonly, this occurs in parallel with the development o f a more malignant 
phenotype, although primaiy glioblastomas would appear to use a different pathway to malignancy, 
one that does not necessarily require immortalisation (Harada et a i  2000c).
3.2.1.4.7 Telom erase activity and proliferation
The correlation of both telomerase activity and proliferation with malignancy has led several 
researchers to examine whether these two features o f cancer are linked. In several studies, 
telomerase activity does indeed seem to correlate with proliferation at least in meningiomas and 
gliomas (Cabuy et a i  2001; Kleinschmidt-DeMasters et al. 1998a; Maes et a i  2005; Santarius et 
a i  1997). Interestingly, in examining breast cancer cells, Ikeda et al, using an 
immunocytochemical restaining method, found that the same cells that expressed TERT 
simultaneously displayed immunopositivity for Ki67, suggesting that in breast cancer cells 
telomerase activity is more directly linked to cell proliferation than in meningiomas, at least (Ikeda 
et al. 2003). One important possible connection between telomerase activity and cellular 
proliferation could be the p21 protein. Telomerase-positive glioma cells, when transfected with 
wild type P2I, demonstrate a decrease in cell proliferation rate with accumulation o f cells at the 
GO/GI phase o f the cell cycle (Harada et al. 2000c). This cell cycle arrest is accompanied by a 
subsequent decrease in TERT mRNA levels and telomerase activity, suggesting that these two 
factors may be linked. Other researchers have also demonstrated an association between 
telomerase activity and the cell cycle (Holt et al. 1997; Sharma et al. 1995), Together these 
findings suggest a situation in which TERT expression and telomerase activity are closely tied to 
the mechanics o f cell proliferation in ways which are as yet poorly understood.
3.2.1.4.8 Interpreting Telomerase R epea t Am plification P rotocol (TRAP) Results
The majority o f the existing data on telomerase activity in human brain tumours has been derived 
from use o f the TRAP assay. However, the sensitivity o f the TRAP assay together with the marked 
heterogeneity o f certain tumour types create potential pitfalls in evaluating current data. One major 
complication is the possibility that homogenised tumour samples may contain small numbers of 
telomerase positive non-neoplastic cells, such as lymphocytes and stem cells, which may lead to 
falsely positive TRAP results (Hiyama & Hiyama 2002). In addition, recent Endings have 
suggested that as well as telomerase activity possibly being present in bystander cells included with 
tumour biopsy unintentionally, in some brain tumours telomerase activity is actively switched on in 
vascular endothelial cells. Pallini and co-workers, using in situ  hybridisation, found that 
telomerase activity within vascular endothelial cells directly correlated with malignancy in
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astrocytic tumours (Pallini et al. 2001). In fact, 100% o f glioblastomas in this study contained 
vascular endothelial cells expressing liTERT mRNA. In addition, glioblastoma cells were found to 
directly induce telomerase activity in vitro in vascular endothelial cells, either following co- 
culturing o f the two cell types, or following addition o f glioblastoma-conditioned medium to the 
endothelial cells (Falchetti et al. 2003).
A study that further illustrates this point was also reported by Falchetti et al (Falchetti et al. 2000). 
These authors used ISH against hTERT RNA and correlated hTERT RNA expression with TRAP 
analysis o f telomerase activity, with RT-PCR analysis o f hTERT and with cellular proliferation in 
34 glioblastomas. This study found that while telomerase activity as assessed by the TRAP assay 
was present in only 23 (67.6%) tumours, ISH detected hTERT RNA expression in all tumours, and 
RT-PCR detected hTERT RNA in all but one tumour. As was described by Kleinschmidt- 
DeMasters et al (Kleinschmidt-DeMasters et al. 1998a), significant variation in ISH staining was 
found within glioblastomas, with 19 cases (55.9%) showing a diffuse pattern, but the remaining 15 
(44.1%) having only focal areas o f hybridisation with liTERT-positive cells scattered within 
neoplastic tissues.
The difference between hTERT RNA expression and TRAP assay results could potentially be 
explained by the presence o f non-functional splice variants ampliEed along with full length 
hTERT. Indeed, Kotoula et al showed that the expression o f different splice variants varies across 
astrocytoma subtypes, with non-functional variants Adel (deletion o f the first 36 nucleotides o f 
exon 6) and Bdel (deletion o f 182 nucleotides from exons 7 and 8) present in all grades o f tumour 
(Kotoula et al. 2004). However, the full length hTERT mRNA transcript was only present in high 
grade tumours and was the predominant variant found in those tumours.
Despite this finding, the difference between RT-PCR and ISH reported by Falchetti et al could not 
be explained by the presence o f different splice variants, as RT-PCR was also performed using 
primers specific to the regions o f splice variants. This did not detect any differences between the 
sizes o f PCR fragments as would be expected with any splice variants present. These results could 
be explained in several ways. It is possible that samples used for the TRAP assay did not contain 
enough telomerase positive cells due to the considerable variability in telomerase activity between 
regions within glioblastomas, as has been noted by other authors (Kleinschmidt-DeMasters et al. 
1998a; Weil et al. 1999). Other possible reasons include: 1) degradation o f telomerase protein 
and/or RNA may have lowered the amount o f detectable telomerase in some cases 2) post- 
translational modifications o f hTERT might be necessary to convert it into the active enzymatic 
form 3) the presence o f hTERT alone may not necessarily imply functioning due to incorrect 
interaction o f telomerase-associated proteins. From these results, it would appear that telomerase 
activity exists in all glioblastomas, but that it may be undetectable by the TRAP assay in 
approximately one third o f cases.
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3.2,2 Canine Brain Tumours
Intracranial neoplasms represent a substantial proportion o f all neoplasms found in dogs. In this 
species, the incidence o f intracranial neoplasia would appear to be greater than in humans, with a 
reported incidence o f 14.5 tumours per 100,000 dogs compared to 3-4 per 100,000 people (Braund 
1994; Holt et a l  1997; Lingaas et aï. 2003; Morrison 1998; Summers et al. 1995). Other figures 
suggest an incidence o f CNS tumours found in 1% - 3% of all canine necropsies, including one 
report that found 2.83% of 6,175 dogs having intracranial tumours at post-mortem examination 
(McGrath 1960). One report examining tumours in young dogs indicated that the 3 most common 
sites for neoplasia were the haematopoietic system, the brain and the skin, in decreasing order 
(Keller & Madewell 1992).
The majority o f intracranial tumours seen in dogs and cats are o f primary CNS origin. The 
spectrum o f primaiy brain tumours reported is broad and is similar to that described in humans (see 
Table 3.2). The most common types o f primary tumours affecting the brains o f dogs are 
meningiomas and glial tumours (Morrison 1998). Pituitary tumours, choroid plexus papillomas 
and ependymomas are also commonly described. Meningiomas are reported to comprise between 
30 and 39% o f all intracranial neoplasms (Braund & Ribas 1986; Heidner et al. 1991 ; Lingaas et al. 
2003; Turrel et al. 1986). O f the neuroectodermal brain tumours, astrocytomas are probably the 
most common, representing 55% o f one report o f 215 cases o f neuroglial tumours (Braund 1994). 
O f the remaining cases, oligodendrogliomas comprised 28%, glioblastoma multiforme 
approximately 12%, choroid papillomas approximately 12% and ependymomas 2%. Metastasis o f 
primary brain tumours to non-neural tissue is rare, although it has been reported (Dugan et al. 
1993; He I man et al. 1980; Lingaas et al. 2003; Schulman et al. 1992). However, a number o f 
tumours may spread within the CNS along CSF pathways, notably medulloblastoma and choroid 
plexus papilloma (LeCouteur et al. 1981), although this is more properly referred to as implantation 
rather than metastasis (Johnson 1990).
Tumours o f the nervous system are most commonly reported in mature and older dogs, with one 
study reporting a peak incidence at 9 year o f age (Heidner et al. 1991; Lingaas et al. 2003), 
although there are sporadic reports o f brain tumours in dogs less than 1 year o f age (Keller & 
Madewell 1992). There would appear to be no gender predisposition, but there is an increased 
incidence o f brain tumours in brachycephalic breeds such as boxers, English bulldogs and Boston 
terriers, especially o f glial tumours (Braund 1994). Meningiomas are more commonly reported in 
mesocephalic and dolichocephalic breeds such as golden retrievers, Dobermans and collies (Gavin 
eta l. 1995).
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T able 3,2: T um our types and predilection  sites in dogs
T issue  o f  O r ig in T u m o u r  T y p e P red i le c t io n  Site
Neuron G anglioneurom a Variable: cerebellum, cranial nerve roots.
Ganglioneuroblas toma
N euroblas tom a
eye, cervical ganglion
Neuroepithelium Ependym om a Third and lateral ventricles
Neuroepithelioma Meninges, TL  spinal cord
Choroid  plexus papil loma Fourth ventricle
Neuroglia A strocytom a Piriform area, convexity  o f  cerebral 
hemispheres, thalamus, hypothalamus
A naplastic A strocytoma As for astrocytom a
G lioblastoma multiforme As for astrocytoma
Oligodendroglioma Cerebral hemispheres, periventricular 
white matter
Anaplastic o ligodendrogliomas As for o ligodendrogliom a
Spongioblastoma Variable, ependymal surfaces: cerebellum, 
optic nerve tracts
M edulloblastom a Cerebellum
Gliomas (unclassified) Periventricular area, esp cerebral 
hemispheres
Peripheral nerves and Schw annom a
nerve sheaths N eurofibrom a
N eurinom a
N eurofibrosarcom a
Peripheral nerves
Meninges, vessels M eningiom as Convexities o f  cerebral hemispheres, floor
and other o f  vault, cerebellopontine angle, falx
mesenchymal cerebri
structures A ngioblas tom a Variable
Sarcom a Variable
Pineal gland, Pinealoma Pineal body
pituitary gland and Pituitary adenom a Pituitary gland
cranio pharyngeal 
duct
C ran iopharyngiom a Hypophyseal/ infundibular areas
Heterotopic tissues Epiderm oid cyst Fourth ventricle, cerebellopontine angle
(malformation D ermoid  cyst Variable
tumours) T  eratoma Variable
Germ Cell Tum ours Base o f  brain above sella turcica
Metastatic tumours M am m ary  gland 
adenocarcinoma, pulmonary 
carcinoma, prostatic carcinoma, 
chemodectoma, malignant 
melanoma, lymphosarcoma, 
salivary gland adenocarcinoma, 
haem angiosarcom a etc
Variable
Primary tum ours Osteosarcoma, lipoma, Variable
from surrounding chondrosarcoma, fibrosarcoma,
tissues nasal adenocarcinoma, 
haemangiosarcoma, multiple  
m yelom a, calcifying 
aponeurotic fibromatosis, 
epidermoid cyst
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The incidence o f metastatic brain neoplasms in animals is unknown, but it is likely that it is 
underestimated, as the cranial vault is uncommonly evaluated during routine post mortem 
examination in cats and dogs. In the human field, the incidence o f silent brain métastasés suggests 
that most epidemiological studies underestimate their occurrence, reported to comprise between 
30% and 50% o f all CNS neoplasms (Johnson 1990). Up to 20% of people with malignant tumours 
have brain métastasés at death, but many o f these patients die o f systemic disease before these 
métastasés become symptomatic. Métastasés often become apparent after neoplastic involvement 
o f the lung, as 15% o f cardiac output returning from the lung goes to the brain.
Classification o f brain tumours in animals has traditionally employed criteria used for human 
tumours, and most commonly follows the grading system established by the World Health 
Organisation for prognostic purposes (Koestner et ah 1999) (see Table 3.3). However, not all o f 
these tumours have been reported in animals, and some authors question the value o f such a 
grading system in animals given the comparatively infrequent attempts at antemortem biopsy and 
definitive therapy (Johnson 1990; Lingaas et a i  2003; Summers et al. 1995). Classification is 
primarily based on the histological and cytological determination o f the cell o f origin, the degree o f 
differentiation, pathological behaviour, topographic pattern and secondary changes within and 
surrounding the tumour (Braund 1994; LeCouteur 1999). Classification may also be facilitated by 
the use o f immunocytochemical studies, although substantial differences exist between staining 
characteristics o f human and animal brain tumours, limiting their usefulness (Summers et al. 1995).
Research has also investigated the expression o f oncogenes and genes which code for growth 
factors or their receptors and thus allow more effective competition with other cells for selective 
growth advantage. Within neoplastic glial cell tumours in humans, growth factors examined have 
included epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and insulin-like 
growth factors (IGF), all o f  which are coded for by separate genes. Progesterone and oestrogen are 
also thought to play a role in the growth o f human meningiomas, and receptors for these sex 
steroids have been identified in some canine meningeal tumours (Adamo et al. 2003; Summers et 
al. 1995). The expression o f Vascular Endothelial Growth Factor (VEGF) in canine meningiomas 
has also been examined (Platt et al. 2005). All o f these studies are indicative o f the increasing 
search for molecular targets present in canine tumours. This search has also been extended to the 
level of the genome, with some papers examining the profile o f canine brain tumours using 
comparative genomic hybridisation (CGH) to examine chromosome-wide gains and losses o f 
genetic material (Dunn et al. 2000). Most recently, the development o f cDNA microarray chips 
has also allowed a survey o f more than 2000 clones matching genes or expressed sequence tags 
(ESTs) and identified a number o f genes expressed differentially in canine brain tumours 
(Thomson et al. 2005). Importantly, several o f these, including ApoD, GREG and NDRG4 show 
similar patterns o f expression in both human and canine brain tumours. In addition, the recent
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publication o f linkage maps o f the canine genome has allowed some authors to investigate the 
possibility o f LOH in the canine equivalent o f  human chromosomes Ip and 19q in canine 
oligodendrogliomas, and suggests that the same finding may be present in dogs although this 
research is still ongoing (Olby 2005). All of these factors suggest that the similarities between 
canine and human brain tumours extend beyond the histochemical level to the molecular level.
Treatments used to treat canine tumours have largely paralleled methods used in human tumours, 
and include surgical removal, radiotherapy and chemotherapy (LeCouteur 1999). Approaches have 
been described for surgical excision o f masses in most part o f the canine brain, including most 
regions o f the cerebral cortex, cerebellum and brain stem. Removal o f lesions from the ventral 
brain and brainstem, and from within the deep cortical grey matter still pose a significant challenge, 
however. Various protocols have been described for irradiation o f intracranial tumours in dogs, 
including hypofractionated protocols and stereotactic radiosurgery (Brearley et al. 1999; Evans et 
al, 1993; Goossens et al. 1998; Lester et al. 2001). In addition, limited case reports have described 
the use o f various chemotherapeutic agents including carmustine, lomustine and cytosine 
arabinoside (Dimski & Cook 1990; Fulton & Steinberg 1999). Analysis o f survival times is 
complicated by the fact that many o f the case series described to date have included relatively small 
group sizes for comparison. In addition, one o f the major challenges in canine neurology has been 
the identification o f outcomes for different tumour types, since many cases are euthanased without 
definitive histopathological diagnosis. At present, the consensus for the majority o f tumours seen 
in dogs is that the longest survival times are seen in those cases treated with surgical excision 
followed by radiotherapy (Platt et al. 2004).
3.2.2.1 Telom erase activity in canine neoplasms
Given the similarities shared between human and canine brain tumours, investigating telomerase 
activity in canine brain tumours would appear to be an important starting point from which to 
develop te 1 omerase-directed therapies to be used either in the treatment o f canine tumours or as a 
preclinical testing ground for human tumour therapies.
The presence o f telomerase in canine tumours in general is considerably less well-established than 
in man. In one o f the earliest reports. Biller et al reported that 24 o f 26 malignant tumours o f 
various origin were telomerase-positive, as compared with 1 o f 4 benign tumours and none o f 3 
normal tissues (Biller et al. 1998). In a survey o f 27 mammary tumours, Yazawa et al found that 
26 o f 27 tumours were positive for telomerase activity (Yazawa et al. 2001). However, there 
appeared to be little correlation between the level o f telomerase activity and tumour grade, and 4 of 
12 normal specimens were also found to be positive for telomerase activity. In a separate study, 
Yazawa et al reported telomerase activity in a panel o f 16 tumours and its correlation with RT-
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PCR, although they did not provide the number o f telomerase-positive tumours (Yazawa et a l ,  
2001). Nasir et al reported telomerase activity in a range o f canine cell lines, and in both normal 
and neoplastic lymph nodes (Nasir et al. 2001). Overall these studies combined suggest that 
approximately 95% of the canine tumours so far examined are positive for telomerase activity 
(Argyie & Nasir 2003). However, none o f these reports have yet investigated the presence o f 
telomerase activity in canine brain tumours.
3.2.2.2 Proliferation in canine tumours
In validating canine brain tumours as a model for research into human tumours, the correlation 
between telomerase activity and proliferation must also be shown to exist in this species. Several 
reports have described the use o f  BrdU, Ki-67 and PCNA labelling in tumours in domestic animals 
(reviewed in (Madewell 2001)), all o f which have been shown to correlate well with other 
prognostic factors in a variety o f  tumours (Fournel-Fleury et al. 1997; Griffey et al. 1999; Lohr et 
al. 1997; Platz et al. 1999; Sarli et al. 1994; Simoes et al. 1994; Zacchetti et al. 2003). O f these 
markers, only PCNA has been examined in brain tumours. Theon et al showed that PCNA 
correlated significantly with outcome in meningiomas treated with surgery and radiotherapy 
(Theon et al. 2000). In addition, Uchida et al reported the use o f PCNA in the diagnosis o f a 
ganglioglioma (Uchida et al. 2003). However, PCNA staining in this tumour was negative, not 
unexpectedly, since gangliogliomas are typically benign tumours. To date, no studies have 
reported the use o f Ki67 in canine brain tumours.
3,2.3 Methods o f  Assessing Telomerase Activity
3.2.3.1 The Telom erase Repeat Amplification Protocol
Specific detection o f telomerase activity in biological samples has been made possible through the 
use o f the PCR based TRAP assay. This assay, first described by Kim and others at the Geron 
corporation in 1994 (Kim et al. 1994), allows detection o f telomerase activity based on the 
presence o f active enzyme in as few as 10 cells in any given sample (Hiyama & Hiyama 2002). 
Using this assay, Shay and Bacchetti went on to demonstrate that approximately 90% of all human 
cancers are TRAP-positive (Shay & Bacchetti 1997).
The TRAP assay relies on the presence o f both the TERT and TR components of telomerase in the 
sample acting as a functional enzyme. In the first step, a synthetic primer acts as a substrate which 
is bound by telomerase, comprised minimally o f the TERT and TR subunits. For this reason, the 
primer, referred to as TS, contains within its sequence a number o f TTAGGG repeats. In addition, 
the TS primer may be labelled in a way that allows detection o f the final products (eg by 
conjugation with biotin for detection by ELISA, or by radiolabelling with ^^P).
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In the second step, the primer is then elongated by the addition o f further TTAGGG repeats. 
Following this, telomerase is first deactivated by heating the sample. Then, the elongated products 
are subjected to PCR amplification using the labelled TS as a forward primer, and a reverse primer 
(CX) complementary to a run o f four TTAGGG sequences. Since the reverse primer is able to bind 
in multiple places along the telomerase-elongated sequence (composed o f TTAGGG repeats), the 
final product lengths differ from each other by multiples o f 6 nucleotides (see Figure 3.1).
In the final step, the PCR products are detected in one o f a number o f ways. In the original assay, 
described by Kim et al, addition o f radioactive bases to the PCR reaction mix (eg [ ’^P]-labeIled 
dCTP or dGTP) resulted in a product that could be detected by autoradiography (Kim & Wu 1997). 
Products can then be subjected to polyacrylamide gel electrophoresis (PAGE) (Kim & Wu 1997) 
In this case, a characteristic ‘TRAP ladder’ is generated, with consecutive bands increasing in size 
by multiples o f 6 nucleotides. Alternatively detection can be performed using an ELlSA-based 
system, in which the TS primer, previously labelled with biotin, binds to a streptavidin-coated 
microplate and products are then detected with an antibody against digoxigenin that is conjugated 
to horseradish peroxidase (Anti-DIG-HRP) and the sensitive peroxidase substrate TMB.
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Figure 3.1: The Telomerase Repeat Amplification Protocol
Principal features o f  the TRAP assay. In the first step, telomerase binds to the forward primer to 
allow elongation to occur (step 2). Then, telomerase is heat-inactivated, leaving the elongation  
products composed o f  tandem (TTAGGG)n repeats. Following this step, PCR amplification 
occurs, but due to the presence o f  repeats containing the same hexanucleotide sequence, the reverse 
primer is able to bind in multiple places, producing amplification products o f  different lengths, 
varying by 6 base pairs. In the final stage (not shown), the amplification products are then 
detected, most commonly by gel electrophoresis or ELISA techniques.
TERT + TR
Forward
Primer
1) Binding
2) Elongation
3) Inactivation
4) PCR Amplification
TTAGGG nucleotide repeats
#
Reverse Primer
no
Szatmari and colleagues described an alternative method o f detecting the PCR products, in which, 
following incorporation o f [’^ ^PJ-iabelled bases in the PCR reaction mix, samples were precipitated 
following amplification and the radioactivity o f the sample measured (Szatmari et al. 2000). 
Particular features o f the primers used and their annealing temperatures meant that reverse priming 
o f the PCR products occurred primarily at the 3’ end o f amplified constructs, reducing the random 
internal reverse priming that occurs with conventional primers. In this way, the radioactive signal 
generated by PCR products increased in a linear fashion with the amount o f telomerase present in 
the sample, rather than in an exponential or hyperbolic fashion. This technique also reduced the 
amount o f post-PCR processing required before detection, shortening the time required.
Quantification o f telomerase activity within samples required modification o f the original 
procedure. In fact, the number o f PCR products generated depends on two factors: the processivity 
o f the enzyme within the sample, and the number o f enzyme molecules present. The first o f these 
factors reflects the number o f telomeric repeats the enzyme adds to the substrate, and the second 
reflects the number o f  substrate molecules simultaneously extended by telomerase. Therefore, 
those methods which measure the strength o f radioactive signal generated following incorporation 
o f radioactive bases into the PCR reaction do not distinguish between enzyme processivity and the 
amount o f enzyme present in each sample.
Kim and Wu described a refinement o f  the original TRAP protocol in which only the TS primer, 
rather than all bases, was radiolabelled (Kim & Wu 1997). In this way, strength o f the signal 
generated by PCR products depends only on the number o f substrate molecules elongated and not 
on the processivity o f  the enzyme. In order to quantify the test, a comparison was then made 
between the strength o f the signal generated from the test sample following PCR amplification, 
with the strength o f the signal generated from a sample o f known telomerase activity. This positive 
control was obtained from an extract o f 293 cells, which are known to be highly positive in 
telomerase activity (W ick et al, 1999). Using this positive control, Kim and Wu described a linear 
relationship between the quantity o f telomerase present in a sample and the total strength o f signal 
generated by amplified products (Kim & Wu 1997). Using this scale, the total product generated 
(TPG) was defined such that I unit o f TPG is equivalent to 600 molecules o f primer TS extended 
for at least 3 telomeric repeats by telomerase within the extract. One TPG is approximately the 
quantity o f telomerase activity present in a single immortal cell. In current versions o f the test, 
quantitiation o f telomerase activity in any given sample is performed by expressing it relative to 
telomerase activity present in a positive control run alongside, often comprising an extract o f 293 
cells. In this way, telomerase activity can be compared between samples.
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3.2.3.1.1 Technical Problem s with the Telomerase R epea t Am plification Protocol
3.2.3.1.1.1 P iim ef-D im ei' form ation and other artefacts
When the first report o f the TRAP assay was described, it became apparent that certain artefacts 
were commonly found (Kim et al. 1994). Following amplification of a synthetic oligonucleotide 
containing four TTAGGG repeats using the TS and CX primers (without prior telomerase 
elongation), PAGE revealed a product ladder with 6 base pair steps extending to the top o f the gel, 
rather than a single product o f original size (Krupp et al. 1997). This was found to be due to 
staggered annealing o f the CX primer to the substrate. The CX primer was originally designed 
with a number o f mismatches, so that efficient priming o f the substrate occurred only when the 
entire primer binds. However, it was shown that binding o f only the first repeat o f the CX primer 
could occur, tolerating the single nucleotide mismatch present. In this case, subsequent 
amplification leads to extension o f the original product by a further 3 repeats (18 nucleotides) with 
each round o f amplification (Figure 3.2).
The second artefact that arose was due to primer-dimer formation. PCR amplification in the 
absence o f any substrate could potentially result in a TRAP ladder being formed, resulting in a 
false positive result. In this situation, the last two nucleotides at the 3 ’ end o f TS and CX would 
bind in a complementary fashion, leading to a 40-bp product. This could be extended, following 
staggered annealing o f the CX primer in successive rounds o f amplification, to yield a complete 
TRAP ladder in the absence o f telomerase activity (Kim et al. 1994) (Figure 3.2).
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Figure 3.2: Basis o f artefacts associated with the TRAP assay
TS Primer
T elom erase elongation  product
TS 5-Ï (GGG n  AGGG TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG
PCR am plification
-5 CX
CX Primer
TS 5 ^ f ^ M T Ô ë ^ T < ^ ^ ^ Â ë i^ p F j [ G G G  TTAGGG TTAGGG TTAGGG t a a g g g  t a a g g g  t a a g g g  f a a g g g  t a a g g g
-5 CX
GGG TAAGGG TAAGGG TAAGGG
TTAGGC AGCTCG TCI -5
1. Nonna! TRAP assay. The TS primer is used by telomerase present within the test sample 
to synthesise TTAGGG repeats (in capitals). The CX primer then binds to a run o f  four 
TTAGGG repeats during PCR amplification o f  the elongation products.
2. Continued extension o f  TTAGGG repeats during PCR amplification. Although the CX 
primer is designed to pair with a run o f  four TTAGGG repeats, in some cases it was found 
that CX could bind a single TTAGGG repeat, tolerating the single nucleotide mismatch. 
PCR amplification then results in extension o f  the elongation product by a further 3 
TTAGGG repeats with every cycle. Lower case ttaggg shows extension after first cycle, 
italicised ttaggg  shows extension after second cycle etc.
3. Primer-Dimer formation. In some cases, the last two nucleotides o f  the TS primer could 
bind to the first two primers o f  CX. This primer-dimer could be extended during the PCR 
amplification step, resulting in complete TRAP ladder in the absence o f  any telomerase in 
the sample.
113
Elimination o f both o f these artefacts was made possible through changes to the CX primer. Krupp 
and colleagues added three additional nucleotides to the 5’ terminus o f the CX primer which were 
non-complementary to telomeric sequence. In this way, amplification o f primer-dimer formation 
or subsequent extension o f already-elongated products was virtually eliminated (Krupp et al. 1997). 
Kim and Wu, who were amongst the group that reported the original TRAP assay in 1994, 
described a very similar modification using a 6bp ‘anchor’ at the 5’ end and solved the problem in 
the same way (Kim & Wu 1997).
3.2.3.1.1.2 T aq-polym erase Inhibitors
Some tissues contain Taq-polymerase inhibitors that have been found to inhibit the PCR 
amplification o f telomerase-elongated products (Wright et al. 1995). In these tissues, performing a 
TRAP assay with the standard amount o f protein (6pg) leads to a negative result, whilst a reduced 
protein level would reveal a positive result. To control for the presence o f either Taq-polymerase 
or other PCR inhibitors within the sample, a number o f modifications o f the TRAP assay include 
an internal standard. The internal standard is an oligonucleotide substrate o f known size, the 5 ’ end 
o f which can be primed by TS, and the 3 ’ end o f which can be primed either by the same reverse 
primer as is used in the initial PCR reaction or a second, specific reverse primer. In both cases, the 
substrate Is amplified in the initial PCR reaction along with the telomerase-elongated sequence. 
However, PCR amplification o f the internal standard results in a product o f  known size.
In the an early report o f  the protocol first described by Kim et al, the internal standard was a 
product 36 nucleotides in length (Kim & Wu 1997). The presence o f Taq-inhibitors in the sample 
results in a failure o f amplification o f the internal standard, enabling detection o f false-negative 
results. Later modifications substituted an internal standard that was 216 bp in length, since it was 
found that the shorter internal standard could sometimes be amplified even in the presence o f Taq 
inhibitors, leading to false negative results. An additional feature o f the inclusion o f the internal 
standard is that it aids quantification o f telomerase activity in samples, since telomerase activity, 
once normalised to the internal standard, displays a linear relationship to the number o f telomerase- 
positive cells in the sample (W right et al. 1995).
3.2.3.2 Reverse Tfanscfiptase-PCR of TERT and TR
RT-PCR allows the detection o f messenger RNA (mRNA) in samples through PCR amplification. 
RT-PCR techniques involve isolating either total RNA or mRNA. This is then followed by 
reverse-transcribing the RNA using a reverse transcriptase enzyme, which synthesises DNA 
complementary to the RNA template (cDNA). This cDNA encodes a modified form of the gene o f 
interest as all non-coding introns have been removed during synthesis o f mRNA. cDNA can then 
be amplified using standard PCR techniques and in this way the expression o f genes in cells can be
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evaluated. PCR amplification o f the gene o f interest is usually performed in conjunction with 
amplification o f a constitutively expressed gene which serves as a positive control for the reaction.
RT-PCR analysis o f telomerase in humans has most frequently involved the amplification o f the 
hTERT gene, as hTERT expression is the rate-limiting step in telomerase activation. In addition, 
some authors have investigated the expression o f liTR (Dome et al. 1999; Gunther et al. 2000; 
Ohyashiki et al. 2005; Swiggers et al. 2004; Takakura et al. 1998; Yi et al. 2001). As well as using 
conventional PCR techniques, quantitative RT-PCR (qRT-PCR) techniques have also been used to 
analyse hTERT expression (Kotoula et al. 2004; Ohyashiki et al. 2005; Tchirkov et al. 2003). 
qRT-PCR allows the quantity o f the product o f interest to be measured by normalising 
amplification levels against those o f a positive control gene which is amplified simultaneously. 
This requires initial optimisation o f the PCR reaction so that the amplification plateau is calculated 
for both the product o f interest and the positive control, with the same amount o f each template 
included at the start o f the reaction. Once this has been performed, using the same conditions, 
amplification o f the product o f  interest can then be quantified using a fluorescent marker 
incorporated into the reaction mix such as a Taq man probe or SYBR Green 1 (Bieche et al. 2000; 
de Kok et al. 2000; Krams et al. 2003; Tchirkov et al. 2003; Wu et al. 2000).
There appears to be good correlation between hTERT mRNA expression and telomerase activity in 
some tumour types, including leukaemia, soft tissue sarcomas, thyroid tumours, gastrointestinal 
tumours, lung carcinomas and cervical cancer (Gunther et al. 2000; Kumaki et al. 2000; Ohyashiki 
et al. 2005; Saji et al. 1999; Takakura et al. 1998; Yan et al. 1999). Within the brain tumour 
subgroup, similar findings have been reported for glial tumours and neuroblastomas (Kotoula et al. 
2004; Krams et al. 2003). Expression o f hTR mRNA, however, does not seem to correlate well 
with telomerase activity, either in vivo or in vitro in the cell lines in which it has been examined 
(Ohyashiki et al. 2005; Swiggers et al. 2004; Takakura et al. 1998). In addition, there appears to 
be little correlation between the expression o f hTERT mRNA and the expression o f hTR mRNA 
(Gunther et al. 2000).
However, although expression o f the hTERT gene generally correlates well with telomerase 
activity, this is not always the case. In colorectal cancer and W ilm s’ tumours in humans, for 
instance, the expression o f hTERT mRNA correlates only weakly with the activity o f telomerase 
(Dome et al. 1999; Palmqvist et al. 2005). In addition, Swiggers and colleagues reported that in 
primary human fibroblast clones with reconstituted telomerase activity, hTERT mRNA levels do 
not seem to correlate with telomerase activity or with telomere length (Swiggers et al. 2004). 
Similarly, Yi and colleagues found that the correlation between telomerase activity and hTERT 
mRNA expression in a number o f immortalised and telomerase-positive cancer cell lines is 
surprisingly weak (Yi et al. 2001). Taken together, these reports suggest that post-transcriptional 
modification o f hTERT is important for producing active telomerase, and therefore that analysis o f
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the presence or absence o f gene expression alone does not provide sufficient information to 
establish this. One important mechanism involved in post-transciptional modification is the 
presence o f splice variants, first described in humans by Kilian and colleagues (Kilian et al. 1997) 
(see 5.2.2.2: Post-Transcritptional Modification o f hTERT). Whilst several splice variants have 
been discovered, only the full-length version o f hTERT is functional in activating telomerase. 
Depending on the location o f the primers used, therefore, some reports analysing hTERT mRNA 
expression may not have necessarily distinguished between full length, active hTERT, and non­
functional splice variants. For instance, Kotoula and colleagues, in investigating the presence o f 
hTERT splice variants in astrocytic gliomas, reported that in 5 grade 1 tumours examined, 3 
displayed the presence o f hTERT mRNA (Kotoula2004). However, in all 3 cases, the transcript 
was found to contain two o f the common deletions (a-del and P-del), resulting in a non-functional 
mRNA. Conversely, all o f the high grade tumours expressing hTERT mRNA showed the full 
length transcript. Expression o f the full length hTERT mRNA transcript has also been found to be 
important for the activity o f telomerase in neuroblastomas (Krams et al. 2001). On the face o f it, 
these findings might suggest that telomerase-positive cells only express the full-length version of 
hTERT mRNA. However, Yi and colleagues showed that, o f the total hTERT mRNA expressed 
within many o f the telomerase-positive cell lines so far characterised, only a small fraction 
(approximately 5%) o f the transcripts were the full length form (Yi et al. 2001). An extra 
complication was uncovered in a report by Ohyashiki and colleagues, who, in examining the 
relationship between hTERT expression and telomerase expression in patients with leukaemia, 
found that generally telomerase expression correlated veiy well with expression o f the full length 
transcript (Ohyashiki et al. 2005). However, in those cases where discrepancy occurred, it was 
found that expression o f hTR RNA was significantly lower, suggesting that although hTR 
expression alone does not correlate with telomerase activity, telomerase activity may require the 
synthesis o f both gene transcripts in a coordinated fashion.
in summary, whilst investigation o f hTERT and hTR mRNA through RT-PCR methods has been 
performed both in vivo and in vitro, there appears to be some disagreement about its correlation 
with telomerase activity. This may be due to post-transcriptional modification, and splice variants 
are likely to play a role in this.
3.2.3.3 In Situ Hybridisation (ISH)
In situ hybridisation techniques make use o f the presence o f single-stranded mRNA in tissue 
samples. Probes consisting o f DNA sequence are designed complementary to the gene o f interest, 
and labelled in one o f a number o f ways, including with dixogenin, or fluorescein (FISH). 
Addition o f the probe to the sample without prior dénaturation ensures that the probes bind to the 
only single-stranded sequence present -  mRNA. Prior treatment with RNase together with the use
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of probes designed to be identical to the sequence o f interest (sense) rather than complementary 
(anti-sense) provide negative controls.
ISH techniques have been described by several authors (Athanassiadou et ah 2003; Baykal et al. 
2004; Fukushima et al. 2004; Kolquist et al. 1998; Liu et al. 1999; Nieh et al. 2005; Norrback et al. 
2001; Saretzki et al. 2002; Soria et al. 2001). Most commonly, probes synthesised from TERT 
have been used, and ISH has been used to examine TERT expression in cytological preparations, 
paraffin-embedded sections and in fresh or frozen tissues. In many o f these reports, the use o f ISH 
has provided important findings regarding the localisation o f telomerase activity, such as the 
finding that germinal centres o f lymphocytes contain telomerase activity only within activated B 
cells (centroblasts) but not in resting or active naïve B cells (Norrback et al. 2001). In addition, 
using ISH, Kolquist et al showed that telomerase activity was present in breast epithelial cells with 
long-term proliferative activity, and that it appeared in tumour cells early in breast tumorigenesis, 
suggesting that in these tumours telomerase activity may possibly precede other neoplastic changes 
(Kolquist g/ rz/. 1998).
Whilst ISH examination o f telomerase activity in situ has been used extensively, the technique is 
somewhat hampered by the fact that it is time- and labour-intensive (Maes et al. 2005). In addition, 
the detection o f mRNA in paraffin-embedded tissues is affected by the length and quality o f sample 
fixation, due to the rapid degradation o f RNA. Therefore, some samples with TERT mRNA 
expression may stain falsely negative if fixation is not optimal.
3.2.3.4 Im m unohistochem ical Detection o f Telom erase Activity
The complications associated with assessing telomerase activity through either TRAP assay or RT- 
PCR techniques are best addressed by utilising techniques that examine telomerase activity in situ. 
In addition to microdissection techniques and In Situ Hybridisation (ISH) analysis o f hTR and 
hTERT mRNA described, other techniques have been described for detecting telomerase activity in 
cancer cells such as immunomagnetic bead separation and sorting by flow cytometry (Waguri et al.
2003). However, these techniques result in limited recovery o f molecular targets, and it may be 
difficult to precisely assess the degree o f sample contamination by non-neoplastic cells because o f 
the sensitivity o f molecular amplification assays.
Another potential method for examining telomerase activity in individual cells is through the 
immunohistochemical detection o f the TERT protein. The advantages o f immunohistochemical 
techniques are that they provide an overall picture o f telomerase activity while also allowing 
examination o f individual cells and cell types (Shroyer 2002). Importantly, they may be used on 
paraffin-embedded archival material, allowing a larger survey o f samples to build a more 
comprehensive picture o f telomerase activity both within and across tumour subtypes. Fixed
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material can potentially be used for ISH techniques and RT-PCR, depending on the quality o f the 
material, but is technically difficult because o f DNA and RNA degradation that occurs during the 
fixation. Thus, histochemical approaches remain the optimal method in many circumstances for 
defining the expression o f specific proteins or RNAs at the cellular level (Shroyer 2002).
Several studies have examined the detection o f hTERT in tumour samples, including in paraffin- 
embedded material, in frozen sections, and in cytological preparations (Cheung et al. 2004; Hiyama 
& Hiyama 2002; Ikeda et al. 2003; Poremba et al. 2000b). Those tumours examined include breast 
tumours, lung cancers, meningioma, neuroblastoma, ameloblastoma, mesothelioma, gynecological 
cancers and colorectal carcinomas (Hiyama et al. 2001; Hiyama & Hiyama 2002; Ikeda et al. 2003; 
Kumaki et al. 2000; Kumamoto et al. 2001 ; Kyo et al. 2003; Maes et al. 2005; Poremba et al. 
2000b; Tahara et al. 1999). Several antibodies have been used, and the staining pattern varies 
slightly depending on the antibody used. The majority o f reports suggest that immunopositivity is 
restricted to the nucleus, and in some cases specifically to the nucleolus (Maes et al. 2005), 
frequently with a granular or speckled pattern. However, in some tumours staining also appears to 
extend to the cytoplasm o f neoplastic cells (Cheung et al. 2004; Kyo et al. 2003). Staining for 
hTERT has also been detected in a small number o f non-neoplastic cells within normal colonic 
mucosa, located at the bottom o f intestinal ci-ypts, and in associated activated lymphocytes 
(Hiyama et al. 2001). hTERT staining has also been reported in telomerase positive BJ+hTERT 
cells (hTERT transfected fibroblasts) and HT1080 cells grown in serum, which possess high 
telomerase activity when actively growing, but not in SW 13-ALT immortal cells or LIT 1080 cells 
deprived o f serum, both o f which lack telomerase activity (Hiyama et al. 2001). In the study 
reported by Hiyama et al (Hiyama et al. 2001), immunohistochemical staining o f hTERT was not 
detected in the majority o f  normal tissues, including cardiac/skeletal muscle, liver, prostate, breast, 
pancreas, brain, lung and kidney. Low to high levels o f telomerase activity were found in germ- 
line tissues, proliferative pre-menopausa! endometrium and tissues containing activated 
lymphocytes. Staining for hTERT was also detected in a small number o f cells within colonic 
mucosa, located at the bottom intestinal crypts, and in associated activated lymphocytes. hTERT 
staining was present in telomerase positive BJ+hTERT cells (hTERT transfected fibroblasts) and 
HT 1080 cells grown in serum, which possess high telomerase activity when actively growing, but 
not in SW 13-ALT immortal cells or LIT 1080 cells deprived o f serum, both o f which lack 
telomerase activity.
Correlation between TERT immunostaining and TRAP activity has not been extensively 
investigated. However, telomerase staining has been found to correlate with TRAP activity in 
some tumours, with those tumours possessing low TRAP activity displaying hTERT staining in a 
small number o f cells, and those tumours with high TRAP activity showing more widespread 
hTERT staining. Poremba et al reported that in the neuroblastomas examined, hTERT staining 
correlated well both with the level o f TRAP activity and with the presence o f hTERT mRNA
(Poremba et al. 2000b). Similar results were reported in ameloblastomas and lung carcinomas 
(Kumamoto et al. 2001; Nakanislii et al. 2002). In addition, TERT staining appears to correlate 
with malignancy, with cellular proliferation and with outcome in the majority o f tumours examined 
(Cheung et a l  2004).
These reports confirm that the immunohistochemical detection o f TERT provides a useful 
technique for the assessment o f telomerase activity in paraffin-embedded tissue, because o f the 
ability to examine telomerase status o f individual cells in situ, the correlation with other methods o f 
assessing telomerase activity, and the ability to survey large groups o f archival samples.
To date, few reports have described the use o f hTERT immunohistochemistry in human brain 
tumours. In one report which examined telomerase expression in 133 neuroblastomas, 39 (29.3%) 
were found to be TRAP positive (Poremba et al. 2000b). The quantification o f both TRAP activity 
and hTERT staining in this study showed that hTERT staining correlated well with TRAP activity. 
In five neuroblastomas with low telomerase activity, 1% to 10% o f cells were found to stain 
positively for hTERT. O f four samples with intermediate telomerase activity, 10% to 50% o f cells 
were found to stain positively for hTERT. Three neuroblastomas with high telomerase activity 
displayed hTERT staining in more than 50% o f cells. In meningiomas Maes et al described hTERT 
immunoreactivity in a series o f meningiomas that recurred following resection (Maes et a l  2005). 
In this study, o f the 27 meningiomas that recurred, positive hTERT staining was found in 26 
tumours, as compared with 6 o f 28 non-recurrent meningiomas. To date, no reports have examined 
TERT immunohistochemistry in canine brain tissues.
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3.3 Aims of the chapter
To date, no reports have evaluated the immunohistochemical detection o f TERT in canine tumours. 
The first aim o f this chapter was therefore to evaluate a number o f commercially available hTERT 
antibodies in canine tissues by correlating TERT staining with TRAP assay, Western blotting and 
RT-PCR. In addition, no reports to date have described the assessment o f cellular proliferation in 
canine brain tumours using Ki-67. Therefore, the second aim o f this chapter was to evaluate Ki-67 
staining in a range o f canine brain tumours and to correlate the MlB-1 labelling index (LI) with 
conventional histological grading to determine its usefulness as a prognostic indicator. Once the 
MlB-1 LI was validated in these tumours, the third aim o f this chapter was to correlate TERT 
staining with proliferation and with malignancy.
120
3.4 Materials and Methods
3.4.1 Sample details
3.4.1.1 Norm al samples
Normal brain tissue samples were obtained from a dog that had been euthanased for a non- 
neurological cause and submitted for post-mortem at GUVS. All necropsies performed at this 
Institute are carried out with informed owner consent. Approximately 1 cm^ tissue samples were 
taken under aseptic conditions from the olfactory lobe, subventricular zone at the level o f  the 
caudate nuclei, and cerebellum within 30 minutes o f euthanasia. Samples were divided into two 
portions, one o f which was flash frozen in liquid nitrogen (LNOi) before storage at -7 0 “ C, and the 
other fixed in 10% Buffered Neutral Formalin (BNF). To serve as a positive control, archival 
material from 3 normal canine testes was retrieved from the pathology archives o f the Institute o f 
Comparative Medicine, University o f Glasgow. These sample had been previously taken, fixed in 
10% BNF and paraffin-embedded as part o f routine post-mortem examination for other reasons.
3.4.1.2 Tumour samples
Tumour samples were retrieved from a total o f 93 paraffin-embedded brain tumours retrieved from 
the pathology archives o f the Institute for Comparative Medicine, University o f Glasgow 
Veterinary School and collaborating Institutes, namely, Institute o f Animal Neurology, University 
o f Berne; College o f Veterinary Medicine, North Carolina State University; Department o f 
Pathology, Utrecht University Faculty o f Veterinary Medicine; Centre for Small Animal Studies, 
Animal Health Trust, UK. Where available, Haematoxylin and Eosin (H&E)-stained slides were 
retrieved from the archives for review. Where slides were not available, fresh sections were cut 
from paraffin-embedded tissue blocks and restained. In some cases, special immunohistochemical 
stains, including glial fibrillaiy acidic protein (GFAP), neurofilament (NF), vimentin, 
synaptophysin and other stains as required were used to confirm the original diagnosis.
All sections used in the study were re-evaluated with Dr S Robinson, NHS Consultant 
Neuropathologist, Department o f  Neuropathology, Southern General Hospital, Glasgow, and the 
diagnosis o f intracranial neoplasia was confirmed. Each tumour sample was classified according to 
the World Health Organisation classification system of tumours (Koestner et al. 1999). Tumours 
were then divided into two grades, 1 and 2, based on their classification, as described in Table 3,3.
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T able 3.3; W H O  C lassification  o f  C anine Brain T um ours and G rad ing  Schem e Used
W H O  Classification Grade
M eningiom a
Low grade meningiom a 1
Anaplastic mening iom a 2
O ligodendrogliom a
O ligodendroglioma 1
Anaplastic oligodendroglioma 2
Astrocytoma
Low grade astrocytoma 1
Anaplastic astrocytoma 2
Glioblastoma multiforme 2
O ther glial tumours
Gliosarcoma 2
Oligoastrocytoma 1
Anaplastic oligoastrocytoma 2
Choroid plexus tumours
Choroid  plexus papilloma 1
Choroid plexus carcinoma 2
Pituitary tum ours
Pituitary adenoma 1
Pituitary adenocarcinoma 2
Primitive Neuroectodermal Tumours
M edulloblastom a 2
Ependymal tumours
E pendym om a 1
Anaplastic ependym om a 2
Metastatic tumours 2
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3.4.1.3 Cell Lines
Cells used in this chapter include the D17, CMT7, U87-MG and K9SF cell lines. The D17 and 
CMT7 cell lines are canine osteosarcoma and mammary tumour cell lines, and the K9SF cell line is 
a canine skin fibroblast primary culture. The U87-MG cell line is a human glioblastoma cell line. 
All cell lines are detailed in Chapter 2. Cells were grown in T75 flasks and passaged routinely 
upon reaching confluence.
For immunohistochemical evaluation, artificial clots were created using cells from the CMT7, D17, 
U87 and K9SF cell lines. Following trypsinisation, cells were counted and an aliquot o f 5 x 10  ^
cells was transferred to a 1.5ml eppendorf tube and pelleted at 3000 rpm for 5 minutes. The growth 
medium was discarded and the pellets washed twice in sterile PBS at 4“ C. Following the second 
wash, cells were centrifuged at 3000 rpm for 5 minutes at 4° C and supernatant was carefully 
decanted. Fifty pi o f bovine plasma was added to the resultant cell pellet, followed by 50 pi bovine 
thrombin, and the cell pellet agitated at 37“ C until a clot had formed. Clots were then fixed in 10% 
BNF and processed as described below.
For Western blotting, cell pellets were created using cells from the CMT7, D17, U87 and K9SF 
cell lines. Following trypsinisation, cells were counted and an aliquot o f  2 x 10  ^ cells was 
transferred to a 1.5ml eppendorf tube and pelleted at 3000 rpm for 5 minutes. The growth medium 
was discarded and the pellets washed twice in sterile PBS at 4° C. Following the second wash, 
cells were centrifuged at 3000 rpm for 5 minutes at 4° C and supernatant was carefully decanted. 
Aliquots were then flash-frozen in LNO2 for storage prior to Western blotting.
3.4.2 Telomerase Activity
3.4.2.1 Telom erase repeat amplification protocol (TRAP assay)
Telomerase activity was measured using the TRAP assay as described in 2.2.10.1: Telomerase 
repeat amplification protocol.
3.4.2.2 Reverse transcriptase-PCR
3.4.2.2.1 Prim ers
Primers were designed as detailed in 2.2.6.1 : Primer Design, and supplied by Sigma-Genosys.
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3A.2.2.2 Sample Preparation
To assess TERT gene expression in D17, CMT7, K9SF and U87 cells, reverse-transcriptase PCR 
was performed. Following trypsinisation and counting, aliquots o f 2 x 10  ^ cells were transferred to 
a DEPC-treated 1.5ml eppendorf tube and pelleted at 3000 rpm for 5 minutes. The growth medium 
was discarded and the pellets washed twice in sterile PBS at 4° C. Following the second wash, 
cells were centrifuged at 3000 rpm for 5 minutes at 4“ C and supernatant was carefully decanted. 
Cell pellets were then flash-frozen in LNO2 and then stored at -7 0 “ C prior to RNA extraction.
3A.2.2.3 R N A  Extraction
RNA was extracted from cell pellets using RNA-Wiz™ (Ambion, UK) as described in 2.2.4.1: 
Extraction and Purification o f RNA.
3A.2.2A  A ssessin g  R N A  Qualit}^
RNA quality was assessed in 2 ways. Firstly, the RNA was visualised using agarose gel 
electrophoresis on a 1% gel. This allowed visualisation o f the 28S and 18S ribosomal subunits. In 
addition, 2pl o f  each sample was diluted 1:50 in autoclaved distilled water and analysed using 
spectrophotometric analysis to assess the concentration and quality o f RNA in the sample.
3A.2.2.5 D N A  R em oval
To ensure RNA samples were not contaminated with DNA, DNA-free'^'^ (Ambion, UK) was used 
as described in 2.2.4.1.2: DNase Treatment o f RNA.
3A.2.2.6 cD N A  F irst Strand Synthesis
Following RNA extraction, cDNA was synthesised using Superscript IIF'^ reverse transcriptase 
(Promega, UK) as described in 2.2.5; First strand cDNA synthesis.
3A.2,2.7 PCR am plification
Following synthesis o f  cDNA, PCR was performed using the primers EX2F and EX2R for canine 
TERT, and DNHTOOIF and DNHTOOIR for human TERT. As a control, amplification o f a 
fragment o f the canine cyclophilin gene was simultaneously performed using the primers CYCLOP 
and CYCLOR, and a fragment o f the human B-actin gene, both o f which are constitutively 
expressed housekeeping genes. These primers are detailed in Table 3.4.
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T able 3.4: Prim ers Used in R T -PC R
Piim ei'
Identification
Oligonucleotide prim er sequence 
(5'-3')
Tm (<>C) & GC 
(%) content
DNHTOOIF A C T G T TCAG CG TG CTCAAC TA 62.6° C : 47 .6%
DNHTOOIR TCATTCAGGGAGGAGCTCTGCT 6 8 .5 °C :5 4 .5 %
CycloF CGTGCTCTGAGTACTGGAGAGAAGGGA 80.2 C : 55.6%
CycloR CCACTCAGTCTTGGCGGTGCAGATGAA 7 5 .0 °C :6 0 .0 %
EX2F CAGGAGCTGCTTGGGAACCA 69.8 C : 60.0%
EX2R CTGGGTTCCCGTGCAGCCAG 74.4 C ; 70.0%
Actin F CAAGAGATGGCCACGGCTGCT 58.0° C : 61.9%
Actin R T C C TTCTG CATCC TG TCG G CA 56.0° C : 57.1%
Platinum High-Fidelity Taq polymerase (Invitrogen, UK) was used for second strand PCR. For 
each sample, 1-5 pi o f  cDNA was mixed in a 0.2pl thin-walled PCR tube with 5pi o f High Fidelity 
PCR buffer, 1 pi dNTP mixture, 2pl MgSO^, 1 pi o f each primer (forward and reverse) used and 
0.2pl Platinum Taq High Fidelity. The reaction mix was made up to a total volume of 50pl with 
autoclaved, distilled water. Samples were kept on ice during pipetting and prior to PCR. As a 
negative control, 5 pi o f  total RNA was also included in each reaction to ensure resultant products 
were not amplified from genomic DNA. Cycling conditions involved dénaturation o f the template 
and activation o f the Taq polymerase at 94° C for 2 minutes followed by 30 cycles o f the following: 
dénaturation at 94° C for 30 seconds, annealing at 55° C for 30 seconds, extension at 68° C for 1 
minute. Finally, the mix was incubated at 72° C for 10 minutes to add a run o f adenosine residues 
to the 3 ’ end o f each template, before being maintained at 4° C.
3.4.2.2.8 A ssessm en t o f  R  T-PCR results
Following PCR, visualisation o f reaction products was performed using 1% agarose gel 
electrophoresis using 5 pi o f  the PCR product.
3.4.3 Immunohistochemistry
Immunohistochemistry (IHC) is a technique that allows identification o f cellular or tissue antigens 
by means o f interaction between a specific antigen-antibody combination. Since the early direct 
labelling experiments performed using a primary antibody conjugated directly to a fluorochrome
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(Coons et al. 1941). Commonly, a modification involving an indirect immunoperoxidase labelling 
approach is used (Sternberger et al. 1970), and this is the method used for the experiments 
described here. This method involves a dual antibody system in which an un label led primaiy 
antibody is bound to a secondary biotinylated ‘bridging’ antibody, derived from a species 
immunised against immunoglobulins o f the species from which the first antibody is derived. A 
complex formed from streptavidin and horseradish peroxidase (HRP) is then conjugated to this 
secondary antibody to provide signal at the site o f the primary antibody. The substrate for the HRP 
is 3,3 diaminobenzidine (DAB; Sigma, USA) which produces a brown end-product at the antigen 
site that is highly insoluble in alcohol and other inorganic solvents. Sections are then stained with a 
counterstain, typically haematoxylin, to visualise negatively-stained structures.
3.4.3.1 Staining Technique
3.4.3.1.1 Staining- Procedure
For this project, staining was performed by Mr C Nixon, University o f Glasgow Vet School. 
Paraffin sections were dewaxed in histo-clear (National Diagnostics, USA), rehydrated in alcohol 
and incubated in 0.5% H2O2 methanol solution for 20 minutes. Sections were then subjected to 
antigen retrieval with 0.01 M sodium citrate (pH6) in a pre-warmed microwave pressure cooker for 
6 minutes. All sections were blocked in 1% normal un label led serum (Scottish Antibody 
Production Unit, UK) in 0.01 M Tris buffered saline for 30 minutes at room temperature and 
incubated for 2 hours at room temperature with one o f a panel o f antibodies against liTERT (at a 
range o f concentrations) or with the MIB-1 monoclonal antibody (at a concentration o f 1/100). A 
standard 1/200 dilution o f the appropriate secondary antibody (polyclonal anti-goat/mouse/rabbit, 
biotinylate; Dako, UK) was then applied and sections were incubated for 45 minutes at room 
temperature. Sections were then washed three times for five minutes in wash buffer before signal 
amplification was achieved by incubation with HRP-conJugated streptavidin-biotin complex 
(DakoCytomation, UK) for 45 minutes. The chromagen DAB (Sigma, UK) was reconstituted in 5 
ml tap water as per manufacturers instructions as ions contained in the tap water enhance the 
reaction and improve the intensity o f final staining. The chromagen was then applied for 5 minutes 
to produce the stable brown insoluble product visible when viewed by light microscopy. 
Counterstaining was performed using G ills’ haematoxylin followed by washing o f the stained cells 
in water, dehydration via a series o f graded alcohols and clearing in Histo-Clear (AGTC 
Bioproducts). Cover slips were then permanently mounted using DPX mounting medium (BDH, 
UK) before being examined by light microscopy. Negative controls were run in parallel with 
omission o f the primary antibody step.
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3.4.3.1.2 Staining O ptim isation
Optimisation o f the staining procedure was performed with a panel o f antibodies against liTERT to 
identify the concentration o f primary antibody that provided the maximum amount o f specific 
staining with the least amount o f  background. A range o f dilutions (1/50, 1/100, 1/200, 1/500, 
1/1000, 1/1200, 1/2000, 1/10,000, 1/20,000, 1/40,000) was used to stain the positive control tissue 
(canine testis). Evaluation o f staining by light microscopy then identified the most favourable 
dilution for each antibody which was then used on all subsequent sections.
3.4.3.2 TER T evaluation
For each section the distribution o f staining within cells and throughout each section was noted. In 
addition, the nature o f  TERT staining within cells was noted. To evaluate TERT staining in tumour 
sections, sections were examined at high power for areas o f TERT positivity and an assessment o f 
the number o f nuclei staining positive was made. In fields with TERT-positive cells, a staining 
percentage o f greater than 10% positive-staining nuclei in each high power field was regarded as 
positive, based on the findings by Poremba et al that >10% of cells from tumours with intermediate 
telomerase activity stain positively for TERT (Poremba et al. 2000b).
3.4.3.3 Ki67 evaluation
In order to evaluate proliferation in tumour sections, Ki-67 staining was evaluated and a MIB-1 
Labelling Index (LI) calculated. A minimum o f 5 fields were selected for each slide from areas 
with the highest number o f positive-staining nuclei. Within these fields, a minimum of 500 nuclei 
per case were counted, and the number o f positive cells expressed as a percentage o f all nuclei 
counted.
3.4.3.4 Statistical Analysis
For comparison o f MIB-1 LI, histological grading, and TERT positivity, the Mann-Whitney U Test 
was used, with the level o f significance set at p<0.05. For comparison o f MIB-1 LI and histological 
grade, the mean MIB-1 LI o f grade 1 tumours in each tumour subgroup was compared with the 
mean MIB-1 LI o f  grade 2 tumours. For comparison o f TERT staining and histological grade, the 
number o f TERT-positive grade 1 tumours in each subgroup was compared with the number of 
TERT-positive grade 2 tumours. For comparison o f MIB-1 LI and TERT staining, the mean MIB- 
1 LI o f TERT-negative tumours in each subgroup was compared with the mean MIB-1 LI o f 
TERT-positive tumours in each subgroup.
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3,4.4 Antibody Evaluation
3.4.4.1 Western Blotting
In order to assess the specificity o f the antibody used, Western blotting was performed using the 
NuPage® Bis-Tris Electrophoresis System (Invitrogen, UK). The NuPage system uses a neutral 
pH, discontinuous Sodium Dodecyl Sulphate (SDS)-PAGE pre-cast mini-gel. The pre-cast gel is 
formulated with a varying gradient o f polyacrylamide (4%-12%) to allow separation o f a range of 
proteins over a range from 1-200 kDa. Samples are reduced using a reducing agent containing 500 
mM dithiothreitol (DTT) at a I Ox concentration. This prevents oxidation o f the samples and allows 
sharper resolution o f bands during electrophoresis. Following addition o f the reducing agent, 
ectrophoresis is then performed with protein either in a denatured (through the addition o f an 
antioxidant to the running buffer) or non-denatured (native) state. Protein is then transferred to a 
nylon membrane and stained with the primary antibody o f interest followed by detection with a 
secondary antibody which is directed against the immunoglobulin molecule of the species in which 
the primary antibody was generated. This secondary antibody is conjugated to a molecule 
(horseradish peroxidase) which produces a colour change when a chromagen is applied that can be 
viewed. This system therefore produces amplification o f the original signal sufficient to allow 
visualisation by light microscopy.
3.4.4.1.1 Sample Preparation
In order to assess the specificity o f staining, several samples were used o f known telomerase 
activity (see 3.4.1 : Sample Details):
Normal canine brain 
D17 Cells 
CMT7 Cells 
K9SF Cells
K9SF Cells transfected with the human DNhTERT construct (see 4.4.1.3: Generation of 
stable trailsfectants)
U-87 Cells
Tissue samples approximately 0.2 mm x 0.2 mm x 0.2 mm in size were used to extract protein. For 
all cell lines, 2 x lO'’ aliquots previously frozen in UNO? were used. To each sample, 200 pi o f 
lysis buffer was added. Lysis buffer was composed o f 0.5% NP40, 150mM NaCI, 50 mM TrisHCl 
(pH 8.0) and shortly before use 1 Complete Mini Protease Inhibitor Cocktail Tablet (Roche, UK) 
was added per 10 ml. Samples were then centrifuged at 13,000 rpm for 30 minutes at room 
temperature. The supernatant was then removed and placed in a fresh 1.5 ml eppendorf tube. The
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protein concentration o f each sample was then assayed using the BCA assay (see 2.2.9: Protein 
analysis).
For Western blotting, initial experiments were performed using 10-30 pg o f protein. Subsequently, 
a total o f 10 pg o f protein from each sample was used. To the volume o f sample was added 5 pi o f 
LDS Sample Buffer containing marker dye (Invitrogen, UK) and 2 pi o f Reducing Agent 
(Invitrogen, UK). The total volume was then made up to 20 pi using deionised water. Samples 
were then heated at 70^ C for 10 minutes for dénaturation prior to electrophoresis. Following 
heating, samples were flash-spun to collect contents in the bottom o f each tube.
3.4.4.1.2 Polyacirylamide G el E lectrophoresis (PAGE)
To perform PAGE, the precast gel was taken out o f its wrapping, the comb and tape removed, 
rinsed with deionised water, rinsed twice with running buffer and then loaded into the Xcell 
SureLock™  Mini-Cell (Invitrogen, UK). Gels were run singly, using the buffer dam instead o f the 
opposing gel. SDS Running Buffer was then made up to a volume o f 1000 ml by adding 50 ml o f 
NuPAGE® 20x MES Running Buffer Stock Solution (Invitrogen, UK) to 950 ml o f deionised 
water and mixed thoroughly. To the outer (lower) buffer chamber o f the Xcell SureLock™  Mini- 
Cell 800 ml o f running buffer was then added. To the remaining 200 ml o f running buffer, 500 pi 
o f NliPAGE® Antioxidant (Invitrogen, UK) was added and mixed thoroughly, before being added 
to the inner (upper) chamber. The antioxidant is added to perform electrophoresis under reducing 
conditions and migrates with the proteins during electrophoresis in order to prevent reoxidation and 
maintain the proteins in a reduced state. The antioxidant also protects sensitive amino acids such 
as methionine and tryptophan from oxidising.
Once the gel was loaded into the Mini-Cell, 20 pi o f each sample was then loaded into each well. 
Twenty microlitres o f a protein mass ladder (SeeBlue™ Plus2 pre-stained standard; Invitrogen, 
UK) was added to the end well o f the gel. Electrophoresis was then performed with a constant 
voltage o f 200 V for 50 minutes.
3.4.4.1.3 M em brane Transfer
Following electrophoresis, proteins were transferred to a nitrocellulose membrane, supplied pre-cut 
with filter paper (Novex® membrane/filter paper sandwiches; Invitrogen, UK). NuPage® transfer 
buffer (Invitrogen, UK) was then made up by adding 50 ml transfer buffer (20x) to 100 ml o f 
methanol. The total volume was then made up to 1000 ml using deionised water. The membrane 
and filter papers were briefly soaked in transfer buffer prior to transfer.
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The gel sandwich was then oriented so that the notched (well side) plastic plate was on top and the 
slotted plate underneath the gel. The plastic plates were separated using the gel knife and the upper 
plate discarded. The wells o f the gel were then cut off using the gel knife. One piece o f pre-soaked 
filter paper was then carefully placed on the gel so no air bubbles were trapped between the gel and 
the filter paper. The lower plate, gel and filter paper were then inverted and the gel pushed o ff the 
plate by pressing the foot o f the gel out of the slot in the plate, and the lower plate discarded. The 
nitrocellulose membrane was then placed on top o f the gel, again making sure that no air bubbles 
were trapped underneath, and the second piece o f filter paper placed on top.
Two blotting pads were soaked in transfer buffer before being placed in the cathode (-) core o f the 
Xcell Blot Module. The gel/membrane/filter paper sandwich was then placed on these pads, 
making sure the gel was closest to the cathode core. Another two blotting pads (pre-soaked) were 
placed on top and the anode (+) core o f the blotting module placed on top. The entire assembly 
was then placed into the buffer chamber using the guide rails and locked in place using the gel 
tension wedge. To the Ix transfer buffer, 1 ml o f antioxidant was added and mixed well before 
adding to the centre o f the blot module. The buffer chamber was then filled with deionised water 
outside the blot module to dissipate heat, the chamber lid was put in place, and transfer performed 
using 30V constant for 90 minutes.
3.4A.1.4 Protein staining
Following membrane transfer, the gel and membrane sandwich was removed and the orientation o f 
the membrane marked so that the lane containing the protein ladder could be identified later. The 
membrane was then briefly stained with Ponceau S solution to confirm protein transfer. The 
membrane was placed in a shallow tray and approximately 5 ml o f  Ponceau S was added. Colour 
was allowed to develop for approximately 30 seconds before the membrane was washed with 
deionised water. Successful transfer was noted by visualising multiple red bands in each lane.
3.4.4.1.5 B locldng
Prior to staining, the membrane was blocked overnight in dried skimmed milk (5%) dissolved in 
0.1% PBS -  Tween at 4° C. Alternatively, the membrane was blocked at room temperature on a 
shaker for 1 hour.
3,4.4.1.6 Staining  -  prim  ary an tibody
After blocking, the blocking solution was discarded and the membrane was washed briefly in 0.1% 
PBS-Tween. In order to titrate the concentration o f antibody required, for the initial experiment the
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membrane was cut into strips, each strip containing a single lane. Each strip was then stained with 
antibody at one o f the following dilutions: 1:100, 1:500, 1:1000, 1:2000. For all subsequent
experiments, a 1:500 dilution o f antibody was used with the whole membrane. The appropriate 
dilution o f antibody was made up in 5% dried skimmed milk dissolved in 0.1% PBS-Tween. Five 
ml was then added to the membrane which was agitated either on a plate shaker or on a roller for 
90 minutes at room temperature.
J. 4.4.1.7 Staining  — secondary an tibody
Following initial staining, the membrane was then washed four times in 0.1% PBS-Tween for five 
minutes per wash. The secondary antibody, consisting o f goat anti-mouse IgG conjugated to 
horseradish peroxidase (Amersham, UK) was then made up to a 1:5000 dilution using 5% dried 
skimmed milk dissolved in 0.1% PBS-Tween. Ten ml was added to the membrane and incubated 
for 60 minutes on a plate shaker at room temperature.
3.4.4.1.8 Visualisation
After staining with the secondary antibody, the membrane was washed four times with 0.1% PBS- 
Tween for five mi nues per wash. Excess liquid was drained from the membrane which was then 
placed on clingfilm. ECL-Plus (Amersham, UK) was made up by adding 125 pi to 5 ml o f reagent 
which was then evenly distributed over the membrane and incubated for five minutes at room 
temperature. The membrane was then sealed within clingfilm and placed inside an autorad x-ray 
film cassette.
In a darkroom, x-ray film was placed inside the cassette together with the membrane and developed 
for 1 minute before being removed and processed using an automatic x-ray film processor. This 
was repeated with exposure times o f 2 minutes, 5 minutes and 10 minutes. From these exposures, 
the most appropriately exposed film was then selected for analysis.
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3.5 Results
3.5.1 Telomerase A ctivity
3.5.1.1 Telom erase Repeat Amplification Protocol analysis o f positive 
and negative control cell lines
In order to confirm the telomerase status o f the cell lines used as positive and negative controls, TRAP 
assays were performed on D17, CMT7, U87 and K.9SF cell lines. TRAP results showed that D17, CMT7 
and U87 cell lines were all positive for telomerase activity, whilst the K9SF cell line was found to be 
negative (Table 3.5).
3.5.1.2 Telom erase Repeat Amplification Protocol analysis of 
telomerase activity in normal canine brain
Tissue extracts obtained from the cerebellum and olfactory lobe o f the canine brain were negative for 
telomerase activity, in contrast, tissue extracts prepared from the caudate nucleus were positive for 
telomerase activity (Table 3.6).
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T able 3.5: T R A P  A nalysis o f  telom erase activity in cell lines used as positive and negative controls.
As is the absorbance o f the sample, Ago is the absorbance o f the heat inactivated version o f each 
sample, AAg is the corrected absorbance o f each sample (calculated by subtracting the mean o f all 
heat inactivated samples (Aso)from As), AAs/Aso is the ratio o f sample to background activity and 
RTA is the telomerase activity relative to the positive control. Samples were considered 
telomerase-positive if the corrected absorbance (AA$) was greater than twice the background 
activity, and if AAs/Àso was greater than 2.0. Using these criteria, samples were designated 
positive (POS) or negative (NEG). The results shown are the mean o f at least two experiments, 
and the assay gave a mean background absorbance o f 0.049 and a (Atss-Ats8,o)/Ats8,is value o f 
2.353 after 10 minutes o f colour development using the high activity positive control.
Cell Line As Aso AAs AAs/ Aso RTA Result
CMT7 0.39 0.07 0.32 4.0 1.7 POS
D17 0.24 0.07 0.17 2.1 0.9 POS
U87 2.61 0.10 2.51 24.0 10.2 POS
K9SF 0.18 0.15 0.03 0.0 0 NEG
Table  3.6: T R A P  Analysis o f  samples taken from norm al canine brain.
As is the absorbance o f the sample, Aso is the absorbance o f the heat inactivated version o f each 
sample, AAs is the corrected absorbance of each sample (calculated by subtracting the mean o f all 
heat inactivated samples (Aso)from As), AAs/Àso is the ratio o f sample to background activity and 
RTA is the telomerase activity relative to the positive control. Samples were considered 
telomerase-positive if the corrected absorbance (AAs) was greater than twice the background 
activity, and if AAs/Aso was greater than 2.0. Using these criteria, samples were designated 
positive (POS) or negative (NEG). The results shown are the mean o f two samples, and the assay 
gave a background absorbance o f 0.10 and a (Atss-Atss.oVAtss.is) value o f 2.597 after 10 minutes 
o f colour development using the high activity positive control.
As Aso AAs AAs/Aso RTA Result
Olfactory Lobe 0.07 0.05 0.02 1.4 0.5 NEG
Cerebellum 0.08 0.04 0.03 1.6 0.6 NEG
Subventricular Zone 0.21 0.05 0.16 4.3 1.7 POS
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3,5.2 Reverse transcriptase-PCR
RT-PCR analysis o f  U87, D17, CMT7 and K9SF ceil lines was performed. The primer pair 
Ex2F/Ex2R was used to amplify a 200 bp fragment from exon 2 o f the canine TERT gene in D17, 
CMT7 and K9SF cells. The primer pair DNHTOO! F/DNHTOOl R was used to amplify a 450 bp 
fragment o f human TERT in U87 human cells. As a positive control, the CycioF/CycloR primer 
pair was used to amplify a 200 bp fragment o f  the canine cyclophilin gene in canine cell lines and 
the ActinF/ActinR primer pair was used to amplify a 200 bp fragment o f the human beta actin gene 
in U87 cells. Agarose gel electrophoresis o f  PCR products revealed a 200 bp product in D17 and 
CMT7 cells, whilst K9SF cells had no such product. Similarly, a 200 bp product was amplified 
from U87 cells, confirming the existence o f the liTERT transcript.
3.5.3 Immunohistochemistry
3.5.3.1 Antibody Evaluation
3.5.3.1.1 A ntibodies
Three commercially available anti-liTERT antibodies were tested. Staining was performed with 
hTERT antibodies supplied by Oncogene (Anti-TERT, which recognises an internal 21 amino-acid 
sequence), Novocastra ( NCL-hTERT, an antibody recognising a 147 amino-acid sequence near the 
N terminal region o f hTERT), and Alpha Diagnostics (EST-22A, an antibody directed against a 21 
amino-acid sequence found in the mid-region o f hTERT) in formalin-fixed and paraffin-embedded 
human tissues by immunohistochemistry (IHC). Staining patterns observed using the Oncogene 
and Alpha Diagnostics antibodies were non-specific and revealed uniform cytoplasmic staining o f 
all cells in positive and negative controls. No nuclear staining was visible and all cells were stained 
equally.
3.5.3.1.2 Staining Pa tterns
Only one antibody (NCL-hTERT; Novacastra) showed sufficient specificity in canine tissues and 
this antibody was used in all subsequent experiments. To determine whether the anti-iiTERT 
antibody could recognise canine TERT protein, TERT immunoreactivity was first examined using 
the NCL-hTERT antibody in positive control D17, CMT7 and U87 cells and in canine testis tissue 
sections. K9SF cells were used as a negative control. In all telomerase-positive cell lines, TERT 
staining was restricted mainly to the nucleus (Figure 3.4A-B), although faint cytoplasmic staining 
was also observed. Staining was particularly prominent in nucleoli, and in some cells nucleolar 
staining was the only detectable pattern. In other cells, staining was distributed throughout the
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nucleus, either in a punctuate/granular pattern or diffusely. Similarly, in normal canine testis 
tissues staining was confined to the germinal cells o f the sperm in itérons tubules (Figure 3.4D). In 
contrast, no immunoreactivity was detected in the negative controls (Figure 3.4C).
3.5.3.1.3 A n tibody Titration
Staining using the NCL-hTERT antibody was performed with the following dilutions: 1/50, 1/100, 
1/200, 1,500, 1/1000, 1/10,000, 1/20,000, 1/40,000 in sections o f canine testis. At dilutions o f 
1/200 and below, strong nuclear and nucleolar staining was seen but some background staining o f 
cells was also observed. At dilutions above 1/500, staining became very faint. At 1/500 dilution, 
staining was restricted to the nucleus, with occasional nucleolar staining. For this reason, staining 
o f all subsequent sections was performed with a 1/500 dilution o f the antibody.
3.5.3.1.4 Wes tern Bio ttin g
Western blotting was performed on samples obtained from the olfactory lobe, subventricular zone 
(in the region o f the caudate nuclei) and the cerebellum of a normal dog. In addition. Western 
blotting was performed on the TRAP-positive cell lines D I7, CMT7 and U87, as well as the 
TRAP-negative K9SF cell line.
Staining o f blots with the NCL-hTERT antibody revealed a number o f bands in all samples (see 
Figure 3.3). The largest band was present in all samples, approximately 100 kDA in size. 
However, no bands o f 127 kDa were present.
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F igure 3,3: W estern Blots
No clear band was identified approximately 127 kDa in size (the expected size o f the canine TERT 
protein) in any lane. Strong bands approximately 100 kDa in size were detected in the CMT7, 
D17, U87 and K9SF cell lines but not in normal brain. A slightly larger, weak band was detected 
in samples derived from the subventricular zone o f the normal brain and in CMT7 and D17 
samples, but not in U87 samples.
Protein Size
(kDa) Marker I
188 
98
Lane 
3 4 5
49
38
28
Sample Details:
Lane Sample
1 Normal brain: Olfactory lobe
2 Normal brain: Subventricular Zone
3 Normal brain: Cerebellum
4 D17Cell Line
5 CMT7 Cell Line
6 U87Cell Line
7 K9SFCell Line
8 K9SFCell Line
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Figure 3.4: Immunohistochemical staining o f TERT in positive and negative controls
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A: D17 Cells, TERT staining. Note intense nucleolar staining, diffuse strong nuclear staining and 
weak cytoplasmic staining. X 400 Magnification.
B; CMT7 Cells, TERT staining. Note similar staining pattern to D17 cells but with weaker nuclear 
staining. X 400 Magnification.
C: K9SF Cells, TERT staining. Note negative nuclear staining. X 400 Magnification.
D: Normal canine testis, TERT staining. Note germinal layer with diffuse nuclear staining 
(arrowheads) but progressive loss of staining of cells with further differentiation. In addition, some 
cells in interstitial areas (white arrow) were found to have isolated nucleolar staining. X 100 
Magnification.
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3.5.3.2 Im m unohistochem ical detection of TERT in the normal canine 
brain
To determine whether TERT protein is expressed in normal canine brain, immunohistochemistry 
was performed on brain sections of the olfactoiy lobe, subventricular zone at the level of the 
caudate nuclei, and the cerebellum. Some cells were found to stain positively in all sections o f the 
brain, largely restricted to neuronal cells (Figure 3.5A-D). In the cerebellum, Purkinje cells 
appeared to be the only cell type stained positively (Figure 3.5E). In general staining appeared to 
be confined to nuclei o f  cells. In Purkinje neurons, nucleoli were not found to stain positively. The 
region o f the brain that showed greatest staining was the subventricular zone, in the region o f the 
caudate nucleus, with large numbers o f neurons and glial cells staining positively (Figure 3.5A-B).
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Figure 3.5: TERT staining o f normal canine brain
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A; Normal canine brain, TERT staining -  subventricular zone. Note large number of positively 
stained cells. The majority of these cells are neurons, displaying a mixture of diffuse nuclear and 
nucleolar staining (black arrowheads), nucleolar staining only (white arrow) and cytoplasmic 
staining (white arrowhead). However, some smaller cells, comprising oligodendroglia and 
astrocytes, also display positive staining (black arrow), x 200 Magnification 
B: Normal canine brain, TERT staining -  subventricular zone. Higher power view of A showing 
neuronal staining, x 400 magnification.
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Figure 3.5 (cont)
C: Normal canine brain, TERT staining -  olfactory lobe. Note lower number of TERT-positive 
cells, all of which are neurons, and some negatively staining neurons (arrowhead).
X 200 magnification.
D: Normal canine brain, TERT staining -  olfactory lobe. Higher power view of C showing 
neuronal staining, x 400 magnification.
E: Normal canine brain, TERT staining -  cerebellum. Note positive staining of Purkinje neurons 
only, with adjacent granule cells staining negatively, x 400 magnification.
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3.53.3  Validation of Ki-67 Staining
Immunoreactivity for the Ki67 antigen was exclusively confined to the nucleus with no evidence o f 
cytoplasmic staining. Staining was strong and diffuse throughout the nucleus. Whilst normal cells 
showed no positivity, proliferating cells stained strongly positive for Ki-67 in all tumour types 
examined. Examples o f staining are shown in Figure 3.6. In those tumours stained for Ki-67, 
MIB-1 LI correlated significantly with tumour grade, with a mean MIB-1 LI o f 1.5% for grade 1 
tumours, as compared with a mean MIB-1 LI o f 21.7% for grade 2 tumours (p « 0 .0 0 0 1 ). The 
highest MIB-1 LI for all grade 1 tumours was found to be 8.9%, which was also the lowest MIB-1 
LI for grade 2 tumours (Figure 3.7, Table 3.8).
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Figure 3.6: Examples o f  MIB-1 staining in canine brain tumours. Right: Corresponding H&E sections
m%s
A; Oligodendroglioma. MIB-1 LI 0.0% x 200 magnification 
B; Anaplastic oligodendroglioma. MIB-1 LI 25.0% x 200 magnification 
C: Astrocytoma. MIB-1 LI 3.2% x 200 magnification 
D: Glioblastoma multiforme. MIB-1 LI 26,1% x 200 magnification
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Figure 3.6 (cont). 
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E: Meningioma. MIB-i LIO.0% x 200 magnification 
F: Anaplastic meningioma. MIB-1 LI 14.8% x 200 magnification 
G: Choroid plexus papilloma. MIB-1 LI 3.0% x 200 magnification 
HiChoroid plexus carcinoma. MIB-1 LI 9.2% x 200 magnification
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Figure 3.6 (cont).
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I: Metastatic Lymphoma. MIB-1 LI 49.3% x 400 magnification 
J: Metastatic carcinoma. MIB-1 LI 10.4% x 200 magnification
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Figure 3.7: Graph showing MIB-1 LI vs grade in 51 canine brain tumours
MIBl LI vs Grade in 54 Canine Brain Tumours
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3.5.3.4 TERT staining in canine brain tumours
In general TERT staining in canine brain tumours appeared to be remarkably similar to that 
described in human tumours. The staining pattern seen varied between tumours, with discrete 
nucleolar staining in some tumours, and more diffuse nuclear staining in others. The strength o f 
this staining also appeared to vary, with some tumours showing only faint nuclear staining and 
other others very strong staining. Some examples o f this staining are shown in Figure 3.8.
There appeared to be no consistent staining pattern associated with particular tumour types, 
although some observations can be made. Overall, oligodendrogliomas and meningiomas tended to 
show diffuse staining patterns, with almost the entire tumour either staining positively or negatively 
(Figure 3.SB). Astrocytomas, on the other hand, tended to show more patchy staining patterns, 
with some areas focally positive, and with individual cells showing positive staining (Figure 3.8C). 
In addition, in some glioblastomas, TERT staining was not restricted to tumour cells but was also 
found to be present in areas o f vascular endothelial hyperplasia (Figure 3.8D). In these areas, 
endothelial cells stained positively, either with nucleolar staining or with a more diffuse nuclear 
localisation. In addition, there appeared to be some background cytoplasmic staining in these cells. 
Cytoplasmic staining was also found in choroid plexus papillomas and carcinomas, both o f which 
tumour types contain cells o f endothelial origin.
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Figure 3.8: TERT staining in canine brain tumours
A
i f
A: Anaplastic astrocytoma, TERT staining. Note discrete nucleolar staining with little 
nuclear staining. X 400 magnification.
B: Anaplastic oligodendroglioma, TERT staining. Note that the vast majority of cells in 
this section exhibit diffuse nuclear staining. X 200 magnification.
C: Glioblastoma multiforme, TERT staining. Note the focus of positive-staining cells 
within a predominantly negative-staining field. X 200 magnification.
D; Glioblastoma multiforme, TERT staining. Note the central vascular endothelial cells 
with positive-staining cells. X 200 magnification.
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Figure 3.8 (cont.)
• w
1
E: Meningioma, TERT staining. Note absence of immunoreactivity X 200 
magnification.
F: Anaplastic meningioma TERT staining. Note mixture of cytoplasmic and nuclear 
staining. X 200 magnification.
G: Metastatic adenocarcinoma, TERT staining. X 400 magnification.
148
3.S.3.5 Correlation between TERT and K167 staining in canine brain 
tumours
A total o f 93 canine brain tumour sections were evaluated for TERT staining, o f which 50 were 
classified as Grade 1 and 43 as Grade 2 (Table 3.7), Positive immunostaining for TERT was 
evident in 16 o f 50 Grade 1 tumours (32%) compared to 29 o f 43 Grade 2 tumours (67%), showing 
a significant association with histological grade (p=0.00012) (Figure 3.9, Table 3.9). Similarly 
TERT staining was found to correlate with malignancy in meningioma and oligodendroglioma 
tumour subtypes (p=0.01 and p^O.004 respectively), but no significant association was evident for 
the remaining subtypes (Figure 3.10).
O f these tumours, 5 1 were also available for MIB-1 staining, o f which 26 were classified as Grade 
1 and 25 as Grade 2 (Table 3.8). When TERT staining was compared with MIB-1 LI, a significant 
association was also found between the mean MIB-1 LI value and TERT expression in brain 
tumours overall (p «  0.0001) and in the meningioma and oligodendroglioma subtypes (p = 0.002 
and p = 0.007 respectively) (Table 3.9, Figure 3.10). A trend for association between TERT 
staining and MIB-1 LI was obvious in other tumour subtypes, although this was not significant 
(Figure 3.10, Table 3.9).
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Table 3.7: Diagnosis, grading and T E R T  staining in 93 brain tumours
Tumour Type Grade No. No. TERT +ve P Value
Astrocytomas
Astrocytoma 1 5 0
Astrocytoma anaplastic 2 5 3
Astrocytoma glioblastoma 2 4 2
14 5 (36%) 0.10
Meningiomas
Meningioma 1 21 8
Meningioma anaplastic 2 6 4
27 12 (44%) 0.008
Oligodendrogliomas
Oligodendroglioma 1 17 7
Oligodendroglioma anaplastic 2 10 8
27 15 (56%) 0.004
Choroid plexus tumours
Choroid plexus papilloma I 6 0
Choroid plexus papilloma: anaplastic 2 1 1
Choroid plexus papilloma: carcinoma 2 Î 0
8 1 (13%) 0.19
Other
Ependymoma 1 1 1
Gliosarcoma 2 1 1
Medullobiastoma 2 1 1
Pituitary adenocarcinoma 2 1 I
4 4 N/A"
Métastasés
Adenocarcinoma 2 6 4
Lymphoma 2 7 4
13 8(61%) N/A'
All tumours
Grade 1 50 16
Grade 2 43 29
93 45 0.00012
a Not applicable due to insufUcient numbers in group
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T able 3.8: Diagnosis, grade, M lB - l  LI and T E R T  staining in 51 canine brain tumours
Tumour Type Grade No. Mean MIB-1 
LI (%)
MIB-1
Range (%)
TERT
+ve
P value
Astrocytomas
Astrocytoma 1 1 3.2 3.2 0
Astrocytoma anaplastic 2 2 11.6 8.9-14.2 1
Astrocytoma glioblastoma 2 2 22.9 19.6-26.1 1
5 2 0.44
Meningiomas
Meningioma 1 10 0.0 0-2.0 0
Meningioma anaplastic 2 5 19.3 13.0-41.4 4
15 4 0.0015
Oligodendrogliomas
Oligodendroglioma 1 10 2.5 0.-8.9 2
Oligodendroglioma anaplastic 2 9 22.3 9.2-37.8 8
19 10 0.007
Choroid plexus tumours
Choroid plexus papilloma 1 5 0.8 0-0.3 0
Choroid plexus papilloma: 2 1 9.2 N/A 0
carcinoma
6 0 0.19
Other
Gliosarcoma 2 1 26.1 N/A" 1
Pituitary adenocarcinoma 2 1 16.9 N/A" 1
2 2 N/A"
Métastasés
Lymphoma 2 3 47.1 19.4-72.5 2
Adenocarcinoma 2 1 19.4 N/A" 0
4 2 N/A"
All tumours
Grade 1 26 1.5 0-8.9 2
Grade 2 25 21.7 8.9-72.5 18
Total 51 20 «0.001
a Not applicable due to iiisufticieiit numbers in group
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Figure 3.9: Graph showing TERT staining vs Malignancy in 93 canine brain tumours
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Table 3.9: Mann-Whitney U Test Calculations -  TERT staining vs Malignancy. P values are
highlighted in bold
T umour type
Meningioma Astrocytomas Oligodendrogliomas Choroid
plexus
tumours
Other
tumours
All
tumours
TERT 14 9 15 7 12 48
negative
TERT 6 5 12 1 5 45
positive
nl 14 9 15 7 12 48
n2 6 5 12 1 5 45
U 78 35 148.5 6.5 3Z5 1581
normal: 2.55 1.67 2.85 1.30 0.26 3.85
P (2 tail) 0.013 0.11 0.00 0.25 0.80 0.00
0.01 0.10 0.00 0.19 0.79 0.00
P(1 tail) 0.00 0.06 0.00 0.13 0.40 0.00
0.01 0.05 0.00 0.10 0.40 0.00
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Figure 3.10: Immunohistochemical hTERT staining vs M alignancy in 93 brain tumours by subtype
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3.6 D iscussion
The primary aims o f this chapter were to examine and validate the use o f commercially-available 
hTERT antibodies in canine paraffin-embedded tissues. In addition, the secondary aim o f the 
chapter was to validate the Ki-67 proliferation marker in canine brain tumours, and then to 
correlate proliferation with telomerase activity in canine brain tumours. Analysis o f three 
commercially available antibodies in telomerase-positive and negative cell lines and in canine testis 
showed that the novocastra antibody NCL-hTERT specifically stained telomerase-positive cells 
and tissues at a dilution o f 1/200.
3,6.1 A ntibody Validation
In general, staining with the hTERT antibody in canine tissues correlated well with TRAP and RT- 
PCR results, with all TRAP-positive cell lines revealing strong TERT staining, and TRAP-negative 
cell lines showing no staining. However, Western blot analysis failed to demonstrate the presence 
o f specific binding o f NCL-hTERT in telomerase-positive samples. Instead, the NCL-hTERT 
antibody detected a 100 kDa band in all samples, irrespective o f telomerase activity (Figure 3.3). 
Since performing this work, the NCL-hTERT antibody has also been found to recognise a 100 kDa 
band in canine cells exogenously expressing wild-type hTERT (1. Nicholson, unpublished data). A 
slightly larger, faint band was detected in samples obtained from the subventricular zone, 0 1 7  and 
CMT17 cells, but not in U87 cells. In addition, a number o f  smaller bands were present in some 
samples, in particular a strong 28 kDa fragment in D17 and CMT7 cells, and a smaller fragment 
was present in all samples with the exception o f those obtained from the normal brain. A single 
faint band approximately 40 kDa in size was also detected in samples obtained from the 
subventricular zone that was not present in any other samples.
Several reasons could explain the lack o f a single 127 kDa band on Western analysis. Firstly, 
technical issues with the process o f Western blotting could be involved. The use o f Sodium 
Dodecylsuiphate (SDS) linearises the proteins in the sample and coats them with a negative charge. 
In addition, the presence o f reducing agents (DTT) reduces the disulphide bonds between peptides. 
This dénaturation alters the three-dimensional structure and in some cases may also alter the 
antigenicity o f the protein. Some antibodies will only recognise the native, unreduced antibody, 
and this may be one o f the reasons the hTERT antibody did not recognise TERT in our samples. 
However, as non-denatured proteins often migrate anomalously through the SDS-PAGE gel used, it 
may be difficult to estimate the size o f any bands detected by the antibody in a non-denatured state. 
Another possibility that may explain the presence o f bands smaller in size than expected is 
proteolytic degradation o f the sample prior to electrophoresis. The presence o f proteases in 
samples can lead to proteolysis o f proteins, and this can be avoided through the use o f  protease
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inhibitors included during sample preparation. Although protease inhibitors were included in our 
sample preparation, it is possible that some proteolysis still occurred.
An alternative reason for multiple bands in the samples examined is the presence o f alternately- 
spliced variants o f the TERT transcript. The NCL-hTERT is raised against a 147 peptide sequence 
located at the amino terminal end o f hTERT. This region does not contain any reported splice 
sites, and so the antibody would be expected to cross-react with all o f  the splice variants known. 
Thus, the NCL-hTERT antibody does not distinguish between catalytically and catalyticaily 
inactive hTERT. However, the presence o f the same 100 kDa band in U87 cells as well as all 
canine cell lines would not be explained by alternate splicing, as splice sites would be expected to 
be different in dogs as compared to humans.
Another reason for the lack o f a 127 kDa-sized band in our samples is the possibility that 
insufficient TERT protein was present in our samples for antibody detection. It is well known that 
only a small number o f copies o f the hTERT mRNA transcript (3-4) are present in any given 
telomerase-positive human cell (Yi et a l  2001). For this reason it may be that the TERT protein is 
equally scarce within telomerase-positive cells. In order to investigate this possibility, protein- 
concentrating or TERT-concentrating techniques such as immunoprécipitation techniques may help 
to clarify this issue by increasing the number o f copies o f TERT molecules present prior to Western 
blotting.
Another unexpected finding when Western blots were examined was the presence o f smaller bands 
in all samples. It is possible that the NCL-hTERT antibody was detecting alternative antigens in 
addition to hTERT itself, suggesting that it was not entirely specific for hTERT. However, given 
the conformational changes undergone by samples when reducing SDS-PAGE is performed, it is 
unknown whether the peptides would also be detected by NCL-hTERT in a natural state. 
Alternatively, the fact that proteolytic digestion may have occurred prior to electrophoresis raises 
the possibility that these fragments are partially-digested forms o f hTERT.
3.6.2 TERT staining patterns
NCL-hTERT staining o f positive controls produced results that are similar to those reported by 
other authors reporting hTERT staining. In particular, the strong nucleolar localisation o f hTERT 
has been reported by other studies investigating the NCL-hTERT antibody (Maes el a l  2005; 
Smith et ai. 2004). This would make sense given that it has been shown that hTERT can be 
concentrated in the nucleolus, and that functional assembly o f telomerase occurs there (Smith et a l
2004). However, after the hTERT mRNA is transcribed, it is transported to the cytoplasm where it 
is translated into protein before being phosphorylated and re-entering the nucleus and locating to 
the nucleolar region. For this reason, cells that are producing TERT in large quantities could be
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expected to show in the nucleus and possibly the cytoplasm, in addition to the nueleolus. It is also 
likely that cells with lower levels o f  TERT expression may only show nucleolar staining, as was 
found in some cells in sections o f the canine testis (Figure 3.4). Additionally, some authors have 
suggested that the speckling pattern seen within the nucleus could be the presence o f the active 
telomerase complex at the chromosome ends (Maes et at. 2005).
3.6.3 TERT staining o f  the normal canine brain
An unexpected finding was the significant staining o f cells in the eanine brain. The number o f 
nuclei stained positively in the subventricular zone was considerably greater than in other areas of 
the brain. In this area, predominantly astrocytes and neurons stained positively, whilst in other 
areas staining was restricted to neurons. In the cerebellum, the only cell type observed to stain 
strongly was the Purkinje neuron, whilst the adjacent granule cells did not stain with NCL-hTERT. 
Interestingly, the nucleoli o f  Purkinje neurons were found not to take up stain, whilst the rest of the 
nucleus stained diffusely (with no obvious speckling).
The staining pattern in the subventricular zone correlated with TRAP results, with this part o f the 
brain showing weak telomerase activity. In itself this is an interesting finding, as the brain contains 
predominantly populations o f terminally differentiated cells that in general are not able to undergo 
further proliferation. Flowever, there is increasing evidence to suggest that even in the brain 
populations o f stem cells and precursor cells exist, which may be stimulated to divide. In fact, the 
subventricular zone is now known to be one area in which these stem cells reside, and in mice this 
part o f  the brain does possess telomerase activity, which may account for this finding (Caporaso et 
al. 2003). However, this does not explain the staining seen in cells from other parts o f the brain. 
Perhaps the simplest explanation for this is that the NCL-hTERT antibody cross-reacts with a 
similar epitope within neurons in the canine brain, and it would be very hard to disprove this 
possibility. Alternatively, as may be the case with Western analysis, it may be that the hTERT 
antibody is recognising a splice variant o f TERT that is non-functional. At this point, it is not 
known whether splice variants o f TERT exist within canine neurons, but an important further study 
would be to determine whether this is the case. Thirdly, it is possible that telomerase activity can 
be upregulated in neurons, under some circumstances. For instance, telomerase can be found in 
neurons in mice following hypoxia induced by middle cerebral artery occlusion, and 
overexpression o f TERT protects these neurons from hypoxic damage (Kang et al. 2004). 
Telomerase has also been shown to promote survival o f neurons in the brain o f mice under other 
circumstances (Fu et al. 2000; Lu et al. 2001). For this reason, it is possible that telomerase 
expression is inducible in the brain under situations o f stress, and that this may occur in canine 
brains. However, given the lack o f telomerase activity in parts o f  the brain other than the 
subventricular zone as determined by TRAP assay, this seems an unlikely explanation for the 
staining pattern seen in this case. Finally, an important caveat to the findings so far described is
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that at this stage only a single canine brain has been examined for telomerase activity and TERT 
staining, and an important first study required would be to determine by TRAP assay whether these 
results are also found in these and other areas o f normal brains o f other dogs. If TRAP assay 
results can be shown to correlate with TERT staining in the brain, it would be interesting to 
examine TERT staining in other pathological states such as hypoxia and cerebral oedema.
3,6.4 Validation o f Ki-67
Our results correlating Ki-67 staining in canine brain tumours suggest that it provides a useful 
marker o f proliferation. Our results are consistent with results described in human brain tumours. 
In our study, a MlB-1 LI o f approximately 9% appeared to be the cutoff between grade 1 and grade 
2 tumours (Figure 3.7). In general, the majority o f grade 1 tumours had a low MIB-I LI, usually 
less than 4%, as is seen in the majority o f benign human brain tumours. One interesting finding in 
our study was that two o f the grade 2 meningiomas had a MlB-I LI o f >20%. However, three had 
a substantially lower MIB-1 o f between 9 and 14%. In humans, the WHO classification includes 
three grades o f meningioma: the benign, atypical and anaplastic variants (Kleihues & Cavenee 
2000). O f these, the atypical variant has been reported to have a MlB-1 LI o f less than 20% whilst 
the anaplastic variant has a MIB-1 LI o f  greater than 20% (Kleihues & Cavenee 1999). It is 
possible that in dogs a third, atypical variant may be present based on a proliferative index o f less 
than 20%, as described in people, although current WHO grading systems only describe two 
variants. Further work correlating survival with grading would be needed to determine this, 
however. Overall, it would appear that the MlB-1 LI for most canine brain tumours is similar to 
that seen in human brain tumours.
3.6.5 TER T  s taining in canine brain tumours
In general, the staining pattern seen in eanine brain tumours appeared to be similar to that described 
in humans. However, some discrepancies were apparent in the proportion o f some tumour types 
positive for TERT. A higher proportion o f canine meningiomas appeared to be immunoreactive for 
TERT as compared with human meningiomas, with 8 o f 21 canine meningiomas (38%) versus 0- 
27% o f human meningiomas being TERT-positive. This may be related to the more aggressive 
behaviour o f  canine meningiomas, which show a tendency to invade into the Virchow-Robin 
spaces and surrounding brain tissue, and which recur as a matter o f course following surgical 
resection (Koestner et a l ,  1999). On the other hand, a lower proportion o f canine astrocytomas 
appeared to be positive for TERT than has been reported in human tumours. Only 5 o f 9 (54%) 
grade 2 canine tumours were positive for TERT. This includes 2 o f 4 glioblastomas. Although the 
number o f  astrocytomas overall was small, some authors have suggested that in humans, 100% of 
glioblastomas are positive for TERT expression, although this expression varies throughout the 
tumour mass and may be missed if careful sampling is not used (Falchetti et a l 2000). In dogs, it
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would appear that less than 100% o f glioblastomas are positive for TERT expression, although a 
larger number would need to be examined to ascertain the true incidence. It may be that this 
reflects a fundamental underlying difference in biological behaviour between the canine and human 
glioblastoma. To date, little work has examined these tumours in dogs to confirm whether they 
possess similar genetic characteristics to those seen in humans, and minimal data (especially 
regarding survival) are available by which to judge their clinical behaviour. It must also be noted, 
however, that studies examining telomerase activity in human astrocytic tumours overall have 
produced wide variations in the stated proportion o f tumours positive for telomerase activity.
Although the numbers within each tumour type positive for TERT appeared to differ slightly, 
staining patterns appeared to be similar for both species. In particular, the more homogenous 
nature o f oligodendroglial tumours appeared to be reflected in the TERT staining pattern seen, 
although this was not always the case. The trend towards more focal, patchy localisation o f TERT 
activity in astrocytomas also appears to parallel the human situation (Kleinschmidt-DeMasters 
1998a). This may reflect the evolution o f these different tumour types. The fact that glioblastoma 
multiforme may arise through one o f several different pathways, either as a de novo tumour or as 
malignant transformation o f more benign astrocytoma subtypes, demonstrates the genetic variation 
underlying this phenotype. Indeed, Harada et al found that a significantly greater proportion of 
secondary glioblastomas possessed telomerase activity as compared with de novo tumours (Harada 
et al. 2000b). Some authors have suggested that telomerase activation occurs early in 
glioblastomas, and that with increasing tumour growth and the development o f necrosis, telomerase 
activity subsequently disappears in some areas (Falchetti et al. 2000). However, other authors have 
suggested telomerase activation may occur in association with areas o f greater anaplasia, a finding 
which could argue against this as anaplasia is more likely to occur later in tumour development 
(Kleinschmidt-DeMasters et al. 1998a). Whether this pattern o f telomerase loss with glioblastoma 
development occurs in dogs as well as in people remains to be seen. The finding that TERT was 
present in endothelial cells undergoing vascular endothelial hyperplasia has also been reported in 
humans (Falchetti et al. 2003; Pallini et al. 2001). The involvement o f  telomerase in tumour 
angiogenesis is likely to be the result o f similar factors responsible for tumour development. For 
instance, the SP-1 transcription factor which is known to be important for the activation o f TERT 
transcription, also acts on the promoter region o f the Vascular Endothelial Growth Factor (VEGF) 
gene, a major player in the initiation o f angiogenesis in tumours as well as in other situations 
(Falchetti et al. 2003). There appeared to be no association between TERT localisation and other 
features o f malignancy, however, such as necrosis or mitotic activity.
At this stage the significance o f cytoplasmic staining in samples is unclear. The staining o f 
endothelial cells may reflect a non-specific interaction with the antibody, as several other 
antibodies stain endothelial cell cytoplasm in a non-specific manner. Indeed, the MlB-1 antibody
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showed frequent cytoplasmic staining o f endothelial cells in some sections of choroid plexus 
papillomas (Figure 3.6).
3.6.6 Correlation between TERT staining and proliferation in canine 
brain tumours
In our study, TERT staining generally appeared to correlate with proliferation in all tumours 
overall, and in the meningioma and oligodendroglioma subtypes. The association between 
proliferation and telomerase activity in human brain tumours is not entirely clear. Whilst many 
studies have found that telomerase activity is associated with proliferation (Cabuy & de Ridder 
2001; Falchetti ei al. 2000; Fukushima et al. 2002; Sal linen et al. 1997; Simon et al. 2000), some 
studies have not (Nakatani et al. 1997). Given that increased proliferation is the most useful 
prognostic indicator for many brain tumour types, and that telomerase activity is commonly 
associated with malignancy, it would be expected that these two characteristic features o f tumours 
should overlap to some degree. Evidenee for a link between cell proliferation and telomerase 
activity has also emerged from somatic cells (Masutomi et al. 2003). However, it is not entirely 
clear whether the two factors are directly linked or whether they stem from a common determinant 
of tumour behaviour. One interesting study in breast cancer cells showed by immunocytochemical 
resta in ing that many o f the cells undergoing proliferation were also expressing telomerase, 
suggesting that at least in some tumour types the pathways initiating these two factors are shared by 
the same cells (Ikeda et al. 2003). However, it is possible that telomerase activation may occur 
either before or after the signal to proliferate. For instance, Maes et al found that TERT expression 
could be found in a subset of benign meningiomas, and that this predicted recurrence (Maes et al. 
2005). Proliferation, however, was not significantly different between recurrent and non-recurrent 
tumours, suggesting that at least in these tumours TERT expression occurs before significant 
proliferation. Although in canine brain tumours overall we found a direct correlation between 
TERT expression and cellular proliferation, significant variation was found between the different 
tumour subtypes. For instance, the most proliferative tumour, a metastatic lymphoma, was found 
not to express TERT. In humans, the level o f telomerase expression in metastatic brain tumours 
does not seem to correlate with either the tumour type or patient survival (Kleinschmidt-DeMasters 
et al. 1998b). However, telomerase activity is a very common finding in metastatic tumours, which 
makes our case surprising. It may be that in canine metastatic tumour cells TERT expression may 
be regulated in a different manner to human tumours.
3.6.7 Potential usefulness o f  TERT staining in canine tumours
Ultimately, the potential usefulness o f TERT staining and telomerase activity in canine cancer cells 
depends on the correlation between telomerase activity and patient survival. In dogs, evaluating
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this is less straightforward than in humans, because o f the variability inherent in measuring patient 
survival. This is influenced by the fact that the endpoint o f caneer in dogs is determined by owner 
issues more often than by the death o f the patient. The decision to euthanase is based on a number 
o f factors, some emotional, some financial, with the result that the point at which owners elect to 
euthanase varies enormously. This is accentuated in patients with brain disease, where the clinical 
signs o f  a tumour may be less dependent on the size of the tumour than its location and its growth 
rate -  a small tumour within the brainstem growing rapidly may lead to severe clinical signs more 
quickly than a larger tumour growing slowly in the cerebrum. In addition, tumours in the cerebrum 
may lead to clinical signs such as seizures and blindness which some owners find unacceptable but 
others are able to accommodate to prolong life for as long as possible. As a result, the assessment 
o f survival in dogs with brain tumours is complicated by the variability inherent in the decision to 
euthanase.
Given this limitation in assessing patient survival, it is important to try to correlate the TERT stain 
deseribed here with clinical outcome. The advantage o f the immunohistochemical stain we have 
described is that it can be applied retrospectively to archival material. Therefore, acquiring a 
sufficient number o f cases to assess survival following definitive treatment can be simplified by 
including retrospective as well as prospective case material.
There is considerable evidence already from the human literature that TERT expression will indeed 
be a useful prognostic indicator. For example, in meningiomas, up to 20% o f the most benign 
subtype will reeur despite surgical resection. Whilst proliferative markers do not predict those 
tumours which go on to recur, Maes et al found that TERT expression does, since recurrent 
tumours were found to have significantly more cells TERT-positive than non-recurrent tumours 
(Maes et al. 2005). Simon et al reported similar findings, finding that all recurrent meningiomas in 
their study had acquired telomerase expression (Simon et al. 2000). Similarly, Harada et al found a 
similar situation in tracking a recurrent pituitary tumour, with successive resections showing an 
increasing level o f  telomerase activity (Harada et al. 2000a). Studies examining telomerase 
activity within individual tumours as they progress are likely to provide useful information on 
tumour progression which is not necessarily available from surveying larger groups of tumours. 
Given the expense and morbidity o f these repeat resections in dogs, it is unlikely in the near future 
that we will be able to perform similar evaluation in dogs as in people. However, given the nature 
o f the stain we have described here, should such a situation arise, it will be possible to examine the 
telomerase activity at any point, which would not be possible without prior preparation with other 
methods o f assessing telomerase activity.
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C h a p t e r  I V
T e l o m e r a s e  In h i b i t i o n  i n  Ca n i n e  Ca n c e r  Ce l l s
4.1 Abstract
Given the importance o f telomerase activation as a means for attaining an immortalised phenotype, 
considerable research has focused on inhibiting telomerase. Several approaches have been 
investigated: using strategies interfering with the function o f either TR or TERT, strategies 
targeting telomerase-associated proteins, and strategies interfering with the interaction between 
telomerase and the telomere. A large number o f naturally-occurring and synthesised moleeules are 
now in existence that fall into one o f these categories. The aim o f this chapter was to investigate 
two o f these in canine telomerase-positive cell lines: the dominant negative mutant o f human 
TERT, DN-hTERT, and the G-quadruplex inhibitor telomestatin, isolated from Streptomyces 
anulatus. We tested the DN-hTERT dominant negative mutant by establishing cell lines stably 
transfected with this construct carried by the selection vector pClNeo, and found that over 50 
population doublings, the DN-hTERT mutant failed to inhibit telomerase activity in telomerase- 
positive D I7 and CMT7 cells. Over this period, growth rates and telomere lengths o f transfected 
cells were similar to those o f negative control mock-transfected cells. Surprisingly, the same 
construct reactivated telomerase activity in teiomerase-negative K9SF fibroblasts. Moreover, 
K9SF cells transfected with DN-hTERT appeared to undergo morphological changes consistent 
with a cancerous phenotype and exhibited accelerated growth as compared to negative controls. 
Investigation o f telomestatin treatment o f telomerase-positive cell lines yielded more encouraging 
results. Treatment o f D17 and CMT7 cells with telomestatin at varying concentrations showed that 
a concentration o f 2 p,M caused a decrease in telomerase activity by approximately 80% as 
compared with negative controls. Over a longer treatment period, telomestatin was also shown to 
cause slower growth and telomere shortening in these cell lines, together with an increase in the 
proportion o f cells undergoing apoptosis. Treatment o f K9SF cells, however, did not cause any 
change in growth rate or apoptosis. These findings suggest that telomestatin treatment specifically 
abrogates telomerase activity in canine telomerase-positive cell lines and warrants further 
investigation o f this promising telomerase inhibitor in canine cells.
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4.2 Introduction
Since telomerase represents a major pathway to the acquisition o f an immortal phenotype in eancer 
cells, considerable research has been performed investigating ways in which to inhibit its activity. 
This work has been carried out for 2  reasons: firstly, to further elucidate the effects o f telomerase 
activity within cells, and secondly to explore new forms o f cancer therapy. Telomerase represents 
an ideal target for cancer therapy since expression is largely restricted to tumour cells and since it 
plays a critical role in promoting tumour cell survival and extended lifespan. This chapter aims to 
explore telomerase inhibition as a means o f treating cancer in dogs. There are several potential 
methods by which this inhibition can be achieved. Broadly speaking, these methods can be divided 
into three groups: I) strategies interfering with the activity o f either TR or TERT; 2) strategies 
targeting the telomerase-associated proteins (eg protein inhibitors); and 3) strategies interfering 
with the binding o f telomerase to the telomere. The agents which have shown most promise within 
each o f these groups will be reviewed briefly here.
4.2.1 Strategies interfering with the activity o fTR or TERT
4.2.1.1 Reverse transcriptase inhibitors
Since the TERT subunit o f telomerase functions as a reverse transcriptase, early searehes for 
telomerase inhibitors foeused on drugs known to inhibit other reverse transcriptases. These 
included the drugs Azidothymidine Triphosphate (AZT), dideoxyguanosine, arabinofuranyl- 
guanosine, dideoxyinosine, dideoxyadenosine, didehydrothymidine and phosphonoformic acid 
(Kelland 2005). Although these drugs have been shown to inhibit retroviral reverse transcriptase, 
their ability to speeifically inhibit the activity o f hTERT have not been promising. Long-term 
treatment o f telomerase-positive B-cell and T-cell lines with these agents in one study resulted in 
telomerase inhibition only with AZT and dideoxyguanosine (Strain 1 & Blackburn 1996) When these 
were then tested in other cultures, only dideoxyguanosine also induced telomere shortening, but 
had no effect on population doubling or cell survivability, despite exposure o f cells to the drug for 
almost 12 months. The effects o f dideoxyguanosine were shown to be due to binding and 
competitive inhibition at the nucleoside triphosphate binding site. The addition o f other agents to 
dideoxyguanosine did not improve the efficacy o f action (Strahl & Blackburn 1996). Importantly, 
a recent study by Argyle et a! has demonstrated that AZT alone is not an effective inhibitor o f 
telomerase activity in the canine telomerase-positive cell lines MDCK and CMT7 (Argyle et al.
2004).
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4.2.1.2 Small m olecule inhibitors o f TERT
Small molecule inhibitors are molecules that target the active site o f TERT. The most extensively 
studied non-nucleoside molecule is BIBR1532. BIBR1532 inhibits telomerase in vitro with a half- 
maximal inhibitory concentration (IC50) o f 93 iiM (Damm et al. 2001) and is a mixed-type non­
competitive inhibitor o f telomerase with a proposed binding site distinct from the sites for 
deoxyribonucleotides or the DNA primer (Pascolo et al. 2002). However, studies in vivo have 
shown that a lag phase exists between enzyme inhibition and subsequent ceil growth arrest, 
apoptosis and tumour growth slowing, similar to that encountered with dominant negative mutants. 
Thus, NCI-H460 non-small eell lung cancer cells required a treatment time o f 120 days in vitro 
before a decrease in cell proliferation became apparent (Damm et al. 2001), and in vivo effects 
were only noticeable when tumour cells used to xenograft nude mice were first pre-exposed in vitro 
for over 100 days prior to implantation. For this reason, the in vivo antitumour efficacy o f 
BIBR1532 appears to be marginal.
A similar mixed-type non-competitive inhibitor o f hTERT is 2,3,7-trichloro-5-nitroquinoxaline 
(TNQX), which has an IC50 o f 1.4 pM (Pascolo et al. 2002). However, as with B1BRI532, in vitro 
effects such as growth inhibition and induction of senescence in telomerase-positive cells have 
required extensive periods o f treatment.
4.2.1.3 Dom inant-negative TERT mutants
The characterisation o f splice variants o f human TERT (see 5.2,2.2: Post-transcriptional 
modification o f hTERT) revealed that one o f the splice variants, the a deletion variant, results in 
the loss o f 12 amino acids in the RT domain A, as the result o f a 36 bp deletion (Kilian et al. 1997). 
This splice variant, in addition to being non-functional, was found to inhibit the activity o f wild- 
type TERT in telomerase-positive cells and thereby to inhibit telomerase activity by competing for 
binding with other components o f the telomerase holoenzyme (Colgin et al. 2000). This finding 
led other groups to examine the impact o f other mutations in the reverse transcriptase A domain 
(Zhang et al. 1999), and Hahn et al subsequently showed that a substitution o f only 2 amino acids 
in the third (A) RT m otif o f hTERT was sufficient to create a dominant-negative mutant o f hTERT, 
DN-hTERT (Figure 4.4) (Hahn et al. 1999a). Mutant hTERT subunits have been effective tools in 
studying the characteristics o f telomerase and several studies have shown that DN-hTERT 
abrogates the expression o f wild-type (WT) hTERT in several telomerase-positive cell lines, 
including ovarian, breast, colon and hepatic cancer cells (Hahn et al. 1999a; Zhang et al. 1999). 
Interestingly, Sachsinger et al demonstrated that telomerase activity was reactivated in murine 
RenCa cells expressing DN-mTERT, suggesting there are fundamental differences in regulation
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between mouse cells and human cells (Sachsinger et al. 2001).
The use o f the DN-hTERT mutant as an inhibitor o f telomerase has led to some interesting findings 
that suggest telomerase inhibition may lead to clinical effects distinct from those induced by 
telomeric shortening. Typically, inhibition o f telomerase in telomerase-positive cell lines leads to 
cell death through crisis over a time-course dependent on the initial length o f telomeres in those 
cells. Cell lines with longer telomeres must therefore go through more population doublings before 
undergoing crisis as compared to cell lines with shorter telomeres. However, DN-hTERT mediated 
inhibition o f telomerase activity has also been shown to reduce the growth rate o f some cell lines in 
vitro and to reduce the ability o f these cells to form tumours xenografted mouse models in vivo, 
confirming the involvement o f telomerase in other features o f malignancy (Hahn et al. 1999a; 
Zhang et al. 2002).
4.2.1.4 Ham m erhead ribozymes
Ribozymes are catalytic anti sense RNAs that cleave RNA substrates in a sequence-specific 
manner, first discovered in satellite RNA o f tobacco rings pot virus (Komata et al. 2002a). 
Ribozymes have been developed that target both hTR and hTERT. Although ribozymal cleavage 
o f hTR has been found to reduce telomerase activity in tumour cells in some studies, no change in 
proliferation occurred in treated cells, suggesting that it is o f  limited use in the clinical setting 
(Kanazawa et al. 1996; Yokoyama et al. 1998). However, other studies have shown that ribozymal 
cleavage o f hTERT leads to shortened telomeres and apotosis as well as senstitising tumour cells to 
inhibitors o f topoisomerase, suggesting that ribozymes targeting TERT may be worth considering 
for further development (Ludwig et al. 2001; Yokoyama et al. 1998).
4.2.1.5 O ligonucleotides
A number o f  strategies have been developed using synthesised oligonucleotides designed to bind in 
a complementary fashion to either hTERT or, more commonly, the hTR component o f telomerase. 
Typical antisense oligonucleotides contain DNA bases that form DNA-RNA hybrids upon binding 
to mRNA. These hybrids are recognised by RNase H which cleaves them and, in thus destroying 
the target mRNA, reduces the level o f expression o f the desired protein. Problems with 
oligonucleotide therapy include their rapid destruction by DNase, the large doses necessary to 
achieve a therapeutic response and the difficulty associated with directing oligonucleotides to target 
cells. However, improvements in their design and synthesis suggest that they may present an 
attractive option for clinical use for several reasons. They can now be administered systemically 
by intravenous injection, methods have been developed for their large scale synthesis, their 
pharmacokinetics are well characterised and toxicity is low (Corey 2002). There are also some 
indications that adequate bioavailability can be achieved following oral administration (Khatsenko
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et al. 2000). Telomerase is an atypical antisense target, because binding o f the oligonucleotide to 
its target site is all that is required to interfere with telomerase activity, with cleavage by RNase H 
being o f secondary importance. As a result, the inclusion o f DNA bases in the structure o f anti- 
telomerase oligonucleotides is unnecessary, and they can be composed entirely o f chemically 
modified bases that bind complementary sequences with elevated affinity. Some o f the 
modifications that have been examined include peptide nucleic acids (PNA), 2 ’-0-aikyl RNA and 
locked nucleic acid (LNA) (Braasch & Corey 2001; Elayadi et a!. 2001; Herbert et al. 1999). In 
addition, modification to the linkages between bases within the oligonucleotide can alter the 
potency o f effects (Corey 2002). The number o f synthesised anti-telomerase oligonucleotides so 
far examined is considerable, and only a few will be discussed here.
4.2.1.5.1 2-5A -linked  A ntisense Oligonucleotides
Kondo et al showed that expression o f a conventional antisense oligonucleotide targeting hTR 
eliminates telomerase aetivity from malignant glioma cells and results in apoptosis after a lag phase 
o f approximately 30 population doublings (Kondo et al. 1998a). Interestingly, in some subclones 
o f cells treated, apoptosis does not occur but cells enter a more differentiated state, as shown by 
increased expression o f glial fibrillary acidic protein (GFAP) and decreased motility. This would 
suggest that telomerase activity is linked in other, as yet undetermined, ways to the dedifferentiated 
phenotype o f these cells.
A more rapid onset o f apoptosis can be readily induced in these cells by linking the anti sense 
oligonucleotide to 2 ’-5 ’ phosphorylated oligoadenylate (2-5A), 2-5A is an activator o f the
endoribonuclease Rnase L, a single-strand specific endoribonuclease that functions in the antiviral 
mechanisms o f interferons (Kondo et al. 1998b). Although Rnase L is a ubiquitous protein, it has 
no detectable ribonuclease activity until it comes into contact with 2-5A. Linking 2-5A to an 
oligonucleotide therefore creates an RNA-degrading molecule that specifically targets a single 
RNA species. The use o f 2-5A linked to the hTR antisense oligonucleotide resulted in rapid onset 
o f apoptosis in malignant glioma cells, both in vitro and in vivo in a nude mouse model (Kondo et 
al. 1998b; Mukai et al. 2000). The onset o f apoptosis in these cells occurred within 5-7 days, too 
rapidly to be aceounted for by telomeric attrition, although the mechanisms underlying this are not 
well understood. In addition, the 2-5A-hTR antisense oligonucleotide shows an additive effect 
when used in conjunction with adenoviral vectors expressing wild type p53, but only in those cell 
lines with a mutated form of p53 (Komata et al. 2000).
4.2.1.5.2 O ligonucleotide N 3 ’-P5*Phosphoram idates
N 3’-P5’ phosphoramidate (NP) oligonucleotides are compounds complementary to hTR sequence 
that have a high in vitro potency for telomerase inhibition. NP oligonucleotides contain a 3’-amino
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group substituted for the 3 ’ oxygen in the 2 ’-deoxyribose rings. These compounds form very stable 
duplexes with single-stranded RNA, are resistant to nuclease degradation and display high 
specificity for RNA and DNA targets. Oligonucleotides directed at both the template region and 
another region 10 0  nucleotides further downstream have been used, and both lead to abrogation o f 
telomerase activity and consequent apoptosis in telomerase-positive cells after a lag phase that 
correlates with initial telomere length (Pruzan et aL 2002). However, the use o f these agents in 
cells requires a lipid-based cellular uptake enhancer for efficient entry into cells. Substitution o f a 
single sulphur atom for an oxygen atom, to create an NP ////ophosphoramidate, results in a 
molecule with similar specificity for target RNA but which is able to enter cells more efficiently 
without the presence o f cellular uptake enhancers.
The most advanced o f the phosphoramidates so far examined is GRN163, which is able to inhibit 
telomerase activity at nanomolar concentrations (Herbert et al. 2002). However, as with BBRl 532, 
antitumour effects are largely dependent on telomere length, with little effect in U266 multiple 
myeloma cells (with long telomeres o f 9kb) after 56 days o f cell culture, but more rapid growth 
inhibition in 28 days in M M .IS cells (with short telomeres o f 2.5 kb) (Akiyama et al. 2003). 
Similar effects have been demonstrated in vivo using xenografted nude mice bearing tumours with 
short telomeres from prostate cancer, myeloma and glioblastoma cancer cell lines (Asai et al. 2003; 
Wang et al. 2004), GRN163L, containing a lipid covalently conjugated to an ami noglycerol 
thiophosphate linker, is currently undergoing late-stage preclinical development in preparation for 
Phase I clinical evaluation.
4.2.1.5.3 2 ’-0-a lkyl- an d  2 ’-methoxyethyl~RNA
The synthesis o f 2 ’-0-alkyl RNA oligonucleotides has provided another potentially useful class o f 
telomerase inhibitor. Both 2 ’-0-alkyl RNA and 2’-methoxyethyl (ME) RNA oligonucleotides 
comprising 13-base oligonucleotides complementary to hTR have been shown to inhibit telomerase 
activity with an IC50 value in cell lysate of approximately 10 nM (Elayadi et al. 2001 ; Herbert et al. 
1999; Pitts & Corey 1998). Introducing phosphorothioate (PS) linkages into these molecules 
improves their pharmacokinetic profile by enhancing resistance to nuclease digestion and 
increasing the serum half-life, with the result that the IC50 can be lowered to 3-10 nM while 
retaining selective inhibition. These agents have been trialled in cell lines o f vaiying telomere 
lengths, and show growth rate slowing after a time lag related to the initial telomere length o f each 
cell line. Importantly, in all cell lines examined, telomere lengths returned to pre-treatment size 
after the agent was removed, and in the cell line with longest (1 2  kb) telomeres, no impact on 
growth rate was seen at all (Herbert et al. 1999). These results suggest that despite their 
pharmacokinetic advantages, the clinical usefulness o f these agents is likely to be marginal.
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4.2.1.6 RNA Interference
Most recently, considerable interest has focused on the growing field o f RNA interference as a 
means o f interfering with gene expression. dsRNA, a hybrid o f a sense and an antisense strand o f 
an endogenous RNA species, can initiate a cellular response that results in the sequence-specific 
degradation o f homologous single-stranded RNA (Kosciolek et a!. 2003). This occurs in a wide 
variety o f eukaryotic organisms and is known as RNA interference, or RNAi. In this process, RNA 
synthesis is not itself affected, but rather the RNA transcript is specifically degraded so that the 
corresponding gene becomes silenced. This apparently represents an old and evolutionarily 
conserved defence mechanism against parasitic RNAs, and is reviewed in (Hannon 2002), 
(Hutvagner & Zamore 2002) and (Sharp 2001). The key trigger o f this response is dsRNA, which 
is processed by double-strand-specific RNase to shorter RNA fragments o f both polarities. The 
enzyme responsible, first identified in Drosophila, is known as Dicer, and is an RNase Ill-type 
enzyme (Bernstein et al. 2001). The product generated following Dicer’s processing is a dsRNA o f 
approximately 21-22 bp, also know as short RNAs, Rather than being composed o f a simple 
double strand, this short RNA has characteristic termini consisting o f two unpaired 3’-terminal 
nucleotides on either side (Elbashir et al. 2001a), and is an important intermediate o f the RNAi 
reaction which then becomes incorporated into a multicomponent protein complex called RISC 
(Hammond et al. 2001). RISC acts as an RNase, the sequence-specificity o f which is conferred by 
the short dsRNA.
The importance o f the short RNAs in this process led several researchers to investigate the 
possibility o f  artificially-generated short dsRNAs to initiate the RNAi response and led to the 
important discovery that chemically-synthesised RNAs that could form a double strand with the 
characteristic two unpaired nucleotides at the 3 ’ termini could initiate RNAi in mammalian cells 
(Elbashir et al. 2001b), and the term ‘siRNA’ was introduced for these short duplexes. As an 
effeetive means o f sileneing genes, siRNA has been utilised in a range o f situations, and most 
recently has been used to silence telomerase expression both through targeting o f hTR and hTERT 
(Kosciolek et al. 2003). The use o f siRNA to inhibit telomerase activity has been successfully 
reported both in vitro and in vivo (Del Bufalo et al. 2005; Guo et al. 2005; Li et al. 2005; 
Nakamura et al. 2005; Sciamanna et al. 2005; Zou et al. 2005), suggesting that it may be a 
promising approach for clinical anticancer therapies. However, perhaps more importantly, results 
o f some o f these experiments have uncovered fundamental links between telomerase activity and 
cancer cell biology that were not previously known. Li et al showed, using RNAi directed at hTR, 
that telomerase inactivation led to rapid slowing o f cell growth independent o f telomere shortening, 
uncapping or the activation o f DNA damage-response pathways such as p53 and p21 (Li et al.
2005). In addition, telomerase activity in telomerase-positive cancer cell lines seems to be 
inextricably linked to other characteristics o f tumour cell behaviour, since inactivation o f 
telomerase activity led to downregulation of a number o f genes, including integrin aV, known to be 
related to cancer cell proliferation, angiogenesis and survival (Cruet-Hennequart et al. 2003;
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Eliceiri & Cheresh 2001; Hutvagner & Zamore 2002; Li et al. 2005). These findings have been 
supported by in vivo experiments in which inhibition o f hTERT expression through RNAi resulted 
in reduced colony-forming ability and tumorigenicity in mice, and also increased sensitivity to 
ionizing radiation and chemotherapeutic agents (Nakamura et al. 2005).
A number o f  useful and important points are worth noting in relation to these studies. Firstly, it 
appears that many o f the effects o f telomerase inhibition such as growth inhibition occur 
irrespective o f whether the target o f  RNAi is hTR or hTERT. Seeondly, these efleets occur 
rapidly, without the time lag attributable to telomere-shortening seen with the majority o f other 
methods o f inhibiting telomerase, such as antisense oligonucleotide treatment or DN-hTERT 
treatment, and also occur without interfering with telomere length or capping. Finally, RNAi 
techniques appear to work by reducing the overall level o f telomerase ribonucleoprotein complex, 
rather than by interfering with the quantity o f enzyme activity. For all these reasons, RNAi 
techniques are worth investigating as methods o f telomerase inhibition.
4.2.2 Strategies targeting telomerase-associated proteins
Heat shock protein 90 (HSP90) is a molecular chaperone that plays a role in protein refolding in 
cells exposed to environmental stress. It is required for the conformational maturation, stability 
and activity o f several proteins involved in signal transduction pathways, but acts on a more narrow 
range o f targets than other chaperones. Target proteins include receptor and non-receptor kinases 
(eg HER-2, epidermal growth factor receptor and Src family kinases), serine/threonine kinases (eg 
e-Raf-1 and Cdk4), steroid hormone receptors (androgen and oestrogen) and cell cycle and 
apoptosis regulators (eg mutated p53) (Hartson & Matts 1994; Sepp-Lorenzino et al. 1995; 
Stancato et al. 1993; Stepanova et al. 1996; Veldscholte et al. 1992; Villa et al. 2003). HSP90 
regulates the half-lives o f these target proteins by forming conformation-dependent higher order 
chaperone complexes. Since all o f  these proteins are involved with the growth and or survival o f 
cancer cells, HSP90 may be a potential anti-tumour target. Studies have also shown that FISP90 
and the co-chaperone p23 are required for efficient telomerase assembly, in a proposed model 
whereby both proteins bind hTERT and influence its assembly with hTR in the formation o f an 
active enzyme (Holt et al. 1999).
The benzoquinone ansamycin antibiotic geldanamycin (GA) and its derivative, 17-allylamino, 17- 
demethoxygeldanamycin (17-AAG) are both inhibitors of HSP90 (Neckers et al. 1999; Schulte & 
Neckers 1998). Treatment o f JR 8 melanoma cells resulted in inhibition o f telomerase activity, and 
apoptosis, although no telomere shortening was seen (Villa et al. 2003). These effects were 
dependent on the level o f telomerase activity within the particular clone o f cells used. 17-AAG is 
currently undergoing Phase 1 clinical trials for its other anti-tumour effects, and it is possible that
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the level o f efficacy o f the drug may be partly related to the levels o f telomerase activity in the 
tumour being treated.
4.2.3 Strategies interfering with telomere-telomerase interactions
A potential strategy to target telomerase activity involves interfering with its ability to bind to the 
telomere. One important way o f doing this would be to physically change the structure o f the 
telomere in such a way that it is no longer aecessible to the telomerase holoenzyme, The highly 
repetitive, G-rich nature o f telomeric sequence allows it to potentially fold into a 4-stranded 
(quadruplex) intramolecular structure, and approaches exploiting this ability have been pursued 
since the 1990s (Kelland 2005). G-quadruplex ligands affect telomere structure by covalently 
binding to the quadruplex and preventing its dissociation. Since the first demonstration o f 
telomerase inhibition by a G-quadruplex-interacting compound (a 2,6-diamidoanthraquinone) in 
1997 (Sun et al. 1997), an enormous array o f G-quadruplex ligands has been described, including 
cationic porphyrins, trisubstituted acridines, dibenzophenanthrolines, ethidium derivative, triazines, 
pentacyclic aeridines, fluoroquinophenoxazines and 2,6-pyridine-dicarboxamide derivatives (Duan 
et al. 2001; Go wan et al. 2001 ; Koeppel et al. 2001; Mergny et al. 2001; Pennarun et al. 2005; 
Read et al. 2001 ; Riou et al. 2002; Shin-Ya et al. 2001; Wheelhouse et al. 1998). Given the vast 
array o f agents, only two o f the most promising will be discussed here -  the trisubstituted acridine 
BRA C019 and naturally-occurring telomestatin.
4.2.3.1 BRAC019
Many o f the first generation G-quadruplex ligands suffered from a relative lack o f selectivity for 4- 
stranded over 2-stranded DNA, resulting in non-specific acute cytotoxicity at similar 
concentrations to those used to inhibit telomerase activity (Harrison et al. 1999). However, the 
resolved crystal structure o f parallel quadruplexes from human telomeric DNA allowed the 
development o f  improved molecules, including B R A C 0I9 (Parkinson et al. 2002). BRA C019 
was shown to induce extensive end-to-end chromosomal fusions in DU 145 prostate cancer cells 
and senescence from 7 days following exposure at non-acute cytotoxic concentrations (Incles et al.
2004). Senescence was associated with an increase in the CDK inhibitor p2 l, consistent with 
senescence being triggered by telomere shortening or loss o f integrity (Herbig et al. 2004). In vivo 
work has also been promising, with significant growth inhibition (96% compared with controls) in 
a uterus carcinoma xenograft model and against DU-145 prostate cancer xenografts (Burger et al.
2005).
4.2.3.2 Telom estatin
Telomestatin is a natural product isolated from Streptomyces aimlatns 3533-SV4 which has been
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shown to be a very potent inhibitor o f  telomerase, with an IC50 o f approximately 2 pM  (Kim et al. 
2002). It possesses structural similarity to the G-tetrad (Figure 4.1) and it is thought that its effects 
are due to its ability to either facilitate the formation o f or stabilise pre-formed G-quadruplex 
structures, thereby sequestering the prim er needed for elongation by telomerase. Telomestatin also 
shows preferential interaction with intramolecular G-quadruplex structures rather than 
intermolecular structures and is 70 times more selective in binding quadruplex structures than 
duplex DNA (Kim et al. 2003a). This affinity for intramolecular G-quadruplexes appears to be 
important in avoiding detrimental side effects such as the formation o f anaphase bridges in 
teiomerase-negative cells (Kim et al. 2003a). In addition to interfering with the function o f 
telomerase, stabilising the formation o f  G-quadruplexes may also have other useful properties, such 
as the ability to down-regulate c-myc expression (Lemarteleur et al. 2004; Seenisamy et al. 2005).
The use o f  telomestatin in telomerase-positive cell lines results in delayed growth arrest and/or 
apoptosis (Shammas et al. 2004; Tauchi et al. 2003). In addition, telomere shortening is also 
obseiwed in these cells, although it occurs earlier than expected for a single mechanism involving 
telomerase inhibition and is limited to only a few kilobases (Gomez et al. 2003). Its use in the 
leukaemic cell lines OM9; 22 and K562 in one study resulted in telomere shortening, and 
telomerase inhibition (Tauchi et al. 2003). Over a period o f 10 days, treatment also resulted in 
significant cell death, through activation o f p21, p27 and the ATM -dependent DNA damage 
response pathway, consistent with telomere uncapping. Similar results in multiple myeloma cells 
have also been reported (Akiyama et al. 2003). These results suggest that telomestatin holds 
considerable promise as a telomerase inhibitor.
F igure 4.1; S tructures o f  G -quadruplex tetrad in relation  to telom estatin
G "Tetrad Telomestatin
(Reproduced with permission from (Kim et al. 2002))
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4.3 Aims of the Chapter
The aims o f this chapter were to investigate two potential methods o f inhibiting telomerase activity. 
The first aim was to investigate inhibition o f canine TERT activity using a dominant negative 
mutant o f canine TERT. However, at the time this work was performed, although the dogTERT 
cDNA sequence had been established, a vector containing the entire canine TERT cDNA was not 
available for mutational analysis o f dominant negative forms o f dogTERT. Given the close 
homology between the canine and human TERT molecules in the regions o f the T and reverse 
transcriptase motifs, these studies were therefore performed using the human dominant negative 
mutant DN-hTERT.
Given the success o f the G-quadruplex ligands in inhibiting human telomerase, the second aim o f 
this chapter was to investigate inhibition of canine telomerase activity through the use o f one o f 
these - telomestatin, and to examine the effects o f consequent telomerase inhibition in telomerase- 
positive canine cancer cell lines.
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4.4 Materials and Methods
4.4.1 Inhibition o f  canine telomerase with the dominant-negative mutant 
D N -hTE RT
4.4.1.1 Cell Lines
D17 (canine osteosarcoma) and CMT7 (canine mammary tumour) are canine cell lines which have 
previously been shown to be telomerase positive (Nasir et al. 2001). Canine primary skin 
fibroblasts (K9SF) are cells which have similarly been shown to be telomerase negative. (Nasir et 
al. 2001) The D17 cell line was cultured in DMEM (Gibco BRL, Grand Island, New York) 
supplemented with 10% fetal calf serum. The CMT7 cell line was cultured in RPMI (Gibco BRL, 
New York) supplemented with 10% fetal calf serum and 2mM L-glutamine. Canine primary skin 
fibroblasts (K9SF) were cultured in M EM -a (Gibco BRL, New York) supplemented with 10% fetal 
calf serum, 2 luM L-glutamine and epithelial growth factor (EGF).
4.4.1.2 Generation o f pC IN eo-D N hT E R T  Plasmid vector
DNhTERT was kindly donated by the laboratory o f RA Weinberg, Whitehead Institute, within the 
plasmid vector pBabepuro. Following restriction digestion with E coR l and S o il, DNhTERT was 
cloned into the plasmid vector pCINeo, which conveys resistance to G418, a eukaryotic analogue 
o f the antibacterial agent neomycin.
4.4.1.2.1 Restriction enzym e digestion o f  vectors
The pBabePuro vector containing the DN-hTERT dominant negative mutant was digested with 
EcoR  I and Sal I restriction enzymes. The pCINeo vector was also digested with EcoR  I and Sal 1 
restriction enzymes. More specifically, the pBabePuro containing DNhTERT (5pg) was digested 
for one hour with EcoR  I (5 units) in buffer D (IOX) in lOpI at 37 C, before adding Sal 1 (5 units) 
to a final volume of 20j,il and continuing with incubation for a further 3 hours at 37 C. The 
recipient pCINeo vector (5pg) was digested with EcoR  I (5 units) and Sal I (5 units) using the same 
protocol. Samples (4pl) were analysed on a TAE agarose gel (1%) by comparing the bands created 
to a lOObp DNA ladder to confirm digestion before purification and ligation.
4.4.1.2.2 Purification, ligation and transformation
Digested DNA samples (linearised pCINeo and released DN-hTERT) were purified using the 
QIAquick®Gel Extraction Kit (Qiagen, UK) and eluted in 30p,l o f sterile water. The DNA was
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quantified (2pl) by gel electrophoresis on a TAE agarose gel (1%) by comparing the bands created 
to a Low DNA Mass™ Ladder (2pl).
The quantity o f vector (pCINeo) and insert (DN-hTERT) for each ligation reaction was calculated 
according to the equation shown in 2 .23  J :  Ligation o f restriction digested DNA fragments. For 
each calculation the vector mass (X) was 100 ng, and the insert size (Y) was approximately 3.6 Kb. 
Ligation was performed using molar ratios o f 3:1 and 1:1 insert to vector, The cut ends o f the 
inserts were ligated to complementary ends of the cut pClNeo vector using T4 DNA ligase 
(Promega, UK) overnight at 16° C. The ligations (20ng) were transformed into 50pl o f One Shot™ 
TOP 10 competent cells which were heat shocked for 45 seconds at 42° C before adding 250pl SOC 
medium, shaking horizontally at 225 rpm at 37 C and then grown overnight at 37° C on 
LB/ampicillin agarose plates. Six to ten colonies were selected from each plate and transferred to 
LB broth for overnight culture at 37° C.
4.4.1.2.3 Isolation and screening o f  recom binant p lasm ids
The DNA constructs were isolated from overnight cultures by the alkaline lysis method o f plasmid 
DNA isolation using the QIAprep®PCR Spin Miniprep Kit (Qiagen, UK) and eluted in 50pl of 
sterile water. The DNA samples were then assessed by spectrophotometry for quantification. 
pClNeo promoter constructs were screened with EcoR  1 and Sal 1 restriction enzyme as described 
in 2 .2.3.1 1: Screening o f transformants for desired recombinant plasmids. Since all the promoter 
inserts were directionally cloned it was not necessary to screen for correct orientation.
4.4.1.2.4 Sequence evaluation
Recombinant plasmids were sequenced and analysed as described in section 2.2.3.11: Screening o f 
transformants. Briefly, plasmid samples were prepared for sequencing with PCR reactions using 
plasmid DNA samples (400 ng) and the Big Dye™ Terminator Cycle Sequencing Ready Reaction 
(ABI Prism) with 0 . 5 | l i M  o f both sense (DNHTOOIF) and anti-sense (DNHTOOl R) primers (Table 
4.1). These primers were designed to amplify a 450 bp fragment containing the mutation site 
responsible for the dominant negative function o f DNhTERT. Samples were amplified, and the 
DNA purified by precipitation methods before samples were loaded into the ABI 310 genetic 
analyser for generation o f automated sequence data. Sequence files were downloaded from the 
chromas file, saved as Word documents using FASTA format, and then lined up with the relevant 
correct sequence for the hTERT sequence using VectorNTI (Invitrogen Bioinformatics).
4.4.1.3 Generation of Stable Transfectants
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Liposomes are one o f a growing number o f chemical reagents used to deliver nucleic acids to 
eukaryotic cells. Transfections were performed using the TransFasf^^ liposome-based transfection 
reagent (Promega, UK). Liposomes are lipid bilayers that form colloidal particles in an aqueous 
medium. Liposome reagents specifically designed for transfection applications incorporate 
synthetic cationic lipids, often formulated together with the neutral lipid L-dioleoyl 
phosphatidylethanolamine (DOPE), which enhances the gene transfer ability o f certain synthetic 
cationic lipids. The TransFast™  transfection reagent is comprised o f the synthetic cationic lipid 
(+)-N,N [bis(2-hydroxyethyl)-N-methyl-N-[2,3-di(tetradecanoyloxy)propyl] ammonium iodide and 
the neutral lipid DOPE. The reagent is supplied as a dried lipid film that forms multilamellar 
vesicles upon hydration with water.
Incubation o f cationic lipid-containing liposomes and nucleic acids results in quick association and 
compaction o f the nucleic acid and the positively charged head group o f the synthetic lipid. The 
liposome-nucleic acid complex is then presented to the cells that are to be transfected. The 
liposome complex neutralises the negative charge o f the nucleic acids, allowing closer association 
o f the complex with the negatively charged cell membrane. The liposome complex then gains 
entry into the cell either through endocytosis or by fusion with the plasma membrane via the lipid 
moieties o f the liposome. Once inside the cell, the complexes often become trapped in endosomes 
and lysosomes. Endosomal disruption is facilitated by DOPE, which allows the complexes to 
escape into the cytoplasm. The manner in which the transfected DNA or Hposome-DNA complex 
gains entry to the nucleus is not precisely known.
Transfections were performed following the supplier’s recommended protocol using a ratio o f 
TransFast™  Reagent:DNA o f 2:1. The day before transfection, 16 x 10  ^ cells were seeded into a 
25 cm^ flask to achieve a confluence o f approximately 50% on the day o f transfection. On the day 
o f transfection, 3 pg o f plasmid DNA (pCINeo-DN-hTERT and pCINeo negative control) was 
added to serum-free medium (2 ml) and vortexed. Then, 18 pi o f TransFasf^'^ reagent (6  pi/pg 
DNA) was added and the mixture vortexed again. The mixture was then incubated for 10-15 
minutes at room temperature. While incubation was occurring, the growth medium was carefully 
aspirated from adherent cells. The TransFast™ /DNA mixture was then added to the cells and 
flasks were returned to the 37° C incubator for 1 hour. At the end o f this incubation, cells were 
overlaid with 4 ml o f complete growth medium.
Forty-eight hours after transfection, cells were trypsinised, counted and plated in 25 cm^ flasks at 4 
different concentrations: 1:5, 1:10, 1:20, and 1:100. In addition, G418 was added to the medium at 
a concentration o f 400 mg/ml. For the remainder o f the experiment, medium was replaced every 3- 
4 days, and fresh G418 added. For the 14 days following addition o f G418, cells were monitored 
for cell death. The flask containing surviving colonies was retained and the remainder discarded. 
When this flask reached confluence, cells were tiypsinised and transferred to 75 cm^ flasks. In
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addition, following initial selection at 400 mg/ml, the concentration o f G418 was increased to 600 
mg/ml over approximately 2  weeks. Cells were trypsinised when they reached confluence 
(approximately every 7-10 days) and reseeded at a cell density o f I X 10  ^ cells per 75 c n r flask.
4.4.1.4 Confirmation of transfection with RT-PCR
4.4.1.4.1 R N A  Extraction
RNA was also extracted from cell pellets containing 2 x 1 0 ^  cells stored at -8 0 “C using RMAwiz’'  ^
(Ambion, UK) as described in 2.2.4.1: Extraction and Purification o f RNA.
4.4.1.4.2 cD N A  Synthesis
Superscript reverse transcriptase was used for first strand cDNA synthesis, which was
performed as described in 2.2.5: First strand cDNA synthesis.
4.4.1.4.3 PC R  amplification and sequencing
Following synthesis o f cDNA, PCR was performed using the DNHTOOIF and DNHTOOIR 
primers. As a positive control, amplification o f a fragment o f the canine cyclophilin gene was 
simultaneously performed using the primers CYCLOF and CYCLOR. These primers are detailed 
in Table 4.1.
Platinum High-Fidelity Taq polymerase (Invitrogen, UK) was used for second strand PCR. For 
each sample, 1-5 pi o f  cDNA was mixed in a 0.2pl thin-walled PCR tube with 5pl o f High Fidelity 
PCR buffer, 1 pi dNTP mixture, 2pl MgS0 4 , 1 pi o f each primer (forward and reverse) used and 
0.2pl Platinum Taq High Fidelity. The reaction mix was made up to a total volume o f 50pl with 
autoclaved, distilled water. Samples were kept on ice during pipetting and prior to PCR. As a 
negative control, 5 pi o f total RNA was also included in each reaction to ensure resultant products 
were not amplified from contaminating genomic DNA.
Cycling conditions involved dénaturation o f the template and activation o f the Taq polymerase at 
94°C for 2  minutes followed by 30 cycles of the following: dénaturation at 94° C for 30 seconds, 
annealing at 55° C for 30 seconds, extension at 6 8 °C for 1 minute. Finally, the mix was incubated 
at 72° C for 10 minutes to add a run o f adenosine residues to the 3’ end o f each product, before 
being maintained at 4° C. PCR products were analysed by agarose gel electophoresis (1.5%) using 
a 1 Kb molecular weight marker.
PCR products were purified using the QIAquick® Gel Extraction Kit (Qiagen, UK) and eluted in
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3 0 | ll1 o f sterile water 4pl o f which was assessed by gel electrophoresis on a TAB agarose gel (1%) 
by comparing the bands created to a I kb molecular weight standard. Sequencing was performed 
directly from PCR products as described in 2.2.7: DNA sequence analysis. Briefly, plasmid 
samples were prepared for sequencing with PCR reactions using plasmid DNA samples (400 ng) 
and the Big Dye™ Terminator Cycle Sequencing Ready Reaction (ABI Prism, UK) with 0.5pM of 
both sense (DNHTOOIF) and anti-sense (DNHTOOIR) primers. Samples were amplified, and the 
DNA purified by precipitation methods before samples were loaded into the ABI 310 genetic 
analyser for generation o f automated sequence data. Sequence files were downloaded from the 
chromas file, saved as Word documents using FASTA format, and then lined up with the relevant 
correct sequence for the hTERT sequence using VectorNTl (Invitrogen Bioinformatics).
Table 4.1: Primers used In RT-PCR
Prim er
Identification
O ligonucleotide prim er sequence 
(5'-3')
T m  («C) & GC 
(%) conten t
DNHTOOIF
DNHTOOIR
Cyclop
CycloR
EX2F
EX2R
ACTGT TC A G C G T G C TC A A C TA
TCATTCAGGGAGGAGCTCTGCT
CGTGCTCTGAGTACTGGAGAGAAGGGA
CCACTCAGTCTTGGCGGTGCAGATGAA
CAGGAGCTGCTTGGGAACCA
CTGGGTTCCCGTGCAGCCAG
62.6°C : 47.6 % 
68.5°C : 54.5 % 
80.2 C : 55.6 % 
75.0°C : 60.0%  
69.8 C : 60.0% 
74.4 C : 70.0%
4.4.1.S Growth Rates
Cell lines were grown as an adherent monolayer in eulture, in either 25 or 75 cm^ tissue culture 
flasks stored in an incubator at 37°C with 5% CO2. Cells were routinely split when they reached 
confluence, counted, and once stable transfectants had been generated, re-seeded at a cell density o f 
I X 10  ^cells per flask. Population doublings were calculated according to the following formula:
PD = Logio (Cell eount),,- Logio (Cell count),,. 1
0.30
Where n^current passage and n-I= previous passage
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4.4.1.6 Telom eiase repeat amplification protocol
Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELISA'’^^  ^ assay 
(Roche, UK), following the manufacturers recommended protocol as described in 2.2.10.1: 
Telomerase repeat amplification protocol.
4,4.1.6.1 Sample Preparation
Samples used for telomerase assay analysis included cell pellets from the DI7, CMT7 and K9SF 
and U87 cell lines. Cells were harvested and counted as described in 2.2.1: Growth and 
manipulation o f mammalian cells. Aliquots o f 2% 10  ^ cells were harvested for each assay. Cells 
were pelleted at 3000g for 5 minutes at 4° C, the supernatant withdrawn, and following a brief 
resuspension in 100 pi o f PBS the cells were again pelleted and the supernatant carefully removed. 
Cell pellets were then resuspended in 200 pi o f ice-cold lysis reagent (Roche, UK) and incubated 
on ice for 30 minutes. The lysate was then centrifuged at 16000g for 20 minutes at 4°C and the 175 
pi supernatant was carefully removed with a micropipette, taking care not to disturb the pellet of 
cellular debris. Cell extracts were then either used immediately or snap frozen liquid nitrogen and 
stored at -80°C.
4.4.1.7 Telom ere Length Analysis
4A.1.7.1 D igestion  o f  DMA with H in f l/R sa l
The selection o f the restriction endonucleases H infl and R sal was based on the fact that these 
enzymes do not contain recognition sequences that cut within mammalian telomeric sequence. 
Although these enzymes are not alone in this respect, they are the most commonly used (Lauzon et 
ah 2000; Nakamura et al. 1999). The use o f these enzymes allows complete digestion o f non- 
telomeric DNA, up to the first recognition site for the enzymes. The remaining intact telomeric 
DNA is referred to as a Telomere Restriction Fragment (TRF). Three pg o f DNA was digested per 
sample at 4U o f enzyme mix per pg o f DNA for 12-16 hours at 37° C. To verify restriction 
enzyme digestion, samples (2 pi) were analysed by agarose gel electrophoresis (1.5%) by 
comparing to a 100 bp molecular weight marker (Figure 4.2).
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Figure 4.2: Representative 1.5% Agarose gel analysis o f Hinf\  / Rsa I digestion of DNA samples from  
CIVIT7 cells transfected with pCINeoDNhTERT. Lane 1: 100 bp marker, lane 2: passage (P) 12, lane 
3: P I8, lane 4: P2I, lane 5: p23, lane 6: Negative control (empty pClNeo) PI3, lane 7: Negative control
(empty pCINeo P15)
5 6
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4.4.1.7.2 D N A  fragm en t sépara tion
4.4.1.7.2.1 Agarose gel electrophoresis and Southern blot
Separation o f digested DNA was achieved by 0.8% agarose gel electrophoresis in IX TAE buffer 
using highly pure agarose (Sigma, UK) following a standard protocoI(The DIG system user’s guide 
for filter hybridisation 2003) (Southern 1979). A DIG molecular weight marker was used (23.1- 
0,12 kb, Roche UK). Equal amounts o f sample were run in each lane and each sample was run in 
duplicate. Individual samples were made up to 20 pi using dHaO and 2 pi o f I OX DNA loading 
buffer. Samples were run at 5 V/cm for between 4 and 5 hours until the loading dye front was 
approximately 2  cm from the base o f  the gel.
Southern transfer (Southern 1975) o f the digested DNA was carried out by capillary action using 
20X SSC as a transfer buffer following a standard protocol (Current protocols in molecular 
biology) to a high quality positively charged nylon membrane (Amersham, UK). Gels were pre­
treated first by submersion in 0.25M HCl for 5 - 1 0  minutes; completion o f this step was indicated 
by a change in colour o f the bromophenol blue loading dye from blue to yellow. Following a rinse 
in dH20 , gels were submerged in a neutralising solution (0.5M Tris-HCl, 3M NaCI at pH 7,5) for 
30 minutes with a change o f solution after 15 minutes. All pre-treatment steps were carried out at 
room temperature and with gentle agitation using a rocking table (Luckham, UK).
Gels were inverted before Southern transfer to reduce the likelihood o f irregularities in the upper 
gel surface resulting in uneven DNA transfer. Transfer was carried out overnight, and the DNA 
was then UV cross linked with 120 mJoules of energy using a trans-illuminator (Sigma, UK) to the 
nylon membrane. After twice washing the membrane with 2X SSC the blot was ready for probe 
hybridisation and chemiluminescent detection.
4.4.1.7.3 H ybridisation an d  chem ilum inescent detection
All hybridisation steps were carried out using a Hybaid Maxi hybridisation oven (Hybaid, UK) and 
standard hybridisation flasks on a rotary mount. Pre-hybridisation was carried out at 42° C for 45 
minutes using 25 ml o f DIG Easy Hyb solution (Roche, UK). This solution was then discarded and 
replaced with 10 ml o f DIG Easy Hyb containing 2 pi of digoxigenin (DIG) labelled telomere 
probe (TTAGGG7). Hybridisation was carried out at 42° C for 3 hours.
Following hybridisation, 2 stringency washes were carried out; the first consisted o f two washes in 
2X SSC, 0.1% SDS for 5 minutes each at room temperature. This was followed by 2 washes in 
0.2X SSC, 0.1% SDS at 50° C for 20 minutes each. Gentle agitation o f the membrane was 
performed during both stringency washes and throughout the detection procedure.
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Membranes were rinsed in a washing solution (0.3% w/v Tween® 20, O.IM maleic acid, 0.15M 
NaCI, pH 7.5) for 5 minutes at room temperature followed by a 30 minute incubation at room 
temperature in freshly prepared blocking buffer (Roche, UK) dissolved in maleic acid buffer 
solution (0.1 M maleic acid, 0.15M NaCl, pH7.5). Blots were then incubated with a DlG-specific 
antibody (750 units/ml anti-digoxigenin, Fab fragments) covalently coupled to alkaline 
phosphatase (Anti-DlG-AP) (Roche, UK). The Anti-DlG-AP working solution was prepared to a 
final concentration o f 75 mU/ml (1:10,000) in blocking buffer (Roche, UK). The antibody solution 
was centrifuged for 5 minutes at 13,000 rpm before careful pipetting from the surface o f the liquid 
to avoid background signal being generated by aggregated antibody.
Incubation in the antibody solution was followed by two further 15 minute washes at room 
temperature in wash buffer (Roche, UK), followed by a 5 minute incubation in detection buffer 
(100 mM Tris-HCl, pH 9.5, lOOmM NaCl). Excess detection buffer was briefly blotted from the 
membrane by placing it DNA side up on a piece o f 3MM Whatman filter paper. The blot was then 
placed on an acetate sheet and approximately 3ml o f substrate solution placed drop-wise onto the 
DNA side before overlaying with another acetate. This system used the chemiluminescent alkaline 
phosphatase substrate CSPD® (25 mM Disodium 4-chloro-3-(4-methoxyspiro(l,2-dioxetane-3,2’- 
(5 ’-chloro)tricyclo[3.3.1.1]decan)-4-yl) phenyl phosphate) (Roche,UK) diluted 1:100 in detection 
buffer. Any bubbles were carefully removed from between the sheets and the composite was 
incubated at room temperature for 10 minutes. Excess substrate solution was then squeezed out 
and the two plastic sheets sealed with sellotape. The sealed membrane was incubated at 37° C for a 
further 10 minutes to aid the chemiluminescent signal. The membranes were then used to generate 
autoradiographs. Exposure time varied between 5 and 20 minutes to achieve optimum image 
quality for analysis.
4,4,1.7.4 Analysis o f  a utoradiograpbs
Autoradiographs were analysed by densitometry by using Total Lab v2.01 software. Each smear 
was divided into equally sized segments, and a densitometric reading taken from each. Mean TRF 
(Kb) values were determined from the densitometric readings according to the formula:
S (Od.L,)TRF (Kb) = S (Odi)
Where Odj is the chemiluminescent signal and Lj is the length o f the TRF fragment at position i. 
The calculation takes into account the higher signal intensity from larger TRF fragments because of 
multiple hybridisation o f the telomere-specific probe. Duplicate analyses were carried out on each 
sample.
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4.4,2 Inhibition o f  canine telomerase with Telomestatin
4.4.2.1 Cell Lines
For Telomestatin assays, the DI7 (canine osteosarcoma) and CMT7 (canine mammary tumour) 
telomerase-positive cell lines, along with the telomerase-negative K9SF cells were used. Culture 
conditions were as described in 2.2.1 : Growth and manipulation of mammalian cells.
4.4.2.2 Telom estatin treatment
Telomestatin was provided as a kind gift from Professor Kazuo Shin-ya, Institute o f Molecular and 
Cellular Biosciences, University o f Tokyo, at a concentration o f 10 niM in DMSO. Telomestatin 
was stored at -20° C until ready for use.
4.4.2.2.1 O ptim isation o f  telom estatin concentration
In order to optimise the concentration o f telomestatin to be used in further experiments, cells were 
plated in 6  well plates at a cell density o f 5 x 10  ^ cells per well in 5 ml o f complete medium. Cells 
were placed in an incubator at 37° C for 4 hours to settle, then withdrawn and telomestatin added 
before cells were replaced in the incubator.
For optimisation, D I7 and CMT7 cells were incubated in telomestatin at the following 
concentrations in order to assess the telomestatin concentration required to give optimal telomerase 
inhibition: 0.1 pM, 1.0 pM, 2.0 pM, 5.0 pM and 10 pM. As a negative control, cells were also 
incubated with an identical volume o f DMSO only. Cells were incubated in the presence o f DMSO 
for 7 days, after which they were trypsinised, centrifuged, washed in PBS and cell pellets stored for 
TRAP analysis. All experiments were carried out in duplicate.
4,4.2.2.2 Prolonged treatm ent with telom estatin
Following the initial optimisation, D17, CMT7 and K9SF cells were plated at a concentration o f 5 
X 10  ^ cells in 25 cm^ flasks with 2 pM telomestatin for a total o f 21 days. As negative controls, 
cells were also incubated in an equivalent volume o f DMSO and without the presence o f any 
additive. At 7 days, 14 days, and 21 days cells in all flasks were trypsinised, and divided into 1 x 
10 ,^ 2 X 10  ^ and 2 x 10  ^ cell aliquots for FACS analysis, TRF analysis and TRAP assays 
respectively. In addition, cells were reseeded at each timepoint at a density o f 5 x 10  ^ cells per 
flask for continued incubation with telomestatin.
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4.4.2.3 Growth Rates
Cells were counted at each passage and the population doubling calculated as detailed in 4 .4 .1.5: 
Growth Rates.
4.4.2.4 D etection of apoptosis
Apoptosis was detected in cells treated with telomestatin using the Annexin-V -  PLUGS kit 
(Roche, UK). In the early stages o f apoptosis, various changes occur at the cell surface, one o f 
which is the translocation o f phosphatidylserine (PS) from the inner part o f the plasma membrane 
to the outer layer, by which PS becomes exposed at the external surface o f the cell. Annexin V is a 
Ca^^-dependent phospholipid-binding protein with high affinity for phosphatidylserine (Vermes el 
al. 1995). This protein can therefore be used as a probe for PS exposure upon the outer leaflet of 
the cell membrane and is therefore able to detect apoptotic cells (Homburg et al. 1995; Koopman et 
al. 1994; Verb oven et al. 1995). Since necrotic cells also expose PS due to loss o f membrane 
integrity, the simultaneous application o f propidium iodide (PI) discriminates these cells by also 
staining DNA. In cells which are in the early stages o f apoptosis, annexin is taken up, but not PL
During all pipetting procedures prior to Annexin V staining, cells were handled gently to avoid 
excessive disruption o f cell membranes and consequent false positive results. Annexin V staining 
solution was made up by diluting 2 pi o f  Annexin-V-FLUOS and 2 pi o f  Propidium Iodide solution 
in 100 pi o f incubation buffer (Roche, UK) per sample. Cells were trypsinised for no more than 5 
minutes, and 1 x 10  ^ cells withdrawn. These cells were washed twice with cold PBS and 
centrifuged at 200g for 5 minutes. The cells were then resuspended in 100 pi o f Annexin V and 
incubated for 15 minutes in the dark at room temperature. After this incubation, 500 pi of 
incubation buffer (Roche, UK) was then added to each sample and placed on ice prior to FACS 
analysis which was performed immediately. Samples were analysed using a FACS flow cytometer 
(Beckman-Coulter Inc., Miami) with an excitation wavelength o f 488 nm and a 515 nm bandpass 
filter for fluorescein detection and a filter >600 nm for PI detection. Analysis was performed using 
Epics XL'^'^ (Beckman-Coulter, Miami) software.
4.4.2.5 Telom erase repeat ampHfication protocol
TRAP assays were performed on 2 x 1 0 ^  cell pellets as described in 2.2.10.1: Telomerase repeat 
amplification protocol.
4.4.2.6 Telom ere restriction fragment (TRF) analysis
TRF telomere length analysis was performed on genomic DNA prepared from cell pellets as 
described in section 4.4.1.7: Telomere Length Analysis.
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4.4.3 Statistical Analysis
For comparison o f telomere lengths in cells treated with DN-hTERT, the Wilcoxon Signed Rank 
Test was used. For each cell line paired values were taken at each passage number with positive 
values for pCINeo-DN-hTERT transfected cells and negative values for pCINeo (negative control) 
transfected cells. A p value o f <0.05 was taken as the limit o f statistical significance.
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4.5 R esults
4.5.1 Inhibition o f canine telomerase with the dominant-negative m utant 
D N hTE R T
4.5.1.1 Generation o f pC IN eo-D N hT E R T  construct
Restriction digestion was performed using the EcoRl and SaJ\ enzymes to subclone DNhTERT 
from the pBabePuro vector into pCINeo. The 3.6 Kb fragment comprising DNhTERT was 
successfully removed from pBabePuro and ligated into pCINeo using T4 DNA Ligase with both 
1:1 and 1:3 vector:insert ratios. Following transformation into One Shot™ TOPIO cells, pCINeo 
containing DNhTERT was then purified and sequenced to confirm the correct insert was present 
(Figure 4.3, Figure 4.4).
4.5.1.2 Generation o f stable transfectants
Following synthesis of the DNhTERT construct, stable transfectants containing pCINeo­
DNhTERT and empty pClNeo (negative control) were established in both the CMT7 and D17 cell 
lines. Following the addition o f G418 to flasks and reseeding at different dilutions, the 1:10 flask 
was selected as having the most appropriate cell density in both cell lines. Initial selection o f cells 
was performed with a G418 concentration o f 400 pg/ml which then was increased to 600 pg /ml. 
Stable transfectants were also generated in the K9SF cells using the pCINeo-DNhTERT construct. 
Untransfected (wild-type) K9SF cells were also maintained as negative control. Despite repeated 
attempts, it was not possible to generate a stable transfectant using the empty pCINeo vector in 
K9SF cells due to slow growth and problems with fungal contamination.
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Figure 4.3: Chromas file sequencing o f pCINeoDNhTERT using DNHTOOIF Primer and comparison 
with wild type hTERT sequence. Mutated site is underlined. Sequence from wild type (W T) hTERT 
in the region o f the mutation from genbank accession No. A FOI 5950 shown boxed for comparison.
110 120 130 140 150
T G  Â G C T G T À C T T T G T C A A G G T C G C G A T C Â C G G G C G C G T A C G Â C A C C Â T
GTCAAGGTGGATGTGACGGGC 
V  K V  D V  T G
Sequence of WT-hTER T in the mutated region from Genbank file 
AFOl 5950 together with translation
Figure 4.4: Illustration o f position o f telomerase specific (T) and reverse transcriptase motifs (1,2, A-E) 
within hTERT mRNA transcript, together with translation o f mutated sequence in RT m otif A used to
generate the DNhTERT construct.
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4.5.1.3 Confirmation of transfection
Following the generation o f stable transfectants, cells were harvested for RT-PCR confirmation o f 
transfection. RNA extraction was performed using RNAWiz® (Ambion, UK) and cDNA synthesis 
was performed using random hexamers. PCR amplification using the DNHTOOIF/R primer pair 
revealed a 450 bp band in the pCINeo-DNhTERT but not negative control cells (Figure 4.5). This 
band was gel purified and sequenced using the DNHTOOIF and DNHTOOIR primers. Sequencing 
confirmed that the pCINeo-DNhTERT-transfected cells contained the mutated sequence.
4.5.1.4 Growth rate analysis
Growth rates o f all cell lines were followed over 50 population doublings to assess the effect o f the 
DNhTERT construet on the growth o f telomerase-positive D17 and CMT7 cells. These are shown 
in Figure 4.6. No significant difference was seen between the pCINeo-DNhTERT-transfected cells 
and negative controls. Interestingly, in the K9SF cells, transfection with pCINeo-DNhTERT 
resulted in a marked increase in growth rate (Figure 4.7). In addition, the morphology o f 
fibroblasts altered, and rather than assuming a spindle shape, cells became more rounded with 
altered growth. With further passaging, cells also showed a tendency to abandon growth in a 
monolayer and to form ‘clum ps’ or ‘spheroids’ of cells. Examples are shown in Figure 4.8. 
Untransfected wild type cells were maintained up to passage 9 (PD 6 ) before growth slowed and 
cells exhibited signs o f senescence.
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Figure 4.5: Representative 1.5% agarose gel electrophoresis o f RT-PCR confirmation o f transfection 
of DI7 and C1VIT7 cells with pCINeo-DNhTERT. A: PCR amplification o f cDNA using DNHTOOIF/R 
primers, B: PCR amplification o f cDNA using CycloF/R primers
Lane:
1 D 17 transfected with pClNeo-DNhTER f
2 Dl 7 transfected with empty pCINeo
3 CMT7 transfected with pCINeo-DNhTERT
4 CMT7 transfected with empty pCINeo
5 - 8  Negative controls: RNA template used for amplification in place o f  cDNA
MW Marker 1 2 3 4 5 6 7 8
600 b p
B MW Marker
600 b p
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Figure 4.6: Growth rates o f CIV1T7 and D17 Cells transfected with either pCINeoDNhTERT (DNHT)
or empty pCINeo (NC).
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Figure 4.7: Growth rate o f K9SF cells transfected with pCINeoDNhTERT. Also shown is the growth 
rate o f untransfected (W T) K9SF cells. These cells were maintained up to PD 6 before growth ceased
and signs o f senescence appeared.
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Figure 4.8: Illustration o f morphological features o f K9SF stable transfectants.
Note spindle shaped appearance and growth pattern o f  wild-type K9SF cells (A ) compared with 
more rounded cell morphology and disordered growth o f  K9SF cells transfected with 
pCINeoDNhTERT (B and C). In addition, later passage cells showed a tendency to grow as 
spheroids rather than in monolayers (C). Magnification: A: x 10, B: x 10, C: x40.
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4.5.1.5 Telom erase activity
TRAP assays were performed on CMT7, D17 and K9SF cells following the establishment o f stable 
cell lines after approximately 25 population doublings had elapsed to evaluate the telomerase 
activity in each cell line following transfection with either pCINeoDNhTERT construct or empty 
pCINeo (negative control). CMT7 and D17 cells transfected with pCINeoDNhTERT were shown 
to have telomerase activity at similar levels to negative control cells transfected with empty 
pCINeo. Interestingly, K9SF cells transfected with pCINeoDNhTERT also showed strong 
telomerase activity with higher levels o f activity than the CMT7 and D17 ceils. These results are 
shown in Table 4.2 and Table 4.3 respectively.
Table 4.2: Telomerase repeat amplification protocol results of CMT7 and D17 cells transfected with
pCINeoDNhTERT (DNHT) or pCINeo (NC)
As is the absorbance o f the sample, Ago is the absorbance o f the heat inactivated version o f each 
sample, AAs is the corrected absorbance o f each sample (calculated by subtracting the mean o f all 
heat inactivated samples (Àso)from As), AAs/Àso is the ratio o f  sample to background activity and 
RTA is the telomerase activity relative to the positive control (AAs/Corrected absorbance o f 
positive control). Samples were considered telomerase-positive if the corrected absorbance (AAs) 
was greater than twice the background activity, and if AAs/Àso was greater than 2.0. The results 
shown are the mean o f at least two experiments, and the assay gave a mean background absorbance 
o f 0.033 and a (Ats8'Ats8.o)/Ats8,is) value o f 0.34 after 10 minutes o f colour development using the 
low activity positive control.
Cell Line As Aso AAs AAs/Àso RTA. Result
D I7 DNHT 0.18 0.03 0.15 4.5 0.44 POS
D I 7 N C 0.18 0.04 0.15 4.4 0.44 PCS
CMT7 DNHT 0.44 0.03 0.41 12.5 1.2 POS
CMT7 NC 0.29 0.04 0.26 7.7 0.76 POS
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Table 4.3: T R A P  results for K9SF cells transfected with pC IN eoD N hT E R T
As is the absorbance o f the sample, Aso is the absorbance o f the heat inactivated version o f each 
sample, AAs is the corrected absorbance o f each sample (calculated by subtracting the mean o f all 
heat inactivated samples (Âso)from As), AAs/Àso is the ratio o f sample to background activity and 
RTA is the telomerase activity relative to the positive control (AAs/Corrected absorbance of 
positive control). Samples were considered telomerase-positive if the corrected absorbance (AAs) 
was greater than twice the background activity, and if AAs/Àso was greater than 2.0. The results 
shown are the mean o f at least two experiments, and the assay gave a mean background absorbance 
o f 0.105 and a (Ats8-Ats8,o)/Ats8,is) value o f 0 .5 1 after 10 minutes o f colour development using the 
high activity positive control.
Cell Line As Aso AAs AAs/Aso RTA Result
K9SF DNHT 3.44 0.10 3.35 31.9 6.57 POS
4.5.1.6 Telomere Length Analysis
TRF analysis o f telomere length was performed on Dl 7 and CMT7 cell lines. Samples for TRF 
analysis were harvested every 3-4 passages over the course o f the experiment. A representative 
picture o f typical TRFs is shown in Figure 4.9. Table 4.4 shows the mean TRF analysis o f all 
tumour cell lines. No significant change in the mean telomere length o f any cell line measured was 
seen over the course o f the experiment. Using the Wilcoxon Signed Rank Test, no statistical 
difference was noted between telomere length o f pCINeo-DNhTERT transfected cells and negative 
controls for either the CMT7 (p=0.62) or Dl 7 (p= 0.25) cell lines.
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Figure 4.9: Representative example o f TRF Autoradiograph. C1VIT7 cells transfected with either 
pCINeoDNhTERT or empty pCINeo. Samples are run in duplicate in adjacent lanes.
IMW Marker 
Size (kb)
i S 10 II 12 13 14 15 16 17 18 19 20
23.1
9.4 
6.6
4.4
2.3
2.0
1 ^ I
Lane Construct Passage
1,20 Molecular Weight marker
2-3 pClNeo DNhTERT 42
4-5 pCINeo DNhTERT 46
6-7 pClNeo DNhTERT 49
8-9 pCINeo DNhTERT 53
10-11 pCINeo DNhTERT 56
12-13 pClNeo 42
14-15 pClNeo 45
16-17 pCINeo 48
18-19 pClNeo 51
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Table 4.4: T R F  analysis o f  C M T 7  and D17 cells transfected with D N h T E R T  and negative controls
Cell Line Construct Passage
Number
Mean TRF 
length (kb)
CMT7 DNhTERT 42 5.73
CMT7 DNhTERT 46 5.15
CMT7 DNhTERT 49 5.51
CMT7 DNhTERT 53 5.95
CMT7 DNhTERT 56 5.90
CMT7 NC 42 5.52
CMT7 NC 45 4.99
CMT7 NC 48 5.46
CMT7 NC 51 6.25
CMT7 NC 55 5.82
D17 DNhTERT 12 5.30
D17 DNhTERT 18 5.26
D17 DNhTERT 21 5.44
D17 DNhTERT 23 5.14
D17 NC 13 4.91
D17 NC 15 4.97
D17 NC 18 5.12
D17 NC 22 5.19
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Figure 4.10: Graphs showing mean TRF lengths of CMT7 (A) and D17 (B) cells transfected with 
pCINeoDNhTERT (DNHT) and empty pCINeo (NC). Each graph represents the mean of two
samples, each run in duplicate.
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4.5.2 Inhibition o f  canine telomerase with Telomestatin
4.5.2.1 Optimisation of telomestatin concentration
In order to assess the optimal concentration to treat D17 and CMT7 cells for prolonged treatment 
with telomestatin, cells were seeded into 6-well plates at a density o f 5 x 10  ^ cells per well and 
treated for 7 days with varying concentrations o f telomestatin in DMSO. Cells treated with 5 pM 
and 10 pM o f telomestatin were found to have undergone cell death within 3 days o f the addition of 
telomestatin, with all cells rounding up and lifting o ff the base o f the wells. Following 
trypsinisation and staining with trypan blue at 7 days, staining confirmed that all o f these cells were 
non-viable. All cells treated with telomestatin and negative controls were prepared for TRAP 
assays as described in section 4.4.1.6.1: Sample preparation.
4.5.2.1.1 TRAP A ssays
TRAP assays were performed on all cells following 7 days o f treatment with telomestatin at 
varying concentration. The results o f these are shown in Table 4.5, Figure 4.11. TRAP assays 
showed that in the 0.1 pM and negative control cells, no significant reduction in telomerase activity 
was seen. Cells treated with 5 pM and 10 pM telomestatin were found to have no detectable 
telomerase activity. Cells treated with 2 pM telomestatin showed approximately an 80% decrease 
in telomerase activity for CMT7 cells and approximately 67% decrease for D17 cells as compared 
with 0.1 pM-treated and negative control cells. Interestingly, the telomerase activity in D17 cells 
was consistently lower than that o f CMT7 cells at all telomestatin concentrations with the 
exception o f 2.0 pM.
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Table 4.5: T R A P  assay results o f  treatment o f  C M T 7 and D17 cells with telomestatin at
concentrations o f  0.1, 1.0, 2.0, 5.0, 10.0 pIM and negative control (N C ) cells for 7 days.
As is the absorbance o f the sample, Aso is the absorbance o f the heat inactivated version o f each 
sample, AAs is the corrected absorbance o f each sample (calculated by subtracting the mean o f all 
heat inactivated samples (Aso)from As), AAs/A sq is the ratio o f sample to background activity and 
RTA is the telomerase activity relative to the positive control (AAs/Corrected absorbance o f 
positive control). Samples were considered telomerase-positive if the corrected absorbance (AAs) 
was greater than twice the background activity, and if AAs/Àso was greater than 2.0. Using these 
criteria, samples were designated positive (POS) or negative (NEG). The results shown are the 
mean o f at least two experiments, and the assay gave a mean background absorbance o f 0.081 and 
a ( A t s 8 - A t s 8 . o ) / A t s 8 , i s )  value o f 0.34 after 10 minutes o f colour development using the low activity 
positive control.
Cell Line T elom estatin
C oncentration
(pM)
As Aso AAs AAs/Aso RTA Result
CMT7 0.1 0.51 0.08 0.43 5.3 1.26 POS
CMT7 1.0 0.25 0.07 0.18 2.2 0.53 POS
CMT7 2.0 0.14 0.07 0.07 0.89 0.21 NEG
CMT7 5.0 0.07 0.08 -0.01 0.1 -0.03 NEG
CMT7 10.0 0.07 0.08 -0.01 0.1 -0.03 NEG
CMT7 NC 0.39 0.07 0.32 4.0 0.94 POS
D17 0.1 0.35 0.1 0.25 3.1 0.74 POS
D17 1.0 0.15 0.09 0.06 0.7 0.18 NEG
D17 2.0 0.14 0.07 0.07 0.89 0.21 NEG
D17 5.0 0.07 0.08 -0.01 0.1 -0.03 NEG
D17 10.0 0.07 0.09 -0.02 0.1 -0.06 NEG
D17 NC 0.24 0.07 0.17 2.1 0.50 POS
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Figure 4.11: Graph showing TRAP activity o f CM T7 and D17 cells treated with telomestatin at
concentrations o f 0.1, 1.0, 2.0, 5.0, 10 plVl and untreated (NC) cells.
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4.S.2.2 Prolonged treatment with telomestatin
Following initial optimisation, the concentration o f  telomestatin that resulted in greatest telomerase 
activity reduction without causing cell death at 7 days was selected for longer term treatment o f  
Dl 7 and CMT7 cells. Cells were therefore seeded into 25 cm^ flasks at a density o f  5 x 10  ^ cells 
per flask and treated with telomestatin at a concentration o f  2.0 pM for the duration o f  the 
experiment. In addition, control cells were cultured in the absence o f  telomestatin. and with the 
same volume DMSO as telomestatin as a second negative control. K9SF cells were also 
maintained with the same conditions as a further negative control. All samples were maintained in 
duplicate. At the end o f  7 days, cells were trypsinised, counted to assess growth rate, and re-seeded 
at a density o f  5 x 10  ^ cells per flask. In addition, aliquots o f  2 x 1 I  x 10^  and 2 x 1 0 ^  cells were 
removed for TRF analysis, apoptosis and TRAP assays respectively. I he same process was 
repeated at 14 days. A final trypsinisation was performed at 20 days and the samples retained for 
TRF, apoptosis and TRAP studies.
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4.5.2.2.1 Growth R ates
Growth rates o f all cells are shown in Figure 4.12. Both CMT7 and D17 telomestatin-treated cells 
showed slower growth than negative controls (untreated and DMSO-treated cells), although this 
was much more prominent in D17 than CMT7 cells. When flasks were examined prior to 
trypsinisation at day 14, it was found that telomestatin-treated CMT7 and D17 cells had not 
reached confluence, and for this reason these flasks were not trypsinised at 14 days but rather at 20 
days. These cells were rinsed, and fresh medium with telomestatin was added. Negative control 
flasks, however, were trypsinised at both 14 and 20 days. At 20 days, a significant proportion o f 
Dl 7 cells were found to have undergone apoptosis, with cells rounding up and no longer adherent 
to tissue culture flasks. This had also occurred in CMT7 cells, although a greater percentage of 
cells were still adherent.
K9SF cells were found to grow very slowly in the culture conditions used. For this reason, flasks 
o f these cells were only maintained for 7 days. However, all flasks showed similar growth rates. 
At the end o f 7 days these flasks were trypsinised and samples removed for apoptosis studies.
1 9 9
Figure 4.12: G row th  rates o f  C M T 7, D 17 and K 9SF  cells fo llow ing  treatm ent w ith  2 .0 uM  telom estatin . 
A: D 17 grow th  rates, B: C M T 7 grow th  rates, C; K 9SF  cell rates. T elo: telom estatin -treated  cells. NC: 
negative control (untreated ) cells. D M SO : negative control (D M SO -treated ) cells. Each graph show s
the m ean for tw o independent experim ents.
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4.5,2.2.2 Telom erase activity
TRAP assays were performed on D17 and CMT7 cells at 7 days and at 20 days, due to the 
pronounced slowing o f growth that occurred. TRAP results showed that all te I omestati n-treated 
cells were negative for telomerase activity at 7 days and at 20 days, with a reduction in TRAP 
activity o f 65% and 75% at day 7 for D17 and CMT7 cells respectively (vs untreated negative 
controls) and with a reduction o f 68% and 65% at day 20. In contrast, all negative control cells 
were positive at these time points (Table 4.6, Figure 4.13).
Table 4.6: TRAP activity of CMT7 and D17 cells treated with telomestatin at 2.0 pM for 20 days.
As is the absorbance o f the sample, Aso is the absorbance o f the heat inactivated version o f each 
sample, AAs is the corrected absorbance o f each sample (calculated by subtracting the mean o f all 
heat inactivated samples (Aso)ft'om As), AAs/Àso is the ratio o f sample to background activity and 
RTA is the telomerase activity relative to the positive control (AAs/Corrected absorbance of 
positive control). Samples were considered telomerase-positive if the corrected absorbance (AAs) 
was greater than twice the background activity, and if AAs/Àso was greater than 2.0. Using these 
criteria, samples were designated positive (POS) or negative (NEG). The results shown are the 
mean o f at least two experiments, and the assay gave a mean background absorbance o f 0.074 and 
a (Atss-Ats8,o)/Ats8,is) value o f 0.27 after 10 minutes o f colour development using the low activity 
positive control.
Cell Line Time
(days)
Telomestatin
Concentration
(|iM )
As Aso AAs AAg/Aso RTA Result
CMT7 7 2.0 0.14 0.07 0.07 0.89 0.26 NEG
CMT7 7 NC 0.33 0.07 0.26 3.51 0.96 POS
CMT7 7 DMSO 0.27 0.07 0.20 Z56 0.74 POS
CMT7 20 2.0 0.14 0.08 0.06 0.77 0.22 NEG
CMT7 20 NC 0.27 0.08 0.19 2.57 0.70 POS
CMT7 20 DMSO 0.29 0.08 0.21 2.68 0.78 POS
D17 7 2.0 0.14 0.07 0.07 0.89 0.26 NEG
D17 7 NC 0.29 0.09 0.20 2.56 0.74 POS
D17 7 DMSO 0.30 0.10 0.20 2.56 0.74 POS
D17 20 2.0 0.14 0.08 0.06 0.77 0.22 NEG
D17 20 NC 0.31 0.07 0.24 3.11 0.89 POS
D17 20 DMSO 0.27 0.08 0.19 2.43 0.70 POS
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Figure 4.13: Graph showing telomerase activity of CIVIT7 (A) and D17 (B) cells treated with 
telomestatin at 2.0 pM for 20 days. NC: negative control cells, DMSO: negative control cells treated
with DMSO.
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4.5.2.2.3 Telom ere length analysis
To assess whether the reduction in telomerase activity was associated with telomeric attrition, 
duplicate samples from CMT7 and D17 cells were analysed to examine the effect o f telomerase 
inhibition on telomere length. The mean TRF value was obtained by averaging the mean TRFs 
obtained from two independent experiments, with each sample run out in duplicate. Results are 
shown in Table 4.7, Figure 4.14. In addition, a representative autoradiograph is shown in Figure 
4.15.
TRF analysis showed that telomere length o f negative control (untreated) CMT7 cells was 4.5 and
4.3 kb after 7 and 20 days respectively. Telomere lengths o f  negative control (DMSO-treated) 
CMT7 cells at equivalent timepoints were 3.99 and 4.33 kb. In contrast, the telomere length o f 
CMT7 cells treated with telomestatin was shorter, at 3.15 and 3.0 kb after 7 and 20 days 
respectively. The mean telomere length o f negative control (untreated) D17 cells was 5.34 and 4.87 
kb in length after 7 and 20 days respectively. The mean telomere length o f negative control 
(DMSO-treated) D17 cells was 5.47 and 4.87 kb in length after 7 and 20 days respectively. In 
contrast, the mean telomere length o f telomestatin-treated D17 cells was 3.00 and 2.95 kb after 7 
and 20 days. These results show that telomestatin treatment resulted in telomere shortening in both 
CMT7 and D17 cell lines. In CMT7 cells, telomeres shortened by 1.45/1.62 Kb at day 7/20 
relative to negative controls -  a change o f approximately 30-40%. In DI7 cells, telomeres 
shortened by 2.01/1.35 Kb at day 7/20 relative to negative controls (untreated) -  a change o f 
approximately 30-40%. Therefore, in both cell lines telomere shortening occurred to a similar 
degree. However, no further shortening appears to have occurred after day 7 since there is minimal 
difference between the telomere lengths at the two timepoints.
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Table 4.7: TRF Analysis o f CM T7 and D17 cells treated with telomestatin at 2.0 pM  fo r  20  d ays
Cell Line Time
(days)
Telomestatin
Concentration
(pM)
As Mean TRF 
length (kb)
CMT7 7 2.0 0.14 3.15
CMT7 7 NC 0.33 4.50
CMT7 7 DMSO 0.27 3.99
CMT7 20 2.0 0.14 2.68
CMT7 20 NC 0.27 4.30
CMT7 20 DMSO 0.29 4.13
D17 7 2.0 0.14 3.00
D17 7 NC 0.29 5.01
DI7 7 DMSO 0.30 5.47
D17 20 2.0 0.14 2.95
D17 20 NC 0.31 4.30
DI7 20 DMSO 0.27 4.13
Figure 4.14: Mean telomere length of CMT7 (A) and D17 (B) cells treated with telomestatin.
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Figure 4.15: Representative TRF autoradiograph o f CIVIT7/D17 cells following treatment with
telomestatin at 2.0 pM  for 20 days
Lane Cell Line Treatment Time
1,20 Mass marker
2-3 D17 Negative control (untreated) 7 days
4-5 D17 Negative control (untreated) 20 days
6-7 D17 Telomestatin 20 days
8-9 D17 N egative control (DM SO) 20 days
10-11 CMT7 Telomestatin 7 days
12-13 CMT7 Negative control (untreated) 7 days
14-15 CMT7 Negative control (untreated) 7 days
16-17 CMT7 Telomestatin 20 days
18-19 CMT7 N egative control (DM SO) 20 days
1 2 3 4 5 6 7 8 9  10 11 12 13 14 15 16 17 18 19 20
IMW Marker 
Size (kb)
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4.S.2.2.4 A poptosis follow ing prolonged  treatm ent with telom estatin
To assess the ability o f telomestatin to induce apoptosis in telomerase-positive cells, annexin and 
PI staining were performed on CMT7, D17 and K9SF cells following 7 days’ exposure to 2 pM of 
telomestatin, and on CMT7 and D17 cells following 20 days’ exposure to telomestatin. Apoptosis 
was assessed by counting the percentage o f cells positive for annexin staining but negative for PI 
staining. The results o f annexin staining for all cells are shown in Table 4.8 and Figure 4.16, 
together with representative graphs in Figure 4.17. At 7 days, D17 cells treated with telomestatin 
showed higher levels o f  apoptosis than negative controls (both untreated and DMSO-treated cells), 
with mean annexin staining o f 3.2% as compared with 1.05% for untreated cells and 1.2% for 
DMSO-treated cells. CMT7 cells showed mean annexin staining o f 3.75% as compared with 
1.86% for untreated cells and 1.65% for DMSO-treated cells. Canine skin fibroblasts showed 
similar levels o f apoptosis in all samples, with annexin staining percentages of between 8.0 and 
8.9% for telomestatin, untreated cells and DMSO-treated cells. However, cell death, as assessed by 
the percentage o f cells staining positively for both annexin and PI was found in all flasks, as 
assessed by the number o f cells staining negative for both annexin and PI (Table 4.8). This was 
particularly marked in K9SF cells.
At 20 days, the levels o f  apoptosis in D17 cells treated with telomestatin were significantly higher 
than at 7 days, with 18.65% o f cells displaying annexin staining as compared with 0.25% of 
negative controls and 0.1% of DMSO-treated cells. By comparison, CMT7 cells showed less 
apoptosis, although still higher than at 7 days, with 6.4% of telomestatin-treated cells annexin- 
positive as compared with 0.5% o f negative controls and 0.4% o f DMSO cells. In all CMT7 flasks 
at both 7 days and 20 days, a significant proportion o f cells had undergone either late apoptosis or 
cell death, with only 74 -  80% of cells showing survival. D17 flasks showed some cell death at 7 
days, with mean survival o f approximately 80 -  87%, but in both negative control flasks at 20 days, 
mean survival was 95.3% and 96.4% for non-treated and DMSO-treated flasks respectively. 
However, in the telomestatin-treated D17 and CMT7 cells, mean survival at 20 days was 
considerably lower than negative control cells, with only 34.6 % and 58.9% cell survival in D17 
and CMT7 cells respectively.
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Table 4.8 Apoptosis and survival in D17, CM T7 and K9SF cells after 7 and 20 days exposure
Cell Line Time
(days)
Telomestatin 
Concentration (pM )
Apoptosis
(%)
Survival (%)
D17 7 2.0 3.2 80.4
D17 7 NC 1.05 87.15
D17 7 DMSO 1.2 86.4
D I7 20 2.0 18.65 34.6
D17 20 NC 0.25 95.25
D17 20 DMSO 0.1 96.4
CMT7 7 2.0 3.75 73.85
CMT7 7 NC 1.86 75.3
CMT7 7 DMSO 1.65 73.7
CMT7 20 2.0 6.4 58.9
CMT7 20 NC 0.5 80.5
CMT7 20 DMSO 0.4 74.1
K9SF 7 2.0 8.9 39.9
K9SF 7 NC 8 44.4
K9SF 7 DM SO 8.4 50.6
Figure 4.16: Graph showing apoptosis (% ) in D17 and C1VIT7 cells treated with telomestatin 
(Telomestatin), negative control -  untreated (NC) and negative control - DM SO-treated (DM SO) cells
following 7 and 20 days’ exposure.
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Figure 4.17: Representative FACS analysis o f  Annexin and PI staining in G M T ? cells at 7 and 20 days
A: Telomestatin-treated cells following 7 days exposure 
B: Telomestatin-treated cells following 20 days exposure 
C: Negative control (untreated) cells following 7 days exposure 
D: Negative control (untreated) cells following 20 days exposure
J l:  Annexin-negative and Pl-positive (dead cells), J2: Annexin-positive and Pl-positive (late 
apoptotic/dead cells), J3: Annexin-negative and Pl-negative (live cells), J4: Annexin-positive and 
Pl-negative (early apoptotic cells).
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4.6 D iscussion
The aims o f this chapter were to investigate two forms o f telomerase inhibition in telomerase 
positive canine cancer cell lines. The first o f these, DN-hTERT is the dominant negative mutant of 
the human TERT reverse transcriptase catalytic subunit. The second, telomestatin, is a naturally 
occurring G-quadruplex ligand, which functions by binding telomeric DNA in a G-quadruplex and 
preventing access o f telomerase.
4.6.1 Inhibition o f Canine Telomerase with D N hTE R T
To evaluate the effects o f inhibition o f the dominant negative mutant DNhTERT, we synthesised 
the construct pCINeo-DNhTERT and used it to generate stable transfected cell lines in the 
telomerase-positive CMT7 and D17 cell lines. As negative controls, we also generated stable 
transfectants in these cell lines using empty pCINeo. In addition, we generated stable transfectants 
in telomerase-negative K9SF cells using the pCINeo-DNhTERT construct, but were unsuccessful 
in our attempts to stably transfect these cells with empty pCINeo.
When we examined the growth rate of transfected cells over time, we found that the pCINeo- 
DNhTERT construct had no impact on the growth rate o f either CMT7 or DI 7 cells (Figure 4.6). 
in addition, TRAP assays performed on these cells showed that telomerase activity was still 
present, despite the confirmation o f successful transfection (Table 4.2, Figure 4.5). In addition, no 
significant change in telomere length was found in these cells over the course o f 50 population 
doublings (Figure 4.10). These findings suggest that the human dominant negative mutant o f 
TERT, DNhTERT, whilst abrogating telomerase activity in human telomerase-positive cells, does 
not have an inhibitory effect on canine telomerase. The reasons for this remain to be determined. 
Although canine and human TERT share a total homology at the amino acid level o f 67%, similar 
enough to allow liTERT to function in canine cells (Nasir et al. 2004), it may be that the homology 
in the region o f the mutation in M otif A (62% across the reverse transcriptase region) is sufficiently 
different to prevent mutations in this region from creating a dominant negative effect. 
Alternatively, it may be that dominant negative splice mutants either do not occur in the dog or 
arise from splice sites not located in m otif A. However, given the similarity between the two 
molecules, it seems reasonable to expect that, given its important for reverse transcriptase 
functioning, alterations to m otif A of canine TERT should interfere with the ability of TERT to 
function and may also result in dominant negative mutants as they do in humans. An important 
experiment to try to confirm this would be to mutate canine TERT in the region o f m otif A (firstly 
by deleting m otif A altogether) and examining the effects o f such mutations in telomerase-positive 
cells. However, the generation o f these mutants requires obtaining wild type canine TERT cDNA, 
a hurdle which has yet to be overcome.
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Interestingly, the growth rate o f the K9SF telomerase-negative cells transfected with pCINeo- 
DNhTERT was significantly increased over untransfected K9SF cells. In addition, these cells 
became telomerase positive and appeared to change their morphology and growth pattern, with 
less-ordered growth and the ability to grow out o f a single monolayer (Table 4.3, Figure 4.8). An 
important caveat must be attached to this last observation however. When further passages o f wild- 
type fibroblasts were grown over a longer period o f time, in one case a single flask appeared to 
develop an area o f cells with similar morphology (results not shown). Thus, it is possible that the 
cells may have undergone spontaneous immortalisation. This seems unlikely since RT-PCR 
confirmation o f transfection revealed the presence o f a 450 bp band when amplified using the 
DNHTOOIF/R primer pair, and also since the change in growth pattern and morphology appeared 
to coincide with the point o f transfection (Figure 4.7), whereas the single transformed flask 
occurred only after several further passages o f these cells had elapsed.
Our findings would appear to suggest that the human DNhTERT mutant functions to restore 
telomerase activity in telomerase-negative canine cells. More significantly, the presence of 
DNhTERT appears to alter the morphology and growth pattern o f these cells, inducing a potentially 
malignant phenotype. An alternate explanation is that in these cells, DNhTERT activity, in 
allowing more rapid growth and division, also allowed other mutations to occur that led to the 
development o f a malignant phenotype. In either case, these findings would appear to be different 
from the situation in human telomerase-negative fibroblasts, in which the induced expression o f 
liTERT allows unlimited cell divisions, but does not change the growth pattern or morphology o f 
cells (Bodnar et al. 1998). An important question that arises from this is whether this effect is 
simply the result o f reactivated telomerase activity or whether structural differences between 
human and canine TERT result in other changes related to a cancerous phenotype in dog cells. 
Several further experiments need to be performed to isolate these. Firstly, it would be valuable to 
repeat this experiment in a different telomerase-negative canine cell line, to confirm our findings. 
In addition, the transfection o f these cells with wild type human TERT as well as the DNhTERT 
mutant should be performed to determine whether any difference in morphology or growth pattern 
is due to the mutated sequence in DNhTERT. If these morphologic changes are confirmed, it is 
then possible to assess whether the induced phenotypic changes are indeed similar to those 
acquired by cancer cells, by examining growth in low-serum conditions, and also by examining 
growth in agar to determine whether these cells acquire invasive potential. Secondly, a vital 
experiment is to transfect canine telomerase-negative skin fibroblasts with wild type canine TERT 
to examine the effects o f immortalisation on these cells. This last experiment, however, again 
relies on obtaining the full length canine TERT cDNA, which has so far proved technically 
challenging.
It should be noted that we were unable to create a stable transfectant using empty pCINeo in
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telomerase-negative K9SF cells. Untransfected fibroblasts from this cell line grow slowly, and 
undergo senescence at approximately passage 8-11. Transfections were performed at passage 4-5. 
In addition, the transfection process resulted in significant cell death and slowed growth. 
Following the initiation o f selection with G418, further cell death in the pCINeo-transfected cells 
combined with the naturally slow growth rate meant that cells did not reach confluence despite 
being maintained for a period o f 4 weeks. Furthermore, technical problems with persistent fungal 
contamination meant that flasks had to be discarded. As a result, despite repeated attempts, stable 
transfectants could not be generated to act as negative controls, and untransfeeted wild-type cells 
were used instead.
4.6.2 Inhibition o f  canine telomerase with telomestatin
Telomestatin showed considerably more promise as a te I om erase- inhibitor in canine cells 
compared to DNhTERT. To evaluate the effect o f telomestatin on telomerase activity, we initially 
incubated CMT7 and D17 cells with telomestatin at varying concentrations for 7 days and 
monitored telomerase activity by performing TRAP assays. This experiment showed that 
concentrations o f 1.0 and 2.0 gM successfully reduced telomerase activity, with the greater 
reduction occurring at a concentration o f 2.0 pM (Figure 4.1 1). Treatment o f cells with either 5.0 
pM or 10.0 pM telomestatin also reduced telomerase activity, but resulted in the death of all cells 
within 2 days. For this reason, longer-term inhibition studies were performed using a telomestatin 
concentration o f 2.0 pM.
Treatment o f CMT7 and D17 cells with 2.0 pM telomestatin led to a reduction in growth rate in 
both cell lines. In addition, TRAP assays, TRF analysis and apoptosis studies showed that 
telomestatin treatment led to decreased telomerase activity (Table 4.6), telomere shortening (Table 
4.6), and cell death (Figure 4.16) that occurred from approximately 7-10 days after initiating 
treatment. Interestingly, the magnitude o f telomerase inhibition, growth rate slowing and apoptosis 
were all greater in D17 cells than in CMT7 cells. This may be due to the fact that D I7 cells 
naturally possess lower levels o f telomerase activity than CMT7 cells, and consequently are less 
resistant to the effects o f telomestatin. Telomere lengths, however, were roughly similar in both 
cell lines, with telomere lengths in treated DI7 cells falling to 3.0/2.95 at 7 and 20 days 
respectively, as compared with 3.15/2.68 in CMT7 cells. There appeared to be no change in 
telomere length between 7 and 20 days for either cell line. This would appear to suggest that 
apoptosis occurred in both cell lines independently o f telomere length, since apoptosis at 20 days 
was considerably higher in both cell lines than at 7 days. Similar results have been reported in the 
human literature, and support the theory that apoptosis in cells treated with G-quadruplex ligands 
occurs through uncapping o f the telomeres and change in telomere structure, rather than as a result 
o f exhaustion o f telomere reserve (Pennarun et al. 2005; Sham mas et al. 2004). An alternative 
explanation, however, is that a telomere length o f approximately 3.0 kb represents the minimal
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viable telomere length for these two cell lines, and that any cells with a telomere shorter than this 
underwent apoptosis. If this were the case, the number o f cells undergoing apoptosis would have 
accumulated as more and more eells reached the critical limit o f telomere length. Given that 
critical minimal lengths in human cell lines can approach 2.0 kb, this seems perhaps unlikely 
(Tauchi et al. 2003). However, in order to prove the means by which the canine cell lines entered 
apoptosis, several other experiments should be performed, Firstly, a number o f other telomerase- 
positive cell lines with telomere lengths o f varying size should be examined to determine whether 
the length o f time between onset o f telomerase inhibition and apoptosis is related to telomere 
length. Secondly, it would be important to evaluate levels o f p21 and p27 expression in these cells 
to examine whether DNA damage response pathways are upregulated, as would be consistent with 
an uncapping model, and to examine whether that upregulation occurs independently o f telomere 
length. Similarly, other factors involved in the DNA damage response pathway, such as ATM, 
should be examined, as they are known to be upregulated with telomestatin treatment (Tauchi et al. 
2003).
The change in growth rate in all cells was an interesting finding. Both cell lines appeared to have 
an initial lag phase o f approximately 7 days in the case o f DI 7 cells and slightly longer than this in 
the CMT7 eells. Some authors have reported that the effects o f telomestatin occur after an initial 
lag phase o f 5-7 days (Shammas et al. 2004), but this time varies between reports, with some cell 
lines requiring exposure for up to 30 days to show a loss in proliferative capacity (Tauchi et al. 
2003). The initial telomere length o f CMT7 cells was approximately 1.0 kb longer than that of 
D17 cells, which could account for this difference if apoptosis was induced by exhaustion of 
telomeric reserve. However, the rate o f telomere loss seems to have been more rapid than this 
would suggest, since both cell lines had mean telomere lengths o f approximately 3.0 kb at 7 days, a 
shortening rate o f approximately 2-3 kb within the first 7 days. In addition, this rate o f shortening 
is much more rapid than that reported in human cell lines, where a loss o f 1.0 kb over 39 days was 
reported in response to exposure o f SW26 cells to telomestatin (Kim et al. 2003a). However, there 
does seem to be disagreement over the amount o f telomere shortening induced by telomestatin, 
with other authors suggesting considerably greater telomeric attrition (Tauchi et al. 2003). In order 
to confirm this, our experiments could be repeated with more frequent evaluation o f telomere 
length. This would also allow a more precise determination of the timepoint at which growth 
inhibition occurred in both cell lines.
The annexin and PI staining appeared to show increasing levels o f apoptosis with prolonged 
exposure to telomestatin. Consistent with our other findings, the level o f apoptosis in D17 cells 
appeared to be considerably higher at 20 days than in CMT7 cells. For this reason it would be 
important to repeat this experiment with a longer duration o f treatment for CMT7 cells to see if 
similar levels o f  apoptosis are reached with longer treatment. An important caveat should be 
attached to these results, however, as evidenced by the high levels o f  cell death that occurred in all
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flasks. Up to 30% o f untreated D17 cells and 20% of untreated CMT7 cells at 7 days were found 
to have undergone either late apoptosis or cell death as shown by positive staining for both annexin 
and PI. These figures were even higher for K9SF cells. The annexin-V staining protocol is 
designed primarily for non-adherent cells in suspension. During trypsinisation and counting o f 
adherent cells, some trauma occurs, leading to exposure of PS on the outer membrane leaflet, with 
the result that some normal cells can show positive staining for annexin (van Engel and et al. 1998). 
To minimise this, tiypsinisation was restricted to no longer than 5 minutes, and all procedures were 
performed slowly to minimise disruption of cell membranes during tiypsinisation and staining. In 
addition, we performed an initial experiment in untreated CMT7 and D I7 cells to assess the 
baseline level o f  annexin-positive staining that occurs, and found this to be generally less than 1% 
(results not shown). However, this does not account for the high number of annexin and Pl- 
positive stained (ie late apoptotic or dead) cells present in negative control flasks. In addition, the 
level o f early apoptosis present in telomestatin-treated cells was considerably higher than in 
negative control cells. It is possible that other factors in the culture conditions were not optimal, 
with the result that cells in all flasks underwent cell death. Alternatively, it is possible that 
handling o f cells resulted in such severe membrane disruption that Pl-positive staining became 
apparent, although this seems unlikely. Another approach to resolving this dilemma would be to 
investigate other means o f assaying apoptosis (eg TUNEL-staining) or alternatively to stain cells 
without tiypsinisation and examine and count both annexin- and Pl-positive staining using 
fluorescence microscopy.
4.6.3 Potential problem s with therapeutic strategies based on telomerase 
Inhibition
The value o f telomerase inhibition as a clinical means o f treating cancer must be tempered by the 
fact that successful inhibition, theoretically, leads only to the restoration o f a mortal phenotype to 
tumour cells, without affecting other characteristics o f cancer growth. Initial studies using the 
dominant negative mutant o f TERT in humans seemed to support this, with growth inhibition 
occurring only after telomeric reserve in treated cells had been exhausted (Hahn et a l 1999a; 
Zhang et al. 1999). In some locations, such as the brain, further expansion of tumour size during 
this ‘lag phase’ following telomerase inhibition may not be possible without causing the death o f 
the patient, rendering this approach on its own unfeasible in many situations. Indeed, in U251-MG 
glioblastoma eells, this lag phase constitutes approximately 30 doublings, or one month (Kondo et 
al. 1998b). However, studies inhibiting telomerase using other means such as ribozymes directed 
at liTERT or oligodeoxynucleotides directed at liTERT mRNA have suggested that growth 
inhibition o f tumour cells may occur more rapidly, due to other effects (Kraemer et al. 2003; 
Saretzki et al. 2001). For instance, expression o f mutant liTR in human telomerase-positive cells 
leads rapidly to a decrease in cell viability and an increase in apoptosis, independent of p53 status 
and initial telomere length (Guiducci et al. 2001 ; Kim et al. 2001; Marusic et al. 1997). The fact
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that such cell death occurs without exhaustion o f telomeric reserve and only in telomerase-positive 
cells is likely to be the result o f a change in the physical state o f the telomere, with uncapping 
leading to the activation o f DNA damage response genes such as p21 (Abdul-Ghani et al. 2000). 
Most studies examining G-quadruplex ligands also support this mode o f action, with apoptosis 
occurring rapidly and independently o f  initial telomere length. These findings suggest that G- 
quadruplex ligands may be worth investigating in the clinical setting. It should be noted that two 
other factors may also allow the use o f telomerase inhibitors in the clinical setting. Firstly, if the 
physical bulk o f tumour cells can be reduced through surgical excision or other means, it may be 
that telomerase inhibition can be employed subsequently to limit tumour regrowth. Secondly, it 
may be that direct inhibition o f telomerase could be employed alongside other telomerase-targeted 
therapies, such as TERT-promoter driven gene expression (discussed in Chapter V). The 
combination o f different approaches targeting telomerase, involving both direct inhibition and 
telomerase-targeted gene expression, holds great promise and may have synergistic effects on 
tumour cell killing.
Another potential problem concerns the development o f resistance to telomerase inhibitors. This 
may occur in several ways, but one important ways involves the developing o f alternative 
mechanisms for maintaining telomere length, such as the ALT pathway. Importantly, a relatively 
high proportion o f glioblastomas have been shown to maintain telomere length using the ALT 
pathway (Carroll et al. 1999). However, the mechanism by which telomestatin and other G- 
quadruplex ligands work suggest that they may still be able to interfere with telomere maintenance 
in ALT cells due to their interaction and stabilisation o f telomere ends. Indeed, work with the 
ALT-possessing SAOS-2 cell line indicates that these cells still undergo apoptosis following 
treatment with G-quadruplex ligands (Pennarun et al. 2005) Thus, telomestatin is worth 
investigating even in ALT cells.
One important question that remains to be answered in particular with respect to the use o f 
telomestatin is whether adequate concentrations can be achieved at the tissue level with systemic 
administration. In the brain, controlled, continuous delivery could potentially be achieved using 
recently developed delivery systems such as osmotic minipumps combined with stereotactic 
techniques (Zhu et al. 1996). However, to date no studies have examined the pharmacokinetics o f 
telomestatin with systemic dosage. Experience with another G-quadruplex ligand, BRAC019, 
which was used in one study at a dose rate o f 2 mg/kg for 2-3 cycles o f 5 daily doses given 
intraperitoneally in a mouse xenograft model suggest that systemic administration should be 
feasible (Kelland 2005). Thus, although pharmacokinetic data still needs to be established, 
telomestatin represents a potentially valuable way o f targeting telomerase-positive tumours, and 
further work examining its use in dogs appears to be warranted.
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Ch a p t e r  V
S e q u e n c i n g  a n d  c h a r a c t e r i s a t i o n  o f  t h e  
C a n in e  T E R T  P r o m o t e r
5.1 Abstract
Several anticancer therapies have been developed using either tissue-specific or cancer-specific 
gene promoters to drive the expression o f transgenes. The only truly cancer-speeific promoters 
currently known are the promoters o f the TR and TERT genes involved in telomerase activity. 
Since telomerase activity is dependent principally on regulation o f the TERT gene, research has 
focused on the activity o f this gene in normal and cancer tissues. Upregulation o f the TERT gene 
depends primarily on transcriptional activity o f its promoter, although post-transcriptional 
modification o f the TERT transcript and méthylation o f the TERT promoter may also play a role. 
The human TERT promoter is GC-rich, has no TATA box and contains multiple binding sites for 
transcription factors including S p l, c-Myc and p53. Using this promoter, several groups have 
developed a number o f promoter-driven therapies to induce apotosis or cell death by other means 
both in vitro and in vivo in nude mouse models, with considerable success. Some groups have also 
utilised the TR promoter in a similar fashion with good results.
The aims o f this chapter were to sequence and characterise the canine TERT promoter and TR 
promoter as a prelude to developing TERT and TR promoter-driven therapies. We successfully 
sequenced approximately 5.4 Kb o f the canine TERT promoter and created deletion constructs to 
identify the core promoter responsible for activity in telomerase-positive cells following luciferase 
assays. The core promoter was identified as a region 3 14 bp upstream o f the ATG start codon, and 
conveyed approximately 50% o f the activity o f a positive control vector in CMT7 and DI 7 cells. 
Importantly, inclusion o f the initial part o f the TERT gene with the core promoter reduced activity 
by approximately 75%, suggesting that important negative regulatory factors exist within the 
canine TERT gene. Transfection o f other telomerase-positive cells with the core promoter 
construct showed promoter activity varied from between approximately 8% to 50% of the activity 
o f the positive control. In addition, transfection o f telomerase-negative fibroblasts with all deletion 
constructs showed that the activity o f the TERT promoter was restricted to telomerase-positive 
cells. A number o f potentially important putative transcription factor binding sites were identified 
within the core promoter, as well as within the TERT gene itself, although there were also 
significant differences between the canine promoter and its human counterpart. In addition to 
sequencing and characterising the TERT promoter, initial sequencing and analysis o f the canine TR 
promoter was performed. In this experiment, genome walking was used to generate approximately 
700 bp o f the canine TR promoter sequence amplified from genomic DNA. The most remarkable 
finding in the TR promoter sequence was the presence o f multiple (TAAAA)n repeats. Although 
the significance o f these repeats is currently unknown, there is some evidence from the human 
literature to suggest that they are important for transcriptional regulation o f some genes. Together, 
these experiments, by elucidating the canine TERT and TR promoters, have provided an important 
tool that can be used in the design o f future telomerase-specific promoter-driven therapies.
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5.2 Introduction
Although telomerase inhibition has shown promise as an anti-cancer strategy, it has limitations 
which have prompted the investigation o f other strategies using telomerase. In particular, the 
possibility that telomerase could be used as a target to guide gene expression specifically in cancer 
ceils has excited considerable interest. This introduction will examine the principles underlying 
such targeted gene expression and the ways in which it has been used to date in designing cancer 
treatments for humans as a background to the development o f similar strategies in dogs.
5.2.1 Promoter-driven gene therapy
Gene therapy involves the transfer o f exogenous genes (transgenes) into the somatic cells o f a 
patient to elicit a desired effect. Early work investigated gene therapy for the treatment o f inherited 
diseases in people, and this strategy is particularly suited to the treatment o f specific conditions 
involving the absence o f a single gene and its product. A good example o f this is the recently- 
published treatment o f autosomal recessive a-mannosidosis in cats (Vite et al. 2005). Gene therapy 
may also be used to treat cancer, either by replacing the function o f defective tumour suppressor 
genes or by introducing genes capable o f killing tumour cells. The challenge facing all forms o f 
cancer therapy is to selectively kill cancer cells whilst sparing normal cells. Conventional anti­
cancer treatments such as radiotherapy and chemotherapy are usually designed to kill rapidly 
dividing cells, but this can include normal cells which are undergoing mitosis. This leads to a dose- 
limiting toxicity in normal tissue and limits their use. However, gene therapy strategies might 
avoid this toxicity if they can be designed to specifically deliver their products to cancer cells.
It has become clear that gene expression is regulated by a complex interplay o f factors that act in a 
cell-type-specific manner to produce a wide range of effects. The diversity o f these effects arises 
from the interaction between tissue-specific transcriptional control elements present in the various 
cell types (Robson & Hirst 2003). These transcriptional control elements, or promoters, can be 
exploited to drive the transcription o f a therapeutic gene either in a tissue-specific or tumour- 
specific manner.
Strategies using tissue-specific promoters employ the promoters o f genes that are switched on only 
in certain tissues. Expression o f transgenes under the control o f these promoters generally results 
in the constitutive expression o f genes throughout the target tissue. One o f the main limitations o f 
this sort o f promoter is that transgene expression may lead to cytotoxic effects in normal tissue as 
well as tumour tissue derived from the same cells. For this reason, the use o f these promoters must 
necessarily be restricted to tissues in which damage is not critical for the survival o f the host, for 
example prostate, melanocytes or thyroid (Robson & Hirst 2003). Notwithstanding this limitation,
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tissue-specific gene expression has been examined using several tissue specific promoters, 
including the tyrosinase (melanocytes), prostate-specific antigen (prostate), glial fibrillary acidic 
protein (glial cells), Nex (neural crest-derived cells), albumin (liver), thyroglobulin (thyroid), and 
ovarian specific (ovaries) promoters (reviewed in (Robson & Hirst 2003)).
The ideal tumour-specific promoter should be highly active in tumour cells and have no activity in 
normal cells. This encompasses a vast number o f promoters, but they have been divided into 
subgroups depending on their characteristics (Harrington et aL 2000). Tumour-specific promoters 
can be described as 1) cancer-specific (i.e. specific for the malignant process without being 
influenced by the tissue type), 2) tumour-type-specific (i.e. specific to the type o f tumour, and 
therefore the cell-type from which it arises), 3) tumour microenvironment-related (i.e. promoters 
which respond to factors within the tumour microenvironment such as hypoxia) and 4) tumour 
vasculature related promoters (i.e. promoters which are more active in the tumour vasculature as 
compared with normal vasculature). Whilst there are a number o f promoters within the other 
groups, the promoters o f only a single enzyme, telomerase, can be considered to be cancer-specific 
(Robson & Hirst 2003), and this chapter will focus on the design o f gene therapy strategies in dogs 
based on these promoters. However, an essential prerequisite for the design o f such therapies is a 
basic understanding o f the regulation o f telomerase activity in normal and cancer cells. Therefore, 
a brief review o f our eurrent understanding o f human telomerase regulation will be covered before 
reviewing the telomerase promoter-based therapies currently under development as a comparison 
for the design o f such therapies in dogs.
5.2.2 Regulation o f  telomerase activity in humans
Several strands o f evidence point to the fact that the regulation o f telomerase expression depends 
primarily on the activity o f the TERT gene. Firstly, although expression o f both the TR and TERT 
genes are necessary for telomerase activity in vitro, TR is widely expressed in somatic tissues 
where TERT is undetectable in most somatic cells (Beattie et ai. 1998; Meyerson et al. 1997; 
Weinrich et al. 1997). Secondly, levels o f TERT mRNA expression in humans temporally parallels 
changes in telomerase expression during cell differentiation and neoplastic transformation 
(Takakura et ai. 1998; Wu et al. 1999). Thirdly, ectopic expression o f liTERT is sufficient to 
restore telomerase activity in some (although not all) telomerase-negative cell lines, including 
human foreskin fibroblasts, mammary epithelial cells, retinal pigment epithelial cells, and umbilical 
endothelial cells (Bodnar et al. 1998; Counter et al. 1998; Vaziri & Benchimol 1998; Weinrich et 
al. 1997). These three findings together suggest that regulation o f the TERT gene is the major 
factor responsible for controlling telomerase expression.
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In general, regulation o f the TERT gene occurs through three mechanisms: regulation o f gene 
transcription, post-transcriptional modifications and promoter méthylation. A brief description o f 
these three mechanisms follows.
5.2.2.1 Transcriptional Regulation
When SV40-transformed HAl cells are maintained in culture, telomerase activity is not found 
during their extended lifespan, but is found after cells have gone through proliferative crisis and 
become immortalised. Cong et al found that transfection o f these cells with a construct containing 
the liTERT promoter driving a luciferase reporter gene resulted in luciferase activity in cells only 
after proliferative crisis (Cong el al. 1999). This experiment showed that telomerase activity 
coincided with liTERT promoter activity, and thus showed that telomerase expression is principally 
regulated at the level o f gene transcription.
5.2.2.1.1 The IiT E R T core prom oter region
Transcription o f any gene is regulated via the upstream regulatory, or promoter, region o f the gene 
-  the region o f DNA extending in a 5’ direction from the ATG start codon. Defining the region o f 
the TERT promoter that conveys greatest activity was an important step in understanding the 
regulation o f TERT prior to the development o f  promoter-driven therapies in humans. Wick et al 
reported that following promoter fragment linkage to the luciferase reporter gene, insertion into a 
plasmid vector and transient transfection o f HEK-293 cells, the promoter fragment 43 -  1125 bp 
upstream o f the ATG start codon conferred greater luciferase expression than fragments o f longer 
length extending further upstream (Wick et al, 1999). However, within this region, Cong et al 
reported that a smaller, core region extending from 330bp upstream o f the ATG start codon to the 
first 37bp o f exon 2 conveyed the greatest activity (Cong et al. 1999). Most other authors refer to 
this as the core promoter o f the TERT gene. However, in addition to core activity being contained 
in the upstream region, several authors have also reported the presence o f detectable regulatory 
activity within exons 1 and 2 and intron 1 o f the hTERT gene (Renaud et al. 2003).
S.2.2.2 Post-transcriptional modification of hTERT
Telomerase has been widely reported to be expressed in a cell and age-specific manner. In higher 
eukaryotes, such tissue and development-dependent regulation o f gene expression often involves 
alternate splicing o f  mRNA transcripts (Cong et al. 1999). In addition to full length hTERT 
mRNA, several authors have described the existence o f six mRNA splice variants (Kilian et al. 
1997; Wick et al. 1999) (Figure 5.1). The variants contain variations in the region comprising the 
RT domains and also in the C-terminal region. Alignment between respective cDNA sequences
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and the genomic hTERT sequence has shown that all the hTERT variants identified ean be 
explained by the use o f alternative splice sites in the hTERT genomic sequence (Wick et a i  1999). 
Deletion variants DELI and DEL2 are characterised by the deletion o f specific sequences. Variant 
DELI, also known as a-f3+, a-del or Adel, comprises a 36 bp in-frame deletion and leads to the 
partial loss o f RT m otif 3, most likely resulting from the use o f an alternative 3 ’ splice acceptor 
sequence in exon 6. The DEL2 variant, also known as a+f3-, (3-del or Bdei, arises when the normal 
5’ splice donor and 3 ’ splice acceptor sequences o f introns 6, 7 and 8 are not utilised. As a result, 
exon 6 is directly fused to exon 9, causing an ORE shift with a translation stop codon present in 
exon 10. The DEL 1+2 (a-p-) variant results from the combination o f DELI and DEL2.
By contrast, a second group o f variants is defined by the insertion o f intron sequences which lead to 
the introduction o f premature translation termination codons. The variant INSl encodes an 
alternative 3 ’-located splice site instead o f the normally used 5’ splice donor sequence o f intron 4, 
resulting in an insertion o f the first 38 bp o f intron 4 between exons 4 and 5. Similarly, fNS2 is the 
result o f insertion o f intron 11 sequences following the use o f an alternative 5’ splice donor 
sequence in intron 11, although the exact alternative 5 ’ splice donor sequence used has not been 
determined. INS3 is generated by the use o f an alternative 3 ’ splice acceptor sequence, causing a 
159 bp insertion o f intron 14 sequence between exons 14 and 15 leaving the 3 ’ part o f intron 14 
unspliced. Finally, a fourth insertion variant, INS4 , was identified from the human leiikaemic cell 
line K562. In this variant, the first 600 bp o f intron 14 replaces exon 15 and the 5’ part o f exon 16. 
Splicing occurs through the use o f  an alternative internal 5 ’ splice donor sequence in intron 14 and 
an alternative 3 ’ splice acceptor sequence in exon 16, leading to an hTERT variant with an altered 
C-terminus.
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Figure 5.1: Genomic Organisation of the HTERT gene. RT motifs (T, 1, 2, A ,B’, C, D, E) and 
alternate splicing sites are shown together with upstream and downstream untranslated regions.
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There appears to be some uncertainty as to the role splice variants play in regulating telomerase 
activity. Yi et al. examined the presence of splice variants in a number o f telomerase-positive 
immortal cell lines and found that there is surprisingly little variation in the proportion o f 
alternatively-spliced forms o f hTERT in different cell lines (Yi el al, 2001). In all cells with 
endogenous telomerase activity, approximately 5% o f the total hTERT mRNA exists as the wild 
type version, and most cell lines have only 1- 30 copies o f total hTERT mRNA per cell (Yi et al. 
2001). Approximately 80-90% o f the total hTERT mRNA exists as a+P- (DEL2) form, and 5- 
15% in a-p- (D E L I+2), and <1% in a-p+ (D ELI) form. However, the fact that there is an 
approximately 20-fold variation in telomerase activity between these cell lines and that these 
proportions remain relatively consistent suggests that telomerase activity is not regulated by the 
presence o f splice variants (Yi et al. 2001). Several studies have also examined the presence o f 
splice variants in tumour tissues o f varying origin, including meningiomas, liver tumours, ovarian, 
uterine and breast (Cabuy & de Ridder 2001; Kotoula et al. 2002; Ulaner et al. 2000; Zaffaroni et 
al. 2002). In all telomerase-positive tissues so far examined, wild-type (a+p+) hTERT mRNA is 
found only together with other variants. However, the a+P- (Bdel or DEL2) variant has been 
reported as the sole transcript expressed in some tissues (Cabuy & de Ridder 2001; Kotoula et al. 
2002; Ulaner et al. 1998; Ulaner et al. 2000; Wick et al. 1999; Zaffaroni et al. 2002). Kotoula et al 
reported that in gliomas, telomerase activity is associated with predominant expression o f the wild- 
type transcript (Kotoula et al. 2004). However, a third of these tumours also possess relatively high 
levels o f the a+P- variant. The a-P+ variant was found in all low grade (I-IIl) grade tumours, the 
majority o f which were telomerase-negative. However, in no tumour was this variant 
predominantly expressed. In addition, it was found in 60% o f high grade (IV) tumours. Overall, 
the total hTERT mRNA level was only associated with the presence o f the wild-type splice variant. 
Although this picture is somewhat complicated, overall it does not appear that telomerase activity 
regulation is heavily influenced by splice variants in these tumours.
5.2.2.3 hTERT promoter méthylation
Several groups have noted the existence o f highly GC-rich sequence within the core promoter. 
Two CpG islands have been identified, 900 bp and 4600 bp upstream o f the start codon in exon 1 
(Wick et a l 1999). A large CpG island, with a GC content >70% and an observed/expected CpG 
ratio >0.6 extends from bp -900  into exon 2. A smaller CpG island, with GC content >60% and 
observed/expected CpG ratio >0.6 extends from bp -4300 to -4600. No TATA- like sequences are 
present in the putative transcription start region.
Given the presence o f these CpG islands and the highly GC-rich status o f the hTERT promoter, 
several authors have investigated the potential for méthylation as a means o f regulating hTERT
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activity. The addition o f methyl groups to cytosine residues alters and restricts the access o f 
tianscription factors to binding sites within the promoter and thus represses promoter activity. 
Several tumour suppressor genes use this mode o f gene silencing (Herman 1999; Zingg & Jones
1997). At this stage, the significance o f méthylation as a means o f regulating hTERT gene 
expression remains unclear, with conflicting reports o f the impact o f méthylation on gene activity. 
hTERT promoter méthylation has been observed in most liTERT-negative normal cells and 
approximately one third o f  hTERT-positive cells, suggesting different means o f regulating hTERT 
expression, with méthylation -dependent and -independent pathways both existing (Dessain et al. 
2000; Devereux et ai. 1999; Guilleret et al. 2002). In normal human oral keratoinocytes and 
fibroblasts, the absence o f telomerase activity is associated with a hypermethylated hTERT 
promoter (Shin et al. 2003). Furthermore, when telomerase-positive human teratocarcinoma (HT) 
and HL60 myeloid leukaemia cells are induced to differentiate into telomerase-negative cells, 
hTERT promoter méthylation gradually increases prior to a drop in telomerase activity, suggesting 
that in these cells promoter méthylation is a means by which the hTERT gene is downregulated 
(Liu et al. 2004). However, telomerase-positive Lan-1, HeLa and Col 15 cells possess 
hypermethylated hTERT promoters, and treatment with a demethylating agent in these cells 
reduces méthylation and hTERT expression (Guilleret & Benhattar 2003). Thus, whilst 
méthylation may still be an important means by which telomerase is regulated in these cells, 
méthylation has the opposite effect -  ie to activate, rather than silence hTERT gene expression. In 
addition, whilst méthylation o f the hTERT gene promoter is seen more commonly in cervical 
cancel than in not mal cervical tissue, the same does not hold true for ovarian cancer, and 
méthylation status does not correlate with gene expression in either tumour type (W idschwendter et 
al. 2004). Collectively these data suggest that méthylation may play a role in regulating hTERT 
gene expression, but the manner in which this occurs and its significance are both likely to vary 
between tumour and cell types.
5.2.3 Characterisation o f  the human TERT gene prom oter
5.2.3.1 Transcription factor binding sites within the core promoter
Using transcription element search software, several authors have reported the existence o f 
canonical and non-canonical motifs for the binding o f numerous transcription factors. These 
tianscription factors can be divided into those that enhance hTERT expression and those that 
repress it. In addition, the function o f some transcription factors is currently poorly understood. 
Those activating transcription factors with binding sites located in the hTERT promoter include c- 
Myc, Spl and oestrogen (Kyo et al. 2000; Misiti et al. 2000; Takakura et al. 1999; Wick et a l  
1999). Binding sites for repressor products have also been elucidated, including WTl (W ilm’s 
tumour suppressor gene protein), MZF-2, p53 and M adl. The location o f all known binding sites
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together with the putative function o f their associate binding factors is listed in Table 5.1, Within 
the most proximal 900bp o f the promoter, Wick et. al reported the presence o f five Spl binding 
sites, one c-Myc binding site, one AP-2 binding site and one CCAC box (Wick et al. 1999). In 
addition, a CCAAT box and a second c-Myc binding site are located 1788 and 3993 bp upstream of 
the start codon respectively. The five Spl binding sites and one c-Myc binding site are contained 
within the promoter region 43 -  1125 bp upstream o f the ATG codon which conferred greatest 
promoter activity. The clustering o f Spl binding sites is common in promoters o f genes that do not 
contain TATA promoter sequences (Wick et al. 1999). Additionally, the oncoprotein c-Myc has 
been shown to induce hTERT expression in HMEC and normal fibroblast cells (Wang et al. 1998).
T a b le  5.1: C h a ra c te r is a tio n  o f  h T E R T  p ro m o te r  t r a n s c r ip tio n  fa c to r  b in d in g  sites
T ra n s c r ip t io n
F a c to r
A c tiv a to r  / 
re p re s so r
P osition  in h T E R T  p ro m o te r  re la tiv e  to  A TG
A P 2 A ctivator -620,-559,-322,-228,-167,-151 ,-139,-131 ,-127,-113,- 
108,-5,+12,+98,+129,+193 ,+315
A P4 A ctivator -853,-618,-531 ,-509 ,-315 ,-192 ,-56 ,-118 ,+ 289
C CA C A ctivator -827
c-Ets-2 A ctivator -247,-29
c-M yb A ctivator -894,+242
c-M yc A ctivator -242,-34
C R E B /A T F /A P l A ctivator -728
ER A ctivator -2754
E R /A Pl A ctivator -794
IK 2 A ctivator -815,-647,-377 ,-227 ,+121 ,-175
M adl R epressor -242,-34
M A Z A ctivator -117
M A Z /Spl A ctivator -151,-108
M yoD A ctivator -183,+214,+319
M ZF-2 R epressor -764,-696,-620,-594
N F l A ctivator -929,-841 ,-458,-232,-96,-17,+68,+149,+343
N F -E 2/S p l A ctivator -206
N F kB /T 3R a/N M Y C A ctivator -669
p53 R epressor -1954,-1317
PR 7 -477
S p l A ctivator -953 ,-806 ,-358 ,-323 ,-262 ,-206 ,-188 ,-168 ,-151 ,-133 ,- 
113,-108,-84,+254
S p l/E R A ctivator -950
W T l R epressor -358
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5.2.3.1.1 Activators o f  h T E R T  gen e expression
5.2.3.1.1.1 c-M yc
Correlation between c-Myc oncogene expression and telomerase activity was first identified before 
characterisation o f the hTERT promoter region had been established. Wang et al induced 
telomerase expression in telomerase-negative human mammary epithelial cells using directed c- 
Myc expression to levels similar to those measured in breast carcinoma cell lines (Wang et al.
1998). These cells showed a 50-fold increase in hTERT mRNA following c-Myc vector 
transfection. Later, characterisation o f the hTERT promoter identified several c-Myc binding sites 
which account for this finding. The c-Myc oncoprotein forms a complex with the Max protein that 
binds as a heterodimer to activate gene transcription (Blackwood & Eisenman 1991). This dimer 
recognises and binds the consensus sequence 5 ’-CACGTG-3’, known as an ‘E-Box’ (Kyo et al. 
2000; Wu et al. 1999). An additional, related sequence, 5 ’-CA(C/T)GCG-3’, also binds the c- 
Myc/Max heterodimer, potentially providing further regulation through binding at these non- 
canonical sites (Wu et al. 1999). Overall, o f  the 29 c-Myc complex binding sites that have been 
identified in the region o f the hTERT gene, 18 are canonical (Wu et a l  1999). O f these, mueh 
research has focused on the two E-boxes located centrally within the hTERT minimal promoter 
(Greenberg et al. 1999; Horikawa et al, 2002; Takakura et a l  1999). Gene reporter analysis using 
the luciferase gene and mobility shift assays have suggested direct activation o f hTERT by c-Myc 
at these E-boxes (Greenberg et al. 1999; Horikawa et a l  2002; Takakura et a l  1999; Wang et al. 
1998; Wu et a l  1999). Additionally, studies revealing that c-Myc-induced up-regulation o f hTERT 
occurs in the absence o f new protein synthesis provide further evidence o f direct activation o f 
hTERT by c-Myc (Greenberg et al. 1999).
The relative importance o f the two E-boxes for full activity o f the hTERT promoter has been 
debated. Removal o f the proximal E-box (at position -34 ) results in a lO-foId decrease in promoter 
activity, similar to expression levels for promoter less constructs (Greenberg et a l  1999). This 
finding, together with the observation that the distal E-box is not conserved in the mouse TERT 
promoter, suggest that c-Myc activation o f hTERT is mediated predominantly through the proximal 
E-box (Greenberg et al. 1999). However, luciferase assay results following distal E-box deletion 
(at position -242) also reveal significant reduction in activity in all cell types studied (Horikawa et 
a l  2002; Kyo et a l  2000; Takakura et a l  1999). These apparently contradictoi-y results suggest 
that a synergistic system may operate in the human TERT promoter, with occupation o f both E- 
boxes by c-Myc necessary for maximal activity. Additionally, in RD rhabdomyosarcoma cells 
induced to differentiate into muscle cells, both E-boxes appear to be essential for regulating 
telomerase activity (Ma et al. 2003). However, some studies have also suggested that E-box- 
dependent regulation o f the hTERT promoter can occur independently o f c-Myc (Ducrest et al. 
2 0 0 1 ).
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5.2.3.1.12 Spl
The co-activity o f Spl and c-Myc in regulating liTERT expression has been examined in some 
depth (Kyo et a l  2000). Co-transfection of a c-Myc or c-Myc/Max expression vector together with 
an Spl expression vector results in an increase in hTERT transcription o f up to seven fold, 
depending on cell type (Kyo et a l  2000). In the absence o f S p l, however, only marginal activation 
occurs, suggesting that Spl is important for full activity o f c-Myc (Kyo et a l  2000). Although Spl 
has traditionally been considered to be a constitutively-expressed factor, expression has been 
reported to vary up to 100-foId in different tissues (Saffer et ai. 1991). In addition, the findings that 
cancer cells express high levels o f c-Myc and Spl while normal cells do not, and that levels o f Spl, 
Myc and hTERT all rise in a co-ordinated fashion during SV40-induced transformation o f 
fibroblasts, both suggest it acts as an important co-operative factor with c-Myc (Kyo et a l  2000). 
Similarly, the decrease in telomerase activity in murine muscle cells during differentiation is 
associated with decreased levels o f Spl (Nozawa et al. 2001). In addition, some reports have 
suggested that Spl may also co-operate with oestrogen to activate hTERT transcription in ovary 
epithelial cells (Kyo et ai. 1999; Misiti et a l  2000).
S.2.3.1.1.3 O estrogen
Whilst most somatic cells do not exhibit telomerase activity, a few important cell types do. These 
include cells with high proliferative potential, such as endometrial cells (Tanaka et al. 1998). 
Telomerase activity during the proliferative phase of the uterine cycle has been shown to correlate 
with rising oestrogen levels (Kyo et al. 2000; Tanaka et al. 1998). Moreover, in vitro treatment of 
breast cancer cells and normal ovarian epithelium with oestrogen induces a rise in hTERT mRNA 
levels and telomerase activity (Kyo et al. 1999; Misiti et al. 2000). Two potential oestrogen 
response elements (EREs) exist within the hTERT promoter. The ERE located 2754bp upstream of 
the ATG start codon binds oestrogen and its receptor (ER), and luciferase reporter assays using this 
sequence show a 10-fold increase in promoter activity following treatment with oestrogen (Kyo et 
al. 1999). However, this effect is not seen in ER-negative cells, suggesting that the regulatory role 
o f oestrogen is limited to ER-positive cells.
The ER site located 950bp upstream of the ATG contains an Spl recognition sequence adjacent to 
an ER half site (ER /SpI) constituting a m otif that functions as an ERE. Although some groups 
have found this potential ERE to be less important for function than the more distal site, mutation 
at this site drastically reduces hTERT promoter activity, suggesting an important role for direct 
activation o f hTERT by oestrogen at this site as well (Kyo et al. 1999; Misiti et a l  2000).
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5.2.3.1.2 Repressors o fh  T E R T g en e expression
5.2.3.1.2.1 W T l
Many o f the studies characterising the hTERT promoter have found evidence for repressors o f 
promoter function in a region between 300 and 700 bp upstream o f the ATG (Horikawa et al. 1999; 
Takakura et al. 1999). Within this area is a binding site for the W ilms’ Tumour 1 tumour 
suppressor gene product (W T l) (Oh et al. 1999). Previously, the anti-oncogenic WTl protein had 
been shown to be involved in growth regulation o f kidney cells (Coppes et al. 1993; Englert 1998). 
However, W Tl is expressed in a very limited range o f tissues, with additional expression in gonad 
and spleen, suggesting that W Tl-m ediated control is regulated in a tissue-specific manner. As 
confirmation o f this, gene reporter assays in which mutation o f the W Tl binding site is performed 
affects promoter activity only in those cells known to express W Tl (Horikawa et al. 2002).
5.2.3.1.2.2 pS3
The possibility that the anti-oncogenic protein p53 might be involved in regulating hTERT 
transcription was first raised by the discovery o f an inverse relationship between p53 levels and 
telomerase activity. Kanaya et al found that overexpressing p53 in SiHa cervical cancer cells 
resulted in significant repression o f hTERT transcription (Kanaya et al. 2000). Two binding sites, 
located at 1954 and 1317 bp upstream of the ATG appeared to be responsible for this finding. 
Importantly, the repressive effects o f exogenous p53 preceded the cell growth inhibition 
traditionally associated with p53 activity, suggesting a possible additional pathway for cell 
proliferation control by p53, perhaps through the direct repression o f hTERT gene expression. 
Interestingly, as with c-Myc and oestrogen, Spl is also likely to play a co-operative role in p53- 
based regulation, since mutation o f Spl binding sites completely eliminates the repressive effects 
o f p53 (Kanaya et al. 2000).
5.2.3.1.2.3 M ZF-2
Although W Tl has been implicated in the negative regulation o f hTERT, the tissue-specific nature 
o f this protein intensified the search for other repressors. Four binding sites for the myeloid- 
specific zinc finger protein 2 (MZF-2) within a region 200 bp upstream of the hTERT core 
promoter (Fujimoto et al. 2000). Promoter constructs with their 5 ’ boundary within this area (ie -  
800 to -600  bp) characteristically have lower activity than other constructs (Horikawa et al. 1999; 
Takakura et al. 1999). However, MZF-2 levels have been found to remain relatively stable during 
cellular differentiation (the time at which telomerase activity is repressed), casting doubts on the 
activity o f MZF-2 alone being responsible for this repression (Fujimoto et a l  2000). Therefore, the
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importance of MZF-2 as a factor controlling hTERT gene expression in most cell types remains 
uncertain.
5.23.1.2.4 M adl
The E-box motifs bind a dimer o f transcription factors that can either contain c-Myc and Max or 
M adl and Max (Gunes et al. 2000). The Max transcription factor is ubiquitously expressed in 
many cells, and dimérisation with c-Myc produces a transcription factor capable o f activating the 
hTERT promoter, whilst dimérisation with M adl produces a transcription factor capable o f 
repressing the hTERT promoter. In undifferentiated cells, as well as most neoplastic and 
transformed cell lines, high levels o f c-Myc expression are generally present, while M adl 
expression is generally minimal (Gunes el al. 2000). Conversely, in cells with minimal expression 
o f hTERT, such as normal somatic cells, the situation is reversed and c-Myc levels are low while 
M adl levels are high (Gunes et a l  2000; Oh et al. 1999). This antagonism between c-Myc and 
M adl in the control o f  hTERT expression suggests that hTERT expression relates directly to the 
relative levels o f  c-Myc and Madl (Oh et al. 1999). Indeed, ectopic expression o f c-Myc in normal 
somatic cell lines with Mad I-mediated repression leads to activation o f hTERT gene expression, 
presumably by outcompeting endogenous M adl levels in dimérisation with Max (Oh et al. 1999). 
Thus, it may be that reversible control o f hTERT gene expression involves the interplay between c- 
Myc and Madl at one or both o f the E-box sequences in the hTERT core promoter.
5.2.3.1.3 R egulatory factors within the h T E R T gen e
Whilst several authors confirmed the extent o f the core hTERT promoter, some evidence began to 
emerge that the hTERT gene itself influences the activity o f hTERT transcription. Takakura et al, 
in their characterisation o f the promoter, created a deletion construct extending from 19 to 78 bp of 
exon I downstream o f the ATG start codon (Takakura et al. 1999). This construct displayed 
significantly less activity than the smallest o f all other deletion constructs (containing 31 bp o f 
promoter upstream o f the ATG as well as 78 bp o f the exon). Following this, Renaud et al 
examined the activity o f promoter constructs containing the minimal promoter together with up to 
1000 bp o f the hTERT gene (Renaud et al. 2003). Surprisingly, whilst the core promoter was 
confirmed to exist within the 297 bp upstream of the ATG, the addition o f exon I and intron I 
sequence decreased the transcriptional activity o f the promoter to 10% of the original. 
Interestingly, as more o f the gene was included in these constructs, the transcriptional activity o f 
the promoter fell by up to 100-fold, with the greatest reduction found in constructs with 1000 bp o f 
exon 2 in addition to exon 1 and intron I (Renaud et al. 2003). Thus, structural elements within the 
hTERT gene appear to be important for repression of transcription.
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5.2,4 Telomerase promoter-driven therapy
The finding that up to 95% o f human tumour cells contain telomerase activity has prompted 
extensive investigation into telomerase promoter-driven gene expression as a cancer-targeting 
strategy designing promoter-driven gene expression using the promoters involved with telomerase 
activation. Since hTERT expression seems to be the major determinant o f telomerase activity, the 
majority o f this work has focused on using the hTERT gene promoter. However, some authors 
have also employed the hTR promoter (Bilsland et al. 2003; Plumb et al. 2001).
The ability to drive gene expression selectively within telomerase-positive cells has been employed 
in a number o f ways. A number o f pro-apoptotic genes have been used, including members o f the 
caspase family, both initiators (caspase-8) and effectors (caspase-6) in the caspase cascade 
(Takeuchi et al. 2004). In malignant glioma cells, using a 378bp fragment o f the core hTERT 
promoter to drive these genes results in apoptosis in 20-30% o f cells, with caspase-6 being a 
slightly stronger inducer o f apoptosis than caspase-8 (Takeuchi et al. 2004). This effect is also 
reproduced in a nude mouse model in which targeted expression o f either gene results in significant 
tumour volume shrinkage that persists for up to 3 weeks following treatment (Komata et al. 2001a; 
Komata et al. 2002b). In other cell lines, caspase-8 expression under the control o f  the hTERT 
promoter can also induce apoptosis in up to 80% o f cells, and result in a 50% shrinkage o f tumour 
volume in a similar nude mouse model (Koga et al. 2000). Similarly, the hTERT promoter has 
been used to direct expression o f the pro-apoptotic Bax gene in vitro and in vivo in tumour cells, the 
systemic administration o f  which normally causes significant liver toxicity (Gu et al. 2000). 
Another pro-apoptotic gene which has been investigated is the FADD gene, which causes selective 
cell apoptosis in transfected cells (Koga et al. 2001 ; Komata et al. 2001 b).
A similar approach is to direct the expression o f genes capable o f causing cell death by means other 
than apoptosis. A number o f genes, including the bacteria! nitroreductase and herpes simplex virus 
thymidine kinase (HSV-TK) genes, are capable of converting harmless prodrugs into a toxic 
byproduct that causes cell death. An advantage o f this approach over the pro-apoptotic gene 
approach is that the toxic by-products, if they diffuse readily between cells, can cause significant 
cell death through a ‘bystander effect’. A number o f groups have investigated the ability o f the 
HSV-TK gene to cause selective cell death in telomerase-positive cells. HSV-TK converts 
gancyclovir (GCV) into a cytotoxic metabolite, resulting in cell death. The hTERT promoter has 
been used to drive expression o f HSV-TK in telomerase-positive cells in several systems, including 
carcinoma cells, ovarian and cervical cancer cells, and in osteosarcoma cells, and has shown 
promising results both in vitro and in vivo (Majumdar et al. 2001; Song et al. 2003; Takeda et al. 
2003). Targeted expression o f the bovine aGal epitope, a major xeno-antigen in human cells, has 
been used to induce antibody-mediated cell lysis in telomerase-positive pancreatic carcinoma cells 
(Sawada et al. 2002). Similarly, targeted expression o f the diphtheria toxin A-chain (DT-A) gene
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in telomerase-positive bladder and hepatocellular carcinoma cells results in significant cell death in 
vitro (Abdul-Ghani et al. 2000).
A slightly different approach also makes use o f telomerase promoters to target telomerase positive 
cells, but rather than driving the expression o f a gene o f interest, the promoters are used to drive 
replication o f a normal ly-quiescent viral vector. In these circumstances, replication o f the virus can 
proceed to such an extent that the resultant viral load causes lysis o f telomerase-positive cells. 
Such ‘conditionally-replicating’ oncolytic viruses have been created usually by replacing the El A 
internal promoter o f adenoviral vectors with the hTERT promoter (Wirth et al. 2003). Kim et al 
went further by modifying the hTERT promoter through the addition o f an extra E-box and Spl 
binding site before using it to drive replication (Kim et al. 2003b). Both wild-type and modified 
promoters have shown promising results both in vitro and in vivo, with several groups reporting 
significant reductions in tumour size following treatment with this strategy (Huang et al. 2003; Kim 
et al. 2003b; Wirth et al. 2003). The advantage o f this approach is that viral infectivity is not 
affected by these modifications, so that infection o f tumour cells with the virus leads to viral spread 
throughout the tumour, but replication and subsequent cell death only occurs within those cells 
possessing telomerase activity.
Although the majority o f  strategies using the telomerase promoter have used the hTERT promoter 
to drive either gene expression or viral replication, some groups have also investigated the hTR 
promoter as a means for driving gene expression (Boyd et al. 2001). Interestingly, although hTR is 
expressed in a greater variety o f normal somatic cells than hTERT, the hTR promoter seems to 
drive gene expression with similar specificity to the hTERT promoter and in some cases is slightly 
stronger (Bilsland et al. 2003). Using the hTR promoter, Bilsland et al showed significant 
reduction o f tumour size following injection with an adenovirus expressing bacterial nitroreductase 
under the control o f the hTR promoter in xenografted nude mice (Bilsland et al. 2003). Similar to 
the HSV-TK construct, bacterial nitroreductase converts the prodrug CBI954 into a readily 
diffusible, active cytotoxic agent, again providing a useful bystander effect.
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5.3 Aims of the Chapter
The overall aim o f this chapter was to begin developing telomerase promoter-driven therapies for 
canine cancer. In order to do this, our first aim was to sequence and characterise the upstream 
regulatory region o f the canine TERT promoter, identifying potential transcription factor binding 
sites within the promoter along with the transeription start site. Secondly, using promoter deletion 
constructs, we set out to identify the minimal promoter region responsible for activity in 
telomerase-positive cells to enable the development o f future telomerase-targeted therapeutic 
strategies. Thirdly, given the potential shown by the hTR promoter in specifically driving gene 
expression in human tumour cells, we also aimed to sequence and characterise the canine TR gene 
promoter.
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5.4 Materials and Methods
5.4.1 Genomic Library Screening
The promoter sequence o f canTERT was initially isolated by Dr S Campbell by lambda library 
screening using a canine genomic DMA Lambda FIX® II Library (Clontech, UK). A radiolabelled 
450bp PCR fragment comprising exon 2 o f the canTERT gene (Nasir et al. 2004) was used as the 
probe. A single colony o f the XL 1-Blue MRA shain was used to inoculate 50ml LB broth. Aliquots 
o f Library suspension (containing 2.5 xlO^ pfii o f  bacteriophage) were mixed with 1.7 ml bacterial 
cell suspension and incubated for 15 minutes at 37"C. NZY top agar was mixed with the infected 
cell preparation and spread evenly over 4 NZY agar plates before incubation at 37°C for 8 hours. 
Plaques were then transferred to nitrocellulose membranes, and membranes were hybridised 
overnight followed by exposure to film. Developed radiographs were aligned in duplicate to 
identify spots corresponding to unique plaques which were subsequently submerged in SM 
buffer/chloroform at 4°C overnight. Phage DNA was isolated from one positive clone using 
standard protocols. The phage DNA contained an insert o f  approximately S.OKbp.
Lambda phage DNA was sequenced using an automated ABl 310 genetic analyser (PE Applied 
Biosystems, UK) using the T7 primer. Based on the sequence generated using the T7 primer, a 
further primer was designed and used to sequence the phage DNA. This was repeated until the 
entire upstream regulatory sequence o f canTERT was identified. From these analyses, raw 
unanalysed sequence data o f approximately SKbp was determined (provided in Appendix B).
5.4.2 Confirmation o f the canine TERTprom oter sequence
In order to confirm the sequence obtained from phage DNA, five forward (sense) primers and three 
reverse anti-sense primers were designed as described in section 2.2.6.1; Primer design, and 
supplied by Sigma-Genosys (Table 5.2) for PCR amplification from genomic DNA. The primers 
were based on initial sequence o f the canTERT promoter obtained from genomic library 
sequencing, and were located as illustrated in Figure 5.2. Each primer o f  25-28 nucleotides in 
length required 40-60% GC content. Using these criteria, sense oligonucleotide primers 
(cTERTprom-5522F, cTERTprom-1572F, cTERTprom-907F. cTERTprom-677F, can3F, 
cTERTprom -172F) and anti-sense oligonucleotide primers (cTERTprom-628R. LG9R, LG7R, 
cTERTprom+487R) were designed.
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Figure 5.2: Location o f forward (blue) and reverse (pink) primers used for sequencing and generation
of deletion constructs
-5522F
UPSTREAM REGULATORY REGION
-1572F -907F -677F
E X O N  1 E X O N  2
Can3F -172F Intron
•  ATG
-628R I.G9R IXÎ7R +487R
Table 5.2: Details o f primers used in sequencing the canine TERT promoter and generation o f deletion
constructs
Primer
Identification
P osition  
(S tart/end  
relative to 
ATG)
O ligon u cleo tid e prim er seq u en ce  
(5'-3')
T m  (»C) & GC 
(%) conten t
cT E R T  prom -5522F -5 5 0 6 /-5 4 7 4 b p GGCTCTCGAGCTCGAGTCTGGGTGACTCCAAA 66.4T : 59%
cT E R rprom -15721' -1 5 5 7 /-I5 3 5 b p GCTCAAGCCAACAACATCAATT 65.OT : 60%
cTERT prom -907 F -8 9 0 /-8 6 7 b p GTCCTGTTCAAAGCGTCATGATGAA 69.2T : 61 %
cT E R T prom -677F -6 6 5 /-6 4 4 b p CTTTTTATCTCCTTTCGTGGAC 60.5"C : 60 %
cT E R T p ro m -172 F -1 7 2 /-I5 0 b p CCGGGCCGGAGAGCAGAGGACG 80.2 C : 77%
Can 3 F -3 l4 /-2 9 0 b p CTGTGACAGGGACAAACCCAAGGAC 75.OT : 60 %
cT E R T prom -628R -6 l2 /-5 7 7 b p CGGTTTTCTCGAGCTCGAGCCCTACTTGCCAGGGA 75.0"C : 60 %
LG9R 4 38 +66bp AGCACCTCCCGGTAGCGGCCCCGCAGCA 75.OT : 60 %
LG7R + 3 1 3 /+ 3 3 3 b p CTCCTTGAGGCAGGACACCT 72.0 C : 60%
cTER  F prom +487R 4 4 5 7 /+ 4 7 9 b p TTACCGTGTTGGGCAGGTAGCT 68.5 C  : 55%
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5.4.2.1 PCR amplification
PCR was performed using the primers detailed in Table 5.2 in order to isolate a 5.6kbp fragment o f 
the canTERT promoter using genomic DNA isolated from PBMC (2p!) as a template in a final 
volume o f 50|ul containing 0.4j.im of forward and reverse primers, 0.2mM of dNTPs, 1.5Mm 
M gCb and 2 units o f  Taq DNA polymerase (Invitrogen, UK). Using a thermal cycler (Perkin 
Elmer) samples were subjected to an initial dénaturation at 95° C for 2 minutes followed by 35 
cycles o f amplification, each cycle consisting o f a dénaturation step o f 95° C for 30 seconds and an 
annealing temperature o f 55-70° C (depending on the annealing temperature o f the primer pair 
used) for 30 seconds followed by an elongation step o f 72° C for 30 seconds per Kb o f expected 
product. The final elongation step o f 72° C for 10 minutes completed the reaction. PCR products (4 
}xl) were visualised by agarose gel electrophoresis (1.5%) gel by comparing the bands created to a 
100 bp molecular weight standard.
5.4.2.2 PCR amplification - Troubleshooting
As initial attempts to clone the entire promoter fragment were unsuccessful, the following 
modifications and PCR sequencing kits were used as detailed below: HotstarTaq, Q solution, 
addition o f 5% DMSO, Failsafe PCR mix (Cambio, UK), PCRx enhancer system. PCR products (4 
f,Ll) were visualised by agarose gel electrophoresis (1.5%) gel by comparing the bands created to a 
100 bp molecular weight standard.
5,4.2.2.1 M odification o f  PC R  cycle conditions
Initial PCR conditions used included an annealing temperature calculated to be 5° C below the 
lower o f the two annealing temperatures o f the primer pair used. Subsequent modifications o f 
cycling conditions included lowering the annealing temperature to 55° C to decrease the specificity 
of primer binding. If PCR using the lower annealing temperature produced a band o f the expected 
size along with other bands (due to non-specific priming), the annealing temperature was 
subsequently increased in 2° C steps with successive PCR attempts until specific priming occurred.
In addition to annealing temperature modifications, a modified ‘hot start’ step was performed to 
reduce mispriming events and primer-dimer formation at low temperatures. To perform a modified 
‘hot start’, the reaction mix was chilled on ice until the thermal cycler had reached a temperature o f 
95° C before adding the reaction. In addition, the initial dénaturation step was increased to 5 
minutes.
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In addition to the above-mentioned modifications, samples were also made up with the addition o f 
Dimethylsulfoxide (DMSO) at 5% or glycerol at 10%.
5.4.2.2.2 H otStarTaq an d  Q  solution
PCR amplification was performed using genomic DNA as a template (< 1 pg) in a final volume of 
100 pi, containing 0.5pm o f forward and reverse primers, 0.2mM o f dNTPs, 10 pi o f lOx PCR 
buffer (containing 15 mM M gCb), 20 pi o f Q solution, and 2.5 units o f HotStarTaq DNA 
Polymerase (Qiagen, UK). A master mix was prepared containing all components necessary for 
the total number o f  assays to be performed with the exception o f the DNA template, and 100 pi 
aliqnoted into each PCR tube. In addition, duplicate reactions were performed without Q-solution. 
DNA template was added to each tube immediately before the tubes were placed in the thermal 
cycler. Samples were then subjected to initial dénaturation o f 15 minutes at 95° C followed by 35 
cycles o f amplification, each cycle consisting o f a dénaturation step o f 94° C for 30 seconds and an 
annealing temperature o f 55-70° C (depending on the annealing temperature o f the primer pair 
used) for 30 seconds followed by an elongation step o f 72° C for 30 seconds per Kb o f expected 
product. The final elongation step o f 72° C for 10 minutes completed the reaction. PCR products (4 
pi) were visualised by agarose gel electrophoresis (1.5%) gel by comparing the bands created to a 
100 bp molecular weight standard.
5.4.2.2.3 Failsafe PC R  m ix
The Failsafe™ PCR Premix kit (Cambio, UK) contains a blend o f thermostable DNA polymerases 
together with a set o f  twelve reaction premixes, designed to amplify difficult or long templates. 
The enzyme blend contains a 3 ’ -  5’ proofreading enzyme for high fidelity amplification, whilst the 
premixes contain a buffered salt solution together with all four dNTPs, vaiying amounts o f MgCI] 
and FailSafe PCR Enhancer (with betaine). The presence o f betaine is designed to improve the 
yield and specificity o f amplification o f many target sequences, especially those containing a high 
GC content or secondary structure. In addition, betaine may also enhance the PCR by protecting 
DNA polymerases from thermal dénaturation. The twelve premixes are designed to rapidly 
optimise the PCR conditions required for maximal amplification o f any given template, with the 
appropriate premix then being used for further amplification reactions once optimisation has been 
completed.
PCR was performed using genomic DNA as a template (5 pi) in a final reaction mix o f 25 pi, 
containing 1 pi o f  each o f the forward and reverse primers, 0.5 pi Failsafe PCR enzyme mix (1.25 
units) and distilled water. A mastermix was made up sufficient for 14 reactions. Then 25 pi o f 
each premix was aliq noted into each o f 12 0.2 ml PCR tubes and 25 pi o f the mastermix added to
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each tube. PCR was then performed using the following conditions: initial dénaturation at 98° C 
for 2 minutes, followed by 35 cycles of: dénaturation at 95° C for 30 seconds, annealing at 55° C 
for 30 seconds and extension at 68° C for 30 seconds per Kb o f expected product, with a final 
extension step o f 68° C for 10 minutes. Samples (4 pi) were analysed by agarose gel 
electrophoresis (1.5%) by comparing the bands created to a 100 bp molecular weight standard.
5.4.2.2.4 K O D  H o t Start Taq Polym erase
KOD Hot Start Taq (Novagen, UK) is an optimised buffer and Taq polymerase designed for 
amplifying GC-rich and complex templates. The Taq polymerase mix includes two antibodies that 
prevent polymerase and 3 ’ to 5 ’ exonuclease activity at ambient temperatures and thereby avoids 
mispriming events during reaction setup and initial temperature elevation. Genomic DNA template 
(2 pi) was amplified in a final volume o f 50 pi containing 5 pi ( IX)  lOX PCR buffer, 0.2 mM 
dNTPs, 1 mM MgS0 4 , 0.3 pM o f each o f the forward and reverse primers, and 1 unit o f KOD Hot 
Start DNA Polymerase. The reaction was assembled in PCR tubes and transferred to the thermal 
cycler. PCR conditions consisted o f an initial denaturation/polymerase activation step at 94° C for 
2 minutes, followed by 35 cycles o f dénaturation at 94° C for 15 seconds, annealing at 60° C for 30 
seconds and extension at 72° C for 30 seconds per Kb o f expected product. Samples (4 pi) were 
analysed by agarose gel electrophoresis (1.5%) by comparing the bands created to a 100 bp 
molecular weight standard.
5.4.2.2.5 P C R x enhancer
The PCRx Enhancer System (Invitrogen, UK) is an optimised buffer and cosolvent system that 
simplifies PCR amplification o f problematic and/or GC-rich templates. The PCRx Enhancer 
Solution offers higher primer specificity, broader optimal magnesium concentration range and 
broader optimal annealing temperature range. The Enhancer Solution lowers the maximum primer 
annealing temperature by approximately 2° C per IX PCRx enhancer Solution concentration, but 
also widens the effective annealing temperature over a much broader range.
in the initial optimisation step, genomic DNA template (1 pi) was amplified in a final volume o f 50 
pi. A master mix sufficient for 30 pi per reaction for six reactions was made up initially, however, 
containing 5 pi ( IX)  o f 1 OX PCRx Amplification buffer, 0.2 mM o f dNTPs, 1.5 mM MgS0 4 , 0.2 
pM of forward and reverse primers, 1 pi of template DNA and 2.5 units o f Platinum® Taq DNA 
polymerase (Invitrogen, UK). Thirty pi o f the master mix was then aliquoted into each o f six PCR 
tubes. Varying amounts o f PCRx Enhancer Solution were then added to each tube to reach a final 
Enhancer Solution o f OX - 4 X  as detailed below.
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C o m p o n e n t F in a l P C R x  E n h a n c e r  S o lu tio n  C o n c e n tra tio n
OX 0.5X IX 2 x 3X 4X
M aster M ix 30 30 30 30 30 30
lOx E nhancer Solution 0 2.5 5 1 0 15 2 0
D istilled W ater 2 0 17.5 15 1 0 5 0
PCR tubes were then placed in the thermal cycler and an initial dénaturation at 95° C for 2 minutes 
was performed, followed by 35 cycles o f dénaturation at 95° C for 30 seconds, annealing at 55° C 
for 30 seconds and extension at 68° C for 30 seconds per kb. A final extension step at 68° C for 10 
minutes was then performed. Products (4 pi) were then analysed by agarose gel electrophoresis.
5.4.2.3 Cloning into pCR2.1®TOPO vector
PCR products amplified from genomic DNA were cloned using methods described in section 
2.2.3.8: Ligation using TA cloning methods.
5.4.2.4 Bioinformatics analysis
The search for putative transcription factor binding sites was performed using web-based motif- 
searching tools TFBIND (http://www.tfbind.hgc.jp), TFSEARCH
(http://www.cbrc.jp/research/db/TFSEARCH.html), TESS (Transcription Element Search System: 
http://www.cbil.upenn.edu/tess/) and MOTIF fhttp://motif.genome.ipf  Transcription factors were 
only considered for analysis if they had the following scores: >12.0, =2.0, Z,/=1.0, 4/=0.
CpG island analysis was performed using the web-based CpG Island Searcher 
(http://www.uscnorris.com/cpgislands/cpg.cgi).
5.4.2.5 Transcription Start Site Identification
To determine the Transcription Start Site (TSS) o f the canTERT gene, the GeneRacer™ kit 
(Invitrogen, UK) was used for RNA ligase-mediated (RLM) rapid amplification o f cDNA ends 
(RACE). This method selectively ligates an RNA oligonucleotide to the 5’ ends o f decapped 
mRNA. Reverse transcription using a primer specific to the gene sequence (GSP) or using an 
oligo(dT) primer specific to the polyA tail o f mRNA can then be used to synthesise cDNA from the 
mRNA. This cDNA can then be PCR-amplified using a forward primer specific to the ligated 
oligonucleotide and a reverse GSP to generate products which can be sequenced to determine the 5 ’ 
untranslated sequence.
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In the first step, total RNA was treated with calf intestinal phosphatase (CIP) to dephosphorylate 
non-mRNA and truncated mRNA. Total RNA (5pg) previously extracted from C17 and D17 cells 
was added to 1 OX CIP buffer (1 pi), RnaseOut'^'^ (40U), CIP (lOU) and the total volume made up to 
10 pi with DEPC-treated water in a 1.5 ml eppendorf tube. This reaction mixture was mixed gently 
by pipetting and briefly vortexed before flash-spinning to collect the contents in the bottom o f the 
tube. The sample was then incubated at 50° C for I hour.
Following incubation, samples were centrifuged briefly and placed on ice before RNA was 
precipitated. To the eppendorf tube, 90 pi o f DEPC-treated water and 100 pi o f phenohchloroform 
were added and the samples vortexed vigorously for 30 seconds. Samples were then centrifuged at 
maximum speed for 5 minutes at room temperature. Following centrifugation, the aqueous phase 
was withdrawn from the top o f the samples and transferred to a new eppendorf tube. To this was 
added 2pl o f 10 mg/ml mussel glycogen and 10 pi o f 3M sodium acetate, pH 5.2, and the tube was 
then inverted several times to mix. Then 220 pi o f 95% ethanol was added and the sample 
vortexed briefly before being placed on dry ice for 10 minutes. To pellet RNA, the samples were 
then centrifuged at maximum speed for 20 minutes at 4° C. The supernatant was then removed, 
taking care not to disturb the resultant RNA pellet, and 500 pi o f 70% ethanol was added. The tube 
was inverted several times and vortexed briefly before centrifugation at maximum speed for 2 
minutes at 4° C. Supernatant was again carefully removed, and brief centrifugation performed to 
collect any residual ethanol in the bottom o f the tube. This was carefully removed and the pellet 
left to air dry at room temperature for 1-2 minutes before being resuspended in 7 pi o f  DEPC- 
treated water.
In the second step, the mRNA cap was removed from intact, full length mRNA using tobacco acid 
pyrophosphatase (TAP). To the eppendorf containing RNA from the previous step was added lOX 
TAP buffer (1 pi), RnaseOut™ (40U) and TAP (0.5U). The mixture was mixed gently by pipetting 
and brief vortexing followed by a flash-spin to collect contents in the bottom o f the tube. The 
sample was then incubated for 1 hour at 37° C, centrifuged briefly and placed on ice. RNA was 
then precipitated as described above.
Following decapping, the GeneRacer'^''^ RNA Oligo was then ligated to the 5’ end o f mRNA in the
third step. The oligo is designed to optimise ligation to decapped mRNA by virtue o f the fact that
it has minimal secondary structure to provide a free 3’ end for efficient ligation and a string o f
adenines at the 3 ’ end to increase ligation efficiency (Uhlenbeck & Gumport 1982). Seven pi o f
dephosphorylated, decapped RNA from step 2 was added to the tube containing lyophilised
GeneRacer™ RNA Oligo (0.25 pg). The sample was pipetted up and down several times to
resuspend the RNA oligo then flash-spun to collect the contents in the bottom o f the tube. The
sample was then incubated at 65° C for 5 minutes to relax the RNA secondary structure then placed
on ice to chill for approximately 2 minutes before re-centrifuging to collect the contents in the
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bottom of the tube. Then, 1 OX Ligase buffer (1 pi), )0 mM ATP (1 pi), RnaseOut™ (40U) and T4 
RNA ligase (5U) were added to the tube which was then incubated for 1 hour at 37° C. The sample 
was then flash-spun to collect the contents in the bottom o f the tube and placed on ice. RNA 
precipitation was then performed as previously, with the RNA pellet resuspended in 10 pi o f 
DEPC-treated water rather than 7 pi.
In the fourth step, the mRNA was reverse-transcribed into cDNA using Superscript'^’^  III RT 
(Invitrogen, UK). To the RNA sample from step 3 was added 10 pM reverse primer (1 pi - 
consisting o f either oligo(dT) or LG7R GSP), dNTP mix (1 pl), and sterile, distilled water (1 pi). 
The mixture was then incubated at 65° C for 5 minutes to remove any RNA secondary structure 
before being placed on ice for 1 minute and flash spinning to collect the contents in the bottom of 
the tube. Then First Strand Buffer 5X (4 pl), 0.1 M DTT (1 pl), RnaseOut™ (40U) and 
Superscript^'^ III RT (200U) were added to the sample which was mixed by pipetting several 
times. The sample was then flash-spun to collect the contents in the bottom of the tube and 
incubated for 30 minutes at 50° C for Oligo(dT) or 55° C for GSP. The RT reaction was then 
inactivated by heating at 70° C for 15 minutes before being placed on ice for 2 minutes to chill. 
The sample was flash spun to collect the contents in the bottom o f the tube, then 1 pl o f RNaseH 
(2U) was added to the mixture which was then incubated at 37° C for 20 minutes to inactivate any 
remaining RNA. The sample containing cDNA was then stored at -20° C until ready for use in 
PCR amplification.
As a positive control, a sample containing total RNA from HeLa cells (Invitrogen, UK) was run in 
parallel to samples obtained from CM T7/DI7 cells. Following the synthesis o f cDNA, PCR 
amplification was then performed using the forward primer specific to the GeneRacer'*'’'^  RNA oligo 
and the GSP (LG7R). Initial PCR was performed as described in 2.2.6: Amplification o f DNA by 
the polymerase chain reaction, using Platinum HiFi Taq polymerase (Invitrogen, UK). Secondary 
PCR was also performed using the nested forward primer specific to the GeneRacer'''''^ RNA oligo 
and a nested reverse GSP (LG9R).
5.4.3 Creation o f  canTERTpromoter deletion constructs
Following confirmation o f the canTERT promoter sequence, selected fragments were PCR-
amplified using plasmid DNA as a template. The same primers used for confirmation o f the
canTERT promoter sequence, shown in Table 5.2 and Figure 5.2, were also used to amplify these
fragments. Following successful amplification and cloning into pC R 2.1® T 0P0 o f a 1.6 kb-sized
fragment o f the promoter together with exon 1, intron 1 and 15 bp o f exon 2 using the
-1572F/LG7R primer pair, purified plasmid DNA derived from this construct was used as a
template for further nested PCR using the following primer pairs: -1572F/LG9R, -907F/LG7R, -
907F/LG9R, -677F/LG9R, can3F/LG7R and can3F/LG9R. PCR products were purified and cloned
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into pC R 2.1® /T 0P0 using methods described in 2.2.3.8: Ligation using TA cloning methods, 
before being sequenced with the M13F and M13R primers as described in 2.2.7: DNA sequence 
analysis.
5.4.3.1 Restriction enzyme digestion of vectors
All pCR®2.ITOPO/canTERT promoter constructs containing the canTERT promoter fragments 
were digested with2f/?o I and Sac 1 restriction enzymes. The luciferase reporter veetor, pGL3-Basic 
(Promega, UK) was also digested with Xho  I and Sac I restriction enzymes. More specifically, the 
pCR®2.1/canTERT promoter vectors (Sjiig) were digested for one hour with Xho I (5 units) in 
buffer D (lOX) together with 0.3fil bovine serum albumin (BSA) in a lOjid total volume at 37° C, 
before adding Sac 1 (5 units) and (lOX) Multi-Core™ buffer to a final volume of 20pl and 
continuing with incubation for a further 3 hours. The recipient pGL3-Basic luciferase reporter 
vector (5pg) was digested with Xho  I (5 units) and Sac I (5 units) using the same protocol. Samples 
(4j.ll) were analysed on a TAE agarose gel (1%) by comparing the bands created to a lOObp DNA 
ladder to confirm digestion before purification and ligation.
S.4.3.2 Purification, ligation and transformation
Digested DNA samples (linearised pGL3-Basic and released canTERT promoter fragments) were 
purified using the QIAquick®Gel Extraction Kit (QIAGEN, UK) and eluted in 30p.l o f sterile water. 
The DNA was quantified (2f.il) by gel electrophoresis on a TAE agarose gel (1%) by comparing the 
bands created to a Low DNA Mass™ Ladder (2 |l i 1).
The quantity o f vector (pGL3-Basic) and insert (promoter fragment) for each ligation reaction was 
calculated according to the equation shown in section 2.23 J :  Ligation o f restriction digested DNA 
fragments. For each calculation the vector mass (X) was 150 ng and the insert size (Y) was 
approximately 2.1, 1.5, 1.2, 1.1, 0.9, 0.8, 0.7 and 0.3 kb for the canTERT promoter deletions (in 
descending size). Ligation was performed using molar ratios o f 3:1 and 1:1 insert to vector. The cut 
ends o f the inserts were ligated to complementary ends o f the cut pGL3-Basic vector using T4 
DNA ligase (Promega, UK) overnight at 16° C. The ligations (20ng) were transformed into 50j.il of 
One Shof'"''^ TOPI 0 competent cells which were heat shocked for 45 seconds at 42°C before adding 
250j.ll SOC medium, shaking horizontally at 225 rpm at 37° C and then grown overnight at 37° C 
on LB/ampicillin agarose plates. Six to ten colonies were selected from each plate and transferred 
to LB broth for overnight culture at 37° C.
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of plasmid 
DNA isolation following the QIAprep®PCR Spin Miniprep Kit (Qiagen, UK) and eluted in 50f.il o f
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sterile water. The DNA samples were then assessed by spectrophotometry for quantification. 
pGL3/canTERT promoter constructs were screened with Xho  1 and Sac 1 restriction enzyme 
digestion as described in 2.2.3.11.2: Restriction analysis o f small scale plasmid preparations. Since 
all the promoter inserts were directionally cloned it was not necessary to screen for correct 
orientation. Recombinant plasmids were sequenced and analysed as described in 2.2.7: DNA 
sequence analysis.
5,4.4 Luciferase reporter assays
The pGL3-Basic luciferase reporter vector was chosen to analyse the canTERT promoter deletion 
constructs since luciferase reporters offer an extremely sensitive system for measuring the activity 
o f regulatory regions o f DNA such as promoters. A variety o f luciferase-based vectors are available 
enabling strictly controlled experiments ineluding a negative control (promoter-less vector, pGL3- 
Basic), positive control (SV40-driven luciferase, pGL3-Control) and a ReniIJa luciferase vector 
(pRL-CMV) as an internal standardised control. This Dual-Luciferase®Reporter assay system has 
the unique ability to assay both the fire-fly and ReniUa luciferase activities sequentially in the same 
sample to control for both cell number and transfection efficiency.
5.4.4.1 Cell lines
CMLIO (canine melanoma), D I7 (canine osteosarcoma), A72 (fibroblastoid tumour), GHK (canine 
kidney), CMT3 (canine mammary tumour), CMT7 (canine mammary tumour) and CMT8 (canine 
mammary tumour) are canine cell lines which have previously been shown to be telomerase 
positive (Nasir et ai. 2001). CML 10, D17, A72 and GHK cell lines were cultured in DMEM 
(Gibco BRL, Grand Island, New York) supplemented with 10% fetal calf serum. CMT3, CMT7 
and CMT8 cell lines were cultured in RPMI (Gibco BRL) supplemented with 10% fetal calf serum 
and L-glutamine. Canine primary skin fibroblasts (K9SF) were cultured in MEM-a (Gibco BRL) 
supplemented with 10% fetal calf serum, L-glutamine and epidermal growth factor (EGF).
5.4.4.2 Transfection o f cells with luciferase reporter constructs
Transient transfections were performed using Lipofectamine™ in the presence o f Plus™ reagent 
(Invitrogen, UK). For each assay, 1.5 x 10  ^ cells were seeded into 6-well plates and transfected the 
following day, when the cells reached a confluence o f approximately 40-50%. For comparison, the 
transcriptional activities o f pGL3basic (negative control) and pGL3control (positive control) were 
also tested. All transfections were performed in triplicate, and the results o f at least 2 independent 
experiments were averaged. Cells were transfected with 1 pg o f pGL3/canTERT promoter vectors 
containing the firefly luciferase gene. For each well, Ipg plasmid DNA was diluted in the presence
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of 100^1 serum free media and precomplexed with 6pl Plus Reagent for 15 minutes at RT. Four \i\ 
o f Lipofectamine diluted in lOOjal serum free media was then added to the precomplexed DNA and 
the solution incubated at RT for a further 15 minutes. Cells were incubated in the presence o f the 
DNA-Plus-lipofectamine complexes at 37°C with 5% CO2 for 3 hours. The medium was then 
replaced with fresh growth medium and cells incubated for a further 48 hours prior to harvesting. 
Co-transfection with the pRL-CMV vector (Promega, UK), containing the ReniIJa luciferase gene 
was used as an internal standardised control to assess transfection efficiency.
5.4.4.3 Luciferase assays
Dual-Luciferase®Reporter assays were performed in triplicate as described in 2.2.8.1: Genetic 
reporter systems. Both firefly and Renilla  luciferase values were attained for each well. The mean 
o f the 3 wells analysed for each sample was calculated, and luciferase values adjusted for cell 
concentration by standardising each sample against the mean protein concentration for all 3 wells. 
The corrected firefly luciferase value for each sample was then expressed as a percentage o f the 
corresponding Renilla luciferase value, which served to correct for transfection transficiency. The 
final corrected luciferase values o f all test samples as well as the negative control were then 
expressed as a percentage o f the positive control (SV40 promoter-driven luciferase).
5.4.5 Sequencing o f  the canine TR promoter
5.4.5.1 PCR amplification of the canine TR gene
Initial sequence searches were performed by screening partial, unannotated canine DNA sequences 
obtained as part o f the canine genome project via NCBI trace files 
(http://www.ncbi.nlm.nih.gov/Traces/trace.cgi?). Trace files were screened using the sequence of 
the human TR gene obtained from Genbank (AF221907). BLAST searches revealed three trace 
files: 271822249, 239572746, 272209162, all o f which showed good alignment with the hTR 
sequence and with each other. One o f these, 271822249 contained 329 bp o f upstream regulatory 
sequence.
The sequence obtained from trace files was used to design primers for amplification and 
sequencing o f the canine TR gene following genome walking. The details o f these are shown in 
Table 5.3. Initial primers dogTR lF  and dogTRIR  were designed to amplify a 286 bp fragment o f 
the canine TR gene from genomie DNA to confirm that the sequence obtained from trace files was 
amplifiable. PCR was performed using the following conditions: initial dénaturation at 95° C for 2 
minutes, followed by 35 cycles o f dénaturation at 95° C for 30 seconds, annealing at 55° C for 30 
seconds and extension at 68° C for 30 seconds per kb. A final extension step at 68°C for 10
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minutes was then performed. The products from this reaction were then analysed by agarose gel 
electrophoresis, cleaned and cloned into pCR2.l® TO PO  as previously described prior to 
sequencing with the T7 forward primer.
5.4.S.2 Genome Walking
The Genome Walking procedure, shown in Figure 5.3, is explained in further detail below.
5'
Figure 5.3: Summary o f genome walking procedure
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All genome walking performed during this part o f the project was undertaken by Ms L. Gault. The 
Genome Walker™ technique (BD Bioscence, UK) provides a method for walking up-stream 
towards promoters from a known DNA sequence (Siebert et al. 1995) and is a simpler and 
potentially faster approach than those protocols involving the generation and screening o f gDNA 
libraries. In summary, canine gDNA was digested with four different restriction enzymes and 
GenomeW alker Adaptors were then ligated to 5' ends o f the cut fragments to form four libraries 
composed o f gDNA fragments. These libraries were then used as templates for each of three 
genome walks, which consisted o f two PCR amplifications using sense adaptor primers and anti- 
sense gene specific primers (GSPs) (Figure 5.3). The GSP sequences were designed based on the 5' 
end o f partial canine TR gene sequence located through trace file screening. PCR products thus 
generated were then cloned and sequenced allowing the design o f new gene specific primers for the 
second and third genome walks.
5.4.5.2.1 Prim er design
Two primers were designed for each genome walk as described in 2.2.6: Amplification o f DNA by 
the polymerase chain reaction, and were synthesised and supplied by Sigma Genosys (Table 5.3). 
Each primer o f 25-28 nucleotides in length required 40-60% GC content to ensure that primers 
would effectively anneal to the template at the recommended annealing and extension temperature 
o f 67° C. Primer sequences were designed to prevent the folding and formation o f intra-molecular 
hydrogen bonds and particular attention was paid to reducing the GC content at the 3' end o f the 
gene specific primers to prevent their binding to the 3' end o f the adaptor primers.
5.4.5.2.1.1 Canine T R  primers
Using these criteria, two anti-sense oligonucleotide primers (GSP-IR, GSP-2R) were designed 
according to the 5' region o f the canine TR sequence obtained from screening trace files. On 
completion o f the first genome walk it was possible to design a third anti-sense oligonucleotide 
primer (GSP-3R) which was used in combination with GSP-2R for the second genome walk along 
the canine TR promoter sequence (Figure 5.12).
5.4.5.2.1.2 G enom eW alker Adaptor primers
Forward primers, specific to the Adaptor sequence attached to the 5' end o f the gDNA fragments, 
were supplied with the kit and are referred to as Adaptor prim er-1 (A PI) and nested Adaptor 
Primer-2 (AP2).
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T ab le 5.3: Prim er seq uences for genom e w alk ing
P rim e r n a m e O lig o n u c le o tid e  p r im e r  s e q u e n c e  5 'to  3 ' T m  (°C) & G C  (% ) 
c o n te n t
DogTRlF T C C G T C T A A C C C T A A C T G A G C A 58.4° C : 52%
DogTRIR G G C T G A C A G A G C C C A A C T C T T 60.2° C : 57%
G SPIR T G A T T G G C C G A A G C C G T C A T C T C G C C T C T 82.6° C : 59%
GSP2R T T T C T C C A C C C C C C T C C C T C T C C A T C 77.3° C : 62%
GSP3R C T A C G G T T C T A C T T C C G G C C G T G A G G A 75.9°C : 59%
API G T A A T A C G A C T C A C T A T A G G G C 58.4°C : 45 %
AP2 AC TA T A G G G C A C G C G T G G T 58.8°C  : 58%
5.4.5.2.2 Preparation o f  canine gen om ic D N A
Canine gDNA was prepared from peripheral blood mononuclear cells (PBMCs) as described in 
2,2.2; Preparation o f canine genomic DNA from peripheral blood mononuclear cells.
5.4.5.2.3 PC R  amplification o f  the canine TR gen e from gen om ic  D N A
In order to confirm the sequence o f the canine TR gene, a 286 bp fragment was amplified using the 
primers dogT R lF  and dogTRIR. PCR was performed using genomic DNA (2 pl) as described in
5,4.5.1 : PCR amplification o f the canine TR gene.
5.4.5.2.4 D igestion  and purification o f  canine gen om ic D N A
Four blunt ended digestions o f canine gDNA (2.5pg) were performed, each in a total volume of 
lOOpl with the appropriate restriction enzyme Stu  I, Dra 1, Pvu  II or EcoK  V (80 units) and 
restriction enzyme buffer (Ix ) combination (Table 2.1 in Chapter 2). Reactions were incubated at 
37° C overnight before samples (5|il) were analysed for complete digestion by TAE agarose gel 
(1%) electrophoresis. For DNA purification, phenol (95pl) was added to each reaction, vortexed 
and flash spun to separate the aqueous and organic phases. The upper aqueous layer from each tube 
was mixed with an equal volume o f chloroform added, vortexed and briefly spun to separate the 
aqueous and organic phases. This time the DNA in the upper layer was precipitated with 2 volumes
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o f  ethanol (95%), l/IO volume 3M NaOAc (pH 4.5) and 20pg o f  glycogen. After vortexing and 
centrifugation at I5,000rpm for 10 minutes, supernatants were decanted and the pellet washed in 
lOOpI ethanol (80%). After a final centrifuge at 15,000 rpm for 5 minutes and supernatant 
discarded the pellet was air-dried and dissolved in 20pl o f  Tris-EDTA (10/0.1, pH 7.5). The quality 
o f  gDNA was again assessed using TAE agarose gel analysis.
5.4.5.2.5 Ligation o f  d ig ested  canine g D N A  to GenomeW alker Adaptors
The digested, purified DNA (4pl) was ligated to the GenomeWalker Adaptors (25pM ) in a total 
volume o f  8 pl with T4 DNA ligase (4 units) and ligation Buffer (Ix )  at 16° C overnight. The 
reactions were incubated at 70° C for 5 minutes before dilution to a total volume o f  80 pl with Tris- 
EDTA (10/1 pH 7.4).
G enom eW alker Adaptor sequence
API
5’ GTAATACGACTCACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT
AP2
5.4.5.2.6 P C R -based D N A  Walking in GenomicW alker Libraries
The four different libraries were subjected to two rounds o f  PCR (primary and secondary) using a 
PE 2400 thermal cycler. For the first genome walk, the primary round o f  amplification used the 
adaptor-ligated gDNA as template with 0.2pM  o f  sense primer ‘Adaptor Primer V (A PI) and anti­
sense ‘Gene Specific Primer’ (G SP-IR ) (Table 5.3), lOX BD Advantage 2 PCR Reaction Buffer 
(40 mM Tris-HCI, 15 mM KOAc, 0.02% Triton X-100), dNTPs (lOmM ), and BD Advantage 2 
Polymerase Mix (50x) (5 units o f  Tth DNA polymerase, 0.5pg o f  TthStart Antibody, 1% glycerol, 
0.2 mM Tris-HCI pH 7.5 and 4.6 niM KCI) in a total volume o f  50pl. Primary PCR conditions 
were held at 94° C for 25s, 72° C for 4 mins for 7 cycles, and 94° C for 25s, 67° C for 4 mins for 32 
cycles, then 67° C for 4 mins. Primary PCR products were diluted 50 fold and I pl was used as a 
template for secondary, nested PCR with 0.2pM  o f  sense primer ‘Adaptor Primer 2 ’ (AP2) and 
anti-sense ‘Gene Specific Primers’ (GSP-2R) (Table 5.3) in a reaction mix as described for primary 
PCR. Secondary PCR conditions were 94° C for 25s, 72° C for 4 mins for 5 cycles, and 94° C for 
25s, 6 7 °C for 4 mins for 20 cycles, then 6 7 °C for 10 mins.
2 4 6
The second genome walk used anti-sense ‘Gene Specific Primer’ (GSP-2R) in the primary round o f 
PCR and nested primer (GSP-3R) in the secondary round o f PCR. PCR conditions were altered 
slightly with the annealing temperature reduced from 72 to 69°C and 67 to 64°C in secondary PCR. 
In addition, 6% DMSO and 3% glycerol were added to the reaction mix. A negative control 
containing al! PCR components (primers, dNTPs, Advantage 2 PCR buffer and Advantage 2 
Polymerase Mix) except template was performed to ensure no contamination o f the PCR reactions 
with extraneous DNA that might serve as a template for PCR amplification.
PCR products were purified and cloned into pCR2.1®/TOPO using methods described in 2.2.3.8: 
Ligation using TA cloning methods, before being sequenced with the M13F and M13R primers as 
described in 2.2.7: DNA sequence analysis.
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5.5 R esults
5.5.1 Sequence analysis o f  the canTERTpromoter
Screening o f a canine genomic DNA library with a 450bp canTERT probe yielded a single positive 
clone. Sequence analysis revealed that approximately 8Kb o f sequences upstream of the canTERT 
ATG were present within this clone. Initial attempts to clone a 5.6 Kbp subfragment using both the 
cTERTprom-5522F/LG7R and cTERTprom-5522F/LG9R primer pairs were unsuccessful. 
However, a smaller subfragment o f  4929 bps using cTERTprom-5522F/cTERTprom-628R was 
successfully amplified and cloned into pC R 2.1® T0P0. Following multiple attempts to amplify 
the proximal upstream fragment, successful amplification of a fragment with the 
cTERTprom-1572F/LG7R primer was achieved using the PCRx'*"''^  Enhancer system (Invitrogen, 
UK). This fragment was also cloned into pCR2.1®TOPO. Sequencing o f these two fragments at 
least 3 times allowed the generation o f a composite sequence o f the promoter region as far 
upstream as -5390  bp with an overlapping region between -600 and -1590 bp. Sequencing 
included the initial part o f  the canTERT gene (the ATG start codon together with exon 1 (218 bp), 
intron 1 (106 bp) and 15 bp o f exon 2. The initial A nucleotide o f the start codon was designated 
+ 1. The canTERT promoter sequenee (5390bp) upstream o f the ATG has been deposited in NCBI 
Gen Bank database: AY563633 and this sequence together with exon 1, intron 1 and the small 
fragment o f exon 2 is given in Appendix B.
5.5.1,1 CpG Analysis
Sequence analysis showed that the canTERT promoter is highly GC rich and has no detectable 
TATA or CAAT boxes. Whilst genomic DNA has an overall GC content o f 40% and an 
observed/expected (O/E) CpG ratio o f 0.25, within the 5390 bp fragment, 4 CpG islands were 
found, defined as areas larger than 200bp with a GC content o f at least 60% and an O/E CpG ratio 
o f greater than 0.6. The largest o f these, with a GC content >80% and an O/E CpG ratio o f 0.8, 
was identified extending from bp -339  into exon 2. A smaller island was identified with GC 
content >60% and O/E CpG ratio o f 0.6 extending from bp -1280 to -1078. Further upstream, two 
other CpG islands, with GC contents >62% and >65% and O/E CpG ratios o f 0.6 were identified 
extending from bp -4471 to -4267 and bp -5042 to -4766 respectively. This is shown in Figure 
5.4.
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5.5.1.2 Transcription Factor Binding Sites
Multiple putative transcription factor binding sites were identified within the promoter and are 
shown in Table 5.4. These include binding sites for the Oestrogen Receptor, MZF-2, a single E- 
box and multiple Spl binding sites. The sequence o f  1.6 Kb o f  the promoter together with potential 
transcription factor binding sites is shown in Figure 5.5. A comparison o f  the canine and human 
TERT 5 ’ promoter regions showed that many o f  the same transcription factor binding sites known 
to be involved in hTERT regulation are present within the canTERT promoter including A PI, c- 
ets-2, c-myb, N F l, Myo D, W T l, c-m yc, GR/PR, MZF-2, ER/Spl and MAZ (Figure 5.6). The 
hTERT promoter also contains one PR and p53 binding site, which were not detected in the 
canTERT promoter. Interestingly, several binding sites unique to the canTERT were also identified 
including GR, c-ets-1, c-jun, myc-CF-1, SRY and MTF-1 (Figure 5.6).
5.5.1.3 Transcription Start Site
Using the GeneRacer™ (Invitrogen, UK) RACE kit, multiple attempts were made to obtain the 5 ’ 
end o f  the transcription sequence. For reverse priming o f  RAC E-ready RNA, both oligo(dT) and 
the gene-specific primer LG7R were used. Initial results revealed the existence o f  multiple, non­
specific bands. Secondary and nested PCR were then performed using platinum HiFi Taq 
Polymerase (Invitrogen, UK) in addition to the PCRx Enhancer system, to try to amplify the 5 ’ end 
o f  the untranslated region. However, all attempts were unsuccessful, yielding only multiple, non­
specific bands (Figure 5.7).
Figure 5.4: CpG Island analysis o f 5.5Kb o f the canTERT promoter, including CpG islands in relation 
to ATG start codon. Exon I/Intron 1/Exon 2 and location o f forward primers used to generate deletion
constructs.
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Figure 5.5: Sequence of approximately 1.6Kb of the caiiTERT promoter together with potential 
transcription factor binding sites (boxed). CpG islands are shown nnderlined, and the ATG start
codon in bold.
-1 5 5 7  CTCAAG CCAACAACAT
■1540 CAATTTTTTT CTGGAACACT TTTCACATTC ATGACGCCGT GATTTCAGAC 
-1 4 9 0  TATC^C^CGC TTCCTGAAAC^GGTGATGGA GGAGATGAAG 
-14  40  a {3GCTGGg | i G AACCCCcjlCC GCC|\TCAGCA CAGTATCAGT C C ^ A C G ^ G ^
-1 3 9 0  [crjrCTCTGCC TTGGTTTCTC CTGTTCCTC^^JTTTCTAAAA ACTG A TG Tg^^^^
-1 3 4 0  TCTGACCAGG TTTCTCCAGG TGAATC^ A G  TAA}gTTTGTT  GGAAA^^GAAcj
-1 2 9 0  I^A T T T C C C C  AGACAGTCGC AAAACCT^ _^ GAGTGGTTC
; 1 2 4 0 TCCATCCTGG CCCTGGAGAC CAC^^ C%ÇTGTCTAG
(^CGCCAGCAC-.1190 _AAGGGCGACA CGTAATCCGA GTGTTACAGG _AAG^_GGCAg | ^ (
-1 1 4 0  CATGAATAT G GAAGCCÇGG C _ CACÇAAGA G ^ ^ ^ G p _ ^ jsGG _ CC]t G ^ ^ A A A
0 90 TGCTAGGGCC ATGAATAAAA GCAATTTCC[t GACCj^CGTAC Gt |tGCCAAAG
-1 0 4  0 GTTAACATTT GTGCAGCCGT CCAGTGTTTG CTGAGCTCAG GAGCATTGTC
-9 9 0  CCCGGGAGCC T C C g ]^ ^ ^ C C  CACAAGAGCC T G T T ^T C A G  CAATTCAAAC
-9 4 0  TTGAACGCGT C TbCGTTTt GR/PR  r ;t  c c t c t g g g p g5C ATGGTCTCAT TA:
-8 9 0  |TCCT|^ ^ C A A  GCGTCATGAT GAACACTGTC A ^ A A C T ^C T  C ^JG G (^T g,y_^
-8 4 0  Gg[3GTGGg |i G GTCT^Ç^^^Tjl T^^TGCAGAG G g ^ T G C A C ^ jg G G C ^ ^ G A ^
-7 9 0  ^ T C T G T G A G  GTCC^^gTGAC c |:[gTCCAGt |3 CCACcjrCC^  CCTGCCCT|i g |
-7 4 0  ' '
- 6 9 0
GCC7GAGCA CGA^IGGCAG^ TGGGAGCGGC^^^AGAGGAGC CTGCACAGGG 
TGCCACCAAG CCCTGTGGCT CCCATTTpTG CCcfr C C ^ J C  ^ ^ ^ C T G T G
-6 4 0  GTTAGGAGGG AGCTGAGTGG GGTTTTTTTG CCTGTpGTGG g |i a [^ ^ ^ G
-5 9 0  AGCCCGAGGA CCTGAAGGAG AAACCACAj^^CTGGGGTCGA GG|\GGTCa {^ ^ ^ j,^
-5 4 0  TCTGGGGGCA GTACTGCCGC TGCCTGpTGG Ct [i CTCACTG G C C G (^^c{rG ]
-4 9 0  jrC C ^T G G G G  CTGCTTGTGC CCGCACCCCC CGTGGCTCA^,/rGpGGCAG|:C
-4 4 0  CTGCTGGCÿ;^ TTCACCCCGT GTATCGTGCA CATTCT:CAC CCTGCTCCCT
- 3 9 0  GCACcjïCCTC c | l ( ^ ^ T ( ^ ^ ^ ^ C C T C T C C C C  CCTCGCCAGC CTCAGGGAGC
-3 4 0  A G C C T C ^^G  _TÇ G C CC C '^T^A ÇA G G G A CA  M ^ ^ ^ A G ^ ^
- 2 9 0  CCCCtTGCCC AGGGGCGCAG AGO 3CAGCAG GTGC X C A T G  TCpG ;C G G pG 1
l24p_ .|GCTj3CCCTGG GTACCCCCGA GCCTCGGCCG ACGGCATCœ 
-1 9 0  _ CGACCCTCGC _.ÇGÇGÇCÇGCC GGGCCGGAGA GCAGA
-1 4 0  CCACGCGCTC CTGGGGCTCC GCACACCTCG GCGCGCACGC CCCCGGGCGC ............... - -Sjfl.......................................  - ......... Spl..............-....................... fitAZ/Spl.........
-9 0  C :CGCCC :t t CCTCCCAGGA GCCjlC G C C ^ _ GGCGCGGACC _pCCTCCCjlCG
-4 0  GC [ :c G c c c |: T TCCTCCCGCG GACC j:cG ccc| CTCCCCGGCC ATG
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Figure 5.6: Comparison o f canTERT promoter with hTERT promoter
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Figure 5.7: Representative example o f attempts to amplify the transcription start site using the 
GeneRacer protocol. RT-PCR: Lane I D17, Lane 2 CMT7. Note lack o f product from D17 cells and 
multiple bands suggesting non-specific priming in CIMT7 cell sample. Approximate size o f the two 
largest bands in the I Kb mass ladder are shown.
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5.5.2 Identification o f  the canTERT core promoter
In order to identify those areas o f  the canTERT promoter that convey strong activity and in order to 
identify potential repressing and activating transcription factor binding sites, deletion constructs 
were created from the 5.6 Kb promoter initially sequenced. Initial PCR amplification o f  a 1929 bp 
fragment using the cTERTprom-1572F/LG7R primer pair was successfully accomplished using the 
PCRx Enhancer system with genomic DNA template. This fragment, termed CTERTPROM l, was 
cloned into pCR2.l® TO PO  and sequenced. Using this initial construct as a template, successive 
PCR reactions were performed with the nested primer pairs: cTERTprom-1572F/LG9R,
cTERTprom-907F/LG7R, cTERTprom-907F/LG9R, cTERTprom-677F/LG9R, can3F/LG7R and 
can3F/LG9R. Following cloning into pCR2.1®TOPO and sequencing, these were termed 
CTERTPROM2, CTERTPROM3, CTERTPROM4, CTERTPROM5, CTERTPROM6 and 
CTERTPROM7 respectively. Constructs CTERTPROM l, CTERTPROM3 and CTERTPROM6 
contained sequence upstream o f  the ATG together with exon 1, intron I and 15 bp o f  exon 2. All 
o f  these constructs are represented in Figure 5.8.
The ability o f  these constructs to direct expression o f  the luciferase reporter gene was assayed by 
transient transfections in D I7 and CMT7 telomerase-positive cells. Luciferase assays showed that 
CTERTPROM 1 was active in both cell lines, with 9.1% and 8.3% o f  the activity o f  pGL3control in
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CMT7 and D17 cells respectively (Figure 5.9). CTERTPROM2, which included the 1557 bp 
upstream o f  the ATG but omitted structural gene sequence, displayed a twofold increase in activity 
relative to CTERTPROM l, with 2l.9% /20.3%  o f  the activity o f  the pGL3control vector in 
C M T7/D I7 cells. CTERTPROM3 and CTERTPROM4, containing 890 bp upstream o f  the ATG 
with and without TERT gene sequence respectively, both displayed similar activity to that o f  
CTERTPROM2, with 17.3% /I8.7%  and 20.0% /22.4%  o f  pGL3control in CM T7/D17 cell lines. 
CTERTPROM5 included 665 bp o f  the promoter but no gene sequence. CTERTPROM6 and 
CTERTPROM7 included 314 bp o f  the promoter with and without gene sequence, respectively. 
CTERTPROM5 and CTERTPROM6 displayed similar activity to CTERTPROM2, with 
I8.3% /15.5%  and I5.5% /I3.7%  o f  the activity o f  pGL3control in C M T7/D I7 cells respectively. 
However, CTERTPROM7, containing the most proximal 314 bp o f  the promoter, displayed 
significantly greater activity than all other constructs, with 54.9%/49.4% o f  the activity o f  
pGL3 control, and a near fourfold increase in activity when compared with 
CTERTPROM6/CTERTPROMI (Figure 5.9). The sequence o f  CTERTPROM7, the core 
promoter together with 65bp o f  exon I, is shown in Figure 5.10.
Figure 5.8: Illustration of deletion constructs
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Figure 5.9: Luciferase activity o f canTERT promoter deletion constructs expressed as a percentage 
relative to pGL3control in telom erase-positive CM T7 and D17 cells
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Figure 5.10: Sequence o f core prom oter (CTERTPROM 7) including exon I, showing binding sites for 
Can3F and LG9R (underlined) and putative transcription factors (boxed). Start codon shown in bold.
( an3F
Promoter:
- 3 1 4  CTGT GACAGGGACA AACCCAAGGASpl MvoD Spl W ri-KTS
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5.5.2.1 Specificity of activity o f the canTERT core promoter
The ability o f the minimal core promoter to direct expression specifically in telomerase-positive 
cells was then investigated in several telomerase-positive cell lines: CMLIO (canine melanoma), 
A72 (fibroblastoid tumour), MDCK (canine kidney), GHK (canine kidney), CMT3 (canine 
mammary tumour) and CMT8 (canine mammary tumour). In addition, specificity o f activity was 
assessed by transfecting telomerase-negative canine primary fibroblasts. The level o f activity o f 
CTERTPROM7 varied in each cell line, with maximal activity o f 52.5% o f  the positive control in 
CMLIO cells. However, the A72 and CMT3 cell lines displayed lower activity, with 13.9% and 
10.3% o f the activity o f the pGL3control respectively. GHK and CMT8 cells showed intermediate 
levels o f  canTERT promoter, with 27.7% and 22.7% o f the pGL3 control respectively (Figure 5.11 ). 
Transfection o f canine primary skin fibroblasts resulted in minimal activity with all constructs, as 
shown in Figure 5.12.
Figure 5.11: Activity o f CTERTPROM ? promoter fragment in different cell lines expressed as 
percentage o f activity o f positive control pGL3Control vector. Activity o f negative control (pGL3Basic
with no insert) shown in maroon.
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Figure 5.12: Activity o f all deletion constructs in telom erase-negative K9SF cells expressed as a 
percentage o f the activity o f positive control pGL3Control (PC). Activity o f negative control 
(pGL3Basic with no insert) also shown (NC).
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5.5.3 Sequence analysis o f  the canTR promoter
Initial PCR amplification o f the canine TR gene was performed. Using the conditions listed in 
2.2.6: Amplification o f DNA by the polymerase chain reaction, a 286 bp fragment was amplified 
from gONA, cloned into pCR2.l® TO PO  and sequenced to confirm the presence o f canine TR 
sequence. Sequence o f this product is shown in Figure 5.13.
Following initial PCR, primers were designed from trace file 271822249 to perfomi genome 
walking. The positions o f  these are shown in Figure 5.13. The first genome walk, using primers 
GSP-IR  and nested primer GSP-2R, revealed the presence o f a 700 bp band in the library created 
with EcoR V and a 500 bp band in the Pvu II  library o f the DNA libraries. Both fragments were 
excised, gel-purified, cloned into pCR2.1®TOPO and sequenced. The sequence obtained was then 
used to design primer GSP-3R primer for a second genome walk. This genome walk was 
performed with primer GSP-2R and nested primer GSP-3R. The nested PCR from the second 
genome walk resulted in a 600 bp product from the EcoR V library and a 400 bp product from the
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Pvu II library (Figure 5.14). These bands were excised, gel purified, cloned into pCR2. l® TO P and 
sequenced. The sequences obtained from all colonies containing correct sequence were 
subsequently aligned and used to generate a consensus sequence o f  700 bp o f  the promoter. The 
consensus sequence is shown in Figure 5.15. Following sequencing and characterisation o f  this 
promoter region, attempts were made to amplify fragments for the generation o f  deletion constructs 
and subsequent luciferase reporter assays, as performed with the canine TERT promoter. However, 
initial attempts at PCR were unsuccessful despite using the same modifications as previously 
described, and due to time constraints, further troubleshooting was not performed. As a result full 
characterisation o f  the core TR promoter could not be completed.
Figure 5.13: canine TR and promoter sequence obtained from trace file 271822249. Forward (blue) 
and reverse (red) primers used for initial PCR and for genome walking are shown, together with the
TATA box (boxed).
Prom oter:
NGGCGGATATTTCGCCTGTTGGTGGAATTCAGAAAAGAAAGAGAAAAGGAAAAGAAAAAAGAAAAAGACC
CTTTAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAGAAAAAAGAAAAGACCTAACATTTTACTT
4 B ( > S P - 3 K  # 0  ( S I - 2 K
AAGGAACGTGGAGGAGGAGGCGGCGCAGGGTCCTCACGGCCGGAAGTAGAACCGTAGGGATGGAGAGGGA
G S P - I K
GGGGGGTGGAGAAAGGGGCGGAAGCCGGCTCTCGCGAGAGGCGAGATGACGGCTTCGGCCAATCAGCGCC
GGCGGCGGGCGCGCCCT TTATAA GCGGCGGCGGCGGGCGGCGGCGGCCG
TATA-box
TR  gene:
AGGTCGCGGAGGGTGGGCCCG
Dog IK IF I B
GGAGAGGCGGCGGCCGGCCTCCGTCTAACCCTAACTGAGCAGGGCGTGGGCGCCGCGCTTTTGTTCCCCG
CGCGCTGTTTTTCTCGCTGACTTTCAGCGGGCGGAAAAGCCTCGGCCTACCGCCGTCCACCGTCCGGGTC
TGCAGCCAACAACAAAAAATGTCAGCCGCTGGCTCGCTCGCCCCTCCCGGGAGCCTGCGGCCGCTCGCCC
GCTCGGCCCCCCGCGTCCCGCCCGGAGGCCGCGGCCGGCCCGGGGCTTCTCCGGAGGCGCCCACTGCCGT 
Dog IK IK
CGCGAAGAGTTGGGCTCTGTCAGCCGCGGGCCGTCTGGNGGCCGCAGGGCTGGGCTCGNGCCGCAGGGAG
AGCTACGGAGCGNGTCCCCTGCGCGCGTGCGTCTCCCTGAGCTGTGGGACTCGCACCCGGNACCGGCTCG
CACCGCNCCNCGCGGGNGCGCTGCTGGGCCCTTGGGNTCTGCGGCTGTCCTCCCCTGGCGNNGCGCCTGC
GTCTCACCGAAAGNAAAAGGGGGGCCCCCG
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Figure 5.14: Fragments amplified from EcoR V and Pvu 11 libraries during genome walking
Genomewalker -  agarose gel analysis o f  primary and nested PCR. Lane I : EcoR V library; Lane 
2: Dra I  library; Lane 3: Pvu II  library; Lane 4: Ssp I  library
A: Second genome walk. Primary PCR using primer GSP2-R. Notice multiple bands in all lanes. 
B: Second genome walk. Nested PCR using primer GSP3-R. Notice 600 bp band in lane 1 and 
400 bp band in lane 3.
600 bp
1 2  3 4 B 1 2  3 4
600 bp
Figure 5.15: Consensus sequence o f canine TR promoter showing TATA box (boxed), TR gene 
(underlined), and position o f primers used for genome walking (purple)
-801 C T T A TT C A TG AGAGACACAG AGACCCAGGC AGAGGGAGAA GCAGGCCCCA
-751 CGCAGGGAGC CCGACGCGGA ACTCG ATCCC ACGACCCCGG GTCACGTCCT
-701 GGGCCGAAGG CAGGCGCCGA ACCGCTGGGC CCCCCCGGCT GCCGTCGAGT
-651 TT C CTTAAAG G TCG CTACCA ACTGCGATGG CGTTTGTGGA AAACAGAGCC
-601 GCGCAGCTGT GCAAGTTAGT TT G T A C T T T C GGAGTAACCT TAG CTCCTTC
-551 CCCTCAAAAT A A A ATAAAAT AAAATAAAAT AAA A T A A A TA A A A T A A A A TA
-501 A T A A A A TA A A TA A A A TA A A A A T A A A A TA A A TAAAAAGAAT AAAAGAAAAA
-451 GGAAAAGAAA GACAAAAAGA AAAAGAAAGA AAAGGAAAAG GAAAAGAAAA
-401 AAGAAGAAGA AAGAAAAAAG GAAAAGGAAA AGAAAAAAAA GAATAAAGGA
-351 AAAGGAAAAA AAGAAAAAGA AAAAAAAGAA AAAAGGAAAA GAAAAAGAAA
-301 GAGAAAAGGA AAAGAAAAAA GAAAAAGAAA AAGAAAAAAG AAAAAAGAAA
-251 AAAGAAAAAA GAAAAAAGAA AAAAGAAAAA AGAAAAAACC T A A C A T T T T AGSP-3R-201 CTTAAGGAAC GTGGAGGAGG AGGCGGCGCA GGGTCCTCAC GGCCGGAAGT(;SP-2R-151 AGAACCGTAG GGATGGAGAG GGAGGGGGGT GGAGAAAGGG GCGGAAGCCG
-101 GCTCTCGCGA GAGGCGAGAT (:SP:|RGACGGCTTCG GCCAATCAGC GCCGGCGGCG
- 5 1  GGCGCGCCCT TTATAAGCGG CGGCGGCGGG CGGCGGCGGC CGAGGTCGCG  
- 1  G
+ 1 A G G G TG G G C ..C C G G G A G A G G ..C G G C G G C œ
+ 5 1  A G C A G G G Ç G T..G G G C G C Ç G C G ..C T TX TG T TC C ..C C
+ 1 0 1  TG ACTTTCAG  CGG
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5.6 D iscu ssio n
The principal aims o f this chapter were to sequence and characterise the promoter of the canTERT 
gene as a potential tool for developing tumour-specific targeting o f gene expression. We screened 
a phage library and identified a clone containing 8Kb o f the promoter region upstream o f the 
canTERT gene. From the sequence obtained from this clone we designed primers which were then 
used to amplify and sequence approximately 5.6 Kb of the promoter from genomic DNA in two 
large, overlapping subfragments. From within this region, 1.5 Kb o f the promoter together with 
approximately 340 bp o f the gene was successfully subcloned into pCR2.1®TOPO and used to 
generate deletion constructs that were subsequently subcloned into the pGE3basic reporter vector 
and transfected into telomerase-positive cell lines. Luciferase assays in telomerase positive and 
negative cells were then used to identify the specificity and strength o f the core promoter, which 
was found to be contained within a region extending 314 bp upstream of the ATG start codon. In 
addition to sequencing and characterisation o f the canine TERT promoter, using primers designed 
from canine DNA trace files retrieved from Genbank, genome walking was performed which 
allowed sequencing o f a 700 bp region o f the canine TR gene promoter as an initial step in its 
characterisation. However, attempts to amplify regions o f the TR promoter to generate luciferase 
reporter constructs were unsuccessful, and as a result full characterisation was not performed.
5.6.1 Can TERTprom oter characterisation
Sequence analysis showed that the canTERT promoter shares some regulatory motifs with the 
hTERT promoter: the 5’regulatory region o f canTERT is GC-rich, lacks TATA and CAAT boxes 
and contains binding sites for multiple transcription factors. In addition, four CpG islands were 
identified within the 5.6 Kb of the promoter. Intrigiiingly, the largest o f these coincides almost 
exactly with the core promoter, with its origin at 349 bp upstream o f the ATG and extending into 
exon 2. This raises the question o f whether méthylation o f the canine TERT promoter is likely to 
play a significant role in regulation o f telomerase activity. In the human literature, the importance 
o f promoter méthylation in regulating hTERT function is as yet unclear, and the clinical relevance 
o f promoter méthylation appears to be slight, and probably tumour-type dependent (W idschwendter 
et al. 2004). Given the similarity in GC-content between the two species, this may also be the case 
in dogs.
Analysis o f deletion constructs revealed that core activity o f the promoter is contained within 314 
bp upstream o f the ATG. This result is consistent with the hTERT promoter where several studies 
have shown that core promoter lies within approximately 300 bp o f the transcriptional start site 
(Horikawa et al. 2002; Takakura et al. 1999; Wick et al. 1999).
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5.6.1.1 Difficulties encountered with amplifying the canTERT promoter
Considerable difficulty was encountered when we attempted to amplify the canTERT promoter for 
sequencing, due to the GC-rich nature o f the proximal part o f the gene. Ultimately, sequencing and 
generation o f deletion constructs was performed over approximately 12 months, considerably 
longer than expected. An initial fragment upstream o f the large CpG island that extends into the 
canTERT gene was amplified, cloned and sequenced with relative ease. However, the promoter 
fragments extending into this CpG island were considerably more difficult to isolate. Regions o f 
genomic DNA containing a high percentage o f guanidine and cytosine residues are commonly 
associated with a high degree o f secondary structure. This is due to the fact that G-C pairs contain 
3 hydrogen bonds, rather than 2 as is the case with A-T pairs. As a result, following the 
dénaturation step o f PCR amplification, which is designed to reduce secondary structure and 
separate the DNA strands, G-C pairing frequently recurs and secondary structure reforms, 
preventing access o f primers to their binding sites and interfering with elongation by DNA 
polymerase.
Various methods exist to deal with these problem areas o f the genome, many o f which are designed 
to alter the melting behaviour o f the DNA strands. DMSO, glycerol and Q-solution are all 
examples o f  additives that are used in this way. Another additive designed to alter the melting 
behaviour o f DNA strands is betaine, present within some o f the buffers provided with the kit 
supplied by Cambio. It may be useful to investigate this in future attempts to amplify the canTERT 
gene in its entirety since we did not employ it as an additive on its own. In addition, many PCR 
protocols involve modifying the percentage of the Mg^ "" in the reaction mix for the same reason. 
Initial attempts at PCR involved lowering the annealing temperature to 55° C during the annealing 
step. In theory, this should lower the specificity o f priming and result in primer annealing to 
multiple sites in addition to the desired site. However, the lower annealing temperature is likely to 
have resulted in reforming o f secondary structure in the area o f interest. Techniques including the 
HotStarTaq and KOD Hot Start Taq protocols are designed to improve the amplifieation o f difficult 
templates by increasing the specificity o f priming and elongation using hot start protocols. 
However, without modifying the melting behaviour o f the GC-rich areas, it seems likely that 
reducing the temperature o f the reaction during the annealing step allowed secondary structure to 
reform and therefore inhibited primer binding and polymerase elongation. Ultimately, the 
proprietary PCRx Enhancer Solution, provided by Invitrogen, was the only additive capable o f 
dealing with our problem template. Using the Enhancer Solution, initial amplification o f the 
largest promoter fragment (CTERTPROM 1) and cloning into pC R 2.1® T 0P0 was achieved. Once 
this fragment was present in a plasmid, it is likely that the amount o f secondary structure present in 
our template was significantly reduced. We were then able to amplify smaller fragments from this
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plasmid with greater success. However, future attempts to amplify or sequence other GC-rich 
regions o f the canTERT gene are likely to be met with similar difficulties.
5.6.1.2 Potential transcription factor binding sites within the core 
canTERT promoter
Transcriptional analysis o f the canTERT promoter demonstrated that the promoter was active only 
in telomerase positive cells, although the levels o f transcription varied between cell lines. In 
contrast, no significant promoter activity could be detected in primary fibroblast cultures.
5.6.1.2.1 Com paring the canine and human T E R T  prom oters
Within the canine core proximal promoter the most obvious feature was the presence o f multiple 
Spl binding sites (Figure 5.6). Several Spl binding sites also exist within the core hTERT promoter 
and Spl mutations have been shown to reduce hTERT promoter activity, indicating a role in 
hTERT transcriptional activation (Kyo et ah 2000). Whilst the exact mechanism by which Spl 
enhances transcription is not known, Spl is a general transcription factor and is ubiquitously 
expressed in a wide range o f cells. The question remains, however, as to how significant a 
contribution Spl makes to specific TERT activation in cancer cells. For instance, the finding that 
adding Spl and c-Myc binding sites to the hTERT promoter increases activity specifically in 
tumour cells suggests that regulation o f the promoter in tumour cells may indeed involve the 
control o f Spl (Kim et al. 2003b). It is likely, however, that this control is complex and involves 
other transcription factor binding sites in conjunction with Spl.
Inclusion o f proximal promoter sequence extending up to -1557  bp reduced transcriptional activity, 
indicating the presence o f silencer/repressor elements within this region (-1557 bp to -314bp). 
However, few potential sites for known hTERT repressor binding elements were identified within 
the canTERT promoter. A single site for the Myeloid Zinc Finger 2 protein (MZF-2) was found at 
position -605 in the canine promoter. MZF-2 binding sites have been reported in the hTERT 
promoter, four o f which exist within a 200 bp region just upstream o f the core promoter (Horikawa 
et al. 1999; Takakura et al. 1999) and constructs with their 5’ end located within this region (-600 
to -800bp) show lower expression, suggesting MZF-2-dependent repression. Interestingly, the 
canTERT promoter seems to follow a similar pattern, with constructs comprising 890bp and 650bp 
o f promoter sequence showing reduced levels o f activity when compared to the construct consisting 
o f 314bp o f upstream sequence. This suggests that MZF-2 may play an important negative role in 
the regulation o f  canine TERT. Furthermore, the inclusion o f exon 1, intron 1 and part o f exon 2 in 
all deletion constructs decreased promoter activity by approximately 50-75%, depending on the 
construct. Transcriptional repression by the structural TERT gene has been demonstrated for the
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hTERT promoter (Renaud et al. 2003), where transcriptional activity is reduced 20- to 50-fold 
depending on the portion o f exon 2 included and constructs comprising up to 753 bp o f exon 2 
result in 100-fold reduced activity . In our study, only a small portion o f exon 2 was included, and 
it would be o f interest to determine whether additional exon 2 sequences would similarly lead to 
further reductions in the transcriptional activity o f the promoter. Other studies have also reported 
involvement o f the human TERT gene in transcriptional regulation (Cong et al. 1999), and support 
the inhibitory nature o f this region. The only known transcription binding factor identified in this 
region that is known to contribute to the inhibition o f hTERT promoter activity is MZF-2, for 
which a binding site is located in exon 1 o f canTERT at bp 121. It is possible that this MZF-2 
binding site is important for downregulation o f canTERT promoter activity, however, eurrently 
there is no evidence for a role o f MZF-2 in cancers and hence the significance o f MZF-2 mediated 
hTERT repression is unknown.
Several additional sites for known hTERT repressor binding proteins were also identified. These 
include a binding site for Wilms Tumor 1 tumour suppressor gene product (W T l), located within 
the core region o f the canine promoter. In the human promoter, one W Tl site is present at position 
-358  bp (Poole et al. 2001) and mutation o f the binding site has been shown to increases activity in 
293T cells but not HeLa cells (Oh et al. 1999). The canine TERT promoter also contains a putative 
E box binding site at -1397  bp. Mad 1/Max heterodimers have been shown to function as a 
negative regulator o f hTERT transcription by binding to E box sequences (Xu et al. 2001). 
Conversely, c-Myc/Max heterdimers can also bind to E box sequences and activate hTERT activity 
(Kyo et al. 2000). The hTERT minimal promoter contains two E-box sequences, however only one 
E box sequence was identified within the canTERT promoter located upstream of the core 
promoter at -1397 bp.
Four putative ER/Spl binding were also identified within the canTERT promoter. Several 
oestrogen-response elements (EREs) have been found within the hTERT promoter region, some o f 
which bind oestrogen together with its receptor (ER) and some o f which bind ER and Spl together 
(Kyo et al. 1999; Misiti et al. 2000). Whilst some reports suggest the more distal ERE, located 
2754 bp upstream o f the start codon, as being important for TERT activation, more recent reports 
have suggested direct activation o f hTERT expression through binding o f ER to a more proximal 
Spl/ER  site located at -950 bp (Misiti et al. 2000). The significance o f these binding sites in the 
canine promoter are currently unknown. However, the presence o f a greater number o f ER/Spl 
binding sites in the canine promoter, along with a greater number o f  PR and GR binding sites 
suggests that hormonal regulation may play a significant role in the canine TERT promoter. 
Further studies examining the activity o f the canine promoter under the influence of these 
hormones are required to verify this, however.
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Other potential transcription factor binding sites shared between the canine and human TERT 
promoters include c-ets-2, MAZ, N F l, MyoD, A PI, c-Myb and PR. Although the importance of 
many o f these transcription binding sites is currently unknown their presence in both the canine and 
the human promoter would suggest that these may be important activators/repressors contributing 
to either telomerase repression in normal cells or activation in cancer cells.
Several putative binding sites within the human TERT promoter were not identified within the 
canine promoter, namely: AP2, AP4, CCAC, NF-E2, NFkB, NMYC or p53. In our transcriptional 
binding site analysis, we identified several sites that appear to be unique to the canine sequence 
including several glucocorticoid receptor binding sites (GR), several GR/PR sites, one SRY site, 
two Myc-CFl sites, one MTF-1 site and one c-jun site (Table 5.4). With the exception o f a myc- 
CFI binding site (-254 bp), all other sites were located outside the core promoter region, however 
the role o f myc-CFl in TERT transcriptional control remains to be established. One transcription 
factor that may be o f particular interest is c-jun. c-jun is thought to play an important role in cell 
proliferation working in conjunction with ras protein and recent studies have shown a dramatic 
increase in c-jun expression in tumour cells from patients with myeloid leukemias, Hodgkins and 
anaplastic large cell lymphomas (Lohr et al. 1997; Weiss & Bohmann 2004).
5.6.1.2.2 O ther p o ten tia l regulatory factors
A wide variety o f potential regulatory mechanisms have been examined in the regulation of 
hTERT, illustrating the complexity underlying the in vivo activation o f telomerase. Interestingly, 
some pathways and mechanisms seem to be implicated in oncogenesis via several routes. For 
instance, the human T-cell lymphotrophic virus type-1 (HTLV-I) upregulates the hTERT promoter 
via the nuclear factor kB (NF-kB) pathway to allow the development o f an immortal phenotype in 
T cells during the progression to adult T cell leukaemia/lymphoma (Sinha-Datta et al. 2004). Other 
viruses also appear to exploit the hTERT promoter. Part o f the Hepatitis B virus, for instance, 
integrates within the hTERT promoter and activates hTERT gene transcription, a factor which may 
be important in the development o f hepatocellular carcinoma (Horikawa & Barrett 2001). Human 
papillomavirus (HPV) downregulates the hTERT promoter via the E2 protein to suppress cell 
division in host cells. This occurs in pre-malignant lesions, with E2 function subsequently being 
lost, allowing the E6 and E7 promoters to act, leading to the development o f a malignant phenotype 
in host cells (Lee et al. 2002b). This mechanism thereby allows the virus to induce a ‘dormant’ 
state in host cells, prior to the development o f cancer (Lee et al. 2002a).
Another potentially important mechanism for regulating the TERT promoter is through 
transcription factors responsive to hypoxic conditions in the external environment. Although they 
were not detected by the transcription factor binding search, the canine promoter appears to contain
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two putative hypoxia response elements (HREs). The first o f these is located within the E-box (5’- 
ACGTG-3’), and the second is located at bp -460  (5’-CCGTGG-3’). HREs, containing the core 
m otif 5 ’-(A/C)CGT(G/C) -3’ (Greco et a!. 2002), are located within promoters or enhancers o f 
genes involved in glycolysis, glucose transport, eiythropoiesis and angiogenesis (Nishi et al. 2004). 
These elements bind the HlF-1 heterodimeric transcription factor, composed o f the basic helix- 
loop-helix PAS protein H IF -la  and the aryl-hydrocarbon receptor nuclear translocator (ARNT -  
also known as H IF-lp) and thereby mediate the transcriptional response to oxygen deprivation. 
H IF-ip is constitutively expressed, but H IF -la  is tightly coupled to oxygen tension in the 
extracellular environment and consequently is the key determinant in HIF-1 activity in hypoxia. 
Since hypoxic stress is known to induce genetic instability by accelerating DMA breakage and gene 
amplification in tumour cells (Russo et al 95), mechanisms by which tumour cells can protect their 
chromosome structure offer a selective proliferative advantage in such situations. Several groups 
have shown that telomerase becomes activated under hypoxic conditions (Seimiya el al. 1999), 
suggesting that telomerase activation may offer just such a protective mechanism for tumour cells 
in humans. The mechanism by which this occurs in has now been shown to be through the 
upregulation o f H IF -la  and its binding to the FIREs present in the hTERT promoter (Yatabe et al. 
2004). Thus it may be that hypoxia plays an important role in regulating the activity o f the canine 
TERT gene, and this will be o f considerable importance in the development o f cancer-targeted 
therapies.
5.6.1.3 Specificity o f canTERT promoter activity
In order to assess the specificity o f the core promoter, we performed transient transfections in a 
range o f telomerase-positive canine cancer cell lines, and telomerase-negative canine fibroblasts. 
No significant promoter activity was observed in the telomerase-negative fibroblasts, confirming 
that the canTERT core promoter is only active in telomerase positive cell lines. A wide range of 
activity was observed in the telomerase positive cell lines, with some cell lines exhibiting low 
transcriptional activity. Interestingly low hTERT promoter transcriptional activity has been 
reported in several human telomerase positive cell lines including MCF7, U737, U87, A543, 5637 
(Bilsland et al. 2003; Koga et al. 2000; Plumb et al. 2001). Given the spectrum o f canTERT 
promoter activity, it will be o f  prime importance to determine which tumour cell lines contain 
sufficient promoter activity to drive potential targeted therapies. It may also be necessary to 
consider enhancing the prom oter’s activity in some cell lines with weak transcriptional activity, an 
approach which has been pursued with the human TERT promoter.
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5.6.2 Sequencing the canTRprom oter
In addition to sequencing and characterising the canTERT promoter, we have also sequenced the 
canTR promoter. The most significant feature o f the canTR promoter is that it contained fourteen 
repeats o f the pentanucleotide sequence TAAAA (Figure 5.14), a finding not reported either in 
humans or in mice (Zhao et al. 1998). The (TAAAA),, repeat element is a common feature o f 
repetitive elements such as alu sequences (Millar et al. 2000) and LINE elements as well as being 
found in the promoter o f some genes, such as the sex hormone-binding globulin (SFIBG) gene 
(Hogeveen et al. 2001). Interestingly, the variation in the number o f repeats is highly variable 
between individuals, and the number o f repeats regulates the expression o f the gene, with 
increasing numbers o f repeats in the SHBG promoter increasing the expression o f human SHBG 
(Hogeveen et al. 2001). In addition, when six TAAAA repeats are present, SHBG expression is 
silenced altogether. The significance o f these repeats in the canTR promoter is currently unknown, 
but it seems likely that the number o f repeats is likely to vary between individuals. Indeed, initial 
attempts to subclone fragments o f the canTR promoter from genomic DNA for luciferase assays 
suggested that allelic variation exists in the number o f repeats within a single individual (data not 
shown). This variation may have an important influence on the levels o f expression o f telomerase 
between individuals. Indeed, it may be the (TAAAA),, repeat number will be shown to have some 
correlation with breed, since some breeds are notable in their predisposition to cancer. One o f the 
original aims o f this part o f  the project was to generate deletion constructs with varying numbers o f 
(TAAAA),, repeats for luciferase reporter assays. However, difficulties were encountered with 
PCR amplification o f the promoter as a single fragment, most likely related to the unusual sequence 
in the region o f these repeats. Despite modification o f the PCR conditions as described with the 
TERT promoter, repeated attempts at amplification were unsuccessful, and due to time constraints 
full troubleshooting was not performed. Therefore, we were unable to completely characterise the 
canine TR promoter. In the future, further analysis o f  other individuals as well as luciferase assays 
with vaiying numbers o f (TAAAA),, repeats will be necessaty to fully characterise the TR 
promoter. In addition, it remains to be seen whether the canine TR promoter shows similar 
specificity to the human TR promoter, and therefore whether it will be useful as a cancer-specific 
promoter.
5.6.3 Future Directions
In defining and characterising the canine TERT gene promoter we are now in a position to evaluate 
canTERT promoter mediated gene expression in canine cells expressing telomerase. This 
knowledge will help build our understanding o f the events that are involved with cell 
immortalisation during canine oncogenesis, an important area o f future research. Further work 
examining the importance o f the different binding sites so far identified may also identify key 
events involved with telomerase regulation in cells in the developing animal, as well as its
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regulation in stem cell populations. In addition, as has been shown in the human literature, TERT 
promoter-driven gene expression can potentially serve a number o f purposes. Whilst several 
strategies have employed the hTERT promoter to drive apoptosis or the expression o f suicide 
genes, others have used the promoter for purposes such as the improved identification o f tumour 
cells (Umeoka et ai. 2004; Yin et al. 2004). One o f the more attractive possibilities for canTERT 
promoter-driven therapies is the specific expression o f the tumour necrosis factor-related apoptosis- 
inducing ligand (TRAIL) gene within tumour cells. TRAIL expression driven by the hTERT 
promoter results in a large reduction in orthotopic pancreatic tumour volume in a nude mouse 
model treated with an adenovirus containing the TRAIL gene driven by the hTERT promoter 
(Jacob et al. 2004). Additionally, TRAIL expression elicits a significant bystander effect through 
the interaction o f TRAIL molecules expressed on the cell membrane with receptors on adjacent 
cells (Kagawa et al. 2001). An additional aim of this project initially was to investigate the ability 
o f TRAIL, expressed under the control o f the core canine TERT promoter, to cause specific 
apoptosis in canine telomerase-positive cells. Although this construct was apparently successfully 
generated with the help o f DJ Argyle, sequencing revealed that a 170 bp region o f the core 
promoter had been lost during cloning. Due to time constraints the reason for this was not fully 
elucidated and troubleshooting was not performed, and consequently we were unable to examine 
the ability o f the core promoter to specifically direct expression o f a pro-apoptotic gene within 
telomerase-positive cells. However, this work is now being continued in our laboratory.
Another approach which could be investigated in the treatment o f canine cancer is the use o f  the 
TERT promoter to drive replication o f an oncolytic virus. This has been successfully performed by 
a number o f groups and shows considerable promise (Kawashima et al. 2004; Zou et al. 2004). 
One o f the problems encountered in the human field is the development o f resistance by some 
tumours to the adenoviral vectors used. This is due, in most cases, to the downregulation o f the 
Coxsackie-adenovirus receptor (CAR), the receptor to which the adenoviral vectors bind and gain 
entty to target cells (Berge I son et al. 1997; Wickham et al. 1993). Modifications to the fibre 
protein which interacts with CAR so that binding to cells can occur via CAR or ubiquitously 
expressed integrins has successfully overcome this limitation (Taki et al. 2005). In animals, the 
development o f adeno-associated vectors offer an alternative to the adenoviral vectors used in 
humans. However, it remains to be seen whether similar problems with resistance to adeno- 
associated viral infection will be encountered in animals. In principle, however, the theory 
underlying the use o f these vectors as oncolytic therapy remains sound and offers a promising hope 
for future cancer treatments.
It may be that the canTERT promoter alone may direct specific expression o f a given gene or
replication o f an oncolytic virus, but that the strength o f expression is limited. If this proves to be
the case, there are a number o f  strategies that may be employed to enhance its strength. Inclusion
of other promoter/enhancer elements in the hTERT promoter has been shown to improve the
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strength o f the promoter with minimal activity in telomerase-negative cells. Initially, some groups 
increased the strength o f the human promoter by adding Spl binding sites and c-Myc binding sites 
(Kim el ciL 2003b). However, given the density o f Spl binding sites in the canine TERT promoter 
it is perhaps unlikely the addition o f further binding sites will increase strength o f expression 
significantly. Some groups have added the SV40 promoter in constructs downstream of the hTERT 
promoter in addition to extra Spl/c-M yc binding sites and used these constructs to drive strong 
expression o f a gene o f interest (Song 2004; Song 2005). This approach may bear more fruit in the 
canine promoter, although specificity o f expression will need to be confirmed if this modification is 
performed.
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C h a p t e r  VI
G e n e r a l  D is c u s s io n
6.1 Work described in this thesis
The aims o f this thesis were to examine potential ways o f using telomerase in the diagnosis and 
treatment o f cancer in dogs. Following on from other work examining telomere and telomerase 
biology in normal canine tissue, in canine cancer cell lines and in canine cancer tissue, there is now 
good evidence to support the theory that telomerase activation is an important step in oncogenesis 
in canine cells as in human cells. There is now an enormous amount o f research in man that has 
Investigated means for using it in cancer diagnosis and therapy, and it is to be hoped that some of 
this knowledge can be applied to canine cancer as well as human cancer. However, this work 
needs to be validated in the canine species before it can be taken into clinical trials, and it is the 
first step o f this process that this thesis tried to achieve.
Before work can begin developing telomerase-based anti-cancer therapy, an absolute prerequisite is 
an accurate picture o f the telomerase activity o f the tumour being treated. The important paper by 
Shay and Bachetti (Shay & Bacchetti 1997) summarised the current state o f knowledge o f 
telomerase activity across a wide spectrum o f tumours. However, more detailed assessments o f 
telomerase activity in brain tumours revealed that within this collective group, there was a wide 
variation in the reported percentage o f tumours that had reactivated telomerase. To some extent 
this is not surprising, given that the number o f tumour types that arise from cells in the brain is 
probably greater than in any other organ in the body. It would be not unexpected, therefore, to find 
that the different tumour subtypes acquire different hallmarks o f malignancy in different ways and 
through different biochemical pathways. However, even bearing this in mind, the variation in 
percentage o f glioblastomas positive for telomerase activity appeared to be very high, with 
anywhere from 28% to 100% o f tumours in this subtype positive for telomerase activity. Leading 
on from this, the study reported by Falchetti et al, in comparing different ways o f assessing 
telomerase activity in glioblastomas, suggested that amount o f this variation could be due to the 
way in which telomerase activity was assessed, with the lowest figures obtained when the TRAP 
assay was performed (Falchetti et al. 2000). This study, and others examining telomerase activity 
in situ found that in fact the vast majority, if not all, glioblastomas, possess telomerase activity, but 
that variation across different regions o f the tumour could lead to false negative results.
With these findings strongly supporting the value o f in situ  methods for detecting telomerase
activity, we attempted to validate an immunohistochemical method for detecting TERT in canine
brain tumours. Canine brain tumours represent a relatively common and debilitating disease in
dogs, as in man. Surgical removal o f these tumours is often challenging, if not impossible without
severely compromising the patient, and adjunctive therapies in the dog are not widely accessible.
In addition, the similarity between the range o f tumours seen in dogs and in humans makes them an
attractive model for studying human disease. Ultimately, our goal is to develop new telomerase-
based therapeutic strategies for their treatment, but since no work so far has examined the
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telomerase status o f brain tumours in dogs, we set out to achieve this. This work raised some 
expected, and some unexpected findings. Firstly, in validating the NCL-hTERT antibody in the 
normal brain, we found that a significant proportion of normal cells stained positively for TERT in 
all parts o f the brain examined. We also found that one part o f  the brain, the region o f the 
subventricLilar zone near the caudate nucleus, appeared to be positive for telomerase activity. The 
significance o f this finding needs to be confirmed since at present only one normal canine brain has 
been examined, and more individuals need to be surveyed. Secondly, in examining TERT staining 
in canine brain tumours, we found both that TERT activity appears to correlate with both 
malignancy and proliferation in canine brain tumours, but also that not all TERT-positive cells in 
canine brain tumours are tumour cells, with some endothelial cells also staining positively for 
TERT. This would appear to validate our decision to assess telomerase activity using an in situ  
technique. Flowever, our study is still incomplete in that we have not compared TERT staining 
with any other method o f assessing telomerase activity, and ideally this should be performed in the 
future. This will take considerably longer, since most other techniques require fresh or frozen 
tissue, and the rate o f sample collection in dogs is much slower than in man, due to the lower 
numbers o f  dogs that present to clinics and the lower percentage o f these cases that undergo 
definitive treatment involving tumour resection. In the future it is to be hoped that such work will 
be carried out using tumour banks derived from collaborative tissue collection at multiple centres, 
but at present these tumour banks are still in their infancy.
Once we had established that telomerase activity is associated with malignancy in canine brain 
tumours as well as in human brain tumours, we assessed two ways o f inhibiting it in vitro', by using 
the dominant negative mutant o f  human TERT (DNhTERT), and by using the G-quadruplex ligand 
telomestatin. The initial intent o f this study was to use canine brain tumour cell lines to perform 
this work. However, no telomerase-positive canine brain tumour cell lines had been isolated at 
GUVS prior to this study beginning, and no cases were obtained during the course o f the study that 
were suitable for establishing cell lines. During the course o f the study, a meningioma cell line was 
generously donated by T. Scase at the Animal Health Trust, Newmarket. However, this was found 
to be contaminated and had to be discarded. For this reason, in vitro work was consequently 
performed in other, previously established, telomerase-positive canine cancer cell lines. Perhaps 
the biggest problem encountered in this part o f the study was the lack o f good negative control cell 
lines for both the DNhTERT study. During the course o f the DNhTERT study it became apparent 
that the K9SF cell line that we had previously isolated from a mature dog was sufficiently close to 
senescence to prove problematic. In the absence o f any transfections, the growth o f these cells 
became slower from approximately passage 8 or 9 and would cease almost entirely by 
approximately passage 11. Transfections in these cells were performed at passage 6, and it became 
apparent that the trauma o f transfection dramatically slowed the growth o f these cells so that they 
would only continue growing for a further 1 or 2 passages. Unfortunately, due to problems with 
contamination in the laboratoiy, this slow growth meant that several flasks o f K9SF cells
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transfected with empty pCINeo became contaminated before stable transfectants could be 
established. In some ways it was fortuitous that the DNhTERT construct conveyed increased 
growth rate to these cells, as otherwise cells constructed with this construct might also have 
become contaminated before establishment o f  stable transfectants.
Inhibition o f telomerase with telomestatin was more successful. Again the issue o f a suitable 
negative control cell line became obvious once we looked at the growth rates o f canine skin 
fibroblasts. An alternative ideal control would be a telomerase negative canine cancer cell line that 
elongates telomeres using the ALT pathway. However, to date, such a cell line has not been 
identified. Instead, we used a commercially available primary skin fibroblast cell line that had 
been isolated from a young beagle. This cell line should have been suitable for our work, but in the 
medium used, the growth rate was too slow to provide enough samples for more detailed 
investigation. Despite these issues, this study showed that canine cells could prove a useful testing 
ground for pharmacological methods o f inhibiting telomerase activity. In addition, this study has 
gone some way to addressing one o f the key concerns o f using telomerase inhibition as an anti­
cancer treatment in clinical settings. Eliminating telomerase activity from cancer cells without 
affecting other characteristics o f tumour behaviour would allow continued tumour growth until the 
majority o f tumour cells had exhausted their telomeric reserve. In dealing with brain tumours, 
particularly, this lag phase may result in the death o f the patient before the death o f the tumour. 
However, our study showed that cell death occurred before the exhaustion o f telomeric reserve 
with telomestatin treatment, probably as a result o f telomere uncapping. In addition, telomestatin 
treatment slowed the growth rate o f both D17 and CMT7 cells, although after a greater lag phase in 
CMT7 cells than D17 cells. Both o f these findings suggest that telomestatin may be useful in a 
clinical setting. The implications for the treatment o f brain tumours in humans are also interesting, 
since a greater proportion o f glioblastomas in humans maintain telomere length through the ALT 
pathway than many other tumours, and since G-quadruplex ligands have a strong effect on these 
cells as well as telomerase-positive cells.
Having confirmed the potential for telomerase inhibition as a strategy for cancer therapy, in the last 
part o f our study we began work that may ultimately lead to strategies utilising telomerase-targeted 
gene expression. Sequencing and characterisation o f the canine TERT gene was achieved, despite 
some problems, and identification o f the core promoter sequence was successfully performed. This 
is a vital first step in the generation o f TERT promoter-driven gene expression. We also began the 
process o f sequencing and characterising the canine TR promoter, although this was not completed. 
Similarities between the canine and human TERT gene promoters were identified, but substantial 
differences were also found. However, two important factors suggest that the canine TERT gene 
promoter may function in a similar manner to the human TERT promoter. Firstly, the core 
promoter region in dogs seems to be remarkably similar to that in people, and coincides almost 
exactly with the largest CpG island identified. Secondly, elements o f the canine TERT gene seem
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to be involved in regulating gene expression, as they are in people. However, a number o f the 
transcription factor binding sites which have attracted most attention in humans are not present in 
the canine promoter or are present outwith the core promoter. This does suggest that the action of 
the canine promoter may be regulated via different mechanisms. For instance, there appears to be a 
greater number o f hormone-related transcription factor binding sites in the canine promoter, as 
compared with the human promoter. A much greater difference appears to exist between the 
human and canine TR promoters, with the presence o f the (TAAAA),, repeats being o f particular 
interest. At this stage the distribution o f TR expression in canine tissues is unknown. Given the 
overall similarity between the presence o f telomerase activity and the correlation between 
telomerase activity and TERT expression in dog and human tissues, it seems likely that these two 
species have evolved with telomerase regulation occurring along similar lines. Therefore we could 
expect TR expression in dogs to mimic that in humans. How the (TAAAA)„ repeats contribute to 
any differences found is an intriguing question that deserves further investigation. Despite this, 
however, this last part o f the study has provided a good foundation for further work designing 
promoter-driven gene expression targeted at telomerase-positive tumours.
6.2 Future Studies
The work carried out in this project has provided some very interesting information. However, in 
many ways this information could be seen as a starting point, providing the foundation for more 
directed studies. Some o f the major themes o f future work are discussed here.
6.2.1 In Situ D etection o f  Telomerase A ctivity
Our investigation o f the immunohistochemical detection o f TERT as an assay for telomerase
activity has provided interesting data. However, it is felt that there is more work to be performed
before we can be certain o f the sensitivity and specificity o f the NCL-hTERT antibody in canine
tissues. Although we have examined the immunohistochemical detection o f TERT in canine
telomerase-positive and -negative cells in tissue culture, we have yet to compare TERT staining in
tumour tissues with other methods o f assessing telomerase activity such as TRAP assays or RT-
PCR. In addition, a more comprehensive survey o f TERT staining in canine brains needs to be
undertaken -  it is certainly possible that the single brain examined is not representative o f the
overall TERT staining status in canine brains. Furthermore, given the presence o f so many TERT-
positive cells in telomerase-negative areas, the sensitivity o f the stain in canine tissue needs to be
confirmed. Another strategy, which we are pursuing at the moment, is to synthesise a novel
antibody directed specifically at canine TERT. Whilst the peptide for immunisation has been
synthesised, immunisation and antibody purification have yet to be completed. A different way o f
assessing telomerase activity in situ would be to use ISH techniques, and this is worth examining to
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compare with immunohistochemical staining. These techniques can be technically demanding and 
rely on good quality RNA, which may not be easily available from paraffin-embedded sections, 
however they are worth attempting.
If validation o f either the NCL-hTERT antibody or a novel, canine-specific TERT antibody can be 
successfully completed, this could prove an enormously powerful tool for surveying telomerase 
activity in a wide range o f tissues and pathological conditions in dogs. For instance, the possibility 
o f telomerase activation within the brain in other conditions, such as hypoxia or trauma could be 
assessed. A definitive survey o f which somatic cells in the body exhibit telomerase activity (eg 
within the gastrointestinal tract) as well as searching for other stem cell populations could be 
performed. With the ability to use archival material, the possibilities for investigating telomerase 
activity become almost boundless.
6.2.2 Telomerase Inhibition
In our study we confirmed that it is possible to inhibit telomerase activity using G-quadruplex 
ligands in canine cells. However, the inability to inhibit canine telomerase using the human 
dominant negative mutant DNhTERT has raised other intriguing possibilities for future research. 
Firstly, unlike the G-quadruplex ligands, the dominant-negative splice variant approach eliminates 
telomerase activity without interfering with telomere capping. For this reason, DNhTERT has been 
used extensively in the human literature to investigate the impact on telomerase-positive cell lines 
o f telomerase inhibition. It would be valuable to perform the same work in canine cell lines. 
Therefore, a number o f studies could be performed that could usefully help this. Firstly, 
sequencing and characterising the full length canine TERT transcript would allow the generation o f 
mutant variants, and thus we could investigate whether changes to the A m otif in the same region 
as the human a  deletion splice variant also produce dominant negative function in canine cells. If 
we could generate such a construct, we could also investigate the possible consequence inhibiting 
telomerase function without changing telomere structure. For instance, does interfering with 
telomerase activity in canine telomerase-positive cells affect growth rate? Are there consequent 
downstream effects within cells that might confound future telomerase-based therapies such as 
compensatory upregulation o f transcription factors (eg Spl, c-myc)? These questions could be 
answered with similar studies to the ones described here, if such a construct could be generated. 
Further work examining the clinical usefulness o f telomerase inhibition could also be performed 
using other pharmacological methods, such as oligonucleotide inhibition or the investigation of 
other G-quadruplex ligands. Importantly, further work characterising the behaviour o f other 
telomerase-positive canine cell lines in response to telomestatin should be performed, to examine 
the growth pattern o f different cell lines in response to telomestatin therapy, in particular to see
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whether the lag phase in growth rate inhibition correlates with the initial telomere length o f those 
cell lines.
6.2.3 Promoter-targeted gene expression
Perhaps the part o f this project which generated the most fertile ground for further work was the 
work investigating and characterising the canine TERT gene and TR gene promoters, in particular 
the TERT gene promoter. In identifying the core promoter o f the TERT gene and confirming the 
strength o f its expression in several telomerase-positive cell lines, we now have very powerful 
system that can be used to drive teiomerase-speciflc gene expression. However, in sequencing the 
TERT promoter and identifying putative transcription factor binding sites, we have also begun the 
process o f characterising the ways in which canine telomerase may be regulated in cancer cells. 
Having obtained the core promoter, the first step should be to identify whether it can be used to 
specifically drive cell death in telomerase-positive canine cancer cells by using it to drive an 
apoptosis-inducing gene such as the TRAIL gene. As well, the core promoter could be used to 
assess the viability o f other genes o f interest, including those that offer some potential bystander 
effect (eg the bacterial nitroreductase gene).
The sequence o f the canine TERT promoter also allows us to investigate the manner in which 
canine telomerase is activated within tumour cells. Given the density o f Spl binding sites, the 
importance o f this as an activator o f gene expression should be investigate, by co-transfecting 
telomerase-positive cells with the pGL3-promoter constructs together with a second vector 
expressing Spl. This would allow us to measure the additional upregulation o f TERT gene 
expression by Spl. A similar strategy could be employed with some o f the transcription factors 
that are currently poorly understood, such as MZF-1 and W T-I. As a control, it would also be 
interesting to transfect telomerase-negative control cells with the same constructs to examine the 
effect o f transcription factors in isolation or even in particular combination with each other. 
Another alternative method o f investigating the importance o f particular transcription factor 
binding sites that could be employed would be to mutate specific sequences to alter their function, 
and then to examine the effects o f these mutations on promoter activity. This approach has 
certainly been used in humans to examine the effect of the E-boxes present within the human core 
promoter, and could be employed to examine the importance o f some o f the hormone-receptor 
binding sites such as ER, PR and GR binding sites. Another intriguing study would be to examine 
the influence o f hypoxic conditions on activity o f the canine TERT promoter, it should be an easy 
study to transfect telomerase-positive cells with the pGL3-promoter construct and incubate them 
under hypoxic conditions to examine the effect on the promoter.
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Having explored the importance o f different transcription factors on the TERT promoter, the next 
task should be to investigate engineering the TERT promoter construct to modify its activity under 
different circumstances. It may be that the first modification would be to increase its strength o f 
expression under all circumstances, by introducing a promoter such as the SV40 promoter. In any 
case, once modification o f the promoter is complete, it could then be tested for its ability to drive 
expression o f an appropriate gene in teloinerase-positive cells. Once this preliminary testing phase 
is complete, the next step would be to investigate the function o f the promoter in vivo, potentially 
using a nude mouse model xenografted with canine tumour cells. This would be the first testing 
ground on the way to final phase I, phase II and phase III clinical trials.
These studies, which could be actively pursued with the canine TERT gene promoter, could 
eventually also be applied to the TR promoter. However, rather more preliminary work needs to be 
performed with the TR promoter, first confrm ing the promoter sequence, and secondly 
investigating the activity o f the TR promoter with different numbers o f (TAAAA),, repeats. In 
itself this work is valuable because these repeats are relatively poorly understood in humans.
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Gl o ssa r y
ALT Alternative Lengthening o f Telomeres
BrDU BromoDeoxy Uridine
canTERT Canine TERT
cDNA Complementary DMA
CGH Comparative Genomic Hybridisation
CTP Cytosine Triphosphate
DAB Diaminobenzine
DIG Digoxygenin
DIG-HRP Digoxygenin-Horseradish Peroxidase
DNA Deoxyribonucleic Acid
DTT Dithiothretol
ELISA Enzyme-linked Immunosorbent Assay
FISH Fluorescent In Situ Hybridisation
gDNA Genomic DNA
GBM Glioblastoma multiforme
GXP Guanidine Triphosphate
hXERT Human TERT
HRP Horseradish Peroxidase
ISH In Situ Hybridisation
LOH Loss o f Heterozygosity
mXERT Murine TERT
NTP Nucleotide Triphosphate
PAGE Polyacrylamide Gel Electrophoresis
PCNA Proliferating Cell Nuclear Antigen
PCR Polymerase Chain Reaction
PS Phosphatidylseriiie
RNA Ribonucleic Acid
RT-PCR Reverse-Transcriptase PCR
TERT Telomerase Reverse Transcriptase
TR Telomerase RNA
TRAP Telomerase Repeat Amplification Protocol
VEGF Vascular Endothelial Growth Factor
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A p p e n d ix  A  
IMMUNOHISTOCHEMISTRY SAMPLE DETAILS: T E R T  
AND M I B - 1  STAINING
T a b le  1: T E R T  S ta in in g  vs M alig n an cy  fo r  93 T u m o u rs
Sam ple D iagnosis G rading T E R T  Staining
1 A strocytom a 1 N egative
2 A strocy tom a 1 N egative
3 A strocy tom a 1 N egative
4 A strocy tom a 1 N egative
5 A strocy tom a 1 N egative
6 A strocytom a: anaplastic 2 N egative
7 A strocytom a: anaplastic 2 N egative
8 A strocytom a: anaplastic 2 Positive
9 A strocytom a: anaplastic 2 Positive
10 A strocytom a: anaplastic 2 Positive
11 A strocytom a: g lioblastom a 2 N egative
12 A strocytom a: g lioblastom a 2 N egative
13 A strocytom a: g lioblastom a 2 Positive
14 A strocytom a: g liob lastom a 2 Positive
15 C horoid p lexus papillom a 1 N egative
16 C horoid  plexus papillom a 1 N egative
17 C horoid  p lexus papillom a 1 N egative
18 C horoid  p lexus papillom a 1 N egative
19 C horoid  plexus papillom a 1 N egative
20 C horoid  plexus papillom a 1 N egative
21 C horoid  plexus papillom a: anaplastic 2 Positive
22 C horoid  plexus papillom a: carcinom a 2 N egative
23 E pendym om a 1 Positive
24 G liosarcom a 2 Positive
25 M edulloblastom a 2 Positive
26 M eningiom a 1 N egative
27 M eningiom a 1 N egative
28 M eningiom a 1 N egative
29 M eningiom a 1 N egative
30 M eningiom a 1 N egative
31 M eningiom a I N egative
32 M eningiom a 1 N egative
33 M eningiom a 1 N egative
34 M eningiom a 1 N egative
35 M eningiom a 1 N egative
36 M eningiom a 1 N egative
37 M eningiom a 1 N egative
38 M eningiom a 1 Positive
39 M eningiom a 1 Positive
40 M eningiom a 1 Positive
41 M eningiom a 1 Positive
42 M eningiom a 1 Positive
43 M eningiom a I Positive
44 M eningiom a 2 N egative
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45 M eningiom a 2 Positive
46 M eningiom a 2 Positive
47 M eningiom a: anaplastic 2 N egative
48 M eningiom a: anaplastic 2 N egative
49 M eningiom a: anaplastic 2 Positive
50 M eningiom a: anaplastic 2 Positive
51 M eningiom a: anaplastic 2 Positive
52 M eningiom a: anaplastic 2 Positive
53 M etastasis: adenocarcinom a 2 N egative
54 M etastasis: adenocarcinom a 2 N egative
55 M etastasis: adenocarcinom a 2 Positive
56 M etastasis: adenocarcinom a 2 Positive
57 M etastasis: adenocarcinom a 2 Positive
58 M etastasis: adenocarcinom a 2 Positive
59 M etastasis: lym phom a 2 N egative
60 M etastasis: lym phom a 2 N egative
61 M etastasis: lym phom a 2 N egative
62 M etastasis: lym phom a 2 Positive
63 M etastasis: lym phom a 2 Positive
64 M etastasis: lym phom a 2 Positive
65 M etastasis: lym phom a 2 Positive
66 O ligodendrogliom a 1 N egative
67 O ligodendrogliom a 1 N egative
68 O ligodendrogliom a 1 N egative
69 O ligodendrogliom a 1 N egative
70 O ligodendrogliom a 1 N egative
71 O ligodendrogliom a 1 N egative
72 O ligodendrogliom a 1 N egative
73 O ligodendrogliom a 1 N egative
74 O ligodendrogliom a 1 N egative
75 O ligodendrogliom a 1 Positive
76 O ligodendrogliom a 1 Positive
77 O ligodendrogliom a 1 Positive
78 O ligodendrogliom a 1 Positive
79 O ligodendrogliom a 2 N egative
80 O ligodendrogliom a 2 Positive
81 O ligodendrogliom a 2 Positive
82 O ligodendrogliom a 2 Positive
83 O ligodendrogliom a: anaplastic 1 N egative
84 O ligodendrogliom a: anaplastic 1 N egative
85 O ligodendrogliom a: anaplastic 2 Positive
86 O ligodendrogliom a: anaplastic 2 Positive
87 O ligodendrogliom a: anaplastic 2 Positive
88 O ligodendrogliom a: anaplastic 2 Positive
89 O ligodendrogliom a: anaplastic 2 Positive
90 O ligodendrogliom a: anaplastic 2 Positive
91 O ligodendrogliom a: anaplastic 2 Positive
92 O ligodendrogliom a: anaplastic 2 Positive
93 P itu itary  adenocarcinom a 2 Positive
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Table 2: MIB-1 LI and T E R T  staining for 51 tum ours
Sam ple D iagnosis G rading M IB l LI 
(% )
T ER T  Staining
1 A strocytom a 1 3.2 N egative
2 A strocytom a: anaplastic 2 14.2 N egative
3 A strocytom a: anaplastic 2 8.9 Positive
4 A strocytom a: g lioblastom a 2 14.8 N egative
5 A strocytom a: g lioblastom a 2 26.1 Positive
6 C horoid  plexus papillom a 1 0 N egative
7 C horoid  p lexus papillom a 1 0 N egative
8 C horoid  plexus papillom a 1 0 N egative
9 C horoid  plexus papillom a I 0.9 N egative
10 C horoid plexus papillom a 1 3 N egative
11 C horoid plexus carcinom a 9.2 N egative
12 G liosarcom a 20.2 Positive
13 M eningiom a 1 0 N egative
14 M eningiom a 1 0 N egative
15 M eningiom a 1 0 N egative
16 M eningiom a 1 0 N egative
17 M eningiom a 1 0.2 N egative
18 M eningiom a 1 0.4 N egative
19 M eningiom a 1 0.4 N egative
20 M eningiom a 1 1.2 N egative
21 M eningiom a 1 1.5 N egative
22 M eningiom a 1 2 N egative
23 M eningiom a: anaplastic 2 13 N egative
24 M eningiom a: anaplastic 2 41.4 Positive
25 M eningiom a: anaplastic 2 9.8 Positive
26 M eningiom a: anaplastic 2 14.2 Positive
27 M eningiom a: anaplastic 2 22.4 Positive
28 M etastasis: adenocarcinom a 2 19.4 N egative
29 M etastasis: lym phom a 2 72.5 N egative
30 M etastasis: lym phom a 2 19.4 Positive
31 M etastasis: lym phom a 2 49.3 Positive
32 O ligodendrogliom a 1 0 N egative
33 O ligodendrogliom a 1 0 N egative
34 O ligodendrogliom a 1 1.1 N egative
35 O ligodendrogliom a 1 2.4 N egative
36 O ligodendrogliom a 1 2.8 N egative
37 O ligodendrogliom a 1 8.9 N egative
38 O ligodendrogliom a 1 0.9 N egative
39 O ligodendrogliom a 1 4.6 N egative
40 O ligodendrogliom a 1 1 Positive
41 O ligodendrogliom a 1 3.5 Positive
42 O ligodendrogliom a: anaplastic 2 14.9 N egative
43 O ligodendrogliom a: anaplastic 2 17.3 Positive
44 O ligodendrogliom a: anaplastic 2 20.4 Positive
45 O ligodendrogliom a: anaplastic 2 37.8 Positive
46 O ligodendrogliom a: anaplastic 2 9.2 Positive
47 O ligodendrogliom a: anaplastic 2 10.2 Positive
48 O ligodendrogliom a: anaplastic 2 13.4 Positive
49 O ligodendrogliom a: anaplastic 2 23.5 Positive
50 O ligodendrogliom a: anaplastic 2 25 Positive
51 P itu itary  adenocarcinom a 2 16.9 Positive
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A p p e n d ix  B 
U n f o r m a t t e d  s e q u e n c e  o f  Ca n is  fa m il ia r is  
TELOMERASE REVERSE TRANSCRIPTASE UPSTREAM 
REGULATORY REGION
> C a n i s  f a m i l i a r i s  t e l o m e r a s e  r e v e r s e  t r a n s c r i p t a s e  p r o m o t e r  e x o n  1 i n t r o n  
1 a n d  i n i t i a l  p a r t  o f  e x o n 2
- 5 3 9 0  CTGCAGAGCA CCTGCCCCCG CCCCCGGCCC CACATGGGCA
- 5 3 5 0  CCCACCGTCC TGGGACACCA G CTCCCCTCC CGCACCTGCC GTTCACCCAT
- 5 3 0 0  G GGTCTTTCC TGTGTCACAG ACC T TC C C T C  CCTGAGTCCT TCA AGATTTG
- 5 2 5 0  TCTAGATGAC AAT GT CCCAG CGCCCCTCAT CCTTGGGGGA CAG CT GT TT C
- 5 2 0 0  CTAGGGGCCC AGCCCCAGAC GGTCGGGGTG TCCTCGCCGG GTTGTGGCCA
- 5 1 5 0  TGCCGCGTGG CTG G T C C C TA  TGT C C A C TC T GCTGGGATGT CCAT G TTG T C
- 5 1 0 0  CCCCAGCAAC AGGGAAGGCC AGGCGGTCTG TCCCCCCAAG CATGTCTCC C
- 5 0 5 0  T G T CTCCCA C GCTCGCCCTG TCCCCCCTGC CGGGCCGTGG TCTGTCCGGA
- 5 0 0 0  GCCCAGACCT CTGCC TGTCC TCAGACCCCG CTCTCGGGCC GCTCTGTGCT
- 4  9 5 0  CTG C T TC C C T CCG TT TG T CC CTC TG CTAC T TCC T T C T T G C  TGAACCTGTC
- 4  9 0 0  CTCAAGGCGC CTATGGCTCC A C A T G TTG T A  CGTGAGCCCC GTGAGCCCTG
- 4  8 5 0  TGGGCACCAT C C CT CTT GC C CCCCCACCCC GGGTGCAGGA AACAGCGTGC
- 4  8 0 0  GCTAGGTTAC CCAATGCGCA GTTGTGCCTG TGCGGTTGGT TGTTGGACAG
- 4  7 5 0  CTCCCGCGTG C C CT CACTAC GGAGTGCCTG GAGGTGTTTG GGGCATGGCG
- 4  7 0 0  GGAATCCTGA AGCCCAGGAT GTCGGTGGCC CCTTCCTGGG GGAACTGGCG
- 4  6 5 0  C TTGTGCCAT TTGCGTCTGC AGGAGCCAGT GTCTCCACGG ACATGAGGCG
" 4  6 0 0  G G TC T TC C C A  GGGCCCCATA GTCACACAGA GGAGCAGATA CAGGGCCCAG
- 4  5 5 0  AGACACCAGA TAC AG TAACT GGTGAAAGCC AGAGCGAAGG G TCTGGATTC
- 4  5 0 0  AAGTCCAGAA GCTGCCAGCA GCCTCAGCAA GTGCTCGCGG GATGTGCCTC
- 4  4 5 0  GCTCGCACCT GTTCTGAAAG TCATTGTGGC CGCCGCCGGG AGGAGGTGGC
- 4  4 0 0  TGGCAGGACA GGAAGCCACA GCCAGGAGAA GACACAAGGA CACCTGGACC
- 4  3 5 0  CACGCCCCCC G T C T T T C T C C  TGCGGAGAGG TGTCTGTGCA GGGCGGGAAT
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- 4 3 0 0 CCAAGTGCCT CTT TG T AAAG TGCAGACGCC CTGGCTCTGC CCT CCTCACC
- 4 2 5 0 TCC TGCCCCA CCTGTGCCCG GGAACCAGCG GGGCCCGGTC CCTGAGCACC
- 4 2 0 0 CGTGTCCTTG GAGAGGCCCT CACCACCAGG ACCCAGGACA TGAGTGGGCA
- 4 1 5 0 CGTGCTGTTC ACAAAAGTAG AGATTAAGGA C T T A A T T C T A TAA GT AAAT T
- 4 1 0 0 C C A C C T T T C A GCCTCCAAGT AGGTCAA TTT A TC TTAA GA T T T T C T T A A A T
- 4 0 5 0 T T T C A T C A A A TAA GTTGCAA GAATGCAGAA ATCCAGAGGC ACACAGGCAA
- 4 0 0 0 CCGGAGCTGA GCTGTGTTTG CCGAGATGCG AGGACCAAAT A C C C T C A C T T
- 3 9 5 0 GGAGGGATTT AAGCCGTAAG C A C C T T T T A T TG G T TTT CAT TAGGTGGTTG
- 3 9 0 0 AGGGCAAGAG AAAGGACACA GCGAGGCGGA TGCAGTCGGG ATG G A T TA A T
- 3 8 5 0 GTGGTGGCAC CACCAGGGGA GGAGGTGAAA GGCCTCACCC ACCGGGGAGG
- 3 8 0 0 GGGACGCACA C TT G TT C C C C CCCGGCGCTG CCAGTCTTCC TGACCTGAGG
“ 3 7 5 0 GC C T T T T C C T GAGGCCCCTG CCCCAGCCCG CTGCC CTCTC TCCTGACCTC
- 3 7 0 0 ACCCAGCACC CAAGCCAGCC GTGCACATGG GGGACCCTGG CCTGGCGCCA
- 3 6 5 0 GAGAACCTGG GTTTG TG T CC TGGCTCTGCC CCGGGGGATC GAGGTTTCCA
- 3 6 0 0 GGAAGCCCCC ACCCTGAACC TGACAGGACG ATGATACTCG TCC ACCTACT
- 3 5 5 0 TTCTGAGGGG CTCAGAGGTC ATGCCCTCAG GTGGGAAATC CCACCGACCA
- 3 5 0 0 G G ACCATTCT T CC CACTGCT GTCTGTCCCC AGCATGAGGG CACAGAGCAG
- 3 4 5 0 C C A C T G T T T T CTC TGCTCA C AGACACCCAC CTGGTAGAAT GAGGCTCAGG
- 3 4 0 0 AAATAAAGAG GGGGCTGCTT TCAGCCCCAG GTTGGGGTGA CAGGAGCAGC
- 3 3 5 0 TGGAACCAGG GGCCAGGAAG ATGCAGCCCG GCCTCACAAC TCCACAGACG
- 3 3 0 0 TGGGGCTTCA CCCCCGCCAT GGCCGTGCAT GCCCTCGCGG GACACTGTGT
-3250 AG TGTCCAGA GGGGTCGCCT CCCCATGACA GGGCGCCGTC CTTCCCCTGC
- 3 2 0 0 AGGGGGCTGG GCCGTGGGGC ACTGGGGTAC GTGTCTGCGG CTGAGCTGAC
- 3 1 5 0 CCGTAGACGG GGCTCCCACC TGAGCCACAC GCTGTTCCCT CTGCC TCTGT
- 3 1 0 0 CTGCCTGGAG GGGTGGTCTG GCCCAGACGG C C T C G TTT C A CACCACTGGT
- 3 0 5 0 TTGTGAGGTG C TA CAGATTT CAGTTCCCAT GGTGACCCTG TGATAAAGTA
- 3 0 0 0 TTGGCAAGGA CCT TG TCAA T CTCTGAGGAT A A T T T T C C C C ACACA CAACA
- 2 9 5 0 A TC C C C C TC C CAGAGGGGAT CTGTGGAGGC TTTGGGGTCC CGGGGTGTCA
- 2 9 0 0 CCCATGTTGC T T CCAGAAAC ACCCCATAAG ACCTAGGTCC CTAAACCTGC
- 2 8 5 0 CCT CCACACC C C C T C C C TT C AATCGTGCGT GGTCTGAAGG ACAGGGCTCC
- 2 8 0 0 TCC CATGACT CG TT G TCT AT GCTCCCTGAG CCTGAACCTG CCACAGGATC
- 2 7 5 0 CTCTCCTGGC CCCGGGGTCA CAGCCTCCCG GGCACCCCAT CCTGGCCGTA
- 2 7 0 0 TCCCTGGCAG CATGCGGACA GTACTGAAGC CCGTCCCATG CACACCCCAC
282
-2650 CAGAGGCTAC AGTAAGAGCC AGCGAGGCCG GCACTGCTGG GAGGGCCCAG
-2 600 GGCAGCAGGA GCCCTAGTGG TGTCCGCCAG AACAGAAGTC AGCACCACCC
-2550 TCC TTA C A G T GTGACCTGGC CGTGGCACTC CTGCTGGACC TTCATCCAGG
-2500 AACAGGACAA CTG A C A TA A T GAGGCACAGA A TC C TG TG T A  CAAACATCCA
-24 50 CAGCAGCTTT CCGTGTCACA GCCCCACAGT GCAAACATCC CCAATGTCCC
-24 00 CTGCCAGGCG TGTGGTCCTG TCCACCGTGC AGCCGCAGCA CCGACTGGGT
-2 350 GCAGCTTCCA GATGGGAAGC AGCAGACTGC TGGCCCCACA GGAGGATGCC
-2 300 GAGCAGAAGG TCAGTGTCCG TGGGTCCTAT GTGCTGTGAC T C C A T T T A T C
-2250 TCC CCACAAT G A CAAT TTC C CTGGTCAGGG GCTCAGGTTC TGGGCTGGGG
-2200 GGGCATAAGC ATGGGGGACC CTGAGGCCAG GGGCACCACC CACAGCCAGA
-2150 ACCGTGCTGG TCATGCCGAT CCACATAGGC AGGGAGAGGA CACGAGCCTC
-2100 CCACACACAC TGGGCCAGGC TTAGTGCGCT GGTTCTGGCC AAGGGTCCCC
-2050 GCGCTCCGGG AGGTCACCCG CTGGGGACAC CAGGAGAGGG TCCTGCAGGC
-2000 AGAGCCAATC AGCAGCTGTA TT C C TA T C A C  ACTGAGGTTG AGGGCTGAGG
-1950 GCCACCCAAG GATGCCGCAT CCTAGCCCTG GAACCTGGGG ATGTGGCCTC
-1900 GCCTGGCAGA G G G ACTTTTT GGTTGGGATT TCTTGAGGGT CAAAGTTAGG
-1850 GGGATGCAGA CTGACACAGA GGCTGGCTTC AGAGCAGCTG GGAGGGTGCA
-1800 GCGTGAAGGC CTTTCCA AGG GGGCAGGGGC CAGCGGGGGA CCCCTGTTGG
■17 50 CAAGGCCACA CTGTGGGCCC CA C T T C T C T C  TCA TG CTG T T GTGAACAGCT
■1700 GTCACAGACA GTGGCTCGCA GGTCACTGAC CG CTC ACATT GGGCTGTTCA
■1650 CGTGGGCAGT GGCCTGGCTG CGGACCGATG TTTGGAGTCG A CCTGTGTGT
-1600 TTGCTGGGGG TTGGGGAGGG TGCCCAGCCA GCTCT TG T AT TC T A G C TC A A
■1550 GCCAACAACA T C A A T T T T T T  TCTGGAACAC T T T T C A C A T T  CATGACGCCG
■1500 TG A T T T C A G A  CTA TCACCCG CTT CCTG AA A CAGGTGATGG AGGAGATGAA
■14 50 GGGCTTCGTT CAGGCTGGGG GAACCCCCCC CGCCATCAGC ACAGTATCAG
■1400 TCCCACGTGT C C T TC TC TG C  CTT G G T T T C T  CCT GT TCCT C T T T T T C T A A A
■1350 A A C T G A TG TT TTCTGACCAG G TTTCTCCAG GTGAATCTGA G TAAC TTT G T
■1300 TGGAAAAGAA C A C A T T T C C C  CAGACAGTCG CAAAACCTCC AGTGGCCGAA
■1250 GTGAGTGGTT C T C CATCCT G  GCCCTGGAGA CCACGGTGCG CCTCGGTGGA
■1200 A C T C T G T C T A  GAAGGGCGAC ACGTAATCCG AGTGTTACAG GAAGGGGCAG
•1150 ACCGCCAGCA CCAT G AATAT GGAAGCCCGG CCACCAAGAG GGTGCAAGGG
■1100 GCCTGTCGAA ATGCTAGGGC CAT GA ATAAA A G CAAT TTC C TGACCACGTA
■1050 CGTTGCCAAA GG TT AACATT TGTGCAGCCG TC C AGTGTTT GCTGAGCTCA
283
- 1 0 0 0 GGAGCATTGT CCCCGGGAGC CTCCTGAGAC CCACAAGAGC C T G T T T C T C A
- 9 5 0 G CAAT TCAAA CTTGAACGCG TCTGCGTTTG CAT GG T CTCA TTAGGGTGGC
- 9 0 0 TCCTCTGGGT G T C C T G TT C A AGCGTCATGA TGAACACTGT CACAACTGTC
- 8 5 0 TCCCTGGGTC TGGGGTGGGG GGTCTGCATT GTAGTGCAGA GGCTCTGCAC
- 8 0 0 TGGGCGGGAA GGGTCTGTGA GGTCCCCTGA CCCGTCCAGT C CCAC CTCCA
- 7 5 0 GCGTGCCCTG GGGCCTGAGC ACGAGGGCAG CTGGGAGCGG CTGAGAGGAG
- 7 0 0 CCTGCACAGG GTGCCACCAA GCCCTGTGGC TC C C A T T T C T GC C C T C C TT T
- 6 5 0 CGTGGACTGT GGTTAGGAGG GAGCTGAGTG G G G TTT TT TT GCCTGTGGTG
- 6 0 0 GGGACAACAG GAGCCCGAGG ACCTGAAGGA GAAACCACAG CCTGGGGTCG
- 5 5 0 AGGAGGTCAG GTCTGGGGGC AGTACTGCCG CTGCCTGCTG GCTGCTCACT
- 5 0 0 GGCCGGGCCT GTCCTCTGGG GCTGCTTGTG CCCCCACCCC CCGTGGCTCA
- 4 5 0 GTGGGGCAGC CCTGCTGGCC CTTCACCCCG TGTATCGTGC A C A T T C T C C A
- 4 0 0 CCCTGCTCCC TGCACCCCCT CCGGGCTGAA CCCCTCCCCC CTCGCCAGCC
-350 TCCAGGGAGC AGCCTCAGTG TCTGGGTCAC TCGCCCCTGT GACAGGGACA
- 3 0 0 AACCCAAGGA CCCCCTGCCC AGGGGCGCAG AGCGCAGCAG GTGCCCCATG
- 2 5 0 TCGGGCGGGG GCTGCCCTGG GTACCCCCGA GCCTCGGCCG ACGGCATCGC
- 2 0 0 TCCCCGCCCG CGACCCTCGC CGCGCCCGCC GGGCCGGAGA GCAGAGGACG
- 1 5 0 GGGCCGGGGC CCACGCGCTC CTGGGGCTCC GCACACCTCG GCGCGCACGC
- 1 0 0 CCCCGGGCGC CCCGCCCCTT CCTCCCAGGA GCCCCGCCCC GGCGCGGACC
- 5 0 CCCTCCCCCG GCCCGCCCCT TCCTCCCGCG GACCCCGCCC CTCCCCGGCC
E x o n  1
+ 1  ATGCCGCGAG CGCCCCGGTG CCGCGCCGTG CGCGCCCTGC TGCGGGGCCG CTACCGGGAG
+ 6 1  GTGCTGCCCC TGGCCACCTT CCTGCGGCGC CTGGGGCCCC CGGGCCGGC TGCTCGTGCG
+ 1 2 1  GCGCGGGGAC CCGGCGGCCT TCCGCGCGCT GGTGGCGCAG TGCCTGGTGT GCGTGCCCTG
+ 1 8 1  GGGCGCGCGG CCGCCCCCCG CCGCGCCGTG CTTCCGCCA
I n t r o n  1
+ 2 2  0 GGTGGGCCGC GGGGGACCCT GCTGGGGCCG GGGCCGGGGC TGGGGCCGGG GCCGGGGCTG 
+ 2 8 0  GGAGGGGGAC GGGCGCGCGG TTCAAGACGC CGCCGCCCCC CCGCAG
E x o n  2
+ 3 2 6  G TGTCCTGTC C TC AA
2 8 4
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